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Parkinson’s disease (PD) is a complex and multifaceted illness characterized by progressive 
dopaminergic neuronal loss and debilitating motor, cognitive, and behavioral symptoms.  A plethora of 
studies demonstrate a link between pesticide exposure and increased risk of PD.  In this context, mounting 
experimental evidence indicate that dichlorvos (DCV), an organophosphate increases the risk of 
developing PD; however, the exact mechanism(s) of neurotoxicity remains elusive.  Hence, understanding 
the cellular mechanisms that increase the vulnerability of dopaminergic neurons to pesticide-induced 
neuronal injury is critical.  In recent years, a redox-sensitive non-receptor c-Abl tyrosine kinase has been 
shown to promote dopaminergic neurotoxicity in experimental models of PD via impaired protein 
clearance and oxidative stress mechanisms.  Given that DCV causes dopaminergic neurotoxicity via an 
oxidative stress mechanism, we hypothesized that exposure of dopaminergic neuronal cells to DCV 
would induce mitochondria-mediated cell death signaling events while triggering impairment in cellular 
proteastasis via a c-Abl-dependent mechanism.  We demonstrate that DCV-treated SH-SY5Y cells exhibit 
increased c-Abl activation, mitochondrial dysfunction, increased Bax/Bcl2 ratio, cytochrome C release, 
disruption of autophagy and proteasomal and delayed apoptotic cell death.  Intriguingly, inhibition of c-
Abl via pharmacological and genetic modulation restored cellular proteastasis and ameliorated 
mitochondria-mediated cell death signaling events, while over expression of c-Abl WT construct 
exacerbated cellular proteastasis and mitochondria-dependent cell death signaling events.  Together, these 
findings indicate that DCV-induced c-Abl activation contributes to disruption of protein degradation 
machinery and associated neuronal apoptosis via the induction of mitochondria-mediated cell death 
signaling events. 
In next set of studies, we investigated the role of c-Abl kinase in microglial activation in response 
to tandem exposure to pathogen-associated molecular pattern (PAMP) activator Lipopolysaccharide 
(LPS), an inflammagen, and danger-associated molecular pattern (DAMP) inducer rotenone (ROT), a 
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mitochondrial complex I inhibitor and a Parkinsonian toxicant.  Increasing evidence from human and 
experimental studies demonstrates a positive association between hyperactivated microglia and PD-
associated dopaminergic neuropathology in the substantia nigra.  The signaling pathways that lead to 
chronic activation of microglia remain poorly understood.  Emerging evidence indicates that microglial 
NLRP3 inflammasome activation may cause neuronal injury in numerous neurodegernerative diseases, 
including Alzheimer’s disease via the induction of mitochondrial oxidative stress-dependent mechanisms.  
Given that c-Abl is a redox sensitive kinase, we hypothesized that c-Abl kinase may act as an upstream 
regulator of NLRP3 inflammasome.  To investigate our hypothesis, we used the two well-characterized 
mouse microglial cell culture systems namely BV2 cells and primary mouse microglia.  Upon sequential 
exposure of microglial cells to LPS and ROT, c-Abl tyrosine kinase activity was upregulated as evidenced 
by hyperphosphorylation at Y412 and Y245 sites, respectively.  The activated c-Abl kinase subsequently 
tyrosine phosphorylated pro-inflammatory kinase PKCδ at Tyr311 site, with concomitant activation of the 
NF-κB pathway, induction of mitochondrial oxidative stress, autophagolysosomal system (ALS) 
dysfunction, and increased NLRP3 inflammasome activation as evidenced by increased caspase 1 
cleavage; and IL-1β and IL-18 release.  The importance of c-Abl in the activation of NLRP3 
inflammasome was further confirmed in an in vivo neuroinflammation model of PD, namely the LPS 
mouse model.  In conclusion, we report that LPS/ROT-induces an early oxidative stress response that 
positively correlated with c-Abl activation, which, in turn accelerated mitochondrial oxidative stress that 
eventually contribute to ALS dysfunction and associated activation of the NLRP3 inflammasome in the 
microglia. 
Interestingly, systemic infection has been shown to increase the risk of PD.  To further 
characterize the impact of infection on PD-related neuroinflammation and dopaminergic neuronal loss, 
we hypothesized that microglia exposed to Parkinsonian toxicant ROT may exhibit increased sensitivity 
to LPS.  First, we demonstrated the critical contribution of lysosomal cathepsin B in ROT/LPS-induced 
activation of NLRP3 inflammasome using genetic modulation techniques and pharmacological inhibitor 
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(CA074) studies in both BV2 cells and primary microglia.  In the next set of studies, we showed that 
ROT/LPS treatment upregulates microglial ER stress response, thereby leading to the activation of 
NLRP3 inflammasome via upregulation of thioredoxin-interacting protein (TXNIP) and downregulation 
of thioredoxin (Trx).  Furthermore, using salubrinal, an ER stress inhibitor, TXNIP gene silencing 
technology, and c-Abl inhibition, we further demonstrated that c-Abl mediated activation of the ROS/Trx/ 
TXNIP signaling axis is involved in ROT/LPS-induced NLRP3 inflammasome activation.  Notably, we 
validated our in vitro findings in aged rats that were sequentially exposed to ROT and LPS, in which 
NLRP3 inflammasome activation positively correlated with ER stress response and TH neuronal loss.  
Taken together, these results indicate that ROT/LPS-induced activation of c-Abl via an ER stress 
mechanism may lead to the activation of TXNIP-associated NLRP3 inflammasome, thereby leading to a 
heightened inflammatory response and associated dopaminergic neuronal loss. 
Collectively, our studies highlight the pivotal role of c-Abl in dopaminergic neurodegeneration 
subsequent to exposure to a pesticide such as DCV.  Additionally, we showed that c-Abl serves as a 
critical upstream regulator of ROT/LPS-induced microglial activation response via cathepsin B activation 
and ER stress-associated TXNIP activation and resultant NLRP3 inflammasome activation.  Importantly, 
for the first time, we demonstrated that LPS augments ROT-induced dopaminergic neurotoxicity via the 
induction of c-Abl-mediated mitochondrial oxidative stress and ER stress-dependent signaling 




CHAPTER 1. GENERAL INTRODUCTION 
Dissertation Organization 
The alternative format was chosen for this thesis and consists of manuscripts that have 
been published, or are being prepared for submission.  The dissertation contains a general 
introduction, four research papers and conclusions/future directions chapters that briefly 
discusses the overall findings from all chapters.  The references for each manuscript chapter are 
listed at the end of that specific section.  The introduction section under Chapter I provides a 
brief background and overview of Parkinson’s disease (PD), overview of pesticides and PD risk 
and talks about role of neuroinflammation in PD pathology, which this thesis is heavily based 
upon.   
The Chapter II demonstrates organophosphate pesticide-mediated mechanisms related to 
dopaminergic neurotoxicity and role of novel protein kinase c-Abl with relevance to PD.  The 
manuscript for Chapter III was published in the December 2017 issue of Journal of 
Neuroimmune Pharmacology.  It explores how c-Abl kinase modulates the pathways leading to 
activation of microglia in PD models, with focused analysis of upstream activators of NLRP3 
inflammasome.  Chapter IV studies the role of lysosomal system in microglia and involvement 
of cathepsin B lysozyme in activating NLRP3 inflammasome.  In Chapter V, ER stress 
mechanisms were evaluated in microglia exposed to pesticide and inflammagen.  It examines the 
link between ER stress and NLRP3 inflammasome in microglia involving thioredoxin-interacting 
protein.  Chapters II, IV and V are in the process of being submitted for publication. 
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This dissertation contains the experimental data and results obtained by the author during 
his Ph.D. study under the supervision of his major professor Dr. Joshua Selsby at Iowa State 
University, Department of Biomedical Sciences. 
Introduction to Parkinson’s Disease 
First described by James Parkinson in 1817 as the shaking palsy, Parkinson’s disease 
(PD) is known today as the second most common neurodegenerative disorder affecting about 1 
million people in the United States and over 4 million worldwide (Lill and Klein, 2017; Tysnes 
and Storstein, 2017).  The disease disproportionately affects the elderly.  Idiopathic PD has a 
median onset of around 61 years and its occurrence increases with age (Ramani et al., 2017).  PD 
manifests clinically as extrapyramidal motor deficits including akinesia, bradykinesia, rigidity 
and postural instability.  The well-known pathological hallmark of PD is chronic, progressive 
neurodegeneration characterized by a significant loss of dopaminergic neurons in the substantia 
nigra pars compacta (SNpc), resulting in severe dopamine depletion in the caudate putamen 
(Braak et al., 2004).  Typically, around 60% of dopaminergic neurons in the SN are lost by the 
time PD is diagnosed based on motor symptoms, and this coincides with about 80% of striatal 
dopamine being depleted (Braak et al., 2004; Dauer and Przedborski, 2003).   
Another hallmark feature of PD in humans is the presence of Lewy bodies and neurites 
containing aggregated α-synuclein (αSyn) and other cellular degradation products (Kordower et 
al., 2008).  According to Heiko Braak’s hypothesis and other recent works (Braak et al., 2003a; 
Braak et al., 2003b; Doty, 2012; Halliday et al., 2008; Recasens et al., 2014; Rietdijk et al., 
2017), the first αSyn-positive aggregates usually occur in enteric neurons and the dorsal motor 
nucleus of the olfactory bulbs before spreading to the medulla oblongata, pontine tegmentum and 
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locus coeruleus, encompassing Braak stages 1 and 2.  By stages 3 and 4, synucleinopathy 
invades the midbrain region, generating Lewy structures in the SN followed by the onset of 
dopaminergic neurodegeneration throughout the nigrostriatal region.  The clinical symptoms of 
PD become evident during the 4th stage.  Lastly, Lewy pathology invades the neocortex, where 
neurodegeneration could contribute to cognitive symptoms associated with advanced PD. 
Neuroinflammation is another prominent pathological feature of the PD brain that is 
evident in clinical subjects and all animal models of the disease (Tansey and Goldberg, 2010).  In 
particular, microgliosis, indicated by the aberrant accumulation of activated microglia, is thought 
to play a major role in the neurodegenerative process (Mcgeer et al., 1988b; Ouchi et al., 2005).  
Activated microglia produce ROS and nitrite, as well as pro-inflammatory mediators that can 
directly affect impair neuron health, and/or bring about further glial activation, perpetuating the 
inflammatory response.  Such chronic activation of microglia contributes to dopaminergic 
neuronal death.  Interestingly, until recently, microglial activation was considered to be a 
consequence of dopaminergic neurodegeneration.  But over the last two decades, the 
accumulating evidence supports a pivotal role for activated microglia in the pathogenesis and 
progressive nature of PD.  We discuss the role of microglial activation in PD in the later part of 
this chapter. 
PD Etiology 
Although aging appears to be the greatest risk factor for developing PD, the exact cause 
of PD pathogenesis remains unclear. Currently, researchers are investigating a range of gene-
environmental factors believed to contribute to the onset and progression of PD (Shastry, 2001; 
Warner and Schapira, 2003; Zanon et al., 2018). 
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With currently known genetic risk factors, familial PD accounts for about 5% of the 
heritability (Keller et al., 2012).  Thus far, 28 common PD risk alleles have been identified as PD 
associated genes (PARK), wherein mutation in these genes can lead to genetic/familial PD 
(Hamza et al., 2010; Mortezaei et al., 2017; Nalls et al., 2014; Satake et al., 2010).  One of the 
major PARK genes associated with PD, known as PARK1 or SNCA, encodes αSyn protein 
(Klein and Westenberger, 2012; Polymeropoulos et al., 1997).  Misfolded αSyn, as a product of 
gene mutation, is one of the major components of Lewy bodies and Lewy neurites.  Recently, 
αSyn aggregates were shown to cause mitochondrial dysfunction by binding to the mitochondrial 
pore complex (Di Maio et al., 2016).  Mutation in other PD associated genes, like PINK1 and 
Parkin, have also been linked to mitochondrial quality control, suggesting that mitochondrial 
dysfunction contributes to PD-related neurodegeneration (Lucking et al., 2000; Pickrell and 
Youle, 2015).  Table 1 summarizes the genes confirmed to be associated with PD. 
Table 1: Summary of all genes confirmed to be associated with familial PD. 





Protein αSyn is thought to play role in 
presynaptic vesicular trafficking. It is a 
major component of Lewy bodies. 
Missense mutation (esp. A53T) 
generates dopaminergic neurotoxicity.  
Mutation SNCA has been reported in 
both familial as well as idiopathic PD. 
(Lashuel et al., 
2013; Pihlstrom 
and Toft, 2011; 








Table 1 (Continued) 





Component of multiprotein E3 
ubiquitin ligase, responsible for 
clearing damaged proteins and 
mitochondria by proteasomal or 
autolysosomal pathways.  Mutation in 
parkin is associated with inadequate 
mitochondrial maintenance and 
neurodegeneration in PD patients.  
(Kitada et al., 
1998; Lucking et 
al., 2000; Malek 





PTEN induced putative kinase 1 
(PINK1), a serine/threonine kinase, 
localizes to mitochondria and is 
believed to regulate the clearance of 
stress-damaged mitochondria.  
Mutation in PINK1 reduces the 
clearance of damaged mitochondria, 
have been reported in early onset PD. 
(Gandhi and 
Plun-Favreau, 
2017; Nalls et al., 






Protein deglycase DJ-1, regulator of 
androgen receptor-dependent 
transcription, modulates chaperone 
activity inhibiting αSyn aggregation 
and protects against oxidative damage 
to neurons.  Mutation in DJ-1 is 
reported in young-onset PD patients.  
(Abou-Sleiman et 








Table 1 (Continued) 





LRRK2 (dardarin) contains 
Ras/GPTase kinase domain for MAP 
kinases and other functional proteins in 
cells. The most common SNP 
(G2019S) has been reported in EOPD 
patients. LRRK2 mutation  associated 
with dysfunctional 
autophagolysosomal system and 
accumulation of αSyn aggregates, 
contributing to neuronal death. 
(Alegre-
Abarrategui et al., 
2009; Martin et 
al., 2014; 






Phospholipase A2 group VI is an 
enzyme that catalyzes the release of 
fatty acids from phospholipids. 
Accumulates within Lewy bodies.  
Mutation in PLA2G6 is associated with 
familial juvenile-onset PD. 
(Miki et al., 2017; 






F-Box only protein 7, a mitochondrial 
protein, is a ubiquitin ligase subunit. It 
interacts with parkin and PINK1 and is 
responsible for mitochondrial 
maintenance. Mutant FBXO7 neurons 
have insufficient UPS, causing 
neurodegeneration and early onset PD 
cases. In postmortem brains of PD 
patients, FBXO7 colocalizes with 
αSyn-stained inclusions.  
(Nelson et al., 
2013; Shojaee et 






Table 1 (Continued) 





Vacuolar protein sorting 35 is involved 
in retrograde transportation of 
endosomal cargo to Golgi and in 
formation of mitochondria-derived 
vesicles, shuttling cargo between 
mitochondria and lysosomes. VPS35 
mutations associated with late-onset 
PD.   
(Vilarino-Guell et 
al., 2011; Wang 
et al., 2016) 
 
Epidemiological and clinical studies are finding a positive correlation between PD and 
environmental risk factors such as traumatic brain injury, exposure to heavy metals and 
pesticides, excess body weight and some surrogate measures such as rural living, drinking well 
water and farming (Dick et al., 2007; Priyadarshi et al., 2001).  Interestingly, several of these 
environmental triggers and toxins mimic Parkinsonian pathophysiological features in 
experimental animal settings.  One such toxin is methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP), a compound produced as an impurity during the illicit synthesis of the narcotic 
Desmethylprodine  (Ballard et al., 1985).  MPTP causes chronic and severe Parkinsonism by 
selectively damaging the substantia nigra, resulting in all the motor features of PD (Appendino et 
al., 2014; Ballard et al., 1985; Langston et al., 1983).  Microglial monoamine oxidase A (MAO-
A) converts MPTP to its cationic metabolite 1-methyl-4-phenylpyridinium (MPP+), which 
selectively gets internalized by dopaminergic neurons via dopamine transporter, causing 
neurotoxicity (Radad et al., 2014; Schober, 2004). 
Other compounds widely used in experimental models to study the etiopathogenesis of 
PD include the narcotic methamphetamine, the dopamine derivative 6-hydroxydopamine (6-
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OHDA), and pesticides such as rotenone, paraquat and dieldrin.  These neurotoxicants cause 
nigrostriatal cell death by interfering with mitochondrial function, inducing oxidative stress, 
inducing protein aggregation and modifying proteasomal function (Ghosh et al., 2013; Jin et al., 
2015; Kanthasamy et al., 2008; Latchoumycandane et al., 2011).  In addition, exposure to heavy 
metals such as iron, lead, mercury, cadmium, arsenic and manganese, as well as exposure to 
metal-based nanoparticles, have been shown to increase the risk of PD through the neurotoxic 
accumulation of metals in the SNpc and by increasing oxidative stress-mediated apoptosis 
(Aboud et al., 2014; Afeseh Ngwa et al., 2009; Afeseh Ngwa et al., 2011; Harischandra et al., 
2015; Kanthasamy et al., 2012; Milatovic et al., 2009). 
Beyond the consideration of risk factors, clues about disease etiology can also be gleaned 
from efforts to better understand factors correlated with a reduced risk of PD. A recent 
epidemiological study found that subjects who engaged in regular physical exercise from high-
school to age 40 were at a markedly lower risk of PD (Ascherio and Schwarzschild, 2016).  
Besides exercise, other daily habits including smoking, coffee or tea (caffeinated beverages) 
intake and physically demanding work have been shown to reduce PD risk (Noyce et al., 2012; 
Shen and Ji, 2015). 
Pathophysiology of PD 
 Together with genetic predisposition, several environmental factors can alter cellular 
homeostasis, leading to the degeneration of dopaminergic neurons. In this section, we discuss the 





1) α-Synuclein aggregation and Lewy body deposits 
 The accumulation of intracellular inclusions composed of proteins and lipids, known as 
Lewy bodies or Lewy neurites, is the key feature of PD pathology (Gibb and Lees, 1988; 
Spillantini et al., 1998).  A 14kDa cytosolic protein from the synuclein family, α-synuclein 
(αSyn), is the major component of these protein aggregates (Spillantini et al., 1997).  Although 
abundant protein expression of αSyn is detected throughout the brain, its exact cellular function 
is still unclear (Dehay et al., 2015; Lavedan, 1998).  A recent review article demonstrates that (i) 
αSyn is predominantly present in presynaptic terminals and may play a role in vesicular 
transportation and release of neurotransmitters at the synapse; (ii) αSyn interacts with various 
cellular proteins (including tyrosine hydroxylase, phospholipase, small GPT-binding protein 
rab3, and DJ-1), however, the mechanistic role of these interactions is unclear; and (iii) 
monomeric αSyn can modulate the chaperone activity and increase neuronal survival (Burre et 
al., 2018).   
 To date, three mutations (A53T, A30P and G188A) have been identified in familial PD 
(Burre et al., 2018; Spillantini et al., 1998).  Additionally, duplication or triplication of the SNCA 
gene has been reported in PD patients, and would be responsible for αSyn protein overexpression 
(Cookson, 2009).  These mutations have been reported to alter protein folding, contributing to 
the accumulation of misfolded αSyn oligomeric aggregates, which are believed to be cytotoxic to 
neurons (Cookson, 2009; Spillantini et al., 1998).   
In general, αSyn toxicity is attributed to elevated intracellular oxidative stress, 
mitochondrial dysfunction and energy depletion, endoplasmic reticular stress, impaired 
proteostasis and aberrant activation of inflammatory cells (Cookson, 2009; Dehay et al., 2015; 
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Yasuda et al., 2013). αSyn-mediated decreases in PGC1α activation, increases in mitochondrial 
DNA damage, and increases in mitochondrial fragmentation lead to mitochondrial dysfunction in 
dopaminergic neurons (Eschbach et al., 2015; Martin et al., 2006; Nakamura et al., 2011). 
Dysfunctions related to the ER implicated in αSyn toxicity include increased ER stress, UPR 
induction, and changes to ER/Golgi trafficking and ER/Mitochondria contacts at the 
mitochondria-associated membrane (MAM) (Colla et al., 2012; Guardia-Laguarta et al., 2015; 
Ito et al., 2010; Ogen-Shtern et al., 2016).  Decreases in lysosomal enzyme activity, 
autolysosome formation, chaperone-mediated autophagy (CMA) cargo loading, and ATG9 
trafficking have been identified as contributing to the autophagy and lysosomal dysfunction 
associated with αSyn (Cuervo et al., 2004; Mazzulli et al., 2011; Winslow et al., 2010; Wong and 
Krainc, 2017).  At the synapse, groups have shown that αSyn toxicity can reduce SNARE 
assembly, alter vesicle motility and size, and decrease neurotransmitter release (Bridi and Hirth, 
2018; Choi et al., 2013; Nemani et al., 2010; Scott and Roy, 2012). Moreover, a number of 
recent studies implicate αSyn in microglial activation through MAPK and nuclear factor κB (NF-
κB) pathway activation in a manner dependent of the type of synuclein protein present (Hoenen 
et al., 2016; Zhang et al., 2017). 
2) Oxidative stress 
 The generation of excessive amounts of ROS (reactive oxygen species such as 
superoxide, hydroxyl radicals and peroxynitrite) combined with reduced levels of intracellular 
antioxidants (glutathione, superoxide dismutase, and catalase) lead to cellular oxidative stress 
(Jenner, 2007; Mittler, 2002).  ROS interacts with and damages several macromolecules in cells, 
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including proteins, lipids and oligonucleotides, significantly contributing to neurotoxicity (Blesa 
et al., 2015; Jenner, 2003).  
Dopaminergic neurons are highly sensitive to oxidative stress and high levels of 
dopamine itself can generate reactive oxidation products (Maguire-Zeiss et al., 2005; Pham et al., 
2009).  In postmortem analysis of PD brains, high levels of oxidative stress markers and reduced 
antioxidant levels have been reported (de Oliveira et al., 2011; Dexter et al., 1989; Sofic et al., 
1992; Takahashi-Niki et al., 2004). Postmortem brains from PD patients have higher levels of 
iron in the SN when compared to controls, and nitrosylated IRP was found in Lewy bodies 
(Castellani et al., 2000; Sian-Hulsmann et al., 2011)). Iron can participate in Fenton reactions 
with superoxide and hydrogen peroxide to generate the reactive hydroxyl free radical (Valko et 
al., 2007). The presence of neuromelanin in SN neurons has also been speculated to contribute to 
their susceptibility, largely due to neuromelanins known interactions with iron (Double et al., 
2003) (Double et al., 2002). An interaction with cytosolic dopamine, αSyn, and calcium has also 
been proposed as a mechanism of selective death of SN neurons due to the metabolic expense of 
intracellular calcium regulation (Mosharov et al., 2009).  
Additionally, the mitochondria-targeted Parkinsonian toxicant 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) dramatically increases oxidative stress and glutathione levels 
in animal and in vitro models of dopaminergic neurotoxicity (Ferraro et al., 1986; Sriram et al., 
1997; You et al., 2016).  The accumulation of αSyn deposits in neurons increases the level of 
ROS (Deas et al., 2016; Maguire-Zeiss et al., 2005), which in turn triggers the post-translational 
modification of αSyn that promotes its aggregation and neurodegeneration (Danielson and 
Andersen, 2008).  Interestingly, many antioxidants have been shown to reduce dopaminergic 
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neurodegeneration in experimental models of PD, further indicating the cytotoxic role of 
oxidative stress in PD pathogenesis (Gunesch et al., 2017; Jin et al., 2014a; Levites et al., 2001). 
Oxidative phosphorylation provides energy necessary for the cell; however, it is also the 
main source of superoxide and hydrogen peroxide.  Thus, mitochondrial dysfunction and 
oxidative stress are closely linked in many disease pathologies.  For example, complex I 
deficiencies are a source of ROS, while ROS can also inhibit complex I (Blesa et al., 2015).  
Several PD-related genes which cause changes in mitochondrial function have been shown to 
increase levels of oxidative stress (Zuo and Motherwell, 2013).  Neuroinflammation coincides 
with activation of enzymes such as NADPH oxidases and nitric oxide synthases in microglia 
resulting in production of ROS, damage to neighboring neurons, and further amplification the 
pro-inflammatory response (Surace and Block, 2012). 
3) Activation of redox-sensitive protein kinases 
 The role of protein kinases has always been considered vital in cellular homeostasis, 
including in neurons, and altering kinase function can generate disease pathology.  For example, 
mutation in LRRK2, one of the leucine-rich repeat kinases encoded by PARK8 gene, is 
considered to be one of the most common PD risk factors (Martin et al., 2011b; Xiong et al., 
2017).  Likewise, our lab demonstrated the crucial role of Protein kinase D1 (PKD1) in 
modulating 6-OHDA (6-hydroxy dopamine)-induced dopaminergic neurotoxicity (Asaithambi et 
al., 2014; Ay et al., 2015).  Similarly, many other kinases, including AMP-activated protein 
kinase (AMPK), c-Src, Fyn, Protein Kinase A, have been linked to dopaminergic neuronal 
survival (Dagda et al., 2014; Dulovic et al., 2014; Kim et al., 2013c; Mucignat and Caretta, 2017; 
Panicker et al., 2015; Recchia et al., 2004). 
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Similarly, a novel protein kinase, c-Abl tyrosine kinase, was recently identified to be 
activated in various PD models (Brahmachari et al., 2016a; Brahmachari et al., 2017; Gonfloni et 
al., 2012; Karuppagounder et al., 2014; Lawana et al., 2017)  as well as in postmortem brains of 
AD (Jing et al., 2009; Schlatterer et al., 2011b) and PD patients (Goedert et al., 2013; Lee and 
Trojanowski, 2006; Martin et al., 2011a).  Laboratory studies using the well-established MPTP 
mouse model of PD have found hyperphosphorylated c-Abl kinase in the SN (Karuppagounder 
et al., 2014; Ko et al., 2010; Wu et al., 2016).  Ko et al. (2010) showed that knocking out c-Abl 
dramatically prevented MPTP-mediated dopaminergic neuronal loss in vivo.  Also, c-Abl 
inhibitors, mainly nilotinib, have been shown to be protective in various pre-clinical models of 
PD (Hebron et al., 2013b; Karuppagounder et al., 2014; Pagan et al., 2016; Tanabe et al., 2014). 
Phosphorylation by c-Abl has been shown to degrade the neuronal levels of parkin (Ko et 
al., 2010).  A study performed in the humanized A53T mouse model showed an age-dependent 
increase in c-Abl activation paralleled by the accumulation of pathologic αSyn-positive 
aggregates (Hebron et al., 2013b).  Other studies demonstrated that c-Abl phosphorylates αSyn 
at the Y39 residue, which disrupts its clearance from dopaminergic neurons (Brahmachari et al., 
2016b; Mahul-Mellier et al., 2014).  Furthermore, substrate for c-Abl is protein kinase C δ 
(PKCδ), a redox-sensitive protein kinase, whose activation plays an important role in inducing 
apoptotic neuronal death in various PD models (Gordon et al., 2016; Jin et al., 2014b; 
Kanthasamy et al., 2006). 
Our group recently analyzed the activation of c-Abl microglia.  We demonstrated that c-
Abl’s modulatory actions in the inflammatory activation of microglia include modulating 
intracellular oxidative and mitochondrial stress, gene transcription and ALS function (Lawana et 
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al., 2017).  In section V of this chapter, titled ‘c-Abl tyrosine kinase’, we further discuss the 
structure and functions of c-Abl kinase.   
4) Mitochondrial homeostasis 
The mitochondrion, the ‘power house’ of every cell, is perhaps the most vulnerable 
organelle in dopaminergic neurons (de Oliveira et al., 2011; Jin et al., 2014a).  The mitochondrial 
inner membrane hosts the electron transport chain (ETC) complexes I to IV, required for 
generating ATP via oxidative phosphorylation (Babizhayev and Yegorov, 2016; Balaban et al., 
2005).  Besides energy production, mitochondria also participate in cell aging and apoptosis 
(Balaban et al., 2005).  Hence, maintaining mitochondrial homeostasis is crucial for neuronal 
survival. 
The accidental discovery of MPTP as a Parkinsonian mimetic opened the door to 
experimental studies uncovering the pivotal role of mitochondrial dysfunction in dopaminergic 
neurons (Przedborski et al., 2004).  Postmortem evidence emerged demonstrating lower 
mitochondrial complex I activity in PD brains (Parker et al., 2008; Schapira et al., 1990).   
Reports on several PD cases have linked mutations in some of the PARK genes (Parkin, PINK1 
and DJ-1) to compromised mitochondrial health (Dodson and Guo, 2007).  Mitochondrial 
dysfunction in dopaminergic neurons results in elevated oxidative stress (Lin and Beal, 2006), 
impaired calcium homeostasis (Henchcliffe and Beal, 2008), reduced proteasomal activity 
(Moon and Paek, 2015), altered autophagolysosomal system (ALS) (Mader et al., 2012), the 
aggregation of misfolded αSyn fibrils and Lewy body formations (Betarbet et al., 2006; Hu et al., 
2016; Sherer et al., 2003c), and activation of caspase-mediated apoptotic death (Afeseh Ngwa et 
al., 2011; Kitazawa et al., 2003) in dopaminergic neurons.   
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Also, many experimental PD models demonstrate altered mitochondrial quality control 
(Dagda and Chu, 2009), showing lower clearance of damaged mitochondria via defective 
mitophagy (Gong et al., 2015; Pilsl and Winklhofer, 2012) and reduced generation of new 
healthy mitochondria (Ay et al., 2017; Shin et al., 2011).  It is now appreciated that mitochondria 
are highly dynamic organelles, with tightly regulated quality control processes in place to keep 
up with changing cellular demands. Mitochondrial dynamics are important for proper 
neurotransmission, synaptic maintenance, and survival, and disruption (McInnes, 2013).  Parkin 
and PINK1 are known to be involved in the degradation of dysfunctional mitochondria through 
mitophagy, but have recently been shown to have roles in protein-protein interactions and fission 
as well (Scarffe et al., 2014).  LRRK2 also mediates mitochondrial dynamics through interacting 
with Drp-1, a fission protein (Saez-Atienzar et al., 2014).  Two Italian families were recently 
shown to have mutations in OPA1, a protein involved in mitochondrial fusion, alongside their 
progressive PD and dementia phenotype (Carelli et al., 2015; Valero, 2014).  Inhibition of a gene 
commonly associated with PD, the glucocerebrocidase (GCase) gene, results in fragmented, 
dysfunctional mitochondria in a mouse model (Cleeter et al., 2013; Migdalska-Richards and 
Schapira, 2016; Osellame and Duchen, 2013). 
Mitochondria biogenesis can be regulated transcriptionally through PGC1a, which is 
decreased in post-mortem PD SN tissue and white blood cells (Zheng et al., 2010).  All 13 
mitochondrially-encoded genes are components of the electron transport chain, and maternally 
inherited mutations in these genes have been identified in some PD patients (Thyagarajan et al., 
2000).  Recently, a paper revealed a decrease in mtDNA copy number in PD patients SN neurons 
(Grunewald et al., 2016).  
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5) Ubiquitin-proteasome system 
The ubiquitin-proteasome system (UPS) is a highly conserved ATP-dependent machinery 
for degrading larger polypeptides.  First, misfolded and unneeded proteins and oligopeptides are 
tagged with various enzymes, namely (in sequence): ubiquitin-activating enzyme (E1), ubiquitin-
conjugating enzyme (E2) and ubiquitin-protein ligase (E3).  Once tagged, these proteins are 
sorted by the 19S regulatory subunit for the 26S proteasome.  This cargo then moves to the 20S 
subunit complex for degradation in to smaller polypeptides or single amino acids and other 
byproducts.  Ubiquitin then gets recycled by deubiquitinating enzymes, such as ubiquitin-
carboxyl terminal hydroxylase (UCH) and ubiquitin-specific processing protease (UBP) 
(Heinemeyer et al., 2004). 
Since UPS degrades the soluble form of αSyn (Liu et al., 2003; Zhang et al., 2008) 
dysfunctional UPS can contribute significantly to PD pathogenesis.  On the other hand, under 
specific cellular conditions which could be present in dopaminergic cells, αSyn was not 
successfully processed by the proteasome and thus could contribute to a selective vulnerability of 
dopaminergic cells to αSyn toxicity (Zondler et al., 2017).  Moreover, αSyn can directly 
contribute to UPS dysfunction, helping to create the environment less conducive to its clearance 
(Emmanouilidou et al., 2010; Zondler et al., 2017).  
Interestingly, mutations in two PD-associated genes directly impact UPS function: i) 
Parkin, an E3 ubiquitin-ligase, is involved in the clearance of mitochondrial and other cellular 
proteins (Kitada et al., 1998; Lucking et al., 2000); and ii) Autosomal dominant UCH-L1 is 
required for recycling neuronal ubiquitin (Lee and Hsu, 2017; Zhang et al., 2000).  CHIP and 
TRAF6 are both E3 ligases that have been implicated in PD, mainly by regulating the 
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ubiquitination of LRRK2 and Pink1, respectively (Kalia et al., 2011; Murata et al., 2013).  CHIP 
can also ubiquitinate αSyn, reducing the load of toxic α-synuclein oligomers (Kalia et al., 2011), 
while TRAF6 can also promote the ubiquitination of DJ-1 and αSyn (Murata et al., 2013). 
Importantly, TRAF6 upregulation was found in postmortem PD patient brains (Chung et al., 
2013). 
Reduced UPS activity in the brain has been reported in sporadic PD patient brains 
(Kumar et al., 2017; McNaught et al., 2003).  Also, animals treated with UPS disruptors develop 
PD pathology (Bove et al., 2006; Kordower et al., 2006; McNaught and Olanow, 2006).  For 
example, the proteasome inhibitor lactacystin can cause dopaminergic neuron loss in rodents 
accompanied by excessive midbrain iron accumulation and oxidative stress, while iron chelators 
have been shown to be neuroprotective against proteasome inhibitor-induced neurodegeneration 
(Le, 2014).  A recent study showed that excessive exposure to zinc in a rat model results in 
reduced UPS-associated enzyme activities and altered expression of subunits of the UPS in the 
nigrostriatal tract  along with loss of dopaminergic neurons and neurobehavioral deficits (Kumar 
et al., 2017).  Many pesticides that have been shown to inhibit proteasome activity, including 
paraquat, rotenone, chlorpyrifos, pendimethalin, endosulfan, fenpyroximate and tebufenpyrad, 
also affect mitochondrial function, suggesting a close link between these mechanisms (Chen et 
al., 2017). 
6) Autophagolysosomal system 
Autophagy is another common process involved in the clearance of cellular 
macromolecular waste as well as damaged organelles.  After receiving signal, the cell prepares 
the autophagic vacuoles (AVs) by initiating the conversion of microtubule-associated protein 
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1A/1B light chain C 3B I (MAP-LC3B I or LC3B I) to LC3B II.  Adding the lipid group 
phosphatidylethanolamine to LC3B I generates LC3B II (LC3B PE), which then interacts with 
autophagy-related gene 7 (ATG7) and ATG3.  This complex then interacts with beclin 1 and 
forms a phagophore (Frake et al., 2015).   Sequestosome 1 (SQSTM1), commonly known as p62, 
is a ubiquitin-binding scaffold protein, which carries the ubiquitin-bound non-degraded cargo 
through C-terminal interactions (Bjorkoy et al., 2009).  Then, p62 binds directly to LC3B and 
anchors the cargo into the AV for degradation (Pankiv et al., 2007).  After formation of an AV, 
the autophagosome fuses with a lysosome for degradation of its contents (Frake et al., 2015).  
This process is called autophagy and is considered pro-cell survival.  However, in recent years, 
much evidence has emerged showing an impaired autophagy in PD models (Wu et al., 2015; Yin 
et al., 2017). 
Clearance of oligomeric αSyn can occur via the ALS (Cai et al., 2009; Mak et al., 2010),  
and PD is one of the lysosomal storage diseases wherein dysfunctional ALS is well documented 
(Cerri and Blandini, 2018; Zhang et al., 2012).  In accordance, Analysis of sporadic PD brains 
orchestrated increased accumulation of autophagosomes (Anglade et al., 1997).  Genetic 
mutations in the autosomal recessive ATP13A2 (PARK9) gene alter lysosomal function in PD 
(Dehay et al., 2012; Djarmati et al., 2009; Ramirez et al., 2006).  In addition, mutations in 
PINK1 and parkin can also impact the ALS and lead to the formation of Lewy bodies and 
dopaminergic neurodegeneration (Narendra et al., 2010; Samaranch et al., 2010).  Inactivation of 
autophagy by deleting Atg7 in animal models predisposes to PD-like pathology, while 
application of autophagy enhancers attenuates it  (Decressac et al., 2013; Lachenmayer and Yue, 
2012; Moors et al., 2017).  Autophagic enhancement has been successfully carried out in various 
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cell culture and animal models of PD by targeting beclin1, AMPK, mTOR, TFEB, SLC2A 
transporters, GCase, and lysosomes (Moors et al., 2017). 
7) ER stress 
 The endoplasmic reticulum (ER) is a crucial organelle required for synthesis, post-
translational modification and transportation of major proteins in cells (Paschen and Frandsen, 
2001).  Accumulation of unfolded proteins in the ER lumen leads to ER stress causing 
malfunction or loss of integrity of the ER (Paschen and Frandsen, 2001).  Induction of ER stress 
leads to the unfolded protein response (UPR) and downstream activation of several other 
pathways including apoptosis (Chinta et al., 2008; Phang et al., 2016; Rao et al., 2004).  The 
UPR is a signaling pathology mediated by the activation of three main stress sensors located on 
the ER membrane, including inositol-requiring kinase 1α (IRE1α), activating transcription factor 
6 (ATF6), and protein kinase RNA-like ER kinase (PERK) (Senft and Ronai, 2015).  Activation 
of UPR-related pathways turns on the genes required for clearing misfolded proteins and 
reducing ER stress (Rao et al., 2004).  However, persistent ER stress leads to activation of eIF2α, 
ATF4, CHOP, Akt, etc., which can lead to cell death (Mercado et al., 2016; Senft and Ronai, 
2015). 
 In toxicant-based PD models, the role ER stress has been evaluated for the past two 
decades (Mercado et al., 2016).  Parkinsonian toxicants such as 6-hydroxydopamine (6-OHDA), 
manganese and MPTP/MPP+ have been reported to upregulate ER stress markers during 
dopaminergic toxicity (Holtz and O'Malley, 2003; Wang et al., 2015b).  Another recent study 
showed that rats exposed to an ER stressor (tunicamycin) showed nigral accumulation of αSyn-
positive aggregates and dopaminergic neurodegeneration (Coppola-Segovia et al., 2017).  A link 
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between ER stress and CMA was recently identified and shown to be mediated through PERK, 
p38 MAPK at lysosomes, and LAMP2A (Li et al., 2017).  Importantly, PD-related toxicants 
were shown to activate this newly identified pathway in mice (Li et al., 2017). 
Additionally, reduced levels of parkin have been shown to induce ER stress and the 
accumulation of intracellular protein aggregates leading to neuron death (Imai and Takahashi, 
2004).  In this context, parkin-overexpressing SH-SY5Y cells exhibited reduced mitochondrial 
dysfunction after being treated with ER stress inducers (tunicamycin and thapsigargin), 
indicating a link between ER and mitochondrial stress during dopaminergic neurodegeneration 
(Bouman et al., 2011).  Furthermore, ATF4 binds to the parkin promoter to upregulate parkin 
levels in response to ER stress (Bouman et al., 2011).  A very recent study confirmed activation 
of PERK/ATF4 signaling in multiple rodent models and postmortem PD brain tissue (Mercado et 
al., 2018). Moreover, they revealed that pharmacological inhibition was neuroprotective and 
improved behavioral outcomes in a rodent model (Mercado et al., 2018). Parkin also modulates 
DJ-1 via a signaling cascade dependent on p53 and XBP-1s (Duplan et al., 2013). 
Increased ER stress in PINK1 and Parkin mutants was recently shown to be mediated by 
mitofusin bridges between dysfunctional mitochondria and ER (Celardo et al., 2016).  PERK 
signaling was suppressed by reducing these contacts and provided neuroprotection despite 
mitochondrial function not improving (Celardo et al., 2016).  Increased  retention of GCase in 
the ER leads to ROS and oxidative stress, but GCase activity and αSyn levels were restored by 
inhibition with ambroxol,  presumably through facilitating trafficking through the ER (Maor et 
al., 2013; Mazzulli et al., 2011).  LRRK2 is necessary for ER exit site assembly and trans-Golgi 
turnover (Beilina et al., 2014; Cho et al., 2013).  Interestingly, LRRK2 was found to localize to 
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the ER, and LRRK2 knockouts were shown to be susceptible to ER stress in the C. elegans 
model (Samann et al., 2009). 
GRP78/BiP is a UPR activator that has been shown to bind to αSyn and is increased in 
αSyn cell culture and animal models (Bellucci et al., 2011; Colla et al., 2012).  The IRE1α/XBP-
1 arm of the UPR was recently shown to be induced in iPSCs derived from PD patients and in 
postmortem PD brains with Lewy bodies (Heman-Ackah et al., 2017).  It was also shown that 
αSyn can directly and indirectly inhibit ATF6 processing, leading to decreased ER associated 
degradation (ERAD) function and increased markers of apoptosis (Credle et al., 2015).  Direct 
inhibition of vesicular trafficking between the ER and Golgi is considered to be a main cause of 
αSyn-mediated induction of ER stress (Mercado et al., 2018; Thayanidhi et al., 2010). 
8) Neuroinflammation and microglial activation 
 Neuroinflammation plays a crucial role in several neurodegenerative diseases, including 
PD, Alzheimer’s disease (AD), and Multiple Sclerosis.  In general, inflammation is considered 
protective and functions to repair, regenerate and remove damaged tissues/cells or infectious 
agents, parasites or toxins from vital organs including the brain (Kulkarni et al., 2016).  Brain 
inflammation is mediated by microglia (host macrophages of the brain), astrocytes, 
oligodendrocytes, and several peripheral inflammatory cells (T-cells, neutrophils and mast cells) 
(Shabab et al., 2017).  However, persistent activation of these cells in the CNS becomes 
neurotoxic, and unlike other cells, once neurons are damaged or degenerated, they are unable to 
be repaired or regenerate in the CNS, resulting in chronic, progressive disease pathology (Qin et 
al., 2007b; Tansey and Goldberg, 2010).  Interestingly, the long-term use of anti-inflammatory 
drugs has been shown to reduce the occurrence of AD in human (Wang et al., 2015a).  While no 
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similar neuroprotective effect was detected in a PD case-control study by Samii et al. (2009), the 
authors suggest that future studies recruiting more patients with more background information 
may help demonstrate a significant association. 
 Microglia in the brain are heterogeneous with various functional phenotypes.  
Commonly, resting microglia are converted to an active state expressing either the M1 or M2 
phenotype (Orihuela et al., 2016).  Extracellular environments rich in proinflammatory triggers, 
such as cytokines (TNFα, interferon γ), certain neuronal signals (amyloid β, αSyn) or bacterial 
debris (LPS), activate resting microglia to the proinflammatory M1 phenotype.  On the other 
hand, IL-4 and IL-13 activates the anti-inflammatory M2 phenotype (Orihuela et al., 2016).  M1 
microglia elevate the extracellular release of inflammatory cytokines, nitric oxide, ROS and 
other neurotoxic substances (Ouchi et al., 2005; Tang and Le, 2016).  Importantly, postmortem 
PD brains exhibit an aberrant accumulation of reactive microglia (Doorn et al., 2014; Mcgeer et 
al., 1988b).  Microglia in the aged brain show a dystrophic, inflammatory morphology with 
elevated expression of inflammatory markers such as TNFα, IL-1β, IL-18 and IL-6 (Niraula et 
al., 2017).  Mice systemically treated with the inflammagen LPS show chronic activation of 
microglia in the nigrostriatum followed by the progressive loss of dopaminergic neurons (Qin et 
al., 2007b); MPTP, 6-OHDA and αSyn similarly activate microglia (Cicchetti et al., 2002; 
Czlonkowska et al., 1996; Zhang et al., 2005c).  Fyn kinase, PKCδ activation, and mitochondrial 
impairment have recently been shown by our group to induce microglia activation and lead to 
neurodegeneration in PD models (Gordon et al., 2016; Panicker et al., 2015; Sarkar et al., 2017).  
 Recently, it has been characterized that activated microglia secrete factors, including Il-
1α, TNF and C1q, which can activate astrocytes to an A1 phenotype (Liddelow et al., 2017). 
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Importantly, these A1 activated astrocytes were shown to be present in PD brains and other 
neurodegenerative diseases; and to be less able to promote survival, outgrowth, and 
synaptogenesis of neurons (Liddelow et al., 2017). Hence, role of neuroinflammation in PD 
needs to be better understood and considered for therapeutic interventions.  Later in this chapter 
we further discuss the mechanisms of neuroinflammation and animal models of relevance to PD, 
under the title “Neuroinflammation and PD” (see ‘section IV’). 
Hence, it is clear that multiple mechanisms mentioned here can contribute to PD 
pathogenesis and it is indeed important to analyze the aforementioned mechanisms in various 
classes of pesticides.  In following section we review the various pesticides, their risk for PD and 
proposed mechanisms of neurotoxicity. 
Epidemiological and Experimental Evidences Linking Pesticides Exposure and PD 
 Since the prevalence of inheritable or familial PD is estimated to be only 5% of PD cases, 
environmental factors likely play a major role in its onset and progression.  Epidemiological 
studies and toxicological animal studies indicate a positive link between exposure to 
environmental toxicants and neurodegeneration.  For example, exposure to heavy metals such as 
iron, lead, mercury, cadmium, arsenic and manganese, as well as metal-based nanoparticles, has 
been shown to increase the risk of PD through the neurotoxic accumulation of metals in the 
SNpc and by increasing oxidative stress-mediated apoptosis (Aboud et al., 2014; Afeseh Ngwa et 
al., 2009; Afeseh Ngwa et al., 2011; Di Lorenzo, 2015; Gorell et al., 1999; Harischandra et al., 
2015; Kanthasamy et al., 2012; Milatovic et al., 2009).  Similarly, agrochemicals have also been 
strongly associated with PD (Singh et al., 2015).  Pesticides such as rotenone and herbicides such 
as Paraquat are now used extensively in research to induce dopaminergic neurotoxicity in 
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animals and cell culture models (Caboni et al., 2004; Gonzalez-Polo et al., 2007; Nistico et al., 
2011; Radad et al., 2014; Rojo et al., 2007; Spivey, 2011; Tanner et al., 2011; Uversky, 2004).  
Here, we review the evidence linking pesticides and PD, including the potential mechanisms of 
toxicity for these compounds. 
Current epidemiological studies, rural living, farming and PD 
 While some epidemiological studies failed to link pesticide exposure and PD, others have 
presented strong evidence for a positive association between pesticides and PD (Baltazar et al., 
2014; Bellou et al., 2016; Brown et al., 2006; Li et al., 2005; Ritz et al., 2016).  The 
inconsistencies among the different investigations have been attributed to variations in study 
design, socioeconomic status, duration and level of exposure, study size, diagnostic criteria and 
statistical tools (Bellou et al., 2016; Kamel et al., 2014; Karami-Mohajeri and Abdollahi, 2011; 
Sparling et al., 2017).   
Rural residents engaged in farming and well water consumption are at an increased risk 
of developing PD (Goldman et al., 2017).  A significant numbers of farmers included in a US 
mortality study were identified to have PD as an underlying or contributing cause of death (Park 
et al., 2005).  Moreover, numerous case-control studies of farmers and other rural residents have 
reported increased odds ratios (OR) for PD (Baltazar et al., 2014; Brown et al., 2006; Karami-
Mohajeri and Abdollahi, 2011; Li et al., 2005; Priyadarshi et al., 2001; Ritz et al., 2016; Tanner 
et al., 2011).  One of the earliest epidemiological studies of early-onset PD found a positive 
association with insecticide exposure (OR=5.75, p<0.001), herbicide exposure (OR=3.22, 
p<0.05), past residency in fumigated houses (OR=5.25, p<0.05) and rural residency (OR=2.72, 
p<0.05) (Butterfield et al., 1993).  Likewise, a meta-analytic review of 31 case-control studies of 
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occupational pesticide exposure in the United Kingdom demonstrated ORs representing a 7X 
greater disease rate than the non-exposed control group (Brown et al., 2006).  A similar 
investigation in Italy also found an increased risk of PD among farmers (Zorzon et al., 2002).  
Priyadarshi et al. (2001) combined 19 studies from North America, Europe and Asia to produce 
an OR of 1.94 linking an elevated risk of PD with pesticide exposure history.   
In the latest revisions in policy, the U.S. Environment Protection Agency (EPA) requires 
increased information about and labor training for handling pesticides, posting notification signs 
for fields with recently applied pesticides, and ensuring that workers wear properly fitted 
protective accessories ((USEPA), 2015; United States Environmental Protection Agency 
(USEPA), 2016).  Although, EPA did not include PD as a major concern due to lack of sufficient 
information, a follow up meta-analysis study by Sparling and coworkers (2017) demonstrated  
that new Worker Protection Standard revisions will be beneficial for reducing PD cases and will 
have economic benefits for chronic diseases including PD.   
Specific pesticides with high risk of PD and related experimental models 
Despite strong experimental evidence linking specific agrochemicals to the risk of PD, 
sufficient epidemiological data remains lacking (Kamel, 2013).  Here, we review case-control 
studies and laboratory data implicating common pesticides and other agricultural chemicals in 
causing an elevated risk of PD.  Table 2 summarizes each pesticide with their risk and 





Table 2: Overview of agrochemicals, mechanisms of toxicity and risk of PD. 
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Originally extracted from plants of the pea family, rotenone (ROT) was traditionally used 
as an insecticide and piscicide until the late-20th century (Tanner et al., 2011).  First registered in 
the US in 1947, rotenone was widely used both in agriculture and in households until 2006, when 
its registration was withdrawn ((USEPA), 2007).  Due to its broad spectrum use under various 
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brand names, the epidemiological assessment of its disease risk is challenging.  A study 
performed by Dhillon et al. (2008) in eastern Texas revealed that the use of ROT for household 
gardening purposes increased the risk of PD (OR=10.9, p<0.05).  A case-control study of 84,000 
agriculture participants from North Carolina and Iowa showed a strong correlation (OR=2.5, 
p<0.05) between ROT exposure and PD (Tanner et al., 2011). 
Experimental evidence and mechanisms of neurotoxicity: 
Researchers employ ROT in one of the most widely used toxin-based animal models of 
PD pathology and phenotype (Coulom and Birman, 2004) because chronic exposure to ROT 
induces specific dopaminergic neurotoxicity (Cannon et al., 2009).  Due to its lipophilic 
structure, ROT readily penetrates in to the brain (Greenamyre et al., 2010) where it binds to and 
inhibits the mitochondrial complex I of the ETC, thereby interfering with ATP production and 
ultimately causing cell death (Cabeza-Arvelaiz and Schiestl, 2012; Choi et al., 2011; Sanders and 
Greenamyre, 2013).  ROT specifically blocks electron transfer from complex I to ubiquinone, 
halting the production of ATP via NADH (Sanders and Greenamyre, 2013; Sherer et al., 2003b).   
In both cell culture and animal models, ROT’s interruption of the ETC significantly increases 
free radicals, resulting in the accumulation of ROS and oxidative stress (Marella et al., 2008; 
Sanders and Greenamyre, 2013; Sherer et al., 2003b).  ROT treatment also depletes cellular 
antioxidant defense and increases lipid peroxidation in dopaminergic neurons (Chinta and 
Andersen, 2006; Xiong et al., 2012).  Treatment with natural antioxidants has been shown to 
reduce the dopaminergic neurodegeneration induced by ROT (Karuppagounder et al., 2013; 
Xiong et al., 2012).   
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Chronic systemic treatment of with ROT can lead to the accumulation of αSyn (Sherer et 
al., 2003c), including the deposition of ubiquitinated proteins in the SN (Cannon et al., 2009).  In 
another study, intravenously administered ROT treatment caused dopaminergic 
neurodegeneration in the midbrain and further mimicked PD pathology (Braak et al., 2004) by 
showing the accumulation of Lewy body-like structures encompassing αSyn aggregates in the 
gastrointestinal tract (Drolet et al., 2009; Ogawa et al., 2005).  ROT treatment has also been 
shown to modulate protein clearance mechanisms.  In this context, ROT-based models have been 
checked for the regulation of autophagic flux (Xiong et al., 2013).  A recent rat study showed 
that an 8-week treatment with 2 mg/kg/d ROT generated PD like behavioral deficits and the loss 
of nigrostriatal TH neurons, which was attributed to impaired autophagic flux (Wu et al., 2015).  
Using the PC12 dopaminergic in vitro model, Wu et al. (2015) further showed that ROT 
treatment leads to the accumulation of LC3-tagged autophagic vacuoles, the upregulation of p62, 
beclin 1 and LC3 II, and the loss of LAMP2 with reduced nuclear translocation of TFEB (a 
lysosomal biogenesis marker). Notably, rapamycin pretreatment can protect against ROT-
induced neurotoxicity by elevating autophagic flux (Filomeni et al., 2012; Pan et al., 2009a) 
Furthermore, rapamycin was shown to reduce oxidative stress and mitochondrial dysfunction in 
ROT-treated neuronal cells expressing the A53T mutant of αSyn (Choubey et al., 2011).  Pan et 
al. (2009b) reported that knocking down the ATG5 gene blocked rapamycin-mediated protection 
against ROT.  These findings strongly suggest that ROT impairs the autophagic flux in cells, 
which contributes to increased oxidative stress and reduced protein clearance, inducing cytotoxic 
effects.  The ROT induced-breakdown of clearance mechanisms also extends to microglia.  We 
showed that LPS-primed microglia accumulate LC3-positive puncta and show upregulation of 
LC3B II and p62 levels, with reduced TFEB expression, indicating dysfunctional ALS (Lawana 
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et al., 2017).  In our study, the LPS/ROT-mediated ALS malfunction in microglia was believed 
to contribute to the activation of NLRP3 inflammasomes and the microglial release of 
inflammatory markers (Lawana et al., 2017). 
Chronic ROT neurotoxicity also overactivates microglia.  Numerous studies show that 
chronic low dose exposure in rats leads to excessive microgliosis in nigrostriatal regions 
(Emmrich et al., 2013; Gao et al., 2002; Liang et al., 2015; Sherer et al., 2003a; Zhang et al., 
2014; Zhou et al., 2007).  ROT also activates the microglial NADPH oxidase, gp91phox 
(phagocyte oxidase), releasing excessive neurotoxic oxidative species (Gao et al., 2003; 
Uversky, 2004; Zhou et al., 2012).  Using a neuron-glia mixed culture, Emmirch et al. (2013) 
showed that while low levels of ROT failed to change mitochondrial integrity in microglia, it did 
increase microglial phagocytosis of DA neurons.  We recently showed that microglia pre-
exposed to LPS are extremely sensitive to ROT exposure, which leads to a dramatic release of 
inflammatory mediators (NO, IL-1β, IL-18, TNFα, NLRP3, Casp 1, etc.) via c-Abl kinase-
dependent activation of the NLRP3 inflammasome complex (Lawana et al., 2017).    
Besides interfering with protein clearance, ROT exposure also reduces the neuronal 
expression of parkin and DJ-1, which are responsible for mitochondrial clearance through 
mitophagy (Gao et al., 2012; Mili et al., 2012).  Interestingly, Chu et al. (2013) showed that a 
low dose of ROT can induce mitophagy by externalization of cardiolipin from the mitochondrial 
inner membrane.  Using a different approach to attenuate ROT’s dose effect, Di Rita et al. (2018) 
recently showed that overexpressing the mitochondrial fusion mediator AMBRA1-ActA in ROT-
treated SH-SY5Y neuronal cells upregulated mitophagy and reduced oxidative stress.  These 
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findings suggest that ROT’s effect on mitophagy, either stimulatory or inhibitory, depends on its 
dose and duration of exposure.  
Its mitochondrial toxicity is one mechanism of action that ROT shares with MPTP as 
Parkinsonian toxins.  ROT exposure alters both mitochondrial dynamics and biogenesis as 
reported by Peng et al. (2017).  In their in vitro studies, ROT downregulated the cellular level of 
PGC1α, a mitochondrial biogenesis marker required for regulating mitochondrial fission/fusion.  
In contrast, overexpressing PGC1α, inhibiting mitochondrial fission or stimulating mitochondrial 
fusion protected the cells against ROT-mediated neurotoxicity.  In another study, Peng et al. 
(2016b) demonstrate that resveratrol, a natural antioxidant, reversed ROT-induced cell death by 
recovering the loss of Drp1, Fis1, OPA, MFN2 (regulators of mitochondrial fission/fusion) and 
PGC1α/TFAM (regulators of mitochondrial biogenesis) in the rat SN and PC12 dopaminergic 
cells. 
Multiple studies from Greenamyre’s group and others demonstrate that ROT indeed 
depletes ATP production and causes mitochondrial damage in rats as well as in in vitro 
dopaminergic neurons (Cannon et al., 2009; Inden et al., 2007; Newhouse et al., 2004).  Arnold 
et al. (2011) demonstrate that ROT changes mitochondrial morphology by first inducing fusion 
as an early compensatory response, followed by damage-inducing fission.  More recently, the 
inhibition of fission was shown to reduce ROT-induced neurotoxicity in primary neurons 
(Imbeault et al., 2014; Peng et al., 2016a). 
ROT also modulates ER stress in PD models (Goswami et al., 2016a; Tong et al., 2016).  
Wu et al. (2013) demonstrated that treating Lewis rats with ROT increased the expression of 
GRP78, ATF4 and CHOP, well-established markers for ER stress, in the ventral midbrain, while 
32 
 
inhibiting ER stress in the ROT-treated rats with an angiotensin II receptor blocker reduced DA 
neuronal loss in the SN of the midbrain.  ROT-induced cell death depends on ER stress-mediated 
ROS generation and calcium deregulation causing the activation of nuclear factor κB (NF-κB) 
(Pahl and Baeuerle, 1996).  Another study demonstrated that ROT-mediated ER stress in human 
neuroblastoma SK-N-MC cells induces phosphorylation of the UPR marker PERK, which then 
phosphorylates the eIF2α transcription factor, resulting in neuronal death (Chen et al., 2008c).  
An inhibitor of eIF2α-mediated ER stress, salubrinal, can dramatically reduce ROT-induced cell 
death by reducing the activation of caspase-12 and -3, as demonstrated by Goswami et al. 
(2016a; 2016b), both in vitro in neuro-2A cells and in vivo in TH-positive neurons of the rat 
midbrain.  When ROT-treated mice are co-treated with 4-phenylbutyrate, a partial ER stress 
inhibitor and chemical chaperon that reverses protein aggregation, not only are aggregated αSyn 
deposits reduced, but so are GRP78 upregulation and caspase-12 activation (Inden et al., 2007).  
In another study, administering a peroxisome proliferator-activated receptor (PPAR)-β/δ agonist 
also reduced ER stress and dopaminergic neurodegeneration in the ROT rat model (Tong et al., 
2016).  These findings strongly suggest that ROT-induced mitochondrial dysfunction and 
oxidative stress contribute to ER stress and subsequent neuronal apoptosis.  
 ROT has been also shown to modulate several key protein kinases linked to 
dopaminergic neurotoxicity.  Activation of c-Jun-N-terminal protein kinase (JNK) and its 
translocation to mitochondria occurs most commonly post-ROT treatment (Chen et al., 2008b; 
Jang et al., 2015; Klintworth et al., 2007; Newhouse et al., 2004).  ROT-induced activation of 
JNK inhibits VMAT2 activity blocking the synaptic release of DA, which increases cytosolic 
DA and ROS levels (Choi et al., 2015).  Activation of MAP kinases, such as p38 and 
extracellular signal-regulated kinase ½ (ERK1/2), has also been demonstrated in ROT models 
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(Hsuan et al., 2006; Junn and Mouradian, 2001; Newhouse et al., 2004).  Rifampicin inhibition 
of GSK3β phosphorylation was shown by Wu et al. (2018) to alleviate ROT-mediated 
neurotoxicity.   
The available evidence shows that ROT triggers mitochondrial ETC disruptions and ROS 
accumulation, which precedes the deregulation of mitochondrial kinetics, elevated ER stress, 
redox-sensitive kinase activation, impaired proteostasis, and the accumulation of αSyn deposits 
and other pro-apoptotic and cytotoxic factors, causing aberrant loss of dopaminergic neurons.  
Additionally, ROT was shown both in vivo and in vitro to activate microglia, which also 
magnifies neuron loss.   Ultimately, all these events lead to PD pathology. Thus, based on its 
suite of pathological markers and behavioral phenotypes, the ROT model of PD is regarded as 
one of the more highly reproducible and translatable experimental toxin-based PD models. 
Paraquat 
Epidemiological Evidences: 
One of the most commonly used herbicides, Paraquat (N, N’-dimethyl-4-4-4’-
bypiridiunium or methyl viologen, PQT), is a pre- and post-emergence crop desiccant and 
defoliant.  PQT causes toxicity in plants by forming a stable free radical, which interferes with 
photosynthesis (Bus et al., 1974).  In 2007, PQT use was banned by the European Union and 24 
other countries due to its toxicity to humans and other animals (Felton-Taylor, 2012; Gunnell et 
al., 2017).  PQT accumulates in the brain after crossing the blood brain barrier via the neutral 
amino acid transporter (McCormack and Di Monte, 2003).  Epidemiologically, at least five case-
control studies have so far demonstrated the effect of PQT on the risk of developing PD (Gatto et 
al., 2009; Hertzman et al., 1990; Kamel et al., 2007; Liou et al., 1997; Tanner et al., 2011; 
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Tanner et al., 2009).  Among these studies, Tanner et al. reported a strong correlation (OR=2.5) 
between PQT exposure and PD among agricultural residents, while Gatto et al found a slightly 
lower association (OR=1.31) among rural residents in central California.  Another study showed 
that wearing personal protective equipment (PPE, e.g., gloves and masks) while handling PQT 
offered no significant protection against the risk for PD (Furlong et al., 2015).  Furthermore, 
people lacking the glutathione-S-transferase T1 (GSTT1) homolog are at even greater risk of PD 
with PQT (OR>11) (Goldman et al., 2012).  The PD risk is further potentiated by exposure to 
PQT in combination with one or more other pesticides, such as Maneb (Costello et al., 2009).   
Experimental evidence and mechanisms of neurotoxicity: 
Although PQT is known to cause dopaminergic neurotoxicity in various models, its exact 
mechanism of toxicity is still unclear.  Given its structural similarity to MPTP, PQT was 
believed to act by similar mechanisms.  However, unlike MPP+ (active metabolite of MPTP), 
PQT is not a substrate for the dopamine transporter (DAT) and does not block mitochondrial 
complex I at low concentrations (Richardson et al., 2005).  Several mechanisms have been 
proposed identifying potential pathways of PQT-induced oxidative stress, mitochondrial 
dysfunction and dopaminergic neurodegeneration.  One of the mechanisms by which PQT 
intensifies oxidative stress in the brain occurs when PQT gets reduced by the microglial NADPH 
oxidase enzyme to an unstable free radical molecule, which in turn donates its extra electron to 
an oxygen molecule to stabilize the PQT compound (Wu et al., 2005).  PQT treatment also 
increases oxidative stress through the production of DA-associated oxidative radicals (Castello et 
al., 2007).  ROS generation additionally arises from the accumulation of PQT within 
mitochondria (Cocheme and Murphy, 2008), where it inhibits mitochondrial complex I and III 
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(Castello et al., 2007; Cocheme and Murphy, 2008), causing dopaminergic neurodegeneration 
(Jones and Vale, 2000; Yumino et al., 2002).  PQT was shown to induce oxidative stress and 
mitochondrial dysfunction via DJ-1, a Parkinsonian gene involved in the antioxidant response 
and mitochondrial complex I regulation (Kwon et al., 2011). In that study, PQT treatment of DJ-
1 knockout SN4741 neuronal cells failed to increase oxidative stress and apoptosis relative to 
PQT-treated wild-type cells.  PQT-mediated toxicity was also significantly attenuated in neurons 
lacking aconitase, one of the enzyme involved in tricarboxylic acid (TCA) cycle (Cantu et al., 
2011).  Co-treatment of PQT with maneb produced a time-dependent elevation in nigral levels of 
glutathione-s-transferase, catalase and lipid peroxidation markers at 3, 6 and 9 weeks (Patel et 
al., 2006).  However, pre-exposure to SOD and catalase mimetic antioxidants prohibited any 
PQT-mediated dopaminergic neurodegeneration (Peng et al., 2004; Peng et al., 2005).  Similarly, 
the glutathione precursor, N-acetyl cysteine (NAC), can also reverse the PQT-mediated oxidative 
stress and dopaminergic toxicity (Ortiz et al., 2016; Peng et al., 2004).  Lastly, PQT-mediated 
oxidative stress has been linked with the proapoptotic JNK signaling (Klintworth et al., 2007; 
Niso-Santano et al., 2006; Peng et al., 2004).  A recent study showed that PQT dose-dependently 
alters mitochondrial bioenergetics in zebrafish embryos (Wang et al., 2018).  PQT also reduces 
nigral levels of Mfn2 and other mitochondrial fusion/fission markers and morphologically alters 
primary neuronal mitochondria, while Mfn2 overexpression protects against PQT toxicity (Zhao 
et al., 2017).  Collectively, these findings strongly indicate the involvement of oxidative stress 
and mitochondrial dysfunction in PQT-mediated dopaminergic cell death.   
The aggregation of αSyn deposits in the SN of PQT-treated mice has been extensively 
reported (Mak et al., 2010; Manning-Bog et al., 2002; Manning-Bog et al., 2003; Mcgeer et al., 
1988b; Mitra et al., 2011; Uversky, 2004).  Manning-Bog et al. (2002) reported that treating mice 
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with 10 mg/kg PQT once per week for 3 weeks heightened oxidative stress, which increased the 
expression and aggregation of αSyn in the SN and frontal cortex.  Later, NADPH oxidase-
mediated ROS generation was shown to induce αSyn aggregation using in vivo and in vitro 
models of PQT (Cristovao et al., 2012).  Interestingly, Nuber et al. (2008) observed increases in 
the presence of αSyn aggregates and DA neurodegeneration in αSyn-overexpressing animals 
treated with PQT, whereas αSyn null mice did not experience the loss of DA neurons after PQT 
treatment. 
PQT treatment also interferes with the two key mechanisms of protein clearance: UPS 
and ALS.   Recent studies show that PQT reduces 26S proteasome activity, without changing 
20S/19S proteasomal activity (Wills et al., 2012), while increasing activity in the Nrf2 (nuclear 
factor erythroid 2-related factor 2)-ARE (antioxidant response element) pathway as a cell 
defense mechanism (Izumi et al., 2015).  In contrast, Yang and Tiffany-Castiglioni (2007) 
claimed that PQT neurotoxicity involves disrupting 19S proteasomal activity in SH-SY5Y 
neuronal cells.  PQT has also been shown to interrupt the ALS in human SH-SY5Y cells as 
indicated by the accumulation of AVs (Gonzalez-Polo et al., 2007), and that inhibiting 
autophagic flux by 3-methyladenine (3-MA) or overexpressing dominant negative Atg5 
exacerbates the PQT-mediated neurotoxicity (Garcia-Garcia et al., 2013; Gonzalez-Polo et al., 
2007).  Furthermore, Mak et al. (2010) showed that PQT treatment increases both the activity of 
lysosomes as well as their amount of αSyn content.  Similary, in the Wills et al. (2012) study, 
PQT treatment stimulated αSyn accumulation by upregulating the mammalian target of 
rapamycin (mTOR) and negatively modulating autophagy.  PQT also stimulates mitophagy in 
neurons.  Using a fly model of PQT, Bingol et al. (2014) showed increased activity of UPS30, a 
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mitochondrial deubiquitinase and inhibitor of PINK1/parkin-dependent mitophagy, which led to 
the accumulation of damaged mitochondria and subsequent neurotoxicity.   
PQT also induces ER stress in various experimental models of dopaminergic neurons 
(Chen et al., 2012; Omura et al., 2013; Yang et al., 2009).  It can upregulate UPR and ER stress, 
as indicated by increased phosphorylation of IRE1a and eIF2a, which led to downstream 
activation of apoptosis signal-regulating kinase 1 (ASK1), thereby inducing autophagy (Niso-
Santano et al., 2011).  Antioxidant treatment can reduce PQT-induced oxidative stress, 
mitochondrial dysfunction and ER stress, as was shown in PC12 neuronal cells receiving the 
synthetic antioxidant L-F001 (Shen et al., 2015).  Li et al. (2015) showed that blocking CHOP 
and GRP78 upregulation by pretreating rat’s with ulinastatin, a protease inhibitor and lysosomal 
stabilizer, protected the hippocampus against PQT toxicity.  Collectively, these studies suggest 
that oxidative stress plays a crucial role in modulating mitochondrial homeostasis, proteostasis, 
αSyn aggregation and ER stress in the PQT model of PD. 
Besides getting converted to a toxic radical by microglial NADPH oxidases on the 
microglial membrane, as previously mentioned, PQT can also activate microglia, thereby further 
contributing to dopaminergic toxicity (Wu et al., 2005).  Rats administered with a PQT/maneb 
cocktail show increased microgliosis in the SNpc (Saint-Pierre et al., 2006), which peaked at 4 
weeks, followed by a loss of the majority of TH-positive neurons between weeks 4-6, indicating 
the neurotoxicity of sustained microglia activation post PQT/maneb exposure (Saint-Pierre et al., 
2006); similar findings were reported by Hutson et al. (2011).  Surprisingly, Smeyne et al. (2016) 
report that unlike MPTP, PQT failed to increase the accumulation of activated microglia and the 





Organochlorine (OC) pesticides, such as dichlorodiphenyltrichloroethane (DDT), aldrin, 
dieldrin, endosulfan, hexachlorobenzene, polychlorinated biphenyls (PCBs), heptachlor, lindane 
and chlordane, are widely used around the world due to their affordability and effectiveness 
(Corrigan et al., 2000).  Having a persistent chemical structure, OCs are difficult to degrade and 
thus bioaccumulate in different organs in their parent forms (Corrigan et al., 2000; Fleming et al., 
1994).  Fleming et al.’s (1994) analysis of postmortem PD and control brains found detectable 
levels of DDT and dieldrin only in neurodegenerative brains and was one of the first reports 
linking OCs and PD.  Similarly, Corrigan et al. Corrigan et al. (2000) showed that the SN of PD 
brains had up to 10-fold higher levels of dieldrin (p<0.04), lindane (p<0.04) and PCBs (p<0.01).  
More recently, Weisskopf et al. (2010) linked higher plasma levels of dieldrin with a greater risk 
of PD (OR=1.95, p=0.003), while Tanner et al. (2011) linked men’s lifetime use of dieldrin with 
a borderline PD risk (OR=1.8).  Additionally, multiple case-control studies show that OC 
exposure significantly increases the risk of developing PD (OR ≥ 2) (Elbaz and Moisan, 2009; 
Hancock et al., 2008; Narayan et al., 2017; Seidler et al., 1996).  
Experimental evidence and mechanisms of neurotoxicity: 
OCs are known to induce the loss of DAergic neurons and create PD-like phenotypes in 
rodent and zebrafish experimental models (Ton et al., 2006; Wilson et al., 2014).  Our research 
group has previously shown that dieldrin treatment can cause a time and dose-dependent increase 
in ROS generation in dopaminergic neuronal cells (Kanthasamy et al., 2008; Kitazawa et al., 
2003).  Pretreating neurons with SOD enzyme or with the SOD mimetic MnTBAP has been 
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shown to dramatically reduce dieldrin-mediated dopaminergic toxicity (Kitazawa et al., 2001).  
In another study, combining dieldrin with lindane potentiated oxidative stress and neurotoxicity 
in N27 dopaminergic neurons, while pretreatment with the antioxidant NAC reduced the 
oxidative stress, mitochondrial damage and cell death (Sharma et al., 2010). Chronic dieldrin or 
heptachlor treatments in mice has been shown to cause dopaminergic neurodegeneration by 
inducing an oxidative stress-mediated decrease in the expression and function of vesicular 
monoamine transporter 2 (VMAT2) (Hatcher et al., 2007; Miller et al., 1999a; Miller et al., 
1999b).  In addition, dieldrin increases the activity of redox sensitive kinases, including Src, Fyn 
and PKCδ kinases, thereby contributing to apoptotic mechanisms in neurons (Kitazawa et al., 
2003; Saminathan et al., 2011).  The activation and proteolytic cleavage of PKCδ has been 
linked to mitochondrial damage and proapoptotic activation of caspase 3, which in turn cleaves 
more PKCδ (Kitazawa et al., 2003).  Dieldrin can also activate the JNK MAP kinase (Chun et 
al., 2001).  Dieldrin-induced ROS generation has been implicated in dopamine depletion (Heinz 
et al., 1980; Kanthasamy et al., 2005; Kitazawa et al., 2003) as well as in altering dopamine 
release and reuptake via modulating VMAT2/DAT activity in primary mesencephalic neurons 
(Sanchez-Ramos et al., 1998). 
Our research group has not only demonstrated that overexpressing Bcl-2 protects against 
dieldrin-mediated PARP cleavage, caspase 3 activation, and DNA fragmentation (Kitazawa et 
al., 2004), we also revealed that dieldrin perturbs epigenetic modifications in neurons (Kitazawa 
et al., 2001; Song et al., 2010).  Specifically, dieldrin induced aberrant hyperacetylation of 
histones H3 and H4 in mesencephalic neuronal cultures and in the SN and striatum of mice 
treated with dieldrin (5 mg/kg) for 30 days.  We further demonstrated that histone acetylation 
was modulated by upregulation of CREB-binding protein (CBP), a transcriptional co-activator 
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with intrinsic HAT activity, which causes apoptotic death in dopaminergic neuronal cells.  
Inhibiting CBP abolished the dieldrin-induced histone acetylation, PKCδ/caspase 3 activation 
and DNA fragmentation in dopaminergic neurons (Song et al., 2010).   
Our group also showed that treating human αSyn-overexpressing dopaminergic N27 
neuronal cells with dieldrin causes UPS dysfunction by reducing 20S proteasomal activity and 
accumulating the heavy molecular weight ubiquitinated protein, leading to the accumulation of 
αSyn aggregates (Sun et al., 2005).  In another study, we demonstrated that a low-dose (10 µM) 
dieldrin treatment upregulated autophagy as indicated by the increased expression of LC3BII and 
beclin 1.  Conversely, higher concentrations (>50 μM) of dieldrin reduced the aforementioned 
markers, indicating a reduction in cellular autophagy, and caused aberrant cell death.  The 
evidence presented thus far suggests that low-dose dieldrin activates ALS as a compensatory 
mechanism to rescue neurons from toxicity; however, higher concentrations overwhelm neuronal 
survival mechanisms (Singh et al., 2015).  Furthermore, we showed that dieldrin increased the 
amount of LC3-stained puncta in dopaminergic N27 cells, which colocalized with ubiquitin-
stained aggregates (Singh et al., 2015).  Likewise, DDT also promotes the formation of vesicular 
buds that can be secreted from cells (Rossi et al., 2007).  A recent mini-review indicates that 
DDT exposure stimulates exosome formation and cell-to-cell transmission of αSyn (Rossi et al., 
2017).  These findings provide some insight into potential mechanisms of OCs’ effects on 
protein clearance mechanisms.  
When microglia are exposed to OCs, such as a combined dose of lindane and dieldrin, 
they show increased ROS generation via activation of the NADPH oxidase pathway (Mao and 
Liu, 2008).  Similarly, in another experiment, dieldrin caused a dose- and time-dependent 
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increase in microglial ROS levels without affecting astrocytes.  Here, Mao et al (2007) showed 
that genetic knockdown or pharmacological inhibition of NADPH oxidase reduced the dieldrin-
induced ROS generation in immortalized microglial cells as well as in primary mouse microglia.  
But due to lack of sufficient evidence, it remains unclear if OCs lead to neurodegeneration by 
promoting inflammation and the release of inflammatory cytokines. 
Organophosphates and Carbamates 
Epidemiological Evidence: 
Exposure to organophosphate (OP) pesticides has also been shown to impact the 
neurodegeneration in humans (Wang et al., 2014).  OPs such as chlorpyrifos (CPF), dichlorvos 
(DCV), parathion, malathion, etc., exert their effect by inhibiting the acetylcholinesterase (AchE) 
enzyme at neuromuscular synapse, paralyzing the insect, leading to death (Bajgar, 2004).  A 
study performed in central California’s rural population suggests a link between exposure to OPs 
(diazepam or CPF) and PD, in individuals with common genetic variant in Paraoxonase 1 
(PON1) gene (OR=4.4) (Manthripragada et al., 2010).  Several other studies show 
inconsistencies in demonstrating stronger association due to lack of significant N’s.  For 
example, while Firestone et al found a large increase in risk of PD among parathion-exposed 
participants (OR = 8.1; number exposed = 6) but not diazinon (OR = 1.04; number exposed = 15) 
(Firestone et al., 2005); Kamel et al noted no associations for organophosphate pesticides, 
including chlorpyrifos (OR = 0.9), diazinon (OR = 0.9), and parathion (OR = 1.1) (Kamel et al., 
2007); and Wang et al also failed to provide a significant correlationship, however indicated a 
possible role of OPs in PD etiology (Wang et al., 2014).  Conversely, other recent 
epidemiological studies show a positive relationship between OP exposure and risk for PD 
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(Freire and Koifman, 2012; Narayan et al., 2017).  However, there is lack of stronger case-
control studies to further strengthen the association of OP and PD (Baltazar et al., 2014).  Hence, 
more detailed epidemiological analysis is needed to understand the risk of exposure of an 
individual class and particular pesticide to PD. 
Experimental evidences and mechanisms of neurotoxicity: 
Prenatal exposure of CPF has been recently linked with tremors in children of 9-14 years 
age (Rauh et al., 2015).  Additionally, some recent studies shows that prenatal exposure of CPF 
in rodents caused significant reduction in DA neurotransmitter levels in different parts of the 
brain (Chen et al., 2011b; Slotkin et al., 2001).  Even more, neonatal rats exposed to CPF showed 
marked loss of dopaminergic neurons in SN at young age (Zhang et al., 2015).  Interestingly, 
prenatal exposure of CPF has been recently linked with tremors in children of 9-14 years age 
(Rauh et al., 2015).  In vitro models of dopaminergic neurons have also been shown to be 
susceptible to CPF exposure (Carlson and Ehrich, 1999; Dai et al., 2015; Park et al., 2013).  Our 
group studied that chronic exposure of CPF to adolescence rats leads to locomotor behavioral 
deficits and nigral TH loss (Lawana et al., 2018).  Similarly, DCV exposure to rats has reported 
to develop behavioral deficits which were coinciding with elevated dopaminergic 
neurodegeneration (Binukumar et al., 2010).  
Although the exact mechanism of OP-mediated dopaminergic neurotoxicity is unclear, 
several recent evidenced suggest the role of oxidative stress as a primary mechanism of OP 
neurotoxicity (Binukumar et al., 2010; Wani et al., 2014).  For example, exposure to DCV has 
been shown to increase the ROS levels in dopaminergic neuronal PC12 cells (Wani et al., 2014) 
as well as in nigrostriatal region of rat brain (Binukumar et al., 2010).  Likewise, CPF also 
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increases oxidative stress in various experimental PD models (Ki et al., 2013; Lee et al., 2014).  
The generation of ROS post OP exposure is further linked with mitochondrial degeneration and 
ATP depletion (Binukumar et al., 2011; Lee et al., 2012; Wani et al., 2014).  In this context, rats 
treated with DCV also demonstrate activation of apoptotic caspase-cascade, PARP1 cleavage 
and nuclear translocation of apoptosis-inducing factor (AIF) (Wani et al., 2014).  Even more, 
DCV treatment showed disruption in cell cycle via p53 pathway in PC12 neuronal cells, causing 
cytosolic release of cytochrome c, mitochondrial accumulation of Bax and DNA fragmentation 
(Wani et al., 2017).  Exposure to CPF has been shown to upregulate protein kinase A (PKA) 
activity, dysregulate cdk5 activity and induces hyperphosphorylation of tau in mice striatum 
(Torres-Altoro et al., 2011).  We recently demonstrated the central role of STAT1 and c-
Abl/PKCδ signaling axis in OP-mediated dopaminergic toxicity.  In this conext, we 
demonstrated that STAT1 KD or a mitochondrial antioxidant cotreatment markedly reduced the 
CPF mediated-dopaminergic toxicity, via attenuating the increased expression of pro-apoptotic 
proteins (such as increased caspase-cascade, Bax upregulation, PARP cleavage, activation of 
PKCδ) and loss of anti-apoptotic proteins (such as Bcl-2) (Lawana et al., 2018), leading to 
abrogation of neurotoxicity.  In another study, we demonstrated that c-Abl inhibition (via RNAi 
KD or pharmacological inhibition) reduced the DCV-mediated mitochondrial impairment and 
activation of apoptogenic pathways in dopaminergic neuronal cells (unpublished). 
Interestingly, chronic DCV treatment to rats results in aggregation of αSyn deposits in 
SN along with ubiquitinated protein accumulation (Binukumar et al., 2010).  Likewise, DCV was 
also found to reduce the 20S proteasomal activity in SH-SY5Y dopaminergic neurons 
(unpublished).  Even more, DCV exposure also increased the nigral microgliosis in rats 
(Binukumar et al., 2010).  These evidences suggest that OP can mimic the parkinsonian toxicants 
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and promote the dopaminergic neurodegeneration.  Further research will provide better 
understanding of that OP-mediated dopaminergic toxicity and PD relevance. 
Concluding Remarks 
For decades, pesticides exposure to humans has been investigated for many chronic 
disease conditions, and increasing number of epidemiological data draws a serious concern of 
pesticides effect on long-term health effects.  In this context, although, there is some 
inconsistency with case-control studies, rising numbers of evidences suggest positive association 
between long-tern exposure to low levels of pesticide (and other agrochemicals) with cancer, 
developmental defects (especially neurodevelopment impairments), reproductive disruptions and 
neurodegenerative disease (including AD and PD).  Interestingly, various classes of pesticides 
have been proposed to carry risk for PD, more than any other health defects (Cicchetti et al., 
2009; Drechsel and Patel, 2008; Moretto and Colosio, 2011).  With the limited knowledge of 
familial history, genetic predisposition, dietary and exercise habits, and exposure to mixture of 
agrochemicals, the current literature limits the clear understanding of pesticide-mediated PD 
pathogenesis. 
Thus, experimental analysis of pesticide’s impact on dopaminergic neurons and PD 
progression can provide better understanding of mechanisms of toxicity and can aid a tool to 
develop therapeutic interventions to delay or halt the disease progression.  For example, 
pesticides such as ROT, PQT and dieldrin have been shown to reproduce several of key features 
of PD in animal models including, loss of TH+ neurons, DA reduction, accumulation of protein 
aggregated, and impaired proteastasis.  Investigations using transgenic models, genetic 
manipulations and pharmacological interventions reveal that mitochondrial damage and 
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oxidative stress are the prime contributors for pesticide toxicity in PD.  Likewise, postmortem 
analysis of human patient brains demonstrate mitochondrial damage and accumulation of 
oxidative stress byproducts in nigrostriatal regions further strengthening an essential role of 
mitochondrial dysfunction during dopaminergic neurodegeneration and disease pathogenesis 
(Chinta and Andersen, 2008; Ganguly et al., 2017; Subramaniam and Chesselet, 2013).  Next, 
oxidative stress-dependent impairments in UPS and ALS are other two crucial pathways 
contributing to aggregation of αSyn deposits and ubiquitin-tagged proteins resulting in neuronal 
death post pesticide treatment.  In accordance, the presence of αSyn aggregates along with 
oxidatively-damaged 
macromolecules in human 
PD brains (Le, 2014; 
Sanders and Greenamyre, 
2013) further draw 
relevance between 
experimental data and 
human disease pathology.  
Lastly, several of the 
pesticide also activates the 
microglial cells stating a 
striking resemblance to 
human PD brains 
(Koshimori et al., 2015; 
Mcgeer et al., 1988b). 
Figure 1: Schematic presentation of proposed or established 
molecular mechanisms and targets for various pesticides, 
promoting dopaminergic neurotoxicity.  ALS- 
autophagolysosomal system; DA- dopamine; DCV- dichlorvos; OCs- 
organochlorines; OPs- organophosphates; PQT- paraquat;  ROS- 
reactive oxygen species; ROT- rotenone; UPS- ubiquitin- proteasome 
system; VMAT2- Vesicular monoamine transporter 2.  
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Collectively, results from experimental models suggest that exposure to one or an 
amalgamation of several agrochemicals can indeed modulate the molecular mechanisms with can 
induce the pathways leading to loss of dopaminergic neurons and can generate an intriguing 
comparability to PD pathogenesis.  This review presents a collective summary of mechanisms of 
PD pathogenesis, human etiological data related to pesticide risk, and experimental evidences 
demonstrating the molecular targets of pesticides.  It is indicative that pesticides indeed alter 
many pathways and can act as parkinsonian toxicants.  However, future studies are needed to 
understand (i) effect of pesticides on other regions of brain and body (including gut) to 
demonstrate the pertinence to non-motor symptoms of PD; (ii) extrapolation of experimental data 
to human relevance (for example, dose, time and route of exposure); (iii) understanding the 
potentiation effects of combination of pesticides from different classes; and (iv) susceptibility of 
various genetic predisposition to pesticide-mediated neurotoxicity.  This understanding will be 
essential for developing targeted therapeutic interventions and safer pesticides. 
Neuroinflammation and PD 
The inflammatory response that normally protects the body against invading pathogens 
and removes dead or dying cell debris can also produce potentially toxic factors that can elicit 
significant pathology if the inflammation is not tightly regulated (Glass et al., 2010).  Persistent 
neuroinflammation is an example of the latter process gone awry within the central nervous 
system.  Such a sustained, heightened neuroinflammatory response has been associated with 
many neurodegenerative disorders, such as Alzheimer’s disease (AD), Huntington’s disease, 
Amyotrophic lateral sclerosis, and Parkinson’s disease (PD) (Block, 2014; Boche and Nicoll, 
2013; Schain and Kreisl, 2017).  Persistent hyperactivation of the glial cells at the site of 
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neurodegeneration is a hallmark of neuroinflammation (Mcgeer et al., 1988b).  The activation 
state of glial cells is defined by their morphology and by the proliferation, migration and 
expression of immune modulatory molecules.  In many of these neurodegenerative diseases, the 
hyperactivation is mediated by aggregated, misfolded proteins or peptides (Block, 2014; Niraula 
et al., 2017).  Until recently, it was thought that the major role of reactive gliosis associated with 
neurodegeneration was believed to be phagocytic clearance of dead and dying neurons, a process 
that was generally thought to maintain homeostasis within the central nervous system (CNS).  
Indeed, microglia have been shown to play a role in establishing synapses within the developing 
brain, and produce numerous trophic factors that contribute to general neuronal health (Aarum et 
al., 2003; Walton et al., 2006).  Microglia are also actively involved in the neuroimmune 
response to infection within the CNS (Lo et al., 2009; Muth et al., 2017; Qin et al., 2015; Rawat 
and Spector, 2017; Wei et al., 2015; Wilkinson et al., 2010).  In most cases after acute brain 
injury or infection, the neuroinflammatory response subsides after clearance of the infection.  
But in neurodegenerative disorders such as PD, neuroinflammatory responses are chronic and 
progressive. This has been shown in many PD animal models such as LPS, 6-OHDA, MPTP, as 
well as post-mortem in PD patients (Imamura et al., 2003; Panicker et al., 2015). 
Role of Microglia in CNS 
Contrary to popular belief, microglial cells do not develop from bone marrow-derived 
hematopoietic stem cells (Schulz et al., 2012).  Studies carried out with parabiotic mice, where 
surgically connected mice share a common circulatory system, suggested that postnatal 
microglial cells are maintained in the CNS independently of monocytes (Leavy, 2010).  
Specifically, microglia stem from primitive myeloid progenitors that arise from the yolk sac 
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(Ginhoux and Prinz, 2015).  About 10-15% of all brain cells are microglia, whose density varies 
regionally within the brain.  For example, the hippocampus and ventral brain, including the SN, 
show higher concentrations of microglia (Yang et al., 2013).  In a healthy adult brain, microglia 
are in their ‘resting’ state, which is normally identified by ramified morphology.  These ‘resting’ 
microglia secrete anti-inflammatory and neurotrophic factors that promote survival and plasticity 
(Carson, 2002).  Many recent studies show that microglia are continuously surveilling their 
external environment for any kind of neuronal injury (Nimmerjahn et al., 2005).  Once microglia 
find a potentially noxious agent, they rapidly transform to an ‘activated’ state while 
simultaneously upregulating cytokine and chemokine receptors, as well as other various cell 
surface proteins.  The transcription of response genes occurs rapidly in activated microglia, 
which produce many factors that alter the environment at the site of injury or cell death (Orihuela 
et al., 2016).  
To maintain neuronal survival and restore homeostasis, microglia release anti-
inflammatory factors such as BDNF, GDNF, IL-10, and TGFβ1, which can prevent neuronal cell 
death and affect differentiation of existing neuronal progenitor cells (Nimmerjahn et al., 2005; 
Orihuela et al., 2016).  They have also been shown to protect neurons from excitotoxicity 
(Eljaschewitsch et al., 2006).  When astrocytic glutamate uptake is impaired, microglia 
upregulate GLT-1, a glutamate uptake protein (Matos et al., 2008; Persson et al., 2005).  Aside 
from these protective roles, microglia also clear cellular debris from the site of injury via 
phagocytosis (Neumann et al., 2009).  They can also aid in synapse removal at a site of injury, 
followed by synapse regeneration (Kettenmann et al., 2013).  These combined roles promote the 
neurogenesis and migration of progenitor cells.  
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Role of Astrocytes in CNS 
Much like microglia, astrocytes respond to injury or toxic stimuli, such as infection, 
ischemia, or neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease.  
Astrocytes are have been reported to be the largest population of glial cells in the CNS, while 
microglia are estimated to make up only about 10-15% of the total cells. Seeing that astrocytes 
make up a large percentage of the glial cells in the brain, it is thought that astrocytes could 
potentially important role in the CNS and could be a therapeutic option, especially for 
neurodegenerative diseases.  
Astrocytes interact with neurons with intricate neuron-glia crosstalk. They support and 
protect neurons via many pathways, for example, astroctyes protect neurons from glutamate 
toxicity, help maintain the blood brain barrier, and produce neurotrophic factors and cytokines. 
Astrocytes are arranged mostly evenly throughout the brain and control both neuronal activity 
and cerebral blood flow by wrapping the neuronal synapses along the brain vasculature.   
The activation of astrocytes is characterized by both molecular and morphological 
changes. Increased expression of glial fibrillary acidic protein, vimentin and nestin are hallmarks 
of astrocyte activation. Comparable to microglia, activated astrocyte, especially when induced by 
an inflammatory stimuli, can cause astrocytes to release higher levels of pro-inflammatory 
cytokines such as IL-1β and TNF-α, along with ROS production, therefore contributing to a 
persistent inflammatory response.  
 On the other hand, activated astrocytes have also been shown to protect neurons by 
increasing the uptake of glutamate, producing reduced glutathione, and formation of glial scars. 
Increased glutathione is important because it can prevent the nitric oxide induced inhibition of 
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complex I of the electron transport chain, therefore reducing the production reactive oxygen 
species. Astrocyte produced chaperones and neurotrophic factors such as GDNF and BDNF have 
been shown to protect against neurodegeneration. While astrocyte activation is still not well 
understood; it can be both detrimental and protective to neurons. This differential activation of 
astrocytes needs to be further investigated. Investigating the signaling pathways that can increase 
the neuroprotective mechanisms in astrocytes can be a vital therapeutic approach for 
neurodegenerative disorders. 
Neuroinflammation and neurodegenerative disorders 
Sites of neuronal loss in neurodegenerative disorders have microglia mostly in their 
activated state (Mcgeer et al., 1988b).  Hyperactivated microglia differ from resting microglia 
not only in morphology but also in what factors are produced from the microglia (Orihuela et al., 
2016).  Many in vitro and in vivo models, as well as post-mortem tissue, show that sustained 
neuroinflammation, caused by persistently activated microglia releasing pro-inflammatory 
mediators, negatively contributes to neuron health and could be a contributing factor in neuronal 
death (Aschner et al., 1999; Glass et al., 2010). 
Evidence of Neuroinflammation in PD  
Much evidence supports the role of neuroinflammation and microglial hyperactivation in 
PD.  Post-mortem studies of PD patients show extensive microglial activation in the nigrostriatal 
system marked by amoeboid microglia surrounding regions where melanized neurons had been 
lost (Lee et al., 2009; Mcgeer et al., 1988b).  These patients also exhibited higher levels of pro-
inflammatory cytokines, such as TNFα, IL-1β and IFNγ, in their cerebrospinal fluid (Reale et al., 
2009).  Cytokine upregulation has also been shown in PD brains as well, indicative of an 
51 
 
ongoing persistent inflammatory reaction that persists throughout the course of the disease (Lee 
et al., 2009).  Lee et al. (2009) also performed PET imaging to confirm microglial activation in 
the striatum and basal ganglia of living PD patients.  Their PET imaging study further revealed 
that activated microglia were present in PD patients regardless of the number of years with the 
disease, when compared to age-matched control patients.  New evidence suggests that the innate 
immune response may not be the only signaling mechanism that goes awry in PD.  The adaptive 
arm of the immune response might influence PD’s degenerative process.  Animal models, as well 
as post-mortem tissue from PD patients, showed the entry of CD8+ and CD4+ cells into the 
substantia nigra (SN), but not B cells (Brochard et al., 2009; Hirsch and Hunot, 2009).  These 
infiltrating T-cells can be neuroprotective; however, based on stimulie they can also release 
chemokines, which contributes to neurotoxicity.  For example, Langston et al.’s (1999) analysis 
of brain tissues from people who were exposed to MPTP and developed rapid-onset 
Parkinsonism showed abundant reactive microgliosis in the SN, which is indicative of a 
sustained inflammatory response.  Arai et al.’s (2004) study found that the toxicant-mediated 
overexpression of IL-1β in the SN of mice contributed to progressive dopaminergic 
neurodegeneration and the concurrent loss of motor function. 
Several genetic studies link single nucleotide polymorphisms (SNPs) to PD development.  
Interestingly, some of these SNPs are found within the promoter region of pro-inflammatory 
genes.  These are linked to the development or early onset of PD through transcriptional 
mechanisms.  For example, the G-174C SNP in the IL-6 promoter is linked to the early onset of 
PD, as is the -511 of the IL-1β gene promoter and -1031 in the tumor necrosis factor gene 
promoter (Nishimura et al., 2001; Nishimura et al., 2000).  Epidemiological studies have 
additionally implicated inflammatory mechanisms in PD as the continual use of non-steroidal 
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anti-inflammatory drugs (NSAIDs) has been associated with a reduced risk of developing PD, 
which has also been shown in animal models of PD (Bassani et al., 2015; Chen et al., 2003; 
Samii et al., 2009).  Wahner et al.’s (2007) research has narrowed this effect down to specific 
classes of NSAIDs.  
Neuroinflammation in Animal Models of PD 
Neurotoxin-based models of PD in rodents, non-human primates and cell culture systems 
have helped elucidate the role of neuroinflammation in PD.  Although none of the animal models 
of PD recapitulates all the pathological features of PD, they have provided some insight into 
disease pathology and the molecular mechanisms involved in the neuroinflammatory response 
associated with PD progression.  Many of the post-mortem findings have confirmed the 
accumulation of activated microglia first identified in animal models of PD.  Generally, the 
microglial neuroinflammatory response in animal models has been greater in the SN compared to 
the striatum, which is also observed in PD patients and post-mortem PD brain analysis (Doorn, 
2015).  Several of these experimental animal models have strongly implicated a role for 
microglial neurotoxicity in the pathophysiology of PD, specifically in disease progression and 
the gradual loss of dopaminergic neurons.  
Neuroinflammation has been a consistent hallmark of PD in every mouse model. The 
following section reviews the current evidence for microglial activation in the various toxicant-
based PD models.  
1. Lipopolysaccharide (LPS) Model 
Some of the strongest mechanistic evidence for the role of inflammation in PD 
pathology comes from cell cultures and animal models that utilized the bacterial 
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endotoxin LPS to induce microglial neurotoxicity.  LPS is a component of the cell wall of 
Gram-negative bacteria and acts as a potent activator to induce a strong inflammatory 
response and gradual dopaminergic degeneration when injected intra-nigrally.  
Intraperitoneal administration of LPS also elicits a quick and sustained 
neuroinflammatory response (Qin et al., 2007a).  This model differs from other 
neurotoxin-based animal models as LPS first selectively activates microglia before 
causing neuronal death (Lawana et al., 2017; Qin et al., 2007a) as LPS is not directly 
toxic to neurons (Dutta et al., 2008).  Furthermore, the results from neurodegeneration 
studies utilizing LPS demonstrate that nigral neuroinflammation alone is sufficient to 
both initiate and sustain dopaminergic degeneration (Dutta et al., 2008; Qin et al., 2007a).  
LPS can also interact synergistically with MPTP (Harkavyi et al., 2008; Hirsch and 
Hunot, 2009) and other mitochondrial toxins such as rotenone (Fan et al., 2011; Lawana 
et al., 2017; Swarnkar et al., 2009), 6-OHDA (Byler et al., 2009; Sawada et al., 2008), 
paraquat (Mangano et al., 2011), and manganese (Dodd and Filipov, 2011) to amplify 
dopaminergic cell death, suggesting that environmental hazards can cause or contribute to 
PD-linked neuroinflammation and neuronal loss.  
2. MPTP Model 
To induce a neuroinflammatory response, many researchers have used an acute 
treatment of the Parkinsonian toxicant MPTP (He et al., 2008), which upregulates pro-
inflammatory proteins within the SN and the striatum, while also causing microglial 
activation in these regions (Czlonkowska et al., 1996).  Non-human primates treated with 
MPTP continue to show the presence of reactive microglia in the SN region for several 
years post-treatment (McGeer et al., 2003).  Diminishing microglial activation by 
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preventing reactive oxygen species (ROS) generation via inhibiting the function of the 
NADPH complex, NOS2 and nuclear factor-κ-light-chain-enhancer of activated B cells 
(NF-κB) was shown to be extremely neurprotective, once again implicating the role of 
neuroinflammation in neurodegeneration  (Koppula et al., 2012).  
3. 6-OHDA Model 
Prior to the LPS and MPTP models being established, many researchers utilized 
the 6-OHDA model to elicit neurodegeneration within the SN (Meredith et al., 2008).  
Despite having been used for many years, this model was only recently shown to cause 
neuroinflammation (Stott and Barker, 2014; Virgone-Carlotta et al., 2013).  Another 
study attempting to map the kinetics of 6-OHDA neurotoxicity in a murine model, found 
that the accumulation of microglia perhaps precedes neuronal loss post-6-OHDA 
treatment (Virgone-Carlotta et al., 2013). 
4. AAV-Synuclein Overexpression 
More recently developed models include the AAV-SYN model of PD, which 
essentially delivers adeno-associated virus overexpressing human αSyn into the SN or 
striatum.  Many studies targeting αSyn overexpression in the SN present a clear role for 
microglial activation, as well as increased pro-inflammatory cytokines, in nigral 
dopaminergic neuronal degeneration (Chung et al., 2009; Theodore et al., 2008).  
Conversely, histopathological analysis of human PD brains suggests no altered 
microgliosis based on major histocompatibility complex (MHC) class II expression 
(Croisier et al., 2005).  According to a recent review of possible mechanisms of αSyn’s 
effect on microglia, after being expelled from neurons, αSyn (in monomeric, oligomeric 
or fibrillar forms) either (i) binds microglial cell surface receptors (for example, TLRs), 
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thereby activating the inflammatory response; or (ii) is internalized by the microglial 
endosomal pathway to undergo degradation via the microglial autophagolysosomal 
system (Schapansky et al., 2015).  Hence, further studies are indeed required to better 
understand the balance between these alternative pathways and their exact molecular 
mechanisms. 
5. MitoPark Model 
The MitoPark model is a transgenic mouse model of PD developed recently as a 
more gradually progressive model of neurodegeneration relative to other toxin-based 
models mentioned previously (Cong et al., 2016; Galter et al., 2010; Gellhaar et al., 
2015).  Researchers selectively knocked down mitochondrial transcription factor A 
(TFAM) in dopaminergic neurons, where it resulted in a progressive loss of 
dopaminergic neurons (Galter et al., 2010).  Our group recently demonstrated an 
increased neuroinflammatory response in the MitoPark model (Langley et al., 2017).  
Furthermore, Langley and colleagues showed that treating MitoPark mice with the 
mitochondria-specific antioxidant mito-apocynin reduced not only protein levels of the 
microglia marker IBA1, but also the accumulation of activated microglia in the SN. 
6. Rotenone model 
Rotenone (ROT) is a commonly used pesticide naturally produced in the roots and 
stems of tropical legumes.  Exposure to this mitochondrial complex I inhibitor (NADH: 
ubiquinone oxidoreductase) (Sherer et al., 2003b) induces neuronal loss specifically of 
dopaminergic neurons in the striatum and the SN (Cannon et al., 2009; Coulom and 
Birman, 2004; Drolet et al., 2009; Emmrich et al., 2013).  Similarly, humans with a 
history of ROT exposure show an increased risk of PD (Sanders and Greenamyre, 2013).  
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Due to these effects, ROT has been used as a oxidative stress-based model of PD.  Some 
of the proposed mechanisms of ROT-induced neurotoxicity focus on the inhibition of the 
electron transport chain leading to energy depletion and ROS generation.  A microglial 
response to ROS production is believed to underlie the neuroinflammation stemming 
from this model (Cannon et al., 2009).  Gao et al. (2002) showed that microglia play a 
crucial neurotoxic role in inducing the dopaminergic neurodegeneration, and that 
treatment with an antioxidant, anti-inflammatory compound reduced ROT-mediated 
neurotoxicity by abolishing microglial activation (Zhou et al., 2007).  Conversely, 
Klintworth et al. (2009) suggest that ROT might not directly activate the microglia.  We 
recently showed that microglia primed with LPS significantly potentiated the ROT-
mediated inflammatory activation by exacerbating the mitochondrial oxidative stress-
induced activation of the NLRP3 inflammasome (Lawana et al., 2017; Sarkar et al., 
2017). 
Mechanisms of Microglial Activation 
The signaling pathways involved in sustained microglial activation and neuro-microglial 
interactions are yet to be fully understood.  The primary signaling mechanism relevant to LPS-
induced microglial activation is the nuclear translocation of NF-κB via TLR4 signaling, which 
then activates downstream proinflammatory genes, thereby increasing the production of various 
chemokines and cytokines (Dutta et al., 2008; Qin et al., 2004; Xu et al., 1998).  
Neurodegenerative mechanisms in the LPS model involve microglial ROS production via 
NADPH and iNOS, and the production of pro-inflammatory cytokines, specifically TNFα (Dutta 
et al., 2008; Qin et al., 2004; Qin et al., 2007a).  Neurotoxicity induced by LPS can be 
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diminished by drugs that target microglial activation (Lawana et al., 2017; Liu et al., 2000; Peng 
et al., 2014; Wang et al., 2002). While the LPS model demonstrates that microglial activation can 
contribute to neuronal degeneration, its translational value remains limited since PD does not 
involve a CNS bacterial infection.  Recent research has shown that misfolded proteins can 
produce an inflammatory response in microglia (Tjalkens et al., 2017).  Alpha-synuclein has 
been associated with PD, and when aggregated in PD-associated Lewy bodies, αSyn induces 
microglial activation (Reynolds et al., 2008; Zhang et al., 2005b).  The αSyn gets phagocytosed 
by the microglia, which in turn produces ROS and various proinflammatory cytokines 
Figure 2: Cross-talk between neurons and microglia during dopaminergic neurodegeneration. 
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(Stefanova et al., 2007).  Although the exact signaling pathways activated by αSyn in microglia 
are not very well understood, TLR2 (Kim et al., 2013a), TLR4 (Fellner et al., 2013), and CD36 
(Su et al., 2008b) have been identified as potential receptors responsible for the inflammatory 
signaling post-αSyn uptake (Schapansky et al., 2015).  
In addition to the environmental toxins implicated in PD, such as rotenone and paraquat, 
that have been shown to cause neuronal loss via microglia activation (Bonneh-Barkay et al., 
2005; Gao et al., 2002), certain endogenous brain chemicals can also activate microglia.  These 
include, for example, neuromelanin, which is a form of melanin found in dopaminergic neuronal 
cells (Wilms et al., 2003; Zecca et al., 2008), and matrix metalloprotease 3 (MMP-3), which 
when secreted by neurons can activate microglia via protease-activated receptors (Kim et al., 
2007).   
Although the role of neuroinflammation in neurodegenerative diseases is still not fully 
understood, the common consensus is that neuronal damage caused either by mutations or 
environmental toxicants can trigger the release of misfolded proteins from damaged neurons 
(Figure 2).  This is then followed by the activation of resident microglia, which release ROS, 
nitrites, and proinflammatory cytokines.  The release of these cytokines can further aggravate 
neuronal injury, thereby repeatedly propagating this whole cycle, resulting in a homeostatic 
imbalance driven by a sustained and heightened neuroinflammatory response.  Discovering the 
signaling mechanisms underlying this damaging cycle could help identify druggable targets that 





Inflammasomes and Microglial Activation 
The inflammasome has been identified as a key player in the activation of microglia.  
Inflammasomes were first characterized in THP-1 cells by Martinon, Burns, and Tschopp 
(2002).  Understanding the mechanisms of inflammasomes is an extremely active area of 
research, and as pattern recognition receptors such as cytosolic inflammasome receptors are 
identified, the cellular signaling processes that occur downstream of their activation are being 
elucidated.  Although inflammasomes play a crucial role in mounting innate immune responses 
to potential pathogens (Franchi et al., 2009), recent discoveries have shed light on how their 
signaling goes awry in a whole host of diseases such as liver diseases, atherosclerosis, type 2 
diabetes, and neurodegenerative diseases (Hoseini et al., 2018; Kim et al., 2016; Ozaki et al., 
2015; Szabo and Petrasek, 2015).   
Structure and activation of inflammasome 
As an extension of the innate immune system, the inflammasomes represent a diverse 
arsenal of effector assemblies necessary for broad host defense via modulation of inflammation.  
Inflammasomes are multiprotein complexes composed of distinct pattern-recognition receptor 
(PRR) sensors along with procaspase-1 filaments, and in general, with filaments of apoptosis 
associated speck-like protein containing a caspase activation and recruitment domain (CARD) 
(ASC) (Guo et al., 2015).  PRRs are cytosolic sensors that include melanoma 2 (AIM2), 
nucleotide binding oligomerization domain (NOD)-containing proteins, NOD-like receptor 
(NLR), and PYHIN [pyrin (PYD) and HIN200 (hematopoietic interferon-inducible nuclear 
antigens with 200 amino-acid repeats)] (Broz and Dixit, 2016).  Figure 3 (adopted from Strowig 
et al. (2012)) shows the protein structure of commonly investigated inflammasomes indicating 
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the domain organization.  NLRs, such as NLRP1, NLRP3, NLRP6, NLRC4 and NLR apoptosis 
inhibitory proteins (NAIP) contain a nuclear-binding domain (NBD) and a variable number of 
Leucine-rich repeat domains (LRR).  More specifically, NLRP1 contains a domain with function 
to find (FIIND) and NAIP has baculoviral inhibition of apoptosis repeat domain (BIR), which 
are unique to these inflammasomes.  Furthermore, AIM2 and IFI16 inflammasomes belong to 
the PYHIN family and are characterized by having, in addition to a PYD, a HIN200 domain, 
which is responsible for ligand binding (Conforti-Andreoni et al., 2011; Lamkanfi and Dixit, 
2012).  Other less characterized 
cytosolic sensors, both inflammasome 
forming and non-forming, have been 
discovered as well (Broz and Monack, 
2013).   
Upon stimulation of the 
inflammasome sensor component, 
assembly of the canonical 
inflammasome complex begins by 
recruitment and nucleation of ASC 
clusters through the PYD domain.  
Subsequently, the ASC filaments 
nucleate procaspase-1 filaments 
through the CARD domain.  This 
oligomerization of procaspase-1 
Figure 3: Protein structures of various 
inflammasomes domains (adopted from 
Strowig et al. (2012)). 
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induces autoproteolytic activation of the zymogen into caspase-1, which can then catalyze the 
maturation of pro-interleukin (IL)-1β and pro-IL-18, the two cytokines associated with 
inflammasome signaling and pyroptosis (Lamkanfi and Dixit, 2014; Lu et al., 2014).  
Upregulation of IL-1β and IL-18 is evident in various neurological conditions, such as 
stroke (Wagner et al., 2006; Yang et al., 2010), multiple sclerosis (Cheng et al., 2012; Link, 
1998), AD (Delaleu and Bickel, 2004; Di Iorio et al., 2003) and PD (Deleidi and Gasser, 2013; 
Nishimura et al., 2000) as well as in the experimental paradigms used to model these disorders.  
As these neurodegenerative disorders are chronic, interventions targeting inflammasome 
components, their assembly, or their downstream catalytic maturation of IL-1β and IL-18 have 
gained much attention.  Furthermore, transgenic knockout models have been developed to 
investigate the inflammasome’s role in brain disease. For example, Asc−/− and Nlrp3−/− mice are 
resistant to experimental autoimmune encephalitis (Gris et al., 2010; Inoue et al., 2012a; Inoue et 
al., 2012b; Walsh et al., 2014). 
The following section reviews the structure, mechanisms of activation and downstream 
effects of some of the widely studied inflammasomes. 
1. NLRP1 inflammasome  
Expressed in adaptive immune cells and neurons, NLRP1 was first discovered to be 
activated by Bacillus anthracis, lethal toxin (LT) (Boyden and Dietrich, 2006).  Structurally, 
NLRP1 contains CARD, which directly recruits and activates the effector enzyme Caspase-1 
without ASC (Nour et al., 2009).  The activation of NLRP1/caspase-1 leads to maturation of IL-
1β and Il-18 (Boyden and Dietrich, 2006).  Recently, K+ efflux or cathepsin B activation were 
found to be another crucial activator of NLRP1 (Chavarria-Smith et al., 2016).  In neurons, 
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NLRP1 activation leads to caspase-1-dependant maturation of IL-1β and caspase-6-mediated 
axonal degeneration (Kaushal et al., 2015). 
2. NLRC4 inflammasome  
NLRC4 is expressed and activated in immune cells of hematopoietic origin and can 
directly activate caspase-1 through its CARD. Structurally, the LRR domain is believed to have a 
negative regulatory role in activating caspase-1, which is required to prevent excessive 
inflammatory activation (Poyet et al., 2001).  Biologically, the NLRC4 inflammasome is most 
responsive to microbial infection, perhaps due to the ability of NLRs to recognize disparate 
bacterial products (Suzuki et al., 2007; Willingham et al., 2007).  Upon induction, NLRC4 
recruits ASC, which ultimately leads to  release of IL-1β and IL-18 via caspase-1 activation (Ip 
and Medzhitov, 2015).  Although ASC-deficient macrophages produce significantly less IL-1β 
and IL-18 (Zhao et al., 2011), ASC is not required for NLRC4-dependent pyroptotic cell death 
(Case and Roy, 2011).  Although many studies have demonstrated the processing and activation 
of NLRC4, its post-translational modifications remain largely unstudied.  So far, only one study 
indicates that redox-sensitive kinase PKCδ phosphorylates NLRC4 at the serine 533 residue, 
which is required for its activation (Qu et al., 2012). 
3. NLRP2 inflammasome  
Similar to other inflammasomes, NLRP2 expressions are mediated by nuclear 
transcription factor NF-κB (Fontalba et al., 2007).  However, unlike most other NLR family 
inflammasomes, NLRP2 blocks the NF-κB pathway, which decreases the production of TNFα in 
macrophages, without affecting the release of IL-1β (Bruey et al., 2004; Conti et al., 2005).  
Although the exact biological role of NLRP2 is not clear, ATP-stimulated astrocytes show 
activation of the NLRP2 inflammasome (Minkiewicz et al., 2013). 
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4. AIM2 inflammasome  
AIM2, initially identified during testing for melanoma tumor (DeYoung et al., 1997), is 
the only non-NLR inflammasome that have been extensively investigated (Hornung and Latz, 
2010). The N-terminal PYHIN domain of AIM2 interacts with ASC, while the C-terminal 
HIN200 domain binds to double-stranded (ds) DNA, which is required for activation (Jin et al., 
2012).  Similar to other inflammasomes, AIM2 recruits ASC and caspase-1 upon activation.  
Since AIM2 gets activated by any cytosolic dsDNA structure, this inflammasome may play a 
role in the response to microorganisms that invade cells.  In this context, Aim2-/- macrophages 
display diminished IL-1β and IL-18 production in response to vaccinia and mouse 
cytomegalovirus (Fernandes-Alnemri et al., 2010; Rathinam et al., 2010). 
5. NLRP3 inflammasome  
The NLRP3 inflammasome is the most extensively studied inflammasome in the CNS 
(Walsh et al., 2014) and has extensive implications in a broad range of inflammatory conditions 
(Schroder and Tschopp, 2010), including asbestosis (Cassel et al., 2008; Dostert and Petrilli, 
2008), malaria (Dostert et al., 2009) and UVB irradiation (Feldmeyer et al., 2007).  As such, 
NLRP3 is capable of responding to a broad range of pathogen-associated molecular patterns 
(PAMP) that include LPS and viruses, and to danger-associated molecular patterns (DAMP) that 
include αSyn and ATP (Lamkanfi and Dixit, 2014).  Although many molecules may serve as 
NLRP3 inflammasome activators, the formation of the complex requires two signals.  The initial 
signal must promote the nuclear translocation of NF-κB, which serves to upregulate Nlrp3 
transcription (Lawana et al., 2017; Luo et al., 2014).  Once an abundance of NLRP3 
inflammasome sensors are present, assembly of the executory complex is contingent upon the 
secondary signal’s ability to promote any of the following occurrences: mitochondrial ROS, 
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mitochondrial DNA release, mitochondrial localization of NLRP3, lysosomal cathepsin release, 
or potassium efflux (Broz and Dixit, 2016; Guo et al., 2015; Lamkanfi and Dixit, 2014; Sarkar et 
al., 2017).  These required changes indicate that NLRP3 does not directly respond to the 
aforementioned agents, but rather the changes induced by them. Most crucially, this signal must 
cause deubiquitination of NLRP3 for assembly to occur and this is mediated by the 
deubiquitinase BRCC3 (Py et al., 2013). With the succession of two signals, nucleation of ASC 
and procaspase-1 filaments initiates to complete the formation of the inflammasome complex, 
which will act to propagate inflammation by maturing pro-IL-1β and pro-IL-18 to IL-1β and IL-
18 via cleavage by caspase-1 (Lawana et al., 2017; Sarkar et al., 2017).  Figure 4 provides a 
Figure 4: Schematic representation of molecular mechanisms of PAMP/DAMP-mediated activation 
of NLRP3 inflammasomes in microglia, leading first to caspase-1-induced cleavage and maturation 
of IL-1β and Il-18, and then to their extracellular release and ensuing inflammatory response. 
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schematic overview of the dual hit model of NLRP3 inflammasome activation leading to 
maturation of inflammatory cytokines. 
Mitochondrial dysfunction and increased ROS are major occurrences in PD, found in 
astrocytes (Bolanos et al., 1995; Gegg et al., 2003), microglia (Beal, 2003; Gao et al., 2003; 
Moss and Bates, 2001; Zhang et al., 2005a), and neurons (Flones et al., 2018; Schapira, 1993; 
Zaltieri et al., 2015).  In this context, treatment of LPS-primed murine microglia with 
mitochondrial complex I inhibitors upregulated NLRP3, IL-1β, and mitochondrial superoxide.  
Our lab has shown that exposure to mitochondria-specific oxidative species scavenger 
(mitoTEMPO) reduced NLRP3 activation in microglia (Lawana et al., 2017).  Likewise, 
pretreatment with MCC-950, a specific NLRP3 inflammasome inhibitor, attenuated the 
mitochondrial dysfunction induced by the complex I inhibitors, and this was accompanied by a 
decrease in NLRP3, IL-1β release, and superoxide generation.  Additionally, the culture media 
from LPS-primed complex I inhibitor-treated murine microglia induced a loss in tyrosine 
hydroxylase neurite length in human dopaminergic LUHMES neuronal cells, while MCC-950 
attenuated the loss of neurite length, demonstrating that inhibition of NLRP3 signaling in 
microglia could be protective to neurons (Sarkar et al., 2017).  Research pertaining to inhibition 
of IL-1β signaling events has stirred controversy (Craft et al., 2005; Shaftel et al., 2007).  Walsh, 
Muruve, and Power (2014) argue that manipulating this downstream signaling is prone to 
experimental variability as immune cells, such as microglia, can polarize towards different 
inflammatory phenotypes depending on the stimulus.  Indeed, manipulating more upstream 
events, such as cross-breeding Nlrp3−/− with amyloid precursor protein/presenilin 1 transgenic 
mice, produced a phenotype that does not develop significant behavioral impairments nor do 
they develop amyloid deposits, but they have high numbers of alternatively activated microglia 
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(Heneka et al., 2013; Walsh et al., 2014). This evidence demonstrates the caution needed when 
hypothesizing therapeutic approaches for these given disorders, and presently it may be 
favorable to target inflammasome activation rather than its downstream signaling.  
Microglia exacerbate and sustain the inflammation in PD by functioning as surveilling 
phagocytes targeting dopaminergic neurons containing Lewy bodies for clearance (McGeer et 
al., 1988a; Zhou et al., 2016).  Hyperactivation or microgliosis is common in the SN and co-
occurs with increased serum IL-1β and caspase-1 levels (Zhou et al., 2016).  Unlike astrocytes, 
microglia express high levels of NLRP3, making them a prime target in PD therapeutics (Gustin 
et al., 2015; McGeer et al., 1988a).  Furthermore, aggregated αSyn treatment of BV2 microglia 
upregulates NLRP3 and promotes inflammasome assembly or complex activation.  This 
activation was dependent on endocytosis of aggregated αSyn and lysosomal damage resulting in 
cathepsin B release, while selective inhibition of both attenuated caspase-1 activation and IL1β 
release (Zhou et al., 2016). 
In addition to PD, NLRP3 inflammasome activation has also been demonstrated in 
various other chronic neurodegenerative conditions.  For example, during traumatic brain injury, 
several mediators (such as ATP, uric acid, etc) are released, which can then activate the NLRP3 
inflammasome in microglia (Gasse et al., 2009; Idzko et al., 2007; Muller et al., 2011; Nakae et 
al., 2003; Riteau et al., 2010).  Cryopyrin-associated periodic syndromes (CAPS) are a set of 
autoimmune diseases that are used to describe three phenotypes depending on the severity of the 
disease.  The mildest phenotype occurs with familial cold autoinflammatory syndrome (FCAS), 
followed by Muckle-Wells syndrome (MWS) with an intermediate disease phenotype, and then 
by neonatal-onset multisystem inflammatory disease (NOMID), which is the severest form of the 
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disease.  CAPS is an autosomal dominant condition, caused by a gain-of-function mutation in the 
NLRP3 gene, leading to the uncontrolled production of IL-1β in immune cells.  In the past few 
years, several drugs to treat this disease have been effectively utilized (Yu and Leslie, 2011).  In 
2008, it was discovered for the first time that the aggregated form of the senile plaque-associated 
protein amyloid-β could activate the NLRP3 inflammasome, and thus establishing the first link 
that inflammasomes may play a role in the pathogenesis of neurodegenerative disorders (Halle et 
al., 2008). This topic will be covered in more detail in the subsequent section.   
Non-canonical activation of NLRP3 inflammasome  
Non-canonical activation of the NLRP3 inflammasome is primarily mediated by Caspase 
11.  This mechanism has been demonstrated to mediate the activation of other Caspases, 
therefore contributing to apoptosis (Kang et al., 2000).  Caspase 11 was subsequently shown to 
be essential for Caspase 1 activation and IL-1β production upon infection with Escherichia coli, 
Citrobacter rodentium or Vibrio cholerae, but was found to not affect the activation of Caspase 1 
downstream of typical NLRP3 activators such as ATP and urate crystals (Kayagaki et al., 2011).  
Incidentally, this was also the study that demonstrated that Caspase1 KO mice inherently lacked 
Caspase 11 as well, necessitating the use of Caspase 11 KO macrophages as negative controls or 
inflammasome activation in many studies. Further, the activation of gasdermin D was shown to 
play a crucial role in caspase 11-mediated non-canonical activation (Kayagaki et al., 2015).   In 
fact, the non-canonical activation was found to be independent of TLR4 signaling, leading to the 
current consensus that a cytosolic receptor mediates Caspase 11 activation to elicit non-canonical 
inflammasome activation (Kayagaki et al., 2013).  In addition, Schmid-Burgk et al. (2015) 
recently showed that caspase 4 can also mediate the non-canonical cleavage IL-1β and 
pyroptosis via the activation of NLRP3 inflammasome human myeloid cells.  Recently, Nyul-
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Toth et al. (2017) detected non-canonical inflammasome activation in human cerebral pericytes.  
Interestingly, macrophages treated with methylene blue, an anti-oxidant and anti-inflammatory 
neuroprotectant, reduced the non-canonical inflammasome activation induced by LPS (Ahn et 
al., 2017).  Future studies are required to understand the preferential activation of canonical or 
non-canonical pathways for inflammasome activation.  
6. NLRP6 inflammasome  
Although earlier evidence failed conclusively identified the protein NLRP6 as being part 
of an inflammasome complex, recent studies demonstrate a distinct role of NLRP6 
inflammasome in mediating intestinal inflammation.  In this context, recent studies have 
expounded a role for this inflammasome in colitis; NLRP6-/- mice are more susceptible to colitis 
in response to colitis inducing agents (Chen et al., 2011a; Elinav et al., 2011; Normand et al., 
2011).  In fact, one study showed that NLRP6-/- mice have spontaneous colitis and inflammatory 
cell recruitment, as well as amplified inflammatory responses to dextran sodium sulfate, an 
inducer of colitis like symptoms, as well as expanded pathobiont gut microbiota.  This 
observation points to a role of the NLRP6 inflammasome in serving as a checkpoint to prevent 
gut inflammation (Elinav et al., 2011).  Several other studies further indicate that microbiota-
modulated metabolites can shape the intestinal microenvironment by regulating NLRP6 
inflammasome signaling (Flavell et al., 2014; Levy et al., 2015; Wlodarska et al., 2014).  
Interesting study from Wang et al. (2017) recently showed that NLRP6 inflammasome can 
reduce the brain injury after intracerebral hemorrhage.  This study showed that NLRP6-/- mice 
with intracerebral hemorrhage had higher NF-κB activity, proinflammatory cytokines levels and 
neurological deficit compare to wild-type intracerebral hemorrhagic mice.  In addition, Wang et 
al also showed that TLR4-/- mice had lower NLRP6 levels.  Hence, as a newer member of NLR 
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inflammasome family, very little is known about NLRP6 inflammasome, but it is evident that it 
can play a significant role CNS inflammation in addition of maintaining the gut microbiota 
signaling. 
Concluding Remarks 
Maintaining well-regulated control over the activation of glial cells is likely a key to 
dopaminergic neuronal homeostasis. Persistent hyperactivation of astrocytes and microglia are 
characteristic of neuroinflammation. While hyperactivation contributes to neurodegenerative 
processes, the complete ablation of the glial cells is also detrimental in lab animal models 
(Hanisch and Kettenmann, 2007). In this context, inflammasomes like the NLRP3-linked 
inflammasome are evolving as key regulators of microglia activation and investigating the 
therapeutic potential of these multi-protein complexes offers a potentially fruitful avenue toward 
alleviating the progression of PD and other chronic diseases. 
c-Abl Tyrosine Kinase 
In late 1960s, Dr. Herbert T. Abelson first discovered the cytoplasmic tyrosine kinase, 
originally named Ableson (Abl in brief), as a virally transduced oncogene that causes murine 
lymphosarcoma (Abelson and Rabstein, 1969; Abelson and Rabstein, 1970).  Subsequently, the 
human orthologue of this protein was identified as a part of the breakpoint cluster region–Abl 
Figure 5: Schematic structure showing domain organization of c-Abl tyrosine kinase.  
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(Bcr-Abl or c-Abl) fusion protein that causes chronic myelogenous leukemia (Ben-Neriah et al., 
1986).  Two proteins are identified as part of Ableson family: c-Abl and Abl-related gene (Arg).  
These proteins are involved in interactions with a multitude of cellular proteins and modulate 
pathways that are responsible for cell growth, differentiation, invasion and survival (Hantschel et 
al., 2003; Hantschel and Superti-Furga, 2004; Pluk et al., 2002). 
Structure of c-Abl kinase and determinants of its activation 
In mammals, c-Abl, a 120 kDa protein, has a myristoylated isoform and a 
nonmyristolated isoform (Bradley and Koleske, 2009).  In both isoforms, the N-terminal region 
of c-Abl is composed of an SH3-SH2-KD (Src homology 3-Src Homology 2-Tyrosine kinase 
domain) cassette, and an upstream Cap region (Colicelli, 2010).  This region regulates the kinase 
activity via autoinhibitory interactions that disrupt specific tyrosine phosphorylation events 
(Colicelli, 2010).  In contrast, the C-terminal region of c-Abl, termed the last exon region, is 
distinct and is composed of multiple cytoskeletal binding elements (Fig. 5).  Although c-Abl 
contain a ‘calponin homology’ like F-actin binding domain, c-Abl has a unique proline-rich 
region that binds to G-actin (Van Etten et al., 1994).  The last exon region of c-Abl also contains 
a DNA-binding domain and nuclear localization and nuclear export sequences, which allow it to 
move back and forth between the nucleus and the cytoplasm under various conditions 
(Taagepera et al., 1998).  Because the substrates of c-Abl kinase are similar to Src kinase family, 
their functional differences are also likely mediated by differential subcellular targeting and 
diversity in their cytoskeletal binding elements.  Crystallographic studies have provided a 
molecular framework demonstrating activation mechanisms by detailing a structural organization 
for regulatory complexes for c-Abl kinase (Filippakopoulos et al., 2008; Nagar et al., 2006; 
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Nagar et al., 2003; Smith et al., 2003).  For example, SH3 domain of the autoinhibitory complex 
interacts with linker connecting to SH2 domain to KD, while SH2 domain binds to the C-
terminal love of the KD.  These interactions are negative regulators and are required for 
maintaining low catalytic activity of KD (Tse and Verkhivker, 2015).   In fact, results from X-
ray scattering confirmed that upon activation, SH3 and SH2 domain becomes elongated proving 
a linear arrangement of KD, SH2 and SH3 domains, which is responsible for kinase activity of c-
Abl (Nagar et al., 2006).  Interestingly, mutations or deletions in the SH3 domain has been 
reported to hamper the autoinhibitory ability and enhances the kinase potential of c-Abl 
(Panjarian et al., 2013b).  In addition, the N-terminal “cap” (or NCap) can also directly bind with 
the SH2 domain or SH3-SH2 linker, further providing a structural benefit for autoinhibition 
(Nagar et al., 2006; Tse and Verkhivker, 2015). 
Phosphorylation of Tyrosine “Y” residues of c-Abl disturbs the autoinhibitory structrure 
and is crucial for activation of the kinase (Brasher and Van Etten, 2000; Roumiantsev et al., 
2001).  Studies demonstrate that phosphorylation of Y89 and Y134 residues of SH3 domain can 
interfere with its binding, interrupting the negative regulation and promoting kinase activation 
(Chen et al., 2008a; Roumiantsev et al., 2001).  Further, phosphorylation of Y245 residue of the 
SH2-linker region has been shown to be crucial for the kinase activation of c-Abl (Chen et al., 
2008a; Meyn et al., 2006).  In fact, it was identified that mutation of Y245 site can dramatically 
reduce the c-Abl activation (Brasher and Van Etten, 2000; Ko et al., 2010).  Conversely, 
mutation of SH2 domain’s Y158 residues leads to destabilizes the SH2 interactions and increases 
kinase activity of c-Abl (Meyn et al., 2006; Pene-Dumitrescu et al., 2008).  Interestingly, 
proteomics and structure-activity relationship (SAR) studies indicate that conformational 
changes in the catalytic core of KD, containing activation loop (A-loop), can also increase the 
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kinase activity of c-Abl.  The A-loop is considered most important for c-Abl kinase activity as it 
provides conformational and autophosphorylation preferences (Levinson et al., 2006; Nagar et 
al., 2002; Schindler et al., 2000; Tokarski et al., 2006).  In this context, phosphorylation of Y412 
residue of A-loop is considered ‘activation site’ (Hantschel, 2012; Panjarian et al., 2013a), which 
offers stability to kinase active conformation and increases the catalytic activity of c-Abl 
(Brasher and Van Etten, 2000; Dorey et al., 2001; Grebien et al., 2011).  In fact, a recent study 
showed that phosphorylation of Y412 leverages stability SH2-KD interactions, which can also 
induce kinase activation by allosteric mechanisms (Lamontanara et al., 2014).   
Interestingly, cocrystalization analysis of pharmacological inhibitors of c-Abl (dasatinib, 
imatinib and nilotinib) demonstrates that they interfere with the conformational folding of the 
protein, downregulating the kinase activity.  For example, imatinib, a 2-phenyl amino pyrimidine 
derivative, provides an “open” conformation, which blocks the SH2-KD interaction and inhibits 
the allosteric activation of kinase activity of c-Abl (Skora et al., 2013).  While, dasatinib, a 2-
methylpyrimidin thiazole, sits between the phosphate-binding loop (P-loop) and linker region by 
forming multiple semi-stable hydrogen bonds.  This forces the conformational rearrangements of 
phosphorylated or unphosphorylated c-Abl, which can negatively regulate the kinase activity by 
inhibiting the catalytic domain activation (Tokarski et al., 2006).  Likwise, nilotinib, 4-pyridin-3-
pyrimindin benzamide, also promotes interaction of P-loop with linker and maintains the 
negative regulatory form of c-Abl kinase (Manley et al., 2005).   The inhibitor activity confirms 
that c-Abl activity require the elongated conformation, which has stable A-loop to function as a 
kinase.  Because of the structural flexibility, c-Abl has been identified to regulate multiple 
cellular pathways, which can contribute to disease pathology.  In the following section we 
discussed the key functions of c-Abl in mammalian cells.  
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c-Abl kinase functions 
Maintaining the cellular shape and endothelial barrier stability 
 The Abl kinase has been shown to be involved in multiple molecular pathways 
modulating the fate of cells.  Primarily, c-Abl has well-described roles in regulating  cell shape 
and migration by supporting the cytoskeletal structure.  c-Abl binds with F-actin filaments, 
phosphorylating cytoskeletal effector proteins, and modulating the activity of nonmuscle myosin 
light chain kinase (MLCK) and Rho family GTPases (Bradley and Koleske, 2009; Cleary et al., 
2014; Colicelli, 2010).  In addition, c-Abl is also involved in regulating the mechanotransduction 
at cell-cell and cell-matrix interactions via phosphorylating a membrane cytoskeletal protein, 
vinculin (Bays et al., 2014).   In fact, c-Abl knockout animals fail to live past neonatal age due to 
multiple systemic and organ-specific defects, including splenic and thymic atrophy, osteoporosis, 
and cardiomegaly (Li et al., 2000; Qiu et al., 2010; Schwartzberg et al., 1991; Tybulewicz et al., 
1991).  Further, c-Abl has been also shown to maintain the epithelial cell-to-cell interactions and 
endothelial barrier stability (Dudek et al., 2010; Finigan et al., 2005; Wang et al., 2011).  In this 
context, imatinib have been shown to improve vascular integrity, restore toxicant-disturbed 
blood–brain barrier (BBB) integrity and decrease infection-associated intracerebral hemorrhage 
in rodents (Letsiou et al., 2015; Ma et al., 2011; Stephens et al., 2014; Su et al., 2008a).  
Similarly, in human umbilical vein endothelial cells, imatinib restores the integrity of adherens 
junctions by blocking the c-Abl-mediated phosphorylation of β-catenin, required for the junction 
formation (Aman et al., 2012; Mehta and Malik, 2006).  Additionally, c-Abl kinase also 
phosphorylates the focal adhesion proteins (Crk/CrkL and paxillin) (Colicelli, 2010; Mehta and 
Malik, 2006), which can be another mechanism by which c-Abl interrupts the endothelial barrier 
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integrity.  Lastly, Moresco et al. (2005) showed that c-Abl and Arg are required for the 
maintaining the neuronal dendritic structure, which is essential for nervous system.  Taken 
together, it is clear to imply an essential role of c-Abl in maintaining the structural stability to 
various cells and in modulating the endothelial barrier stability. 
Mediating oxidative stress and downstream pathways 
 A growing amount of evidence shows a major for a role of c-Abl kinase in ROS signaling 
pathways.  Abl kinases are activated in response to oxidative stress in multiple cell types, hence 
referred as redox-sensitive tyrosine kinase (Adler et al., 1999; Gonfloni et al., 2012; Sinha et al., 
2013; Vazquez et al., 2012).  The exact mechanism of oxidative stress mediated c-Abl activation 
is not clear but studies suggest that ROS activates ataxia-telangiectasia mutated (ATM) kinase, 
which then activates c-Abl (Meltser et al., 2011).  Interestingly, cellular antioxidant protein 
peroxiredoxin I (Prx1) inhibits c-Abl by binding to its SH3 domain (Wen and VanEtten, 1997).  
Conversely, RNAi-mediated knockdown of c-Abl results in increased level of Prx1 (Li et al., 
2004).  Inhibition of c-Abl has been shown to attenuate the oxidant-induced decline in 
expression of the antioxidant proteins catalase and glutathione, which ultimately decreases 
cellular injury (Cao et al., 2003a; Cao et al., 2003b; Kumar et al., 2003; Stephens et al., 2014).   
Additionally, c-Abl also have been shown to regulate the oxidative stress-dependent 
phosphorylation of Caveolin-1, a scaffold protein (Sanguinetti and Mastick, 2003); IRE1α, an 
ER stress response regulator (Morita et al., 2017); c-Jun-N-terminal kinase, a MAP kinase 
regulating cell proliferation (Pandey et al., 1996); Egr-1, a transcription regulator for cell mitosis 
(Pagel and Deindl, 2012); and several carcinogenesis inducers (Greuber et al., 2013).  
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Collectively, c-Abl activation is considered pro-oxidant and inhibition of c-Abl can alter the 
cellular oxidative stress.  
Modulating NF-κB activity and inflammation 
 Activation of NF-κB transcription factor can result in increased gene transcription of 
inflammatory genes, leading to release of inflammatory cytokines and increased recruitment of 
more immune cells (such as neutrophils, macrophages and monocytes), resulting in inflammation 
(Collins et al., 1995; Salminen et al., 2008).  NF-κB complex contains three main subunits: p65, 
p50 and inhibitory IκB.  Upon activation of IκB kinase (IKKβ), the IκB subunit gets 
phosphorylated and degraded, which allows the NF-κB-p65/p50 heterodimer to translocate to 
nucleus to turn on the gene transcription (Yamamoto and Gaynor, 2001).   Several upstream 
regulators have been modulate the activity of NF-κB.  In this context, c-Abl was shown to 
increase the production of inflammatory cytokines (TNFα, IL-6 and IL-8) in LPS-exposed 
human pulmonary artery, while imatinib or c-Abl knockdown blocked the release of these 
cytokines and reduced inflammation (Kim et al., 2013b; Letsiou et al., 2015).  Likewise, in 
human melanoma cells, c-Abl increased NF-κB activity by modulating IKKβ activity (Tripathi et 
al., 2018).  Interestingly, protein kinase C (PKC) isoforms are also one of the key substrates for 
c-Abl kinase.  Studies suggest that c-Abl modulates NF-κB activity also by PKC-dependent 
mechanisms (Mencalha et al., 2014).  Consistent with this, we recently showed that dasatinib 
blocked the nuclear translocation of p65/NF-κB subunit in LPS and rotenone treated murine 
microglia and reduced the mRNA levels of inflammatory cytokines in brain (Lawana et al., 
2017).  Likewise, c-Abl inhibitors have been shown to reduce the inflammation in various cell 
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types (Akhmetshina et al., 2009; Gu et al., 2012; Lewis et al., 1996; Rizzo et al., 2016; Wolf et 
al., 2005). 
Involvement in aging and neurodegeneration 
 In last decade, involvement of c-Abl has been repeatedly reported in various 
neurodegenerative diseases including AD and PD.  In this context, hyperphosphorylated Y412 
residue of active c-Abl was observed in postmortem PD patients brains, compared to aged 
matched controls (Hebron et al., 2013a).  Detailed role of c-Abl in neurodegeneration was 
reported in two reviews (Gonfloni et al., 2012; Schlatterer et al., 2011a).  In brief, c-Abl has been 
shown to promote amyloid β plaques and Tau phosphorylation in AD models (Alvarez et al., 
2004; Derkinderen et al., 2005; Tremblay et al., 2010).  Likewise, in PD models, c-Abl 
phosphorylates α-Synuclein at Y39 and Y125 residues leading to reduced degradation and 
pathogenic aggregation of the α-Synuclein (Brahmachari et al., 2016a; Hebron et al., 2013a; 
Mahul-Mellier et al., 2014), which contributes to dopaminergic neurodegeneration and disease 
pathology (Fujiwara et al., 2002; Sato et al., 2013).    
Elevated oxidative stress can also activate c-Abl in neurons (Alvarez et al., 2004; Shi et 
al., 2017), which then turns on the apoptotic pathways leading to neuronal loss (Alvarez et al., 
2008; Pan et al., 2014; Rojas et al., 2015).  In dopaminergic neurons, inhibition of c-Abl has 
been shown to decrease the oxidative stress-mediated mitochondrial damage (Zhou et al., 2017).  
Parkin, a ubiquitin ligase, is involved in clearance of dysfunctional mitochondria via mitophagy.  
In PD models, c-Abl was shown to phosphorylate and degrade parkin, impairing the mitophagic 
clearance of damaged mitochondria, causing neurotoxicity (Imam et al., 2011).  In addition, c-
Abl also negatively regulates mitochondrial biogenesis further contributing to neurotoxic 
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pathways (Andrew, 2018; Lee et al., 2017; Shin et al., 2011).  Recently, we showed a pro-
inflammatory role of c-Abl in microglia, activating NLRP3 inflammasome and leading to release 
of neurotoxic cytokines (Lawana et al., 2017).  Interestingly, c-Abl also phosphorylates and 
activates PKCδ, a redox-sensitive serine/threonine kinase (Sun et al., 2000).  Our lab and other 
have extensively shown that activation of PKCδ promotes apoptosis in dopaminergic neurons 
(Anantharam et al., 2002; Gordon et al., 2012; Kanthasamy et al., 2008; Latchoumycandane et 
al., 2005; Shin et al., 2012) and induces inflammatory pathways in microglia (Gordon et al., 
2016; Panicker et al., 2015).  Hence, increasing evidences suggest that c-Abl activation in brain 
promotes neurotoxicity, directly or indirectly via promoting inflammation.  
Therapeutics targeting c-Abl kinase 
 Based on the broad-spectrum role of c-Abl as described above, several inhibitors have 
been developed and are approved or are under trials for multiple medicinal uses.   FDA-approved 
imatinib (brand name: Gleevec) is currently used as a primary treatment for chronic 
myelogenous leukemia (CML) and other blood cancers (Druker et al., 2001; Hochhaus et al., 
2016).  However, imatinib-resistant CML are now being cured by second-generation c-Abl 
inhibitors, such as nilotinib (brand name: Tasigna) and dasatinib (brand name: Sprycel) 
(Doggrell and Christensen, 2011; Kantarjian et al., 2010; Nakamae et al., 2017; Saglio et al., 
2010), and third-generation Bcr-Abl inhibitors, such as ponatinib (brand name: Iclusig) and 
bosutinib (brand name: Bosulif) (Brummendorf et al., 2015; Muller et al., 2017).  Interestingly, 
imatinib and dasatinib have been also shown to be successful in gastrointestinal stromal tumor 
and dermal sarcomas (Schiffer, 2007).  Furthermore, recent clinical trials indicate a potential use 
of these inhibitors in the treatment of proliferative lung diseases, pulmonary hypertension, and 
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idiopathic pulmonary fibrosis (Daniels et al., 2004; Hoeper et al., 2013).  Imatinib has been also 
shown beneficial in systemic inflammatory disorders including rheumatoid arthritis (Paniagua et 
al., 2006). 
 Inhibitors of c-Abl are also being investigated in PD experimental models and preclinical 
trial.  For example, imatinib have been shown to protect against a Parkinsonian toxicant (MPTP)-
induced neurotoxicity (Imam et al., 2011; Ko et al., 2010; Shin et al., 2011).  However, studies 
show that imatinib has a poor permeability through BBB and may not affectively protect against 
neurotoxicity in a therapeutic range (Breedveld et al., 2005).  Interestingly, a recent 
pharmacokinetic analysis reveals that nasal administration of imatinib may provide a better 
access to brain (Hada et al., 2017).  Nilotinib, unlike imatinib, offers better BBB penetration and 
is more specific to c-Abl (Hebron et al., 2013a; Weisberg et al., 2006).  In this context, a recent 
two studies showed that nilotinib protected against the disease pathogenesis and behaviors 
deficits in animal models of PD (Karuppagounder et al., 2014; Tanabe et al., 2014).  Recently, 
another second-generation c-Abl inhibitor bafetinib has also been shown to cross BBB and 
demonstrate beneficial effects in preclinical models of PD (Imam et al., 2013).  We demonstrated 
that chronic dasanitib pretreatment to mice prevented the LPS-induced microgliosis in SN region 
and reduced neurodegeneration in cultured neuron-glia in vitro (Lawana et al., 2017).  Taken 
together, diverse set of research demonstrate a potential role of c-Abl and its inhibitors offer a 
positive effect in neurodegeneration.  Developing a more selective, safe and BBB-permeable 
molecule for c-Abl inhibition in brain will provide a possible treatment for reducing the 




Current Treatment Strategies for PD 
 All presently available treatments for PD are symptomatic without slowing or stopping 
disease progression. Currently, a combination of pharmacologic treatments is given to patients 
often accompanied by deep brain stimulation and supportive therapies (physiotherapy, speech 
therapy, etc.) based on the disease severity and patient’s condition.  Oral Levodopa (L-Dopa), 
which is a precursor for dopamine, and dopamine agonists are the most common medications at 
all stages of the disease for supplementing the lack of dopamine production in brain.  L-Dopa 
therapy reduces behavioral symptoms and improves quality of life (Fahn et al., 2004).  Another 
effective dopamine replacement therapy is the Duodopa pump which relies on intrajejunal 
infusion to assure a more constant, non-pulsatile supply of circulating Dopa. Hence, it is 
recommended for severe dyskinetic patients or those not responding to oral L-Dopa (Olanow et 
al., 2014).  Dopamine agonists, such as bromocriptine, cabergoline, pergolide, pramipexole, 
ropinirole, are given in the early stage of disease or in combination with L-Dopa (Adler et al., 
1997; Hauser et al., 2007; Oertel et al., 2006).  Other approved drugs for PD include modified 
forms of L-Dopa, such as melevodopa and carbidopa.  
 Another approach designed to prolong dopamine availability at the synapse is to reduce 
dopamine recycling.  Monoamine oxidase B (MAO-B) converts dopamine to 3,4-
dihydroxyphenylacetic acid (DOPAC), while catechol-O-methyl transferase (COMT) converts it 
to 3-methoxytyramine.  Hence, centrally active inhibitors of MAO-B (e.g., rasagiline, 
safinamide, selegiline) or COMT (e.g., entacapone, opicapone, tolcapone) have been used as one 
component of combination pharmacotherapy.  A slow-release formulation of the dopamine 
promoter and antiviral agent amantadine has also proven successful, especially at reducing 
advanced-stage dyskinesia (Pahwa et al., 2016).  
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 Deep brain stimulation (DBS) of the ventral intermediate nucleus and pallidus pars 
internus is the newest non-drug treatment for reducing PD-associated symptoms without 
affecting the progression of neurodegeneration.  DBS does require the stereotaxically guided 
surgical implantation of electrodes with additional feedback from either neuroimaging in 
anesthetized patients or from microelectrode recording in awake patients.  Once electrodes are 
properly positioned, DBS not only allows physicians to directly alter dysfunctional neuronal 
firing patterns propagating through striatal-cortical circuits, but also to considerably reduce L-
Dopa supplementation.  
 Drug discovery aimed at modifying disease progression and providing better 
symptomatic relief is still an evolving field.  The noradrenalin precursor L-threo- 
dihydroxyphenylserine (also known as L-DOPS or Droxidopa), the adenosine 2A receptor 
antagonists istradefylline, tozadenant and anti-dopaminergic, and the D2-antagonist aripiprazole 
have been shown to alleviate motor dysfunction and are currently in clinical trials.  Similarly, the 
5HT2A receptor inverse agonist pimavanserin and the histamine receptor antagonist pitolisant 
are in clinical trials for PD-related non-motor psychosis and sleep disturbances.  The AchE 
inhibitor Donepezil is being tested for dementia, while the opioids oxycodone and naloxone are 
proposed for pain relief in PD patients.  Additionally, therapeutic agents modulating the 
aggregation of αSyn are under development.  ANLE138b, a novel compound in this category, 
has been shown to reduce the formation of αSyn aggregates in animal models (Fellner et al., 
2016; Turriani et al., 2017).  Intriguingly, a few non-conventional therapeutic agents, such as 
caffeine, nicotine and isradipine (a Ca2+ channel blocker), have entered the developmental phase 
of clinical trials for treating PD (Ilijic et al., 2011; Luthra et al., 2009; Postuma et al., 2017; Quik 
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Abstract 
Numerous studies have suggested a positive association between pesticide exposure and 
the risk of developing Parkinson’s disease (PD).  Previous studies indicated that dichlorvos 
(DCV), an organophosphate (OP) pesticide induced nigrostriatal dopaminergic neuronal death; 
however, the molecular mechanisms underlying DCV-induce cell death remains elusive.  Using 
multiple approaches including, subcellular fractionation, immunofluorescence analysis, 
enzymatic assays, and gene silencing technology, we show that Abelson murine leukemia (c-
Abl) tyrosine kinase is linked to DCV-induced dopaminergic cell death.  Exposure of human 
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neuroblastoma SH-SY5Y cells or primary rat mesencephalic neuronal culture to DCV, induced 
cell death via the upregulation of c-Abl, proteolytic cleavage and phosphorylation of PKCδ, 
mitochondrial dysfunction, and apoptotic events involving Bax upregulation, activation of 
caspase-9 and 3; and DNA fragmentation.  Furthermore, a concomitant impairment in 
mitochondrial biogenesis (decreased TFAM & PGC1α levels); and protein clearance 
mechanisms, as assessed by the accumulation of ubiquitinated aggregates and enhancement of 
autophagic markers (LC3IIB & BECN-1) were found to precede DCV-induced cell death.  In 
order to examine the role of c-Abl in DCV-induced cell death we used dasatinib (DAS), a 
pharmacological inhibitor of c-Abl and gene silencing of c-Abl via siRNA.  Both strategies 
ameliorated DCV-induced apoptotic cell death by attenuating the aforementioned deficits namely 
mitochondrial dysfunction, protein clearance mechanisms, and mitochondrial biogenesis.  On the 
contrary, over expression of c-Abl exacerbated the DCV’s neurotoxic effect.  Our findings 
identify c-Abl tyrosine kinase as a novel upstream regulator of mitochondrial homeostasis and 
that phosphorylation of c-Abl is a key posttranslational modification that is pivotal for the 
impairment in mitochondrial function and protein clearance machinery, thereby leading to the 
induction of cell death in dopaminergic neuronal cells exposed to DCV. 
Introduction 
Dichlorvos (DCV) is a synthetic OP pesticide and can also get in to the environment as a 
degraded product of other OPs, such as trichlorfon and naled (Hofer, 1981; Pettigrew et al., 
1998).  DCV-induced toxicity in humans and animals has been shown to occur via the inhibition 
of AchE (Balali-Mood and Shariat, 1998); however in recent years dichlorvos exposure has been 
shown to promote dopaminergic neuronal loss and associated neuro behavioral deficits including 
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motor and cognitive impairments in various PD models (Binukumar et al., 2011; Binukumar et 
al., 2010a; Binukumar et al., 2010b; Binukumar and Gill, 2010; Wani et al., 2014). 
Epidemiological studies suggest that exposure to environmental pollutants, and 
pesticides, in particular, are positively correlated with Parkinson’s disease (PD) etiology 
(Betarbet et al., 2000; Dauer and Przedborski, 2003; Firestone et al., 2005; Frigerio et al., 2005; 
Kwon et al., 2013; Sveinbjornsdottir, 2016; Teschke et al., 2014; Tuchsen and Jensen, 2000; 
Wirdefeldt et al., 2011).  Several case-control studies in agriculturally advanced countries, 
including USA, Canada, Germany, China and Australia have reported compelling associations 
between pesticide exposure and PD (Chan et al., 2003; Elbaz et al., 2009; Firestone et al., 2005; 
Gamache et al., 2017; McCann et al., 1998; Pezzoli and Cereda, 2013; Seidler et al., 1996). 
The organophosphate (OP) family of chemicals belongs to a diverse group of chemicals 
that are routinely used in agricultural and industrial setting worldwide (Coskun et al., 2015; 
Greaves and Letcher, 2017; Kumar et al., 2016).  OPs exert their activity by inhibiting carboxy 
ester hydroxylase, specifically acetylcholine esterase (AchE) at nerve terminals (Fukuto, 1990; 
Greaves and Letcher, 2017).  The AchE binds irreversibly to OP becoming unavailable for 
converting acetyl choline, a neurotransmitter, to choline and acetic acid.  This results in 
overstimulation of postsynaptic muscarinic and nicotinic receptors.  Some of the commonly used 
OP compounds include insecticides (chlorpyrifos, dichlorvos, trichlorfon, diazinon, fenitrothion, 
naled etc), herbicide (merphos and tribufos), antihelmintics (trichlorfon), nerve agents (soman, 
sarin), and industrial agents (tricresyl phosophate).  Due to such wide spread use of these 
compounds, their pathological effects in humans remains a significant concern.   
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PD is a complex multifactorial neurodegenerative disease, affecting 1-2% elderly 
population over the age of 60 years and 5% over the age of 85 years (Martin et al., 2011a; Salum 
et al., 2016).  The loss of dopaminergic neurons in nigrostriatal regions of brain leads to PD 
pathogenesis (Braak and Braak, 2000).  Though exact cause of PD is unknown, a variety of 
gene-environmental factors have been identified as risk facctors for PD.  For example, oxidative 
stress, mitochondrial dysfunction and impaired protein clearance pathways lead to dopaminergic 
neurodegeneration (Baltazar et al., 2014; Franco et al., 2010; Gomez-Sanchez et al., 2016; 
McNaught and Olanow, 2006; Onyango et al., 2017).  Indeed, oxidative stress and apoptotis 
have been implicated in DVC-mediated neurotoxicity (Binukumar et al., 2012), however, the 
underlying mechanism is unclear.   
c-Abl has been implicated in numerous cellular mechanisms including apoptotic/cell 
cycle arrest, neuronal development, DNA damage response, and oxidative stress and notably has 
been identified as a key player in neurodegenerative diseases (Alvarez et al., 2004; Jing et al., 
2009).  A postmortem analysis of PD brain and brain from A53T the transgenic mouse model 
showed an increased activation of c-Abl kinase particularly in the SN and the striatum (Hebron 
et al., 2013; Ko et al., 2010).  Moreover, inhibition of c-Abl reduced the oxidative stress, 
mitochondrial damage and microglial activation caused by LPS and rotenone (Lawana et al., 
2017); reduced the mutant super oxide dismutase induced cytotoxicity in motor neurons 
(Katsumata et al., 2012); and decreased  neurodegeneration in an amayotropic lateral sclerosis 
mouse model (Katsumata et al., 2012).  Collectively, these studies suggest that c-Abl tyrosine 
kinase may play role in promoting the neurodegeneration, however, the exact downstream 
mechanism of cytotoxicity still remains unclear.   
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In the present study, we investigated the exact contribution of c-Abl tyrosine kinase in 
DCV-induced dopaminergic neurotoxicity.  Using a well-characterized human dopaminergic SH-
SY5Y cells and primary neurons collected from mesencephalic region of mice embryos, we 
investigated a systemic time course analysis of DCV-induced dopaminergic neurotoxicity.  We 
explored the role of oxidative stress, mitochondrial homeostasis, impaired protein clearance 
systems and apoptosis in DCV-exposed neurons.  To investigate the role of c-Abl activation, we 
employed genetic manipulation techniques as well as pharmacological interventions.  Our studies 
demonstrate that c-Abl is a crucial for DCV-induced dopaminergic neurotoxicity and that c-Abl-
mediated induction of mitochondrial dysfunction and disruption of cellular protein homeostasis 
presumably via heightened oxidative stress response contributes to dopaminergic 
neurodegeneration.  
Materials and Methods 
Cell Culture:  SH-SY5Y neuroblastoma cells were obtained from ATCC and grown in DMEM-
F12 medium, supplemented with 10% Fetal Bovine Serum (FBS), 1% Penicillin-streptomycin 
(P/S), 1% Glutamine (Q).  Cells were treated with 50 µM DCV for 6-24h. For c-Abl inhibition 
studies, cells were pre-treated with dasatinib (100nM), for 1 h, followed by cotreatment with 
DCV for 6-24h.  
Gestational 15-day-old mouse embryos were used for primary mesensephalic neurons 
isolation as described previously (Sarkar et al., 2017b).  This protocol was approved by the Iowa 
State University IACUC committee.  Briefly, E15 mouse embryos were dissected, 
mesencephalic tissues were isolated and maintained in ice-cold DMEM media.  The 
mesencephalic tissues were dissociated using 10ml of trypsin-0.25% EDTA (TE) for 15 min in a 
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37°C water bath.  Post incubation in trypsin, tissues were washed twice in 10% DMEM followed 
by a final wash in Neurobasal media and made into a single cell suspension by titurating using a 
10 ml sterile pipette and passed through a 70 µm filter.  The dissociated cells were then plated on 
PDL-coated coverslips.  Cultures were maintained in neurobasal media supplemented with B-27 
supplement, 500mM L-glutamine, 100IU/ml penicillin, and 100μg/ml streptomycin.  The cells 
were maintained in a humidified CO2 incubator (5% CO2 and 37°C) for 24h.  One-half of the 
culture media was replaced every other day.  6-7 day old cultures were used for experiments. 
Transfection:  siRNA knockdown, c-Abl WT overexpression and c-Abl Mutant transfection in 
SH-SY5Y cells were performed using Amaxa Nucleofector Kit (Lonza).  Briefly, 3X106 SH-
SY5Y cells were suspended in 100μl transfection buffer (400 μM ATP-disodium, 600 μM 
magnesium chloride, 100 μM potassium hypophosphate, 20 μM sodium bicarbonate, and 5 μM 
glucose).  The 1.5 nM of c-Abl siRNA (ThermoFisher, CAT #162296), control siRNA (Santa 
Cruz Biotechnology, CAT# sc-37007) or overexpression plasmids were added to the transfection 
mix.  A-23 program of Lonza NucleofectorTM 2b devise was used to transfect the cells (Lawana 
et al., 2017).  The cells were grown for 48h prior to treatments.  
Western Blot:  We performed immunoblot analysis according to previous published protocols 
(Panicker et al., 2015).  Briefly, cell pellets were homogenized in modified RIPA buffer and 
incubated for 10 minutes in ice.  After incubation, the samples were sonicated for 2.5 mins with a 
pulse of 30 secs and centrifuged at 20,000 g for 45 mins.   Bradford assay was performed for 
protein estimation, following centrifugation.  10-15 % SDS-acrylamide gels were loaded with 
25-40µg of protein in each well and ran for 2h for 110V following which, proteins were 
transferred to a nitrocellulose membrane at 27V for 18h at 4°C.  After transfer, the membranes 
were blocked using blocking buffer for 1 h and incubated in primary antibodies for 3h to 18h, 
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washed with PBS-Tween, incubated in IR-secondary antibodies obtained from Rockland, washed 
again with PBS-Tween and scanned using Odyssey® CLx imaging system (LI-COR 
Biosciences, Lincoln, Nebraska).  The following antibodies were used- c-Abl and TH (Millipore, 
1:1000), p-c-Abl Y412, p-PKCd Y311 (Santa Cruz, 1:1000), 4-HNE, 3-NT, Bax, Blc-2, PKCd 
and TFAM (Santa Cruz, 1:1000), PARP, p62, beclin 1, LC3B and PGC-1a (Cell Signaling Tech., 
1:1000) and ubiquitin (Dacko Labs, 1:200).  Secondary antibodies were used according to 
manufacturer’s instruction (IRdye, Rockland).    
Immunocytochemistry (ICC):  SH-SY5Y and primary neurons were plated on PDL-coated 
coverslips in a 24-well cell culture plate.  Post treatment, cells were fixed in 4% 
paraformaldehyde (PFA) for 30 min followed by blocking with 1.5% BSA, 0.05% Tween, and 
0.5% Triton for 1 h.  Primary antibodies were prepared in 1% BSA and incubated overnight at 
4°C.  The following primary antibodies were used TH (Millipore, 1: 2000), LC3B (Cell 
Signaling Tech., 1:300), and ubiquitin (Santa Cruz, 1:200).  Following primary antibody 
incubation, cells were washed with PBS five times, and then incubated with secondary antibody 
for 1 h.  Hoechst (1:3000) was used to stain for cell nuclei, and mounted on slides using the 
Fluoromount mounting medium (Sigma).  Slides were dried overnight and then imaged using a 
Nikon Eclipse C1 microscope.  
Cell Death Assay:  MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt] assay was performed according to our previous 
publication (Sarkar et al., 2017a).  Briefly, cells were treated for 24h after which 10µl of MTS 
dye was added and incubated for 45mins at 37°C. Following incubation, a plate reader was used 
to record the absorbance at a wavelength of 490nM and 640nM for background subtraction.  
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Caspase activity Assay:  Caspase-3 enzymatic activity was performed using Ac-DEVD-AFC 
(Santa Cruz, 25μm) and Caspase-9 enzymatic activity was performed using Ac-LEHD-AFC 
(Santa Cruz, 25μm), a fluorometric substrates for the reaction, as described previously (Gordon 
et al., 2016).  Fluorescent signals were recorded using Synergy-2 multi-mode microplate at an 
excitation/emission of 400nm/505nm.  The data generated was normalized by determining 
protein concentrations and were converted to percent of control group. 
Mitochondrial Membrane Potential Assay:  Lipophilic JC-1 dye (Invitrogen) was used to 
measure mitochondrial membrane integrity (Lawana et al., 2017).  Briefly, post-treatment cells 
were incubated with 2μg/ml JC-1 dye for 30 mins, following which cells were washed with PBS 
and analyzed by measuring red fluorescence at an excitation/emission of 590 nm/600 nm and 
green fluorescence excitation/emission of 485 nm/535 nm.  The monomeric dye (green) turns red 
after polymerization by mitochondrial outer membrane.  However, cells with damaged 
mitochondria have reduced accumulation of red polymers.  The change in mitochondrial 
potential is represented as the ratio of Red:Green florescence. 
Cytochrome C Assay:  The cytochrome C Assay kit was obtained from Abcam (ab109909) and 
the assay was performed following manufacturer’s protocol.  Briefly, SH-SY5Y cells were lysed 
using mitochondrial fractionation kit (Thermo Fisher Scientific) following manufacturer’s 
protocol.  Then the mitochondrial and the non-mitochondrial fractions were incubated in an 
ELISA plate for 3h.  Post incubation 200µl of assay buffer was added to each well and the 
optical density was measured at 550nm. The change in FU was converted to percent control and 
were plotted for mitochondrial and cytocolic fractions. 
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ROS generation assay:  The cells were plated in 96-wellplate.  Posttreatment, the cells were 
incubated with redox sensitive CM H2DCFDA dye (Invitrogen, 1μM) for 1h.  Following 
incubation, the cells were washed with PBS two times, and a plate reader was used to detect the 
fluorescent intensity at an excitation and emission wavelength of 488nm and 525nm, 
respectively.  The change in FU indicated the level of ROS post-treatment. 
DNA fragmentation assay:  For the DNA fragmentation assay, SH-SY5Y cells were plated in 
6-well plates treated the following day.  Posttreatment, cells were lysed using the lysis buffer 
centrifuged at 200 x g for 10 min and supernatant were collected.  The extent of DNA 
fragmentation was then quantified using the Cell Death Detection ELISA Plus assay kit (Roche 
Applied Science) according to previously published methods (Gordon et al., 2016).  A plate 
reader was used to record the absorbance at a wavelength of 405nm and 690nm for background 
subtraction.  The amount of protein in each sample lysate were used to normalize the raw 
absorbance values. 
Statistical Analysis:  GraphPad 5.0 was used for statistical analysis with p<0.05 considered 
statistically significant. One-way ANOVA was used for comparing multiple groups. In most 
cases, Tukey post analysis was applied. For comparing 2 groups, Student’s t-test was used. 
Results 
DCV induces dose and time-dependent cell death in dopaminergic SH-SY5Y 
neuroblastoma cells 
Initially we sought to investigate the vulnerability of SH-SY5Y neuroblastoma cells to 
DCV-induced cell death.  For this purpose the SH-SY5Y neuroblastoma cells were exposed to 
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increasing concentrations of dichlorvos (DCV) (1µM - 1000µM) and cell viability was assed at 
24h using MTS mitochondrial metabolism assay (N = 6-8).  DCV-induced a concentration 
dependent reduction in MTS metabolism whereby 10, 30, 100, 300, 500 and 1000μM DCV led 
to an 8, 24, 36, 48, 82 and 91%, reduction in the metabolism compared to non-treated control 
group.  These studies suggested that DCV reduces the viability of SH-SY5Y cells.  Moreover, 
the three-parameter nonlinear regression analysis revealed an IC50 of 305.1µM for DCV in SH-
SY5Y cells.  We chose 50µM for the reminder of the studies based on the minimum 
concentration that elicited a significant increase in cell death. 
DCV causes a time-dependent increase in oxidative stress markers and an accompanying 
reduction in the cellular antioxidant status in SH-SY5Y neuroblastoma cells 
As others have found DCV-mediated ROS prodciton, we examined the generation of 
reactive oxygen species (ROS) in DCV treated cells.  Figure 1(B) shows that DCV treatment 
caused time-dependent increase in ROS levels as compared with vehicle treated cells.  In this 
context, DCV-induced a significant increase ((p<0.05); 54%) in ROS levels as early as 6h, and 
maximal elevation (300%) was evidenced at 24h post treatment as compared with vehicle treated 
cells (p<0.001).  Next, we examined the influence of DCV on cellular GSH levels, a marker of 
cellular antioxidant status.  Starting at 6h, DCV caused a 12% reduction in GSH levels, and a 
sustained reduction (40-80%) was evidenced during the remaining treatment period (figure 
1(C)). 
Lipid peroxidation has been shown to occur following excessive oxidative stress in 
neuronal cells (Butterfield and Lauderback, 2002; Coyle and Puttfarcken, 1993; Dexter et al., 
1989; Furukawa et al., 2004).  To further assess the impact of DCV on lipid peroxidation-related 
139 
 
markers, we utilized WB analysis.  For this purpose, SH-SY5Y cells were exposed to 50µM 
DCV for the indicated time period and at the end of the incubation period cell lysates were 
prepared and probed for 4-HNE and 3-NT using immunoblotting analysis.  As shown in figure 
1(E), treatment with DCV caused statistically significant increases in both 4-HNE and 3-NT as 
compared with vehicle treated cells.  More specifically, densitometric analysis revealed a 2-3-
fold increase in both 4-HNE and 3-NT levels at 24h post DCV treatment as compared with 
vehicle treated cells.  These results, together with other published studies support the prooxidant 
role of DCV in SH-SY5Y dopaminergic neuronal cells. 
DCV treatments depletes mitochondrial membrane potential in SH-SY5Y dopaminergic 
cells 
Previous studies have demonstrated that free radicals and lipid peroxidation products 
alter the mitochondrial integrity by creating membrane permeability pores on the outer 
mitochondrial membrane (Kirkland et al., 2002; Ott et al., 2007).  These pores result in the loss 
of mitochondrial membrane potential (∆Ψm) leading to the disruption of electron transport chain 
homeostasis and eventually ATP depletion (Giaime et al., 2012; Thomas et al., 2012).  To 
examine whether DCV-induced oxidative stress response is associated with the collapse of MMP 
we determined MMP following exposure of SH-SY5Y cells to DCV (50µM) using a cationic 
carbocyanine dye, JC-1.  JC-1 exhibits red flurescence in healthy cells and green fluorescence in 
cells with a collapsed MMP (Catedo et al., 2002).  In fact, plate reader analysis revealed time-
dependent a shift from red to green fluorescence indicative of collapse of ∆Ψm in SH-SY5Y cells 
exposed to DCV. 
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DCV-induces mitochondria mediated apoptotic cell death signaling events in SH-SY5Y 
cells 
Previous studies have implicated apoptotic cell death in the mechanism of DCV-induced 
dopaminergic neurodegeneration (Park et al., 2013).  Exposure to DCV enhanced both caspase-9 
and 3 activity in a time-dependent manner (Fig. 2 (B,C)).  Increased activation of the latter was 
evidenced in a delayed fashion.  To further ascertain caspase-3 mediated apoptotic cell death we 
assessed PARP cleavage, a caspase 3 substrate, in DCV treated cells.  As expected, DCV 
treatment induced the maximal cleavage of PARP at 24h (Fig. 2(F)), which coincided with 
elevated caspase-3 activation.  Our results suggested that DCV-induced apoptotic cell death via 
the caspase-3 dependent PARP cleavage in SH-SY5Y neuronal cells. 
We further investigated the downstream signaling mechanisms underlying DCV-
mediated dopaminergic neurotoxicity.  Induction and activation of c-Abl, a redox sensitive 
protein kinase, has been recently identified as a key factor in dopaminergic neurodegeneration 
(Brahmachari et al., 2016; Imam et al., 2011; Karuppagounder et al., 2014; Ko et al., 2010).  
Therefore, we first examined the effect of DCV on protein expression and phosphorylation of c-
Abl tyrosine kinase, in SH-SY5Y cells treated with 50µM DCV for 6, 12, 18 and 24h using WB 
analysis.  Densitometric analysis showed that DCV treatment caused a 2.5- and 3.2-fold increase 
in c-Abl and c-Abl Y412 phosphorylation, respectively, at 24h in DCV-treated cells as compared 
with vehicle-treated cells. 
Studies from our group have shown that exposure to dopaminergic neurotoxicants causes 
activation of PKCδ, a redox-sensitive serine threonine protein kinase, via phosphorylation and 
proteolytic cleavage via caspase-3 (Anantharam et al., 2002; D'Costa and Denning, 2005; 
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Kanthasamy et al., 2003)(Fan et al., 2006; Kanthasamy et al., 2008).  Furthermore, PKCδ is a 
substrate for c-Abl kinase leading to phosphorylation at tyrosine 311 residue (Gonfloni et al., 
2012; Liu et al., 2011; Lu et al., 2007).  Given this, we evaluated PKCδ phosphorylation and 
cleavage in DCV-treated SH-SY5Y Upon treatment of SH-SY5Y dopaminergic cells, an 
increase in phosphorylation at Y311 residue of PKCδ (figure 2(A)) as well as cleaved products 
(figure 2(D)) were evidenced in a time-dependent manner.  Moreover, DCV significantly 
(p<0.05) hyperphosphorylated PKCδ at the tyrosine residue 311 (Y311) starting at 12h post-
exposure, and an aberrant increase (650%) in pY311 band intensity was evidenced at 24h time-
point (figure 2(A)).  Likewise, a marked time-dependent increase in the formation of cleaved 
fragments of PKCδ was found in DCV-treated cells as compared with vehicle-treated cells.   
During apoptotic cell death many Bcl protein family members play a crucial role in 
regulating mitochondrial function, whereby upregulation of proapoptotic Bax is found to 
accompany the downregulation of antiapoptotic Bcl-2 prior to cell death (Ola et al., 2011; Reed, 
2006).  Previous studies have identified that excessive oxidative stress leads to accumulation of 
Bax (Lin and Beal, 2006; Steckley et al., 2007; Xu et al., 2008) and degradation of Bcl-2 protein 
levels (Pugazhenthi et al., 2003; Ray et al., 2000; Xu et al., 2008).  As shown in Fig. 2(E), 
exposure of SH-SY5Y cells to DCV (50µM) caused a time-dependent increase in the expression 
levels of Bax and an accompanying reduction in Bc-2 levels.  
DCV-induces impairment in cellular proteastasis in SH-SY5Y cells via a c-Abl dependent 
mechanism 
During PD neurodegeneration, neurons exhibit dysfunctional protein degradation and 
clearance mechanisms, owing to the disruption of the ubiquitin-proteasomal activity (Martins-
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Branco et al., 2012; Sun et al., 2007) and autophagic degradation (Kanthasamy et al., 2012; 
Nixon, 2013).  Consistent with these reports, we observed that treatment of SH-SY5Y cells with 
DCV led to a time-dependent decrease in proteasomal activity as determined using the 20S-
proteasome substrate.  Our results indicated that DCV caused 33, 36, 52 and 64% reduction in 
proteasomal activity after 6, 12, 18 and 24h, respectively post-DCV treatment, compared with 
control group.  Accumulation of heavy molecular weight (HMW)-ubiquitinated proteins is 
indicative of dysfunctional ubiquitin-proteasomal system (UPS) due to loss of proteasome 
activity and resulting reduced clearance of ubiquitinated proteins.  Our analysis shows that 50µM 
DCV treatment causes time-dependent increase in the accumulation of HMW-ubiquitinated 
proteins. The western blot shown in figure 5(C) revealed a 1.75-fold increase in aggregated 
proteins (p<0.05) starting at 6h following OP treatment and a substantial increase (2.7-fold) at 
24h (p<0.001) as compared with vehicle-treated controls. 
In addition to UPS, autophagy is another important cellular protein clearance mechanism 
that facilitates the clearance of damaged organelles and long lived proteins (Azad et al., 2009; 
Cherra and Chu, 2008; Gozuacik and Kimchi, 2007; Lin et al., 2012; Mizushima et al., 2008).  
Accumulation of autophagic vacuoles (AV) may indicate impairment in autophagic flux (Geng et 
al., 2010; Lin et al., 2012; Yamamoto et al., 1998).  To determine whether CPF-induces 
autophagic mechanisms in SH-SY5Y cells, cells were incubated with 50µM CPF for the 
indicated time periods.  Subsequently, we determined the expression levels of LC3 (microtubule-
associated protein 1 light chain 3) and p62 by western blotting.  Immunoblotting analysis 
revealed that DCV treatment enhanced the expression of LC3 and beclin-1 in a time dependent 
manner.  Intriguingly, p62 which targets ubiquitinated proteins for autophagic degradation 
showed a time-dependent increase in DCV treated cells suggesting an impairment in autophagic 
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degradation (Fig. 5(E)).  Densitometric analysis indicates a 1.95-fold increase of LC3B II by, 
3.5-fold increase in beclin-1 and a 1.9-fold increase in p62 at 24h post-DCV treatment as 
compared with vehicle treated controls.  To further confirm our WB results, we performed dual 
ICC labeling analysis for LC3B and ubiquitin.  The results showed increased co-localization of 
LC3 positive punctate structures (green) with ubiquitin positive aggregates (red) in DCV-treated 
SH-SY5Y cells as compared with vehicle-treated cells.  These data suggest that DCV treatment 
impairs cellular proteostasis in SH-SY5Y cells. 
Studies indicate a positive correlation between c-Abl kinase and accumulation of 
dysfunctional autophagosomes (Ertmer et al., 2007; Yogalingam and Pendergast, 2008).  
Moreover, recently researchers showed that c-Abl tyrosine kinase controls proteasome activity 
and c-Abl upregulation leads to inactivation of proteasome (Li et al., 2015; Liu et al., 2006).  To 
investigate the role of c-Abl in our study, we depleted c-Abl via gene silencing (c-Abl KD) and 
chemical inhibition (DAS).  Both methods of c-Abl inhibition restored the proteasomal activity 
by 60% post DCV exposure (Fig. 5(C)) and attenuated drug-induced accumulation of ubiquitin-
positive heavy molecular protein aggregates (Fig. 5(D)).  Intriguingly, DCV-mediated 
conversion of LC3B I to II was completely abrogated (p<0.05) (Fig. 5(G)).  Likewise, DCV-
mediated increase in beclin1 and p62 was also significantly (p<0.05) reduced (36-45%) in c-Abl 
siRNA-transfected cells as compared with scrambled siRNA-transfected cells (Fig. 5(H)).  
Furthermore, in c-Abl siRNA-transfected cells, ICC studies further confirmed the lack of 
colocalization of LC3 and Ub-positive structures.  Likewise, in DAS-treated cells DCV treatment 
failed to cause LC3 and Ub colocalization (Fig. 5(I), bottom 2 rows), consistent with previous 
studies that c-Abl is a critical regulator of autophagic clearance mechanisms and UPS (Lawana et 
al., 2017; Li et al., 2015). 
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DCV-mediates the loss of mitochondrial biogenesis markers via c-Abl in SH-SY5Y cells   
Next, we investigated whether alteration of mitochondrial biogenesis markers may 
accompany DCV-induced mitochondrial dysfunction and to what extent it may be regulated by 
c-Abl.  Peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) and TFAM 
are key transcriptional regulator of mitochondrial respiration, antioxidant system and 
thermogenesis systems (Borniquel et al., 2006; Jones et al., 2012; Liang and Ward, 2006; Wu et 
al., 1999).  Our WB results revealed a time-dependent decrease in the expression of these 
mitochondrial biogenesis related proteins.  PGC1α and TFAM levels reduced by 78%, 72%, 
56% and 28% at 6, 12, 18 and 24h after DCV treatment, respectively as compared with vehicle 
treated control group (Fig. 6(A)).   Taken together, our results suggest that impairment in 
mitochondrial biogenesis combined with mitochondrial dysfunction may partly contribute to 
DCV-induced apoptotic cell death 
Oxidative stress is thought to play a key role in degrading PGC-1α (Chen et al., 2011; 
Shi and Gibson, 2007) and TFAM (Choi et al., 2001; Xu et al., 2009).  Having demonstrated a 
positive correlation between c-Abl activation and oxidative stress in DCV-treated SH-SY5Y 
cells (figure 2), we next determined whether c-Abl tyrosine kinase is a critical regulator of 
mitochondrial biogenesis.  For this purpose, we again downregulated c-Abl activity via c-Abl 
siRNA transfection or DAS pretreatment, and subsequently determined the protein expression of 
mitochondrial biogenesis marker proteins in DCV-treated cells.  Western blot analysis revealed 
that c-Abl downregulation attenuated DCV-induced loss of PGC-1α and TFAM levels.  
Specifically, 100nM DAS pretreatment followed by DCV exposure showed elevated (41%) 
levels of PGC-1α and TFAM (57%), respectively, as compared with DCV-treated group. 
Similarly, c-Abl RNAi-transfected cells displayed 38 and 40% increase in PGC-1α and TFAM 
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levels, respectively, in response to DCV treatment as compared with scrambled siRNA-
transfected cells exposed to DCV (Fig. 6(B)).  These results further support the negative 
regulatory effects of c-Abl on mitochondrial biogenesis in DCV-treated cells.  
c-Abl contributes to DCV-mediated apoptotic cell death in SH-SY5Y cells 
Having demonstrated above that redox sensitive kinase such as c-Abl levels are activated 
as early as 6h, we next investigated the contribution of c-Abl in DCV-mediated cell death in SH-
SY5Y dopaminergic neuronal cells.  In the present study we hypothesized that c-Abl is a critical 
determinant in DCV-induced apoptotic cell death.  Therefore, to further evaluate this hypothesis 
we implemented various strategies to modulate c-Abl levels including siRNA mediated c-Abl 
knock-down (c-Abl KD), pharmacological inhibition by dasatinib (DAS), or overexpression of 
either c-Abl wild-type constructs (c-Abl WT) or kinase deficient mutant of c-Abl (c-Abl Mut).  
Upon modulation of c-Abl levels using the afore mentioned strategies, cells were exposed to 
50µM DCV for 24h and DNA fragmentation was examined to measure apoptotic cell death.  
Figure 3(A) shows that exposure to DCV-induces a significant increase in DNA fragmentation; 
however, c-Abl inhibition via DAS, siRNA-mediated knockdown or by expressing mutant kinase 
reduced DCV-induced cell death by 46%, 51% and 32% respectively in SH-SY5Y cells.  On the 
other hand, overexpression of wild-type c-Abl potentiated the cell death induced by DCV by 
12%.  Taken together, these results strongly suggest that increase in c-Abl activation might 





Inhibition of c-Abl activation attenuates DCV-induced oxidative stress response in SH-
SY5Y cells 
Previous studies have highlighted the pivotal role of c-Abl in modulating cellular 
oxidative stress response upon exposure to diverse stressors (Cao et al., 2003b; Kumar et al., 
2001; Sattler et al., 2000; Sun et al., 2000).  Additionally,  c-Abl has been shown to regulate 
intracellular levels of glutathione peroxidase and GSH (Cao et al., 2003b).  Having demonstrated 
that DCV-induced c-Abl activation positively correlates with oxidative stress response in SH-
SY5Y, we then investigated the effects of DAS or siRNA targeted against on DCV-induced 
upregulation of markers of oxidative stress in SH-SY5Y cells.  siRNA-mediated c-Abl KD show 
significant (p<0.0001) resistance against DCV-mediated oxidative stress response.  Both DAS 
and c-Abl siRNA reduced the aberrant increase in ROS generation by 44 and 51% (Fig. 3(C)), 
respectively, and depletion of GSH levels by 52 and 39% (Fig. 3(D)), respectively in DCV-
treated cells.  Likewise, DAS abrogated DCV-induced upregulation of 4-HNE (40%) and 3-NT 
levels (220%) in SHSY cells (Fig. 3(E)).  Similarly, c-Abl KD reduced DCV-mediated increase 
in 4-HNE expression by 30% and 3-NT expression by 45%, respectively (Fig. 2(F)).  These 
results confirm that DCV promotes oxidative stress in SH-SY5Y dopaminergic cells, via a c-Abl 
tyrosine kinase dependent mechanism. 
DCV-induced impairment in MMP in dopaminergic neuronal cells is regulated by c-Abl 
kinase 
A previous study performed in prion cell culture model pointed that c-Abl may play a 
central role in regulating mitochondrial health (Pan et al., 2014).  Moreover, another study 
suggested that activated c-Abl may translocate to mitochondria and impair the MMP (Cao et al., 
2003b).  Since increased oxidative stress has been shown to reduce MMP (Giaime et al., 2012; 
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Pan et al., 2014), we investigated the role of c-Abl in DCV-induced MMP loss.  As anticipated, 
c-Abl KD and DAS inhibited DCV-induced loss of MMP by 45 and 49%, respectively (Fig. 
3(F)).  Our results strongly suggests that collapse of MMP after DCV treatment is mediated via a 
c-Abl kinase-dependent mechanism which is in accordance with previously published findings 
(Cao et al., 2003b; Karuppagounder et al., 2014; Kumar et al., 2001; Lawana et al., 2017; Pan et 
al., 2014).  
Inhibition of c-Abl attenuates caspase activation and mitochondrial release of cytochrome 
C in DCV -treated dopaminergic neuronal cells 
Reduction in MMP leads to the release many proapoptotic factors including cytochrome 
C from mitochondrial intermembrane to the cytoplasm (Gomez-Lazaro et al., 2007; Junn and 
Mouradian, 2001; Rasola and Bernardi, 2007), followed by the induction of intrinsic cell death 
signaling events via the activation of initiator caspase-9 and then effector caspase-3 (Kitazawa et 
al., 2003; Perier et al., 2007).  Hence, we measured the the post-mitochondrial events in DCV-
treated neuronal cells.  First, the release of cytochrome C was measured in SH-SY5Y cells 
treated with 50µM DCV for 24h.  The 24h time-point was chosen because an increased 
magnitude in MMP loss was observed at this time point (Fig. 1(E)).  The cytochrome C levels 
were determined by cellular fractionation strategies involving the separation of mitochondrial 
and cytosolic fractions and subsequently subjected to ELISA analysis.  Our results revealed that 
DCV caused a significant (p<0.0001) increase in cytosolic cytochrome C (by 2.4-fold) and a 
concurrent depletion in mitochondrial cytochrome C levels (by 80%), indicative of mitochondrial 
release of cytochrome C (Fig. 4(A)).  Given that inhibition of c-Abl reversed MMP impairment 
caused by DCV (Fig. 3(F)), we next examined its effects on DCV-induced mitochondrial release 
of cytochrome C.  As anticipated, c-Abl inhibition significantly inhibited DCV-induced 
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cytochrome C release from mitochondria to cytoplasm (p<0.0001).  Both DAS and c-Abl KD, 
reduced mitochondrial release of cytochrome C levels by 50-60% post-DCV exposure and were 
comparable to control cells (Fig. 4(A)).  
The translocation of cytochrome C from mitochondria to cytoplasm triggers the 
activation of intrinsic pathway of apoptosis by first activating caspase-9 followed by activation 
of caspase-3 (Kitazawa et al., 2003; Perier et al., 2007).  Exposure of c-Abl-depleted SH-SY5Y 
cells (DAS and c-Abl KD) showed significantly less activation of caspase-9 (by 50% (p<0.001)) 
and caspse-3 (by 45% (p<0.0001), respectively, as compared with DCV treatment group.  These 
results closely parallel the preservation of MMP and inhibition of mitochondrial release of 
cytochrome in c-Abl inhibited cells exposed to DCV.  Together, our studies demonstrate the 
upstream role of c-Abl in the regulation of DCV-mediated dopaminergic neurotoxicity via 
oxidative stress and mitochondria dependent mechanisms. 
c-Abl regulate the activation of PKCδ in DCV-treated dopaminergic neuronal cells 
Our previous study demonstrated that c-Abl phosphorylates PKCδ at Y311 in activated 
microglia (Lawana et al., 2017).  On the other hand, study performed in β cells demonstrated that 
pharmacological inhibitors of c-Abl kinase prevented the proteolytic cleavage and activation of 
PKCδ (Karunakaran et al., 2015).   In this context, we evaluated the PKCδ phosphorylation and 
cleavage in DCV-treated SH-SY5Y and identified the similar pattern of PTM of PKCδ.  SH-
SY5Y dopaminergic cells treated with 50μM DCV showed a time-dependent elevation in 
phosphorylation at Y311 residue of PKCδ (up to 5.5-folds) (Fig. 3(B)) and PKCδ cleaved 
products up to 11-fold (Fig. 4(A)) in SH-SY5Y cells.  Using c-Abl KD and DAS pretreatment, 
we further investigated the role of c-Abl in the activation PKCδ.  Downregulation of c-Abl via 
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RNAi-mediated gene silencing and DAS-mediated inhibition was confirmed using western 
blotting technique shown in Fig. 1(C).  In both cases, significant (p<0.01 for DAS and p<0.001 
for c-Abl KD) reduction in Y412 phosphorylation of c-Abl was noticed, indicating lack of kinase 
activity.  Most intriguingly, in DAS and c-Abl siRNA transfected cells, DCV-mediated aberrant 
hyperphosphorylation (Fig. 1(C)) as well as cleavage of PKCδ was comparable with control cells 
(p<0.01) (Fig. 4(B)).  These results indicate that c-Abl is an upstream regulator of PKCδ.  
DCV-induced modulation of apoptosis related proteins in dopaminergic neuronal cells 
requires c-Abl 
Having demonstrated the upregulation of PKCδ in DCV-treated cells, we next checked 
the expression of Bax and Bcl-2 in SH-SY5Y cells pretreated with DAS or transfected with c-
Abl siRNA.  Fig. 4(D) shows that DAS and c-Abl KD reduced the DCV-mediated Bax 
upregulation by almost 60% (p<0.05), while almost completely abolished the loss of Bcl-2 
protein levels (p<0.05).  Since, activation of PARP is directly proportional to caspase-3 
activation (Krupinski et al., 2002) and that c-Abl is a positive regulator of caspase activity (Raina 
et al., 2005), we examined PARP expression in DCV-treated cells that were subjected to DAS 
and c-Abl KD.  As expected, the DCV-induced PARP cleavage was almost completely blocked 
in c-Abl depleted SH-SY5Y cells (Fig. 4(F)).  Our studies further bolster the central role of c-Abl 
tyrosine kinase in the regulation of intrinsic mitochondria mediated cell signaling events.  
Gene silencing of c-Abl and DAS abrogates DCV-induced impairment in proteostasis 
During PD neurodegeneration, neurons exhibit dysfunctional protein degradation and 
clearance machinery, mostly via loss of ubiquitin-proteasomal activity (Martins-Branco et al., 
2012; Sun et al., 2007) and autophagic degradation (Kanthasamy et al., 2012; Nixon, 2013).  
Cellular accumulation of ubiquitin-positive protein aggregates has been shown to promote 
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neuronal injury (Casarejos et al., 2011; Kanthasamy et al., 2012; Lin et al., 2012; Sun et al., 
2007; Wang and Figueiredo-Pereira, 2005).  In this context, loss of proteasomal activity leads to 
cytotoxic accumulation of misfolded proteins within the cell (Casarejos et al., 2011; Kanthasamy 
et al., 2010; Sun et al., 2007).  Moreover, DCV has also been shown to promote the aggregation 
of α-synuclein and ubiquitin positive aggregates in substantia the nigra region of DCV exposed 
rats (Binukumar et al., 2010b).  Interestingly, a study in liver samples zebrafish showed that gene 
expression of UPS-related markers was upregulated after DCV treatment (Bui-Nguyen et al., 
2015).  In this study we observed that SH-SY5Y cells subjected to DCV treatment showed time-
dependent decrease in proteasomal activity, as assessed by degradation of 20S-proteasomal 
substrate (Fig. 5(A)).  The bar graph shows that DCV caused 33, 36, 52 and 64% reduction in 
proteasomal activity after 6, 12, 18 and 24h post DCV treatment, compared with control group.  
To further ascertain UPS dysfunction using WB analysis, we next determined the magnitude of 
accumulation of HMW-ubiquitinated proteins, indicative of dysfunctional ubiquitin-proteasomal 
system (UPS).  Our analysis shows that 50µM DCV treatment causes time-dependent increase in 
accumulation of HMW-ubiquitinated proteins.  The western blot shown in Fig. 5(C) revealed 
that non-treated control showed almost no accumulation of ubiquitinated proteins, whereas 
DCV-treatment starting at 6h displayed a 1.75-fold increase in aggregated protein levels (p<0.05) 
eventually leading to an aberrant 2.7-fold increase at 24h (p<0.001).  
In the next set of studies we examine the status of autophagic mechanisms which 
represents another important cellular protein clearance mechanism.  Accumulation of autophagic 
vacuoles (AV) may indicate alteration of autophagic flux (Geng et al., 2010; Lin et al., 2012; 
Yamamoto et al., 1998).  Immunoblotting (Fig. 5(E)) and immunocytochemical images (Fig. 
5(I)) of LC3B, an autophagy marker, revealed that DCV treatment caused the increase in 
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autophagosome formation and accumulation of AVs in SH-SY5Y cells.  Autophagy can a play 
both pro-survival and pro-apoptotic role (Ouyang et al., 2012).  In a normal cellular homeostasis 
ubiquitinated cargo is tagged to sequestosome-like protein such as p62, which then binds with 
vesicular membrane formed by multi-macromolecular complex which includes beclin1 and 
LC3B II and are ultimately subjected to degradation by lysosomes (for detailed review (Green 
and Levine, 2014)).  Next, using WB analysis we analyzed autophagic markers using WB 
analysis.  Western blot analysis revealed an upregulation of beclin1 and p62 as well as 
conversion of LC3B I to active LC3B II (LC3B-PE) in a time-dependent manner (Fig. 5(E, G)).  
Densitometric analysis further revealed an increase in LC3B II (by 1.95-fold), beclin-1 (by 3.5-
fold) and p62 (by 1.9-fold) at 24h post DCV treatment as compared with vehicle treated controls.  
These results parallel impairment in UPS activity further confirming dysfunctional protein 
clearance machinery in DCV treated SH-SY5Y cells.   
Studies indicate a positive correlation between c-Abl kinase and accumulation of 
dysfunctional autophagosomes (Ertmer et al., 2007; Yogalingam and Pendergast, 2008).  
Moreover, c-Abl upregulation has been shown to lead to the inactivation of proteasomal function 
(Li et al., 2015; Liu et al., 2006).  Therefore, we next investigated the influence of c-Abl on 
DCV-induced autophagosmal dysfunction.  For this purpose, we depleted the c-Abl via gene 
silencing (c-Abl KD) and chemical inhibition (DAS).  Both methods of c-Abl inhibition restored 
the proteasomal activity by 60% post DCV exposure (Fig. 5(B)) and failed to display an 
accumulation of ubiquitin-positive heavy molecular proteins (Fig. 5(D)).  Intriguingly, the DCV-
mediated conversion of LC3B I to II was completely abrogated (p<0.05) (Fig. 5(F)).  Likewise, 
DCV-mediated increase in beclin1 and p62 was also significantly (p<0.05) reduced to 36-45% 
by DAS or c-Abl siRNA (Fig. 5(H)).  Concordant with WB findings, immunofluorescent 
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analysis in c-Abl KD or DAS-pretreated SH-SY5Y cells failed to display accumulation of AVs 
and ubiquitinated proteins in DCV-treated cells (Fig. 5(I), bottom 2 rows).  Collectively, our 
results indicate that DCV-induces impairment in protein degradation machinery via c-Abl. 
c-Abl regulates DCV-mediated loss of mitochondrial biogenesis markers 
In the aforementioned studies, we demonstrated that DCV-induced the loss of 
mitochondrial biogenesis marker, PGC1α and TFAM (Fig. 6(A)).  Therefore, in the next set of 
studies we analyzed the impact of c-Abl.  As shown in Fig. 6(B), c-Abl inhibition abrogated 
DCV-mediated loss of PGC-1α and TFAM expression levels.  Specifically, 100nM DAS 
pretreatment followed by DCV exposure showed 41% higher PGC-1α and 57% higher TFAM 
levels compared with DCV alone group. Similarly, DCV treatment of c-Abl RNAi-transfected 
cells had 38 and 40% greater PGC-1α and TFAM levels, respectively, compared with DCV 
group.  These results support a model in which c-Abl is a critical regulator of DCV-induced 
mitochondrial dysfunction. 
DAS confers resistance against DCV neurotoxicity in primary mesencephalic dopaminergic 
neuronal culture 
Having established that inhibition of c-Abl attenuated DCV-induced apoptotic cell death 
via inhibition of mitochondria mediated cell death signaling events in a PKCδ-dependent 
manner, we next validated our findings in primary midbrain neuronal cultures.  Primary 
mesencephalic neurons serve as an ideal in vitro model for dissecting dopaminergic neurotoxic 
mechanisms.  Researchers have extensively used this model for evaluating the neurotoxic 
potential of Parkinsonian toxins (Asaithambi et al., 2014; Batelli et al., 2015; Collo et al., 2013; 
Radad et al., 2014; Salum et al., 2016; Weinert et al., 2015).  Primary mesencephalic neurons, 
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isolated from E15-E18 C57b mice embryos, were pretreated with 100nM DAS for 1h followed 
by 50µM DCV for another 24h.  After treatment, cell lysates were subjected to immunoblotting 
using TH antibody.  WB analysis revealed that DCV exposure caused a 68% reduction in TH 
levels (p<0.01) (Fig. 8(A)).  Interestingly, DAS pretreatment induced a near complete abrogation 
of DCV-induced TH loss (92%) as compared with DCV only treated group (Fig. 8(A)). Next, to 
further confirm DCV-induced alteration of dopaminergic neuronal morphology, we probed 
midbrain cultures with TH antibody (red) and counter stained the nucleus with Hoechst (blue) 
stain.  The ICC studies revealed that DCV treatment reduced both the total number and length of 
neurites in TH+ neurons (Fig. 8(B, C and D)).  The third row from top in Fig. 8(B) shows the 
cells treated with 50μM DCV showing TH-stained dopaminergic neuron; whereas, last row 
shows the cells pre-treated with 100nM DAS followed by DCV.  First, we noted that DCV 
caused 50% reduction in total numbers of TH-stained neurons, which was effectively prevented 
by DAS pretreatment (p<0.05) (Fig. 8(C)).  Next, Fig. 8(D) demonstrates the analysis done using 
ImageJ® software revealing the significant (p<0.001) reduction in neurites length by DCV (by 
74% compare to control).  Likewise, DAS pre-exposure showed protective effect on DCV 
toxicity by improving the total neurite length by 52% higher than DCV alone group (25% lower 
than control, Fig. 8(D)). 
Further evaluation involved the western blot analysis of mesencephalic cultures treated 
with DCV with or without DAS.  Fig. 8(E) demonstrates that DCV treatment caused aberrant 
upregulation of c-Abl kinase protein levels to about 2.4-folds higher than control (p<0.05).  
Additionally, increase in phosphorylation of c-Abl at Y412 residue by 3-folds and PKCδ at Y311 
residue by 2.1-folds were evident.  To establish the DCV effect in primary mesencephalic 
neuronal culture similar to SH-SY5Y neuronal cells, immunoblots were employed to check for 
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apoptotic markers, autophagy markers and mitochondria biogenesis markers.  Fig. 8(F) shows 
that primary mesencephalic neurons treated with DCV increased beclin1 protein levels by 2.9-
folds indicating the increase in autophagy, while loss of PGC-1α and TFAM protein levels by 58 
and 45%, respectively, and indicates the loss of healthy mitochondria production.  At last, the 
increase in proapoptotic Bax protein expression by 2.9-folds and decreased antiapoptotic Bcl-2 
expression by 72%, compared to control, indicate the commencement of apoptotic machinery 
after DCV treatment.  
It stays crucial to evaluate the role of c-Abl in these toxicity mechanisms. To evaluate, 
cells were pretreated with DAS (100nM, 1h) followed by DCV (50μM, 24h) treatment.  
Immunoblot presented in Fig. 8(E) shows that DAS pretreatment had 30, 27 and 35% lesser 
increase in DCV-mediated c-Abl expression, c-Abl Y412 phosphorylation and PKCδ Y311 
phosphorylation, respectively, compared to DCV alone group.  Next, the densitometry of western 
blots shown in Fig. 8(F) reveal that DAS rescues the primary neurons from autophagy 
upregulation via diminishing the increase in beclin1 to about 50% compare to DCV alone group.  
The loss of mitochondrial biogenesis markers, PGC-1α and TFAM, were recovered with DAS by 
40 and 34%, respectively.  Moreover, the modulation of Bax and Bcl-2 expressions were 
significantly abrogated with DAS pretreatment (p<0.05). 
Discussion 
Organophosphates (OPs) exert their effects by blocking the AchE, paralyzing and killing 
parasites, hence, are widely used in agriculture as insecticides.  In recent years mechanisms 
independent of  inhibition of AChE including oxidative stress and mitochondrial dysfunction 
have been implicated in OP-induced neurotoxicity (Kaur et al., 2007; Sanchez-Santed et al., 
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2016; Shenouda et al., 2009; Wani et al., 2014; Xu et al., 2012).  The primary objective of this 
study was to systematically characterize the mechanism of DCV induces apoptotic cell death in 
SH-SY5Y dopaminergic neuronal cells.  Our data indicate that DCV-induced apoptotic cell 
death in SH-SY5Y dopaminergic neuronal cells via oxidative stress mechanisms, mitochondria 
mediated proapoptotic cell signaling events, PKCδ activation, and impairment in cellular protein 
degradation machinery in a c-Abl-dependent manner. 
DCV is present in several house-hold pest-control sprays and strips in US (ATSDR, 
1997; USEPA, 2000).  Accumulating evidence implicates neurobehavioral alterations including 
cognitive deficits in both humans exposed to DCV and animal models of DCV (Binukumar et 
al., 2011; Masoud et al., 2011; Verma et al., 2009).  In this context, DCV was found to induce 
Parkinson-like behavioral phenotypes in rats (Binukumar et al., 2011; Binukumar et al., 2010b).  
Furthermore, DCV was found to induce dose dependent cell death in PC-12 dopaminergic cells 
(Wani et al., 2014).  In accordance with this finding, in the present study using both SH-SY5Y 
cells and primary midbrain cells in culture we demonstrate that DCV exposure leads to dose 
dependent toxicity, and loss of TH positive neurons in primary ventral midbrain culture, further 
strengthening the dopaminergic neurotoxic potential of DCV.   
A study using a rodent model of DCV toxicity revealed that DCV induced oxidative 
stress and mitochondrial impairments (Binukumar et al., 2010b).  Oxidative stress is one among 
the major contributors to dopaminergic neurodegeneration (Blesa et al., 2015; Jenner, 2007).  
Parkinsonian compounds including MPTP, rotenone and 6-OHDA have been reported to induce 
oxidative stress in experimental PD models (Jenner, 2007; Lindholm et al., 2006; Testa et al., 
2005).  Furthermore, postmortem PD brains show elevated markers of oxidative stress and 
reduced antioxidant levels (Ilic et al., 1999; Jenner et al., 1992; Serra et al., 2001; Sofic et al., 
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1992).  Previous studies form our lab and others have revealed that pesticide exposure to 
dopaminergic neurons induces an aberrant increase in oxidative species generation (Kitazawa et 
al., 2001; Singh et al., 2007).  In the present study we demonstrated a time dependent increase in 
oxidative stress mechanisms including increased generation of ROS, mitochondria derived 
superoxide and collapse of mitochondrial membrane potential in DCV treated dopaminergic 
neuronal cells. 
In recent years a novel protein kinase, c-Abl tyrosine kinase, has been shown to be 
activated in PD models (Brahmachari et al., 2016; Brahmachari et al., 2017; Gonfloni et al., 
2012; Karuppagounder et al., 2014; Lawana et al., 2017).  c-Abl upregulation and activation, has 
been reported  in postmortem brains of AD (Jing et al., 2009; Schlatterer et al., 2011b) and PD 
(Goedert et al., 2013; Lee and Trojanowski, 2006; Martin et al., 2011b) as well as rodent models 
of PD (Brahmachari et al., 2016; Karuppagounder et al., 2014).  c-Abl kinase inhibitors have also 
been shown to reduce the oxidative stress (Cao et al., 2003a; Cao et al., 2003b; Lawana et al., 
2017; Shaker et al., 2011; Sourbier et al., 2014).  Importantly, we demonstrated that DCV 
treatment resulted in the profound and sustained activation of c-Abl.  Moveover, we 
demonstrated that inhibition of c-Abl activation via knockdown and inhibor strategies not only 
prevented c-Abl activation but also attenuated oxidative stress, mitochondrial dysfunction, and 
proteastasis impairment, as well as maintained autophagy and mitochondrial biogenesis.  These 
compelling data implicate c-Abl activation as a critical step in DCV-mediated cell death and 
likely in the progression to PD. 
Glutathione, a natural antioxidant, protects against cellular oxidative stress by converting 
two molecules of reduced glutathione to one oxidized molecule (GSSG) (Schulz et al., 2000).  
Increase in oxidative stress causes lipid peroxidation, which can be determined by evaluating the 
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levels of 4-HNE, a byproduct of lipid peroxidation (Ayala et al., 2014).  Postmortem brains of 
PD patients as well as rodent models of PD have lower levels of GSH (Ferraro et al., 1986; Meng 
et al., 2017; Molina-Jimenez et al., 2004; Sofic et al., 1992).  Our group have previously shown 
that N-acetyl cysteine, a precursor for glutathione, pretreatment protects against 
methamphetamine-induced dopaminergic neurodegeneration (Chandramani Shivalingappa et al., 
2012).  Further, we and others have demonstrated that levels of 4-HNE and 3-NT increases in 
SNpc in animal treated with MPTP (Ghosh et al., 2012; Liberatore et al., 1999; Lv et al., 2012).  
Current study identifies c-Abl as a key regulator of proxidant markers including GSH, 3-NT and 
4-HNE and that inhibition of c-Abl ameliorate the afore mentioned response. 
Several Parkinsonian toxicants, including rotenone, MPTP and 6-hydroxydopamine,  
mediates the dopaminergic neuronal cell death by damaging mitochondrial homeostasis 
(Giordano et al., 2012; Glinka and Youdim, 1995; Gomez-Sanchez et al., 2016; Lindholm et al., 
2006; Moon et al., 2005; Sanders and Greenamyre, 2013).  OPs have also been shown to induce 
mitochondrial dysfunction in neurons (Binukumar et al., 2010a; Carlson and Ehrich, 1999; 
Giordano et al., 2007a; Lukaszewicz-Hussain, 2010; Singh et al., 2015).  Our lab and others have 
shown that mitochondrial toxicants, MPTP, and rotenone, causes a collapse of MMP in 
dopaminergic cells (Ghosh et al., 2010; Moon et al., 2005; Nakamura et al., 2000; Radad et al., 
2014).  Consistent with these reports, in the present study we showed a time dependent reduction 
in MMP that preceded cell death suggesting that mitochondrial dysfunction may be linked to 
DCV-induced dopaminergic neurotoxicity.  
 Reduction in MMP has been shown to partially contribute to the formation of 
mitochondrial permeability transition pore, which leads to leakage of contents, including 
cytochrome C, from within mitochondrial inner/outer membranes to cytosol (Gottlieb et al., 
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2003).  Previously, cytosolic translocation of cytochrome c has been demonstrated in a rodent 
model of CPF toxicity (Kaur et al., 2007).  Further, mitochondrial complex I inhibitor rotenone 
has been shown to induce cytosolic translocation of cytochrome C by causing the collapse of 
MMP in rat brain (Clayton et al., 2005).  Here, we show that DCV exposure leads to time 
dependent aberrant translocation of cytochrome C from mitochondria to cytoplasm (Fig. 4(A)).  
Conversely, a previous study demonstrated that genetic depletion of c-Abl failed to induce 
mitochondrial release of cytochrome C upon H2O2 treatment (Sun et al., 2000).  In line with this 
finding, c-Abl inhibition attenauted the translocation of cytochrome c and also restored MMP in 
DCV treated cells further supporting the damaging effects of C-Abl on mitochondria upon 
exposure to DCV.    
Cytochrome C translocation to cytoplasm have been previously shown to active the  
caspase cascade, leading to apoptosis (Wani et al., 2014).  In a recent study, Wani et al showed 
the DCV induces apoptotic death of dopaminergic neuronal cells via a caspase-3 dependent 
mechanism (Wani et al., 2017).  Additionally, previous studies from our lab have demonstrated 
that PKCδ is proteolytically cleaved in response to diverse oxidative stressors, ultimately leading 
to dopaminergic neurodegeneration (Kanthasamy et al., 2006; Kanthasamy et al., 2003; 
Kanthasamy et al., 2008).  Moreover, phosphorylation of PKCδ at Y311 residue is considered to 
represent an alternative mode of activation of this serine/threonine kinase (Gonfloni et al., 2012; 
Kaul et al., 2005; Lu et al., 2007).  c-Abl has been shown to phosphorylate PKCδ at tyrosine 311 
moiety (Gonfloni et al., 2012; Lu et al., 2007).  Consistent with these reports, DCV-induced c-
Abl activation was accompanied by PKCδ activation (both proteolytic cleavage and enhanced 
phosphorylation), increased ratio of pro-apoptotic Bax/anti-apoptotic Bcl-2, and increased 
cleavage of PARP.  Intriguingly, c-Abl inhibition reduced the activation and cleavage of the pro-
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apoptotic kinase PKCδ and intrinsic mitochondria mediated pro-apoptotic cell signaling events.  
Taken together our studies suggest that c-Abl mediates its dopaminergic neurodegenerative 
effects atleast in part via the activation of mitochondria mediated PKCδ dependent proapoptotic 
cell signaling events.  
In the present study we showed that DCV-induced a decrease in mitochondrial biogenesis 
markers in dopaminergic neuronal cultures (Fig. 6(A), Fig. 8(F)).  Mitochondrion, a semi-
autonomous organelle, is perhaps the most crucial cellular target that regulates dopaminergic 
neuronal integrity in response to cellular stress (Jones et al., 2012; Lindholm et al., 2006; 
Onyango et al., 2017).  Biogenesis of new healthy mitochondria in neurons is a highly regulated 
process and is essential for cellular adaptation in response to mitochondrial malfunction (Keeney 
et al., 2009; Oyagbemi et al., 2017).  Adaptations in mitochondrial biogenesis mechanisms have 
been reported in neurodegenerative disease models, and these mechanisms have been considered 
crucial for neuronal survival (Gomez-Sanchez et al., 2016; Keeney et al., 2009; Oyagbemi et al., 
2017).  Our research group recently showed that neuroprotective natural flavanoid, quercetin, 
upregulated the levels of two vital mitochondrial biogenesis master regulators, PGC-1α and 
TFAM, in dopaminergic neurons using both in vitro and in vivo models of PD (Ay et al., 2017).  
Our results demonstrate that DCV not only disrupt functioning of healthy mitochondria (Fig. 
1(E)) but also negatively regulate the generation of new mitochondria by interfering with the 
generation of mitochondrial biogenesis regulators (Fig. 6(A), Fig. 8(F)).  Recent evidences 
suggest that these mitochondrial biogenesis regulators are essential for survival of dopaminergic 
neurons (Clark et al., 2011; Langley et al., 2017) and overexpression of PGC-1α or TFAM can 
protect against the toxicant-mediated neurodegeneration (Aguirre-Rueda et al., 2015; Clark et al., 
2012; Xu et al., 2009).  The results generated with DCV mimics the mechanisms associated with 
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known dopaminergic toxicants and positively correlates with dopaminergic apoptotic cell death 
in our in vitro cell culture model.  
A growing body of evidence suggest that c-Abl can phosphorylates parkin at Y143 
leading to the inhibition of Parkins’s E3 ligase function and resultant accumulation of its toxic 
substrates, including PARIS, AIMP2 and FBP1.  Under pathologic conditions, where parkin 
function is impaired, levels of PARIS increase leading to mitochondrial dysfunction via down 
regulation of PGC-1α and ultimately leads to loss of dopaminergic neurons in a PARIS-
dependent manner (Andrew, 2018; Brahmachari et al., 2017; Lee et al., 2017).  Additionally, in 
line with this evidence studies performed in conditional parkin knockout mice revealed that 
PGC-1α expression is dramatically reduced (Imam et al., 2011; Ko et al., 2010).  Another crucial 
regulator of mitochondrial biogenesis, TFAM, is shown to be regulated by oxidative stress and 
PGC-1α (Aguirre-Rueda et al., 2015; Taherzadeh-Fard et al., 2011).  Previous studies have 
suggested that PGC-1α regulates the generation of new mitochondria by upregulating TFAM 
levels (Finck and Kelly, 2007; Kang and Ji, 2012).  Hence, modulation in expression of PGC-1α 
can have direct effect on TFAM levels.  Given that c-Abl a negative regulator of PGC-1α, in the 
present study we demonstrated that c-Abl inhibition significantly blocked the DCV-mediated 
loss of PGC-1α and TFAM (Fig. 6(B), Fig. 7(B)), whereas overexpression of c-Abl WT further 
reduced protein levels of these mitochondrial biogenesis markers in neuronal cells (Fig. 7(B), 
Fig. 8(F)).  Our data suggest that c-Abl can negatively impact dopaminergic neuronal survival 
via down regulation of mitochondrial biogenesis markers including PGC-1α and TFAM. 
Accumulation of misfolded proteins and cellular components is a pathological hallmark 
of PD and other Lewy Body diseases (Cook et al., 2012; Dehay et al., 2010; McNaught and 
Olanow, 2006; Winslow and Rubinsztein, 2008).  Dysfunction in two major mechanisms that 
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contribute significantly to protein clearance, namely autophagy and ubiquitin-proteasomal 
system (UPS) (Singh et al., 2015; Vilchez et al., 2014), leads to aberrant accumulation of 
proteins in neurons causing cellular stress (Cook et al., 2012; Sun et al., 2005; Vilchez et al., 
2014) and  neuronal death (Betarbet et al., 2006; Martins-Branco et al., 2012; Park et al., 2013; 
Sun et al., 2007; Winslow and Rubinsztein, 2008).  Interestingly, a recent study by Binukumar 
showed that chronic DCV exposure in rats results in accumulation of α-Syn positive inclusion 
and ubiquitinated proteins in SN (Binukumar et al., 2010b).  Similarly, our lab has previously 
shown that dieldrin, an organochloride pesticide and dopaminergic neurotoxicant, induces its 
cytotoxic effects by inducing the UPS malfunction in dopaminergic neurons (Sun et al., 2005; 
Sun et al., 2007).  Intriguingly, c-Abl has been shown to phosphorylate the PSMA7 subunit of 
20S proteasome complex compromising its protein degradation function thereby leading to the 
accumulation of ubiquitin bound proteins (Li et al., 2015; Liu et al., 2006).  Consistent with this 
report, our data showed DCV caused an impairment in proteasomal function and that c-Abl 
inhibition markedly rescued the DCV-mediated loss of proteasomal activity and accumulation of 
HMW ubiquitinated proteins (Fig. 5(C,D)).   
Autophagy is another major cellular clearance system in cells.  Dysfunctional autophagy 
leads to the accumulation of autophagosomes within cells.  Even though, the role of autophagy in 
cell survival is still unclear, it is becoming increasingly clear that dysfunctional autophagic 
system may contribute to cell death (Gozuacik and Kimchi, 2007; Kanthasamy et al., 2012; 
Mizushima et al., 2008; Xue et al., 1999).  Moreover, accumulation of autophagic vacuoles 
(AVs) has been previously reported with organophosphate pesticides (chlorpyrifos) (Park et al., 
2013), herbicide (paraquat) (Gonzalez-Polo et al., 2007), organochloride pesticide (dieldrin) 
(Singh et al., 2015), heavy metals (Manganese) (Afeseh Ngwa et al., 2011), psychotropic 
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substances (methamphetamine) (Lin et al., 2012) and other parkinsonian toxicants (rotenone, 
MPTP) (Mader et al., 2012; Niu et al., 2016), ultimately contributing to dopaminergic neuronal 
death.  In this study we demonstrated that DCV treatment caused an upregulation of autophagic 
protein LC3B (Fig. 5(E)) as well as accumulation of LC3B positive vesicles (Fig. 5(I)).  
Furthermore, protein expression of p62 and beclin1 was also increased in dopaminergic neurons 
exposed to DCV (Fig. 5(F)).  A concurrent increase in the levels of p62 along with beclin1 and 
LC3B is indicative of impaired autophagic degradation (Zhang et al., 2016).  To our knowledge, 
there is no direct evidence implicating autophagic dysfunction in DCV-induced dopaminergic 
neurotoxicity.  Moreover, ubiquitinated protein aggregates were found to be colocalized with 
autophagic vesicles (AVs) positive for LC3B further confirming DCV-induced dysfunction in 
cellular proteastasis.  Intriguingly, in the present study inhibition of c-Abl rescued cells from 
autophagic and proteasomal impairment further supporting the role of c-Abl in regulating 
cellular proteastasis (Fig. 7(B), Fig. 8(B)).  Our results are indeed consistent with a previous 
study from our lab demonstrating that c-Abl inhibition blocked the LPS/rotenone mediated 
autophagolysosomal dysfunction in microglia, by reducing cellular oxidative stress (Lawana et 
al., 2017).  Several other studies suggest that increased oxidative stress leads to AV 
accumulation, resulting in neuronal demise (Choi et al., 2010; Hariharan et al., 2011; Larsen et 
al., 2002; Wang et al., 2016).  Together, our results indicate that c-Abl may impair autophagic 
flux via an aberrant cellular oxidative stress mechanism, thereby leading to dopaminergic 
neuronal death.   
In summary, our studies demonstrate that inhibition of c-Abl may be beneficial in the 
reversal of DCV-induced dopaminergic neurotoxicity.  In this context, using dopaminergic SH-
SY5Y cells and mouse midbrain neuronal culture, our data demonstrates that DCV causes 
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dopaminergic neurotoxicity by inducing oxidative stress, mitochondrial impairment, PKCδ 
activation, and mitochondria-mediated apoptotic pathways in a c-Abl dependent manner. We 
also demonstrated that c-Abl negatively regulates mitochondrial biogenesis and cellular 
proteastasis in response to DCV in dopaminergic neuronal cells.  To our knowledge, this is the 
first study demonstrating the upstream role for c-Abl tyrosine kinase in pesticide-induced 
dopaminergic neurodegeneration.  Our research opens new avenues for developing brain 
penetrable c-Abl therapeutics targeted to halt or slow the progression of PD and other 
debilitating neurodegenerative disorders. 
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Figure 1: DCV induces dose-depended cell death and time-dependent increase in oxidative 
stress and mitochondrial damage. (A) Does response curve for DCV exposed to SH-SY5Y 
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cells for 24h.  DCV induced cell death in human dopaminergic neuroblastoma SH-SY5Y cells in 
a dose-dependent manner (Mean ± S.E.M., N = 8).  (B, C) DCV-induced ROS generation (B) 
and depletion of GSH levels (C) in SH-SY5Y cells after exposure for 6-24h (Mean ± S.E.M., N 
= 6). (D) Western blot analysis showed an increase in oxidative stress markers, 4-HNE and 3-
NT, after 50μM DCV treatment to SH-SY5Y cells, normalized to β-actin (Mean ± S.E.M., N = 
4).  (E) DCV treatment caused time-dependent decrease of MMP (Mean ± S.E.M., N = 6). *p < 





Figure 2: DCV causes time-depended activation of c-Abl tyrosine kinase and mitochondria-
mediated apoptosis mechanisms.  (A) DCV caused time-depended increase in c-Abl tyrosine 
kinase expression.  Concurrent increase in phosphorylation at tyrosine 412 residue of c-Abl and 
phosphorylation of PKCδ at tyrosine 311 site was also observed in time-dependent manner post 
DCV treatment (Mean ± S.E.M., N = 4).  (B-C) Activation of initiator caspase-9 (B) and 
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caspase-3 (C) was present following 50μM DCV treatment (Mean ± S.E.M., n = 6-8).  (E) DCV 
induced expression of cleaved PKCδ starting at 12h. The densitometry analysis is represented by 
histogram, red bar represents cleaved bands intensity (Mean ± S.E.M., N = 4).  (E) DCV 
increased expression of pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins.  (F) PARP 
expression increased in a time-dependent manner after DCV exposure.  Red bars on 
densitometry graph represents intensity of cleaved PARP band normalized to β actin. (Mean ± 








Figure 3: c-Abl regulates the DCV-mediated dopaminergic neurotoxicity by alleviating 
oxidative stress and mitochondrial dysfunction.  (A)  DAS pretreatment or siRNA-mediated 
c-Abl gene silencing and expressing mutant c-Abl attenuated DCV-mediated apoptosis, while 
cells overexpressing c-Abl kinase potentiated the DCV-induced DNA fragmentation (Mean ± 
S.E.M., N = 8). (B) Pretreatment with DAS (100nM, 1h) or transfection with siRNA against c-
Abl followed by DCV treatment reduced c-Abl expression compared to DCV alone.  
Downregulation of c-Abl caused a significant reduction in phosphorylation of c-Abl (Y412) and 
PKCδ (Y311) compared with DCV treatment alone.  DCV caused an upregulation of c-Abl, p-c-
Abl and p-PKCδ expressions, which was reduced in case of dasatinib or c-Abl KD (Mean ± 
S.E.M., N = 3).  (C, D) DCV-mediated increase in generation of reactive oxidative species (C) 
and the loss of GSH (D) was significantly inhibited in case of dasatinib pretreatment and c-Abl 
gene silencing.  (E) DAS pretreatment for 1h or c-Abl knockdown hindered the DCV-mediated 
induction of oxidative stress markers, 4-HNE and 3-NT by 50% and 80%, respectively (Mean ± 
S.E.M., N = 4).  (F) c-Abl downregulation reduced the loss of MMP caused by DCV (Mean ± 
S.E.M., N = 8). #p < 0.01, # #p<0.001, # # # p < 0.001 and # # # #p < 0.0001 compare to control; ***p 







Figure 4: DCV-induced modulation of apoptosis related proteins in dopaminergic neuronal 
cells requires c-Abl.  (A) Pretreatment with DAS (100nM, 1h) or transfection with scramble 
siRNA or c-Able siRNA, attenuated increased cytoplasmic cytochrome c levels induced by DCV 
(Mean ± S.E.M., n = 6).  (B, C) Elevation in caspase-9 activity (B) and caspase-3 activity (C) 
was significantly attenuated with DAS pretreatment or c-Abl knockdown (Mean ± S.E.M., N = 
6).  (D) c-Abl downregulation reduced the expression of cleaved PKCδ induced by DCV (Mean 
± S.E.M., N = 3).  (E, F) Cells pretreated with DAS or transfected with siRNA against c-Abl 
diminished the DCV induced modulation of Bax/Bcl-2 (E) and PARP (F).  β-actin was used as a 
loading control.  Histogram represents the densiometric analysis (Mean ± S.E.M., N = 5).  #p < 
0.01, # #p<0.001, # # #p < 0.001 and # # # #p < 0.0001 compare to control; ***p < 0.001 or ****p < 









Figure 5: Influence of c-Abl on DCV-induced impairment in proteastasis.  (A) 50µM DCV 
induced a reduction in proteasomal activity in a time-dependent manner in SH-SY5Y neuronal 
cells.  The normalized enzymatic activity is presented as percentage of control group. (Mean ± 
S.E.M., N = 6).  (B) Immunoblotting for ubiquitinated proteins in SH-SY5Y cells exposed to 
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DCV for 6-24h.  Densitometric analysis normalized to β actin is presented as histogram, 
represented as mean ± S.E.M., N = 4.  *p < 0.05, **p < 0.01 ***p < 0.001 or ****p < 0.0001 
compared to non-treated control group.  (C) Estimation of 20S-proteasomal activity in SH-SY5Y 
cells treated with DCV (50µM, 24h) with or without DAS (100nM, 1h) pretreatment or c-Abl 
RNAi-mediated knock down (Mean ± S.E.M., N = 6).  (D) H.M.W.-ubiquitinated protein 
accumulation in case of dasatinib and c-Abl gene silencing was shown to alleviate the loss of 
UPS function induced by DCV.  Normalized band intensity represented as mean ± S.E.M., N = 
4. # # # #p < 0.0001 compare to control; whereas, **p < 0.01 or ***p < 0.001 compare to DCV 
alone group.  (E-F) Upregulation of autophagy was determined by checking the protein 
expression of microtubule-associated protein light chain 3B (MAP LC3B), Beclin 1 and p62.  
DCV induced the conversion of LC3B I (16kDa) to LC3B II (14kDa) in a time dependent (E).  
Similarly, increased expression of Beclin 1 and p62 was seen with an increase in exposure time, 
indicating an upregulation of autophagy (F).  Histogram represents the densitometry analysis 
normalized to β actin levels for respective lanes (Mean ± S.E.M., N = 4).  Each data set is 
expressed as percentage of control group and represents ± S.E.M. for experiment performed with 
duplication. *p < 0.05, **p < 0.01 or ***p < 0.001 compare to control.  (G, H) DAS and c-Abl 
KD significantly blocks induction of autophagy markers LC3B, beclin 1 and p62.  Normalized 
band intensity represented as mean ± S.E.M. for each experiment performed at least twice. # # # #p 
< 0.0001 compare to control; **p < 0.01, ***p < 0.001 or ****p < 0.0001 compare to DCV 
alone group.  (I) Immunocytochemical images of intracellular accumulation of autophagy 
vacuoles and colocalization with ubiquitinated-proteins in SH-SY5Y cells treated with DCV 
(50µM, 24h) with or without pre-exposure to DAS (100nM, 1h) or c-Abl siRNA transfection.  
The last column from the left represents merged images of LC3B staining (green), ubiquitinated-
protein (red) and nuclear staining Hoechst (blue).  Rows represented different treatments as 





Figure 6. DCV-induced depletion of mitochondrial biogenesis markers in dopaminergic 
neuronal cells is attenuated by c-Abl knock down and dasatinib.  (A) Immunoblotting for 
DCV induced the down regulation of PGC1α and TFAM in a time-dependent manner.  Each data 
set is expressed as percentage of control group and represents ± S.E.M., N = 4. *p < 0.05, **p < 
0.01 or ****p < 0.0001 compare to control. (B) DAS or gene silencing by c-Abl siRNA inhibited 
the down regulation of PGC1α and TFAM induced by DCV.  Normalized band intensity is 
represented as mean ± S.E.M. for each experiment performed with N = 5.  # # # #p < 0.0001 





Figure 7. c-Abl overexpression and expression of c-Abl mutant gene modulates the DCV-
mediated expression of various proteins in SH-SY5Y cells.  Dopaminergic SH-SY5Y cells 
were transfected with empty vector (E.V.), c-Abl wild-type (WT) constructs or c-Abl dominant 
negative mutant (Mut) constructs followed by treatment with DCV (50µM, 24h).  (A) Western 
blots were performed to analyze the p-PKCδ (Y311).  Expression of oxidative stress markers (3-
NT and 4-HNE), proapoptoic bax and antiapoptotic bcl-2 proteins were analyzed.  β actin 
normalized band intensities were calculated as percentage of E.V. control group and represents 
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mean ± S.E.M. for experiment performed with N = 3-5.  (B) Expression of autophagy markers 
(Beclin1, p62) and mitochondria biogenesis markers (PGC1α and TFAM) was performed using 
WB.  Densitometric analysis was performed and values were normalized with β actin for each 
group.  Values calculated as percentage of E.V. control group and represents mean ± S.E.M. for 
experiment performed with N = 4-5. # # #p < 0.001 or # # # #p < 0.0001 compare to E.V. control 







Figure 8. Primary mesencephalic neurons pretreated with dasatinib exhibit protection 
against DCV.  (A) WB analysis for TH from DAS-pretreated DCV-treated primary midbrain 
neuronal cell lysates.  Histogram represents the band intensity normalized to β actin, calculated 
as % control (Mean ± S.E.M., N = 4).  (B) Immunocytochemical images for primary neuronal 
cultures treated with DAS and DCV followed by staining with TH (red).  Hoechst (blue) was 
used as nuclear stain.  (C) Total number of TH-stained neurons and (D) average neurite length 
per TH neurons from the midbrain neuronal cultured treated with DCV (50µM) with or without 
DAS (100nM, 1h) pretreatment (Mean ± S.E.M., N = 4-8).  (E) Immunoblotting for c-Abl, p-c-
Abl (Y412) and PKCδ (Y311) in primary mesencephalic neurons treated with DCV (50µM) with 
or without DAS (100nM) pretreatment.  Values calculated as percentage of non-treated control 
group and represents mean ± S.E.M, N = 3.  (F) Pretreatment with DAS hindered the DCV-
induced modulation of autophagy marker (beclin1), apoptosis markers (Bax and Bcl-2) and 
mitochondria biogenesis markers (TFAM and PGC1α) in primary mesencephalic cultures.  
Values calculated as percentage of non-treated control group and represents mean ± S.E.M, N = 
5.  # # #p < 0.001 or # # # #p < 0.0001 compare to control group; *p < 0.05 **p < 0.01 or ***p < 
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Abstract 
A growing body of evidence suggests that excessive microglial activation and pesticide exposure may 
be linked to the etiology of PD; however, the mechanisms involved remain elusive.  Emerging 
evidence indicates that intracellular inflammasome complex namely NLRP3 complex is involved in 
the recognition and execution of host inflammatory response.  Thus, in the present study, we 
investigated the hypothesis that NLRP3 inflammasome activation is linked to rotenone (ROT)-induced 
microglial activation which is dependent upon a priming stimulus by a pathogen-associated molecular 
pattern (PAMP) or damage associated molecular pattern (DAMP), respectively.  Herein using both 
BV2 cells and primary microglial cells, we show that LPS priming and subsequent ROT stimulation 
enhanced NLRP3 inflammasome activation, c-Abl and PKCδ activation, mitochondrial dysfunction, 




Mechanistic studies revealed c-Abl acts as a proximal signal that exacerbated the activation of the 
afore mentioned markers.  Intriguingly, siRNA-mediated depletion or pharmacological inhibition of c-
Abl via dasatinib abrogated LPS and ROT-induced microglial activation response via attenuation of 
NLRP3 inflammasome activation, mitochondrial oxidative stress, and ALS dysfunction.  Moreover, 
mitoTEMPO, a mitochondrial antioxidant, attenuated NLRP3 inflammasome activation effects via 
blockade of c-Abl and PKCδ activation.  In LPS treated mice, dasatinib attenuated NLRP3 
inflammasome activation, c-Abl and PKCδ activation; and sickness behavior.  Together our findings 
identify an exaggerated ROS/c-Abl/NLRP3 signaling axis in the heightened microglial activation 
response evidenced in LPS-primed ROT-stimulated microglial cells and suggest that targeting c-Abl-






A characteristic feature of neurodegenerative disease is the proliferation of activated microglia 
a condition refered to as microgliosis.  Microglia are the resident immune cells of the brain and plays a 
pivotal role in CNS development, maintenance, and disease.  Most notably they mediate the clearance 
of toxic cellular debris and support tissue repair.  However, protracted activation of microglia exerts 
deleterious effects on the brain such as neurodegenerative diseases (Tremblay et al., 2011).  In fact, 
analysis of postmortem PD brains revealed microglial activation markers, accumulation of 
proinflammatory cytokines and indices of oxidative stress (McGeer et al., 1988).  Activated microglia 
release a diverse array of toxic mediators including proinflammatory cytokines, nitric oxide and 
superoxide, which has been shown to play a critical role in the pathogenesis of neurodegererative 
disorders such as AD, prion disease and PD (Chao et al., 1995; Mosley et al., 2006; Tansey and 
Goldberg, 2010; Tansey et al., 2007).  In fact, chronic inflammation has been implicated in the delayed 
and progressive dopaminergic neurodegeneration (Gao et al., 2002a; Gao et al., 2002b; Gao et al., 
2011; Qin et al., 2007).  The factors released by activated microglia have been linked to 
neurodegenerative conditions (Block et al., 2007; Gao et al., 2002b).  Therefore, there is an urgent 
need to understand the mechanism underlying persistent microglial activation and to develop novel 
pharmacological strategies that limits microglial activity during PD pathogenesis. 
Rotenone (ROT) exposure has raised great concerns as a potential environmental risk factor for 
inflammation related neurodegenerative disorders.  ROT inhibits complex I of the electron transport 
chain and promotes the generation of mitochondrial superoxide production during complex I substrates 
oxidation (Andreyev et al., 2005; Keeney et al., 2006).  Systemic ROT administration has been shown 
to induce Parkinsonian features in rats including selective dopaminergic neurodegeneration (Betarbet 
et al., 2000).  Moreover, Gao et al. demonstrated that the contribution of microglial cells may be 




2003; Gao et al., 2002b).  Thus, ROT-induced degeneration of dopaminergic neurons may not be 
entirely dependent upon inhibition of neuronal mitochondrial complex I activity but may also involve 
the contribution of microglial cells (Gao et al., 2002a).  Taken together, the afore mentioned studies 
highlight the proinflammatory effects of ROT. 
c-Abl is a 120 kDa protein that belongs to the cytoplasmic tyrosine kinase family.  c-Abl has 
been shown to be activated via oxidative (Stuart et al., 2005; Sun et al., 2000) or genotoxic stress 
(Yuan et al., 1999).  Interestingly, c-Abl has also been implicated in the CNS development, including 
neurogenesis, neurite outgrowth, and neuronal plasticity (Moresco and Koleske, 2003; Moresco et al., 
2003).  A growing body of evidence from several experimental model systems has also demonstrated 
that c-Abl is activated in neurodegenerative diseases including Alzheimer’s disease (Cancino et al., 
2008; Jing et al., 2009; Tremblay et al., 2010), Parkinson’s disease (Imam et al., 2011; Ko et al., 2010; 
Mahul-Mellier et al., 2014) and synucleinopathies (Estrada et al., 2011).  In this context, c-Abl has 
been shown to promote tyrosine phosphorylation of parkin in the N-terminal domain, and STI-571, a c-
Abl kinase inhibitor has been shown to inhibit tyrosine phosphorylation thereby maintaining in a 
catalytically active and protective state (Ko et al., 2010).  
The inflammasomes are multiprotein signaling platforms that are assembled following 
exposure to pathogen-associated and damage associated molecular pattern molecules (PAMP and 
DAMP, respectively) and environmental stimuli (Rubartelli, 2014).  Presently, inflammasomes are 
placed under two families namely the nucleotide oligomerization domain (NOD)-like receptor (NLR) 
family and the pyrin and HIN200 (hematopoietic interferon-inducible nuclear antigens with 200 
amino-acid repeats) domain containing protein (PYHIN) family.  The NLR family comprises NLRP1, 
NLRP2, NLRP3, NLRP6, NLRC4 and NLRP12. The PYHIN family includes absent in melanoma 2 
(AIM2) and γ-interferon-inducible protein (IFI16) (reviewed in (Benetti et al., 2013)).  The NLRP3 




complex includes a specific member of the NOD-like receptor protein (NLRP) subfamily, apoptosis-
associated speck like protein containing a CARD- an adapter protein, and procaspase-1 (Ippagunta et 
al., 2010; Stehlik et al., 2003).  The inflammosome and its associated components are an integral part 
of the body’s immune system, where they participate in the defense against invading pathogens.  The 
NLRP3 inflammosome is tightly controlled and has been shown to require two distinct steps. First, 
under basal conditions the pro-form of IL-1β and NLRP3 proteins are expressed at very low levels, 
therefore a priming step is essential to induce their transcription (Jha et al., 2010; Ozaki et al., 2015).  
This is mediated via the activation of Toll like receptors or NOD2 to initiate the NF-κB signaling 
cascade leading to the transcription of NLRP3 and prointerleukin-1β (pro-IL-1β) (Sutterwala et al., 
2014); this step is termed as ‘priming’.  Second, upon priming, the activating stimuli originating from 
pathogens or the host induce the assembly of NLRP3 inflammasome components and subsequent 
caspase-1 mediated proteolytic processing of pro-IL-1β and pro-IL-18 into mature peptides, which is 
eventually released into the extracellular milieu to elicit the downstream effects (Kim et al., 2016; van 
de Veerdonk et al., 2011).  Thus, NLRs serves as a nexus between disturbance in cellular homeostasis 
and the generation of proinflammatory cytokines (Khare et al., 2012; Latz, 2010; Martinon et al., 
2009), providing further impetus for studying the role of this receptor in neurodegenerative diseases.  
There are a plethora of studies that demonstrates NLRP3 activation in bone-marrow derived 
macrophages and dendritic cells (Burm et al., 2015); however, only scant evidence are available 
regarding the mechanisms regulating the priming and activation of NLRP3 inflammasome in the 
microglia (Gustin et al., 2015).  In the present study, we investigated the inflammatory mechanisms 
involved in ROT-stimulated LPS-primed microglia using BV2 microglial cell line and mouse primary 
microglia.  We show that LPS priming in rotenone-stimulated cells amplifies the microglial activation 
response via the ROS/c-Abl/NLRP3 signaling axis.  Our data provide further mechanistic insight into 




activation in the microglia may serve as a novel pathway for limiting persistent microglial activation 
evidenced in numerous inflammation associated neurodegenerative diseases including PD. 
Materials and Methods 
Chemicals and Reagents: Cell culture supplies including DMEM/F-12 media, RPMI 1640 media, 
penicillin/streptomycin, L-glutamine, fetal bovine serum (FBS), CM-H2DCFDA dye and MitoSox® 
dye were purchased from Invitrogen.  Rotenone, mouse anti-β actin antibody, mitoTEMPO, 
disuccinimidyl suberate (DSS), BSA lyophilized powder and acridine orange (AO) were purchased 
from Sigma-Aldrich.  Lipopolysaccharide (E. Coli O111:B4) (LPS) and c-Abl antibody were 
purchased from EMD Millipore. Dasatinib (DAS), p-c-Abl (pY412), PKCδ, p-PKCδ (pY311), 
phospho-IκBα, iNOS, ASC, TOM20, lamin B, tubulin and p65 antibodies were purchased from Santa 
Cruz Biotechnology.  Beclin1, NLRP3, caspase-1, LC3B, p-c-Abl (pY245), IL-1β and IL-18 
antibodies were purchased from Cell Signaling Technology. TFEB antibody was Bethyl laboratories, 
Inc. Caspase 1 (p10) antibody was purchased from Adipogen.  The mouse IL-1β and IL-18 ELISA kits 
from eBiosciences.  
Cell Culture and Treatment: Immortalized mouse microglial BV2 cell line were cultured and 
maintained at 37°C in RPMI 1640 medium containing 10% heat inactivated (HI) FBS, 2mM L-
glutamine, 100mg/ml penicillin and 100mg/ml streptomycin.  Cells were first primed with 1µg/ml LPS 
for 3h, media was replaced and cells were subsequently stimulated with followed by treatment with 
rotenone at concentrations of 0.1, 0.25 or 0.5µM. Cells were pretreated with 100nM DAS for 1h before 
exposing them to LPS and ROT.  Post treatment, BV2 cells were either collected for mRNA extraction 
or for protein analysis by qRT-PCR or western blotting, respectively. 
Primary Microglial Culture: Primary mixed glia were was prepared from postnatal (P1) mouse pups 




carefully removed, and then immediately placed in DMEM/F-12 medium (containing 10% HI-FBS, 
2mM L-glutamine, 100mg/ml penicillin, 100mg/ml streptomycin and 2mM sodium pyruvate).  The 
brains were triturated to make a single cell suspension. The cells were then plated in flask for 2 weeks 
at 37°C.  Microglia were separated from this mixed glial cell culture using either shake off method or 
via magnetic separation kit (EasyStepTM Mouse Cd11b positive selection kit) from Stem Cell 
Technologies (Gordon et al., 2011).  
siRNA transfection: Transfection of BV2 microglial cells and primary microglia was performed using 
Amaxa Nucleofector Kit (Lonza).  Briefly, 3X106 BV2 cells were suspended in 100µl transfection 
buffer containing 400µM ATP-disodium, 600µM magnesium chloride, 100µM potassium 
hypophosphate, 20µM sodium bicarbonate and 5µM glucose.  The 1.5nM of c-Abl siRNA 
(ThermoFisher, CAT # 162296) or control siRNA (Santa Cruz Biotechnology, CAT# sc-37007) were 
added to the transfection mix. The cells were then transfected by electroporation using A-23 program 
of Lonza NucleofectorTM 2b devise.  Detailed protocol can be found in our previous publication 
(Panicker et al., 2015).  Post transfection, the cells were incubated for 48h followed by various 
treatment. 
Animal Study: Six to eight weeks old C57bl/6 mice were obtained from Charles River and housed 
under standard conditions at 22 ± 1°C and 30% relative humidity with 12h light cycle as per IACUC 
protocol.  Mice were randomly assigned in four different groups. DAS (25mg/kg/day) was 
administered orally for 30 days prior to LPS treatment.  The well-characterized acute LPS 
neuroinflammation model for PD was used for this study (Qin et al., 2007).  Mice were injected 
intraperitoneally with either saline or LPS (5mg/kg). Six hours post treatment, the mice were subjected 




for behavior analysis.  After behavior tests, animals were euthanized and brain tissues from substantia 
nigra region were collected and stored at -80°C. 
ROS, NO and MitoSox Assays: The cells were plated in 96-wellplate and primed with LPS for 3h. The 
primed cells were further stimulated with ROT for various time points.  Post treatment, the media was 
removed and the cells incubated with redox sensitive 1µM CM-H2DCFDA dye for 1h.  Following 
incubation, the supernatant containing unabsorbed dye was aspirated out.  The cells were washed with 
PBS twice and the change in fluorescent intensity as indicator of ROS generation, was carried out by 
using fluorescence microplate reader with excitation and emission wavelength of 488nm and 525nm, 
respectively.  For nitric oxide (NO) assay, the cells supernatant media was collected post treatment 
completion and nitrite levels were determined spectrophotometrically using Griess’ reagent as per the 
manufacturer protocol.  To analyze the generation of mitochondrial superoxide, post treatment cells 
were incubated with 5µM MitoSOX dye for 20min, followed by two washings with HBSS buffer.  
Change in mitochondrial superoxide generation was quantified using fluorescence microplate reader 
with excitation and emission wavelengths of 510nm and 580nm, respectively. 
Mitochondrial Membrane Potential: The mitochondrial membrane integrity was measured using a 
lipophilic JC-1 dye (Invitrogen) as described by Ghosh et al. (Ghosh et al., 2010).  In brief, post-
treatment cells were exposed to JC-1 (2µg/ml) dye.  After 30min incubation, cells were washed with 
PBS and analysis was performed by measuring red fluorescence excitation at 590nm over 600nm 
emission and green fluorescence excitation at 485nm over 535nm emission.  JC-1 dye accumulated 
within healthy mitochondria forming red aggregates however, the dye stays as green monomer in non-
healthy cells.  The ratio of RED:GREEN represents change in mitochondrial membrane potential. 
MTS Cell Viability Assay: The BV2 cells were plated in 96-wellplate at the seeding density of 




without LPS (1μg/ml, 3h) priming and cell viability was assessed as described by Jin et at, 2014 (Jin et 
al., 2014).  In brief, post treatment cells were exposed to Cell Titer 96® AQueous One Solution Cell 
Proliferation (MTS) Assay kit from Promega.  After 45min (37°C) incubation with 10μl MTS dye the 
formazan crystals were dissolved with 25μl of dimethyl sulfoxide (Sigma-Aldrich), the change in color 
was measured spectrophotometrically at 490nm, values were plotted at % of control and were plotted 
as bar graph.  
qRT-PCR: RNA extraction from microglial cells were performed using Trizol® Reagent as described 
(Seo et al., 2014).  RNA was converted into cDNA using AffinityScript qPCR cDNA synthesis system 
(Agilent Technology) following the standard kit protocol.  The RT2 SYBR Green Master Mix and pre-
validated primers were obtained from SA Biosciences and were used for Quantitative PCR assays.  
Mouse 18s was used as housekeeping gene for internal normalization.  The ∆∆Ct method was used to 
determine the fold change in gene expression, using threshold cycle (Ct) value of the housekeeping 
gene and respective target gene. 
Western Blotting: The whole cell lysates were prepared using modified RIPA buffer as described 
previously (Panicker et al., 2015).  To analyze the intracellular translocation, nuclear and cytosolic 
fractions were collected using NE/PER kit (Thermo Fisher).  Protein amount was estimated using 
Bradford reagent and equal amount of protein was resolved on a 7.5-15% SDS-polyacrylamide gel.  
Resolved protein were transferred to nitrocellulose membrane and membranes were blocked for 1h by 
incubating with Rockland blocking buffer, followed by incubation with specific primary antibody 
overnight at 4°C.  Membranes were washed and incubated with specific fluorescent labelled secondary 
antibody.  The membrane containing antibody-bound protein was scanned using Odyssey IR Imaging 




Immunoblotting of media supernatant: After treatment, cell supernatants were collected and were 
concentrated using TCA method as explained by Chakrabarti et al (Chakrabarti et al., 2015). Briefly, 
72μl of 100% (w/v) tricholoroacetic acid (Sigma-Aldrich) and 30μl of 5% (w/v) sodium cholate 
(Sigma-Aldrich) were added per ml of media.  After 20 minutes incubation on ice, samples were 
centrifuged at 12,000Xg for 10min at 4°C. Pellets were carefully washed with ice-cold acetone at least 
2 times and were allowed to dry to evaporate acetone.  Concentrates were then dissolved in SDS 
sample buffer containing 33.34mM NaOH (Sigma-Aldrich). Standard western blotting protocol, as 
described above, was followed for these samples.  
Immunocytochemistry and Confocal imaging: Immunostaining was done with both BV2 cells and 
primary microglia (Panicker et al., 2015).  In brief, cells were plated on glass cover-slips and were 
exposed to desired treatments. Post-treatment, fixed with 4% paraformaldehyde for 30 minutes 
followed by 3 washes with PBS and blocking with 2% BSA solution containing 0.5% Triton-X and 
0.05% Tween 20.  After blocking step, cells were incubated with primary antibodies (rabbit anti-
NLRP3 (1:300), goat anti-TOM20 (1:300), mouse anti-p-c-Abl Y412 (1:300), rabbit anti-LC3B 
(1:300) and rabbit anti-p65 (1:250)) at 4°C overnight and then 90 minutes incubation with secondary 
antibodies (Donkey anti-goat Alexa Fluor® 555, Donkey anti-rabbit Alexa Fluor® 488 or Donkey Anti-
mouse Alexa Fluor® 555).  Lastly, cells were exposed to Hoechst (10μg/ml) for 10min to stain nuclei. 
After each step cells were washed with 1XPBS thrice.  Coverslips were mounted on glass slides using 
FluoroshieldTM mounting medium (Sigma-Aldrich) and were allowed to dry overnight in dark.  The p-
c-Abl (pY412), p65 and LC3B samples were visualized using an inverted microscope (Nikon TE-
2000U) and were captured using Spot digital camera (Diagnostic instruments).  LC3B stained puncta 




Confocal imaging was performed to visualize NLRP3 and TOM20 colocalization.  Leica 
DMIRE2 laser scanning confocal microscope with the 63X-oil immersion objective and Leica confocal 
software from Iowa State University Microscope Facility were used to capture images.  The Z-stack 
images were processed using Imaris software. 
ASC oligomerization detection: ASC pyroptosome analysis was detected using immunoblotting 
method as described by Juliana et al (Juliana et al., 2010).  Briefly, cell pellets were washed and 
resuspended in lysis buffer (20mM HEPES, 150mM KCl, 1% NP-40, 0.1mM PMSF and 1X protease 
phosphatase inhibitory cocktail) and were kept on ice for 30min, followed by centrifugation at 
5,000Xg for 10min at 4°C.  The pellets were washed with ice-cold PBS twice and then were 
resuspended in freshly prepared 4mM DSS (crosslinking agent) for 30min, centrifuged at 5,000Xg for 
10min at 4°C.  The pellets were then resuspended in 10% SDS buffer and were subjected to western 
blot analysis as mentioned before.   
Cytokine estimation: The BV2 or primary microglia were seeded in the 96-wellplate.  Post treatment, 
cytokines such as IL-1β, IL-18 was measured using ELISA based immunoassay kits as per 
manufacturer instructions. 
c-Abl Activity Assay: The c-Abl Activity was performed as described earlier (Schlatterer et al., 2011b).  
Briefly, post treatment, the BV2 cell lysate was prepared in the cell lysis buffer (25mM HEPES, pH 
7.5, 20mM β-glycerophosphate, 0.1mM sodium orthovanadate, 0.1% Triton X-100, 0.3M NaCl, 
1.5mM MgCl2, 0.2mM EDTA, 0.5 mM dithiothreitol, 10mM NaF, 1x protease–phosphatase inhibitor 
cocktail).  The cell lysate was centrifuged at 10,000rpm for 10 minutes. Equal amount of protein from 
each treatment group was loaded in Streptavidin coated 96 well plates and incubated with the 5μl of 
ice-cold 10x kinase buffer containing 200mM HEPES, pH 7.4, 10mM MnCl2, 10mM MgCl2, 10mM 
DTT, 10mM Na3VO4, 10mM Sodium ATP, 5μg of biotin conjugated c-Abl substrate, Abltide (EMD 




Abl enzyme (EMD Millipore, CAT # 14-459) was used as positive control at 1μg/reaction. The 
reaction was started by incubating the plate at 30°C for 30 minutes.  The reaction was stopped by 
adding 250μl of 2% ice-cold BSA.  Subsequently, the plates were washed three times with wash 
buffer. The plate wells were further incubated for 1h at room temperature with 4G10® anti-
phosphotyrosine antibody (1:1000) (EMD Millipore, CAT # 05-321).  Plates were washed three times 
and incubated for 1h with HRP-conjugated secondary antibody (1:1000).  Post incubation, the wells 
were washed 5 times with wash buffer and incubated with HRP substrate for 20 minutes.  The change 
in color development was read with spectrophotometer at 405nm.  
Caspase-1 Activity: Caspase-1 activity in BV2 cells was measured using the caspase-1 specific 
substrate YVAD as per manufacturer instructions (BioVision Inc., CAT # K111-25).  Briefly, 2 million 
cells per treatment group were collected following treatment completion and lysed in ice-cold cell lysis 
buffer containing protease-phosphatatse inhibitor cocktail for 10 minutes.  The cell lysate was 
centrifuged at 10,000rpm for a minute and supernatant was collected. 100μg of protein from each 
treatment group was incubated at 37°C with the reaction buffer containing caspase-1 specific Ac-
YVAD-pNA substrate for 1 hour.  The cytosolic caspase-1 activity was assayed by determining the 
increased absorbance at 405 nm using a SpectraMax® M2e microplate reader. 
Acridine Orange (AO) Assay: Activity of intracellular acidic sacs can be viewed by acridine orange 
dye, which tends to accumulate in acidic vacuoles and produce red fluorescence. BV2 cells were plated 
in 24-well plate.  Post treatment, the cells were incubated with  5μg/ml AO solution for 20min at 37°C, 
followed by washing with PBS (Moriyama et al., 1982).  The images were captured using FLoidTM 
Cell Imaging System by Invitrogen at 480nm excitation for green channel and 580nm excitation for 




Statistical Analyses: Results were expressed as mean ± SEM. All the data were analyzed with Prism 
6.0 software (GraphPad).  P-values were determined using one-way ANOVA, followed by post hoc 
Tukey Test to compare means of different treatment groups.  Differences with p<0.05 were considered 
statistically significant. Students’ t-test was used for comparing two groups. 
Results 
LPS priming induces a rapid activation of NLRP3 inflammasome components in ROT-
stimulated microglial cells 
Due to the multifactorial nature of PD, in the present study we evaluated the influence of prior 
microglial activation in an environment of mitochondrial stress (ROT), which recapitulates heightened 
microglial activation in PD-like neuropathology.  Treatment of murine macrophages with ROT leads to 
NLRP3 activation and IL-1β release in a delayed fashion although only in the presence of an 
inflammasome activator ATP (Won et al., 2015).  Mitochondria targeted toxins have been shown to 
influence cell viability (Ferger et al., 2010), in order to rule out toxic effects of ROT on our 
experimental end points first we determined the effects of ROT and LPS on cell viability using the 
MTS assay, which measures mitochondrial dehydrogenase activity.  For this purpose, microglia were 
treated with LPS (1μg/ml, 3h) or varying concentrations of ROT (0.1, 0.25 and 0.5μM) or in 
combination with varying concentration of ROT for 6, 12 and 24h. In this context, at 3h post LPS cells 
were washed and exposed to fresh medium containing varying concentrations (0.1-0.5μM) of ROT for 
6h.  MTS assay revealed that treatment of BV2 cells with ROT concentrations ranging from 0.1-0.5µM 
did not induce loss of cell viability (Fig. 1(A)) as compared with control cells at 6h time point, 
indicating that microglial activation may not be related to microglial death.  Likewise, both LPS and 
sequential treatment with LPS and ROT failed to elicit loss of cell viability at 6h post drug treatment.  




time points (Ferger et al., 2010). Intriguingly, at later time points (12 and 24h), a marked increase in 
cell death was evidenced in cells that were sequentially stimulated with LPS and ROT (Fig. 1(A)).  
Since 6h time point failed to elicit toxicity, all subsequent experiments were performed until this time 
point. 
LPS is an inflammatory activator that is widely used to study microglial activation.  Pro-IL-1β 
is not constitutively expressed in the microglia (Dostert et al., 2008), therefore the cells were primed 
with 1μg/ml LPS for 3h to stimulate pro-IL-1β synthesis and to upregulate inflammasome components 
and substrates as well as to mimic excessive microglial activation, which is implicated in PD (Kim and 
Joh, 2006).  Initially, we determined whether ROT, a mitochondrial electron transport chain inhibitor, 
influenced the NLRP3 inflammasome activation in LPS-primed BV2 microglial cells.  BV2 cells were 
treated with different concentrations of ROT in the presence or absence of LPS (1μg/ml, 3h) for 6h and 
NLRP3 related markers were determined by WB analysis.  As shown in Fig. 1(B-D), cells treat with 
ROT (0.5μM) or LPS alone caused a significant increase (p < 0.05) in NLRP3 expression as compared 
with control cells.  However, in cells that were primed with LPS and subsequently stimulated with 
ROT a dose-dependent increase in the expression of NLRP3-related markers were evidenced.  In this 
context, >1.5-fold increase was evidenced in relation to NLRP3 markers (NLRP3, caspase-1 p20, 
cleaved IL-1β) in LPS-primed ROT-stimulated cells as compared with control cells.  
Next, we sought to further investigate the kinetics of NLRP3 inflammasome activation in LPS-
primed BV2 microglia that were stimulated with ROT for different periods of time (1, 3, 6h) to 
confirm NLRP3 inflammasome activation.  We observed that all three NLRP3 related markers were 
upregulated by several folds in LPS/ROT stimulated cells as compared with ROT treated cells (Fig. 
1(E, F)).  Data shown in Fig. 1(E) demonstrates that upon stimulation of LPS-primed BV2 microglia 
with ROT, activation of NLRP3 related markers were increased in a time-dependent manner.  In this 




2.1-fold, respectively, at 6h.  Likewise, we saw a pronounced time-dependent secretion of mature IL-
1β, caspase-1 (p10) and NLRP3 starting at 1h in LPS-primed ROT-stimulated cells as compared with 
control cells as assessed via immunoblot analysis of concentrated supernatants (Fig. 1(E)).  To further 
verify NLRP3 inflammasome activation, we performed ELISA analysis.  We measured IL-1β and IL-
18 secretion upon stimulation of BV2 microglial cells with LPS or ROT or LPS and ROT for varying 
time points (1-6h).  We observed a significant increase in IL-1β (p < 0.05), IL-18 (p < 0.05) and TNFα 
(p<0.001) secretion in LPS stimulated cells.  Likewise, a marked increase (>2.5-fold) in IL-1β and IL-
18 secretion and > 4-fold increase in TNFα secretion was evidenced at 6h post LPS and ROT 
sequential stimulation as compared with ROT treated BV2 cells (Fig. 1(F)).  
Subsequently, we performed quantitative Real Time-PCR (qRT-PCR) to determine whether 
changes in mRNA transcript levels might have accounted for the elevated NLRP3-related marker 
levels in LPS and ROT sequentially stimulated BV2 microglial cells.  We observed a significant 
increase in NLRP3-related markers at all time points with levels increasing by more than 1.5-fold at 3h 
and 6h, respectively, upon LPS and ROT sequential stimulation as compared with ROT stimulated 
cells (Fig. 1(G)).  However, caspase-1 transcript levels remained unchanged at all time points exposed 
to either LPS or ROT or LPS and ROT as compared with control cells, supporting transcription-
independent caspase-1 activation mechanisms (Fig. 1(G)).  
The rapid response to LPS and ROT was mirrored in mouse primary microglial cells (Fig. 1(H, 
I)).  In a recent study, priming of primate primary microglia with varying concentrations (4-500ng/ml) 
of LPS resulted in similar amount of IL-1β release at least at the 4h time point (Burm et al., 2015).  
Therefore, experiments were performed at a similar time point with primary microglia.  For this 
purpose, we exposed the primary microglial cells for 3h with a low concentration of LPS (10ng/ml) 




revealed that LPS priming and ROT stimulation of mouse primary microglial cells elicited a marked 
increase (>20-fold) in both IL-1β and IL-18 as compared with ROT treated cells (Fig. 1(I)).  
Additionally, immunoblot analysis of concentrated cell culture supernatant from LPS and ROT 
sequentially stimulated cells revealed the appearance of mature IL-1β and caspase-1 (p10) as well as 
NLRP3 (Fig. 1(H)).  Our results further confirm the validity of our model to study the impact of 
sequential treatment with LPS and ROT in the induction of a pronounced microglial proinflammatory 
signaling cascade especially, NLRP3 inflammasome activation.  Subsequent experiments were carried 
out at the afore mentioned concentrations of both LPS and ROT to determine the levels of 
inflammatory cytokines and ALS related markers.  Collectively, our studies suggest that ROT alone 
induces a suboptimal increase in NLRP3-related markers; however, additional factors such as LPS 
priming would be required to induce heightened inflammatory response via potentiation of NLRP3 
inflammasome activation.  
LPS priming and ROT stimulation enhance intracellular ROS generation, nitrite production and 
dissipation of MMP in BV2 microglia  
It is well established that ROT induced inhibition of electron transport chain leads to ROS 
generation (Indo et al., 2007; Li et al., 2003).  To examine whether ROT-induced changes in ROS 
generation may be linked to NLRP3 inflammasome activation, we determined ROT-induced ROS 
generation in BV2 cells using the cell permeant ROS indicator, CM-H2DCFDA, and subsequent 
quantification using fluorescence plate reader assay.  The exposure of BV2 microglial cells to LPS for 
3h resulted in a significant (p < 0.05) increase in ROS generation, as compared with controls.  Upon 
ROT stimulation, BV2 cells demonstrated a time-dependent (Fig. 2(A)) increase in ROS generation. In 
this context a 50%, 65% and 110% increase in ROS generation was evidenced at 1, 3, 6h, respectively, 




cells. In this context, BV2 cells sequentially treated with LPS and ROT, displayed an 80, 120 and 
210% increase at 1, 3, 6h, respectively, as compared with control cells (Fig. 2(A)).  
As DCF fluorescence studies detects intracellular changes in ROS generation and fails to detect 
the exact source, we used mitoSOXTM red, a probe that is targeted to the mitochondria and fluoresces 
when oxidized by O2
-.  Treatment with ROT caused a 1.3 and 1.5-fold increase in mitochondrial 
superoxide production at 3 and 6h, respectively (Fig. 2(B)).  However, in cells that were sequentially 
treated with LPS and ROT a similar increase (>2-fold) in mitochondrial ROS generation was 
evidenced at 3h and 6h, respectively. 
Next, we examined the effect of LPS priming on ROT-induced NO production in BV2 cells.  
The BV2 cells were subjected to the same treatment conditions as detailed above.  LPS induced NO 
generation by more than 2-fold as compared to control cells.  On the contrary, LPS priming induced a 
dose-dependent increase in NO generation in ROT stimulated cells.  In fact, greater than 3-fold 
increase in NO generation was evidenced in LPS-primed ROT stimulated cells at 6h as compared to 
ROT treated cells.   
As ETC inhibitors can cause mitochondrial dysfunction leading to mitochondrial depolarization 
and energy depletion (Charli et al., 2016; Plaza Davila et al., 2015), we next assessed the impact of 
ROT on mitochondrial membrane potential (MMP, Δψm).  The outer membrane of mitochondria is 
highly susceptible to reactive free radicals and increased free radical generation within the cell can 
damage the structure of the outer membrane, creating pores and making the membrane leaky (Chipuk 
et al., 2006; Kowaltowski et al., 2001; Tait and Green, 2010).  To evaluate the mitochondrial 
membrane permeability, we examined the mitochondrial membrane potential using the JC-1 assay. JC-
1, a cationic dye, indicates mitochondrial depolarization via a reduction in the ratio of red to green 
fluorescence. As shown in Fig. 2(C), 0.5µM ROT treatment caused significant (p < 0.05) and time-




stimulation with ROT for 1, 3 and 6h resulted in a further time-dependent collapse of MMP.  In this 
context, an 18, 46 and 36% reduction of MMP (Fig. 2(C)) were evidenced in these cells at 1, 3 and 6h, 
respectively. Taken together, our results demonstrated that electron transport chain inhibitor enhance 
LPS-induced ROS generation concomitant with lowered membrane potential associated with 
dysfunctional mitochondria.  Thus, it is plausible that exaggerated mitochondrial ROS generation in 
LPS-primed ROT-stimulated microglial cells may contribute to an enhanced microglial activation 
response via NLRP3 inflammasome activation. 
c-Abl and PKCδ activation is augmented in a time-dependent manner in LPS-primed ROT-
stimulated microglial cells 
To this point our data indicate that LPS priming and subsequent ROT stimulation enhances 
NLRP3 inflammasome activation.  In order to identify the signaling pathways utilized by LPS and 
ROT stimulation to enhance NLRP3 inflammasome activity, we considered redox sensitive signaling 
pathways likely to be activated during LPS and ROT stimulation.  Accumulating evidence indicates 
that the non-receptor tyrosine kinase c-Abl participates in numerous neurodegenerative diseases and 
that its activation can cause neuroinflammation and oxidative stress-induced neuronal injury in mouse 
model of AD and PD (Alvarez et al., 2004; Schlatterer et al., 2011a; Schlatterer et al., 2011b).  Thus, 
we first assessed whether heightened oxidative stress response and perturbation of mitochondrial 
function impact c-Abl activity upon exposure of cells to ROT for increasing duration (1-6h) in BV2 
microglial cells and c-Abl activation was also determined by WB analysis.  In cells that were exposed 
to ROT or LPS, a modest increase in the magnitude of phosphorylated levels of c-Abl was evidenced.  
Conversely, LPS priming and subsequent stimulation with ROT elicited robust increase (>1.6-fold 
increase) in c-Abl phosphorylation at 3h and a sustained activation was evidenced for the remainder of 
the treatment period consistent with an aberrant activation state (Fig. 3(A)). In this context, the extent 




and Tyr412) in LPS/ROT stimulated cells as compared with LPS or ROT only treated cells.  c-Abl 
phosphorylation at Tyr245 and Tyr412 serves as an indirect measure of c-Abl activation (Dorey et al., 
2001; Ko et al., 2010). In fact, they are well established regulatory phsophotyrosine residues that are 
required for c-Abl activation (Brasher and Van Etten, 2000; Katsumata et al., 2012).  Densitometric 
analysis confirmed that LPS priming induced a significant time-dependent increase in the 
phosphorylation of c-Abl (p < 0.01) (Fig. 3(A)).  To further determine whether LPS or ROT or 
combination-induced alteration of p-c-Abl levels could be attributed to transcriptional changes, we 
determined the transcript levels of c-Abl in BV2 cells exposed to these agents (data not shown).  
We next determined the expression of p-c-Abl Y412 in primary microglial cells either exposed 
to LPS or ROT or sequentially exposed to LPS and ROT by fluorescence microscopy.  We observed a 
modest expression of p-c-Abl Y412, which is depicted as red fluorescence in LPS or ROT treated cells 
as compared with control cells; however, strong immunoreactivity for p-c-Abl Y412 was evidenced in 
LPS/ROT treated cells as compared with control cells (Fig. 3(C)).  To further ascertain c-Abl 
activation, next we investigated whether the expression of c-Abl and p-c-Abl was altered in mouse 
primary microglial cells exposed to low dose of LPS or ROT or LPS/ROT using WB analysis.  A 
marked increase in Y412 phosphorylated and Y245 phosphorylated c-Abl protein levels were 
evidenced in LPS-primed cells that were subsequently stimulated with ROT as compared with control 
cells (Fig. 3(B)), further corroborating immunofluorescence analysis.  A modest increase in p-c-Abl 
levels were evidenced in LPS or ROT alone treated cells.  These results indicate that sequential 
treatment with LPS and ROT accentuates c-Abl activation in microglial cells.   
Previous studies have demonstrated that c-Abl plays an essential role in PKCδ activation in 
response to oxidative stress (Gonfloni et al., 2012).  In this context, c-Abl has been shown to 
phosphorylate PKCδ on tyrosine 311, which has been linked to apoptotic death in H2O2 treated cells 




upregulation and microglia activation and that genetic ablation of PKCδ attenuated LPS-induced 
proinflammatory response (Gordon et al., 2016).  Therefore, we examined whether exposure to LPS or 
ROT or in combination activated PKCδ, a downstream mediator of c-Abl.  Similar to the temporal 
pattern of activation of c-Abl, a time-dependent parallel increase in p-PKCδ Y311 expression levels 
were evidenced in ROT-stimulated cells that were primed with LPS as compared with LPS or ROT 
alone treated cells (Fig. 3(A)).  Our results suggest that LPS-induced generation of intracellular ROS in 
conjunction with high grade mitochondrially derived ROS originating from ROT-induced disruption of 
mitochondrial ETC might have contributed to a heightened oxidative stress environment which in turn 
might have been conducive for the aberrant activation of c-Abl and PKCδ. 
Mitochondria-derived ROS drives the NLRP3 inflammasome activation and redox sensitive 
kinase activation in ROT stimulated cells 
Studies have implicated ROS-derived from dysfunctional mitochondria may be linked to 
sustained NLRP3 inflammasome activation and IL-1β secretion (Bauernfeind et al., 2011; Chen et al., 
2015; Jang et al., 2015; Kauppinen et al., 2012; Tschopp and Schroder, 2010; Zhou et al., 2011).  
Numerous NLRP3 activators have been shown to trigger mitochondrial ROS production in a variety of 
cells.  For example, fatty acid palmitate has been shown to promote NLRP3 inflammasome activation 
and IL-1β release via mitochondria-generated ROS dependent fashion (Wen et al., 2011a).  Because 
ROT treatment revealed the potential involvement of mitochondria-derived ROS in the enhanced 
oxidative stress response, we next utilized mitochondria-targeted antioxidant to dissect in detail the 
role of mitochondrial ROS on NLRP3 inflammasome activation and IL-1β secretion.  In these 
experiments, BV2 cells were pretreated with mitoTEMPO (200 and 500µM), mitochondria-targeted 
ROS scavenger (Nakahira et al., 2011), for 1h prior to LPS priming and subsequently stimulated with 
ROT. Notably, the LPS and ROT-induced mitochondrial ROS production in BV2 cells was markedly 




was reduced by 20 and 40% following treatment with 200 and 500µM mitoTEMPO, respectively (Fig. 
4(A)). Notably, mitoTEMPO (200, 500µM) elicited significant reduction (p<0.01) in ROS generation 
correlated with diminished secretion of IL-1β and IL-18 in response to ROT and LPS (Fig. 4(D)).  
Additionally, repression of expression of NLRP3, caspase-1 cleavage was also evidenced in 
mitoTEMPO pretreated cells that were stimulated with ROT subsequent to LPS priming (Fig. 4(B)).  
Given that PKCδ and c-Abl are redox sensitive protein kinases and were activated upon stimulation 
with ROT in LPS-primed cells, we further investigated the importance of mitochondria-derived ROS 
on the activation of the two pro-oxidant kinases.  We found that ROT induced phosphorylation of c-
Abl at both 412 and 245 sites and PKCδ at Y311 site was blunted (p < 0.01) at both 200 and 500µM 
mitoTEMPO, respectively (Fig. 4(C)) as detected via WB.  Together, these results indicate that 
mitoTEMPO attenuated NLRP3 inflammasome activation and activation of redox sensitive kinases 
such as c-Abl suggesting that mitochondria-derived ROS may mediate NLRP3 inflammasome 
activation via c-Abl/PKCδ signaling axis in response to LPS and ROT in microglial cells. 
Mitochondrial dysfunction and NLRP3 inflammasome activation is elicited in a c-Abl dependent 
manner in LPS primed ROT stimulated microglial cells  
A growing body of evidence indicates that c-Abl inhibitor could suppress neurotoxicity and 
neuroinflammation in experimental models of PD and AD (Brahmachari et al., 2016; Estrada et al., 
2011; Jing et al., 2009; Karuppagounder et al., 2014).  In an effort to assess the anti-inflammatory 
effects of DAS, a dual c-Abl/c-Src kinase inhibitor (Lombardo et al., 2004), we used the LPS-
stimulated BV2 microglial cells as a model of neuroinflammation.  DAS attenuated the expression of 
key inflammatory markers in a concentration-dependent manner.  More specifically, DAS treatment 
decreased the secretion proinflammatory cytokines and NF-κB nuclear translocation (sup. fig 1).  
Given that DAS effectively suppressed the induction of proinflammatory markers at 100nM, we used 




study, phosphorylation of c-Abl in NSC-34 cells expressing mutant or WT SOD was found to be 
reduced at 100nM (Katsumata et al., 2012).  Stimulation of BV2 microglial cells with LPS (1μg/ml) 
and ROT (0.5μM) for 6h induced a 1.8-fold increase in active p-c-Abl levels (Y412 and Y245) (Fig. 
3(A)) with a concomitant increase in c-Abl kinase activity (4.5 fold) as compared with ROT treated 
cells (fig 5(A)).  However, upon 1h pretreatment with 100nM DAS a near complete abolition in c-Abl 
kinase activity was evidenced in LPS/ROT treated cells.  These studies indicate that DAS inhibits c-
Abl activation in LPS/ROT-stimulated microglial cells confirming the inhibitory effects of the drug on 
c-Abl activation (Fig. 5(A)).  In fact, our WB findings corroborated our c-Abl enzymatic analysis 
whereby a marked reduction in p-c-Abl levels (Y412) was evidenced in LPS/ROT treated cells that 
were pretreated with DAS (Fig. 5(B)).  Alternatively, the inhibitory effects of DAS on Src kinase 
cannot be excluded.  
We next explored whether DAS inhibits ROS generation and NLRP3 inflammasome activation 
in LPS/ROT-stimulated BV2 microglial and mouse primary microglial cells.  Interestingly, DAS 
pretreatment significantly inhibited loss of MMP, generation of ROS and nitrite production (fig 5(C-
H)), NLRP3 expression (fig 6(A-C)), ASC oligomerization (sup. fig 2), caspase-1 activation (fig 6(D)) 
and secretion of IL-1β and IL-18 (fig 6(E)) under these experimental conditions in BV2 microglial 
cells.  Likewise, DAS pretreatment suppressed expression of NLRP3 related markers in primary 
microglia subjected to the afore mentioned treatment conditions (fig 6(F,G)).  
To further ascertain the role of c-Abl in NLRP3 inflammasome activation in our experimental 
conditions, we utilized a siRNA system to specifically downregulate c-Abl protein levels in BV2 
microglia and studied the microglial activation response in response to ROT in LPS-primed cells.  In 
pilot experiments, we obtained optimal suppression of c-Abl protein at 48h following transfection as 
assessed via WB analysis.  We found an 80% reduction in the levels of c-Abl in cells that were 




of BV2 microglial cells with siRNA targeted to c-Abl inhibited LPS and ROT-induced increase in the 
expression and secretion of NLRP3 by approximately 85% (fig 7(B)).  Additionally, in LPS and ROT 
sequentially treated cells c-Abl siRNA prevented secretion of cleaved NLRP3, casp-1 (p10) as well as 
IL-1β by 80%, 84% and 70%, respectively as compared with scramble ROT-treated cells (fig 7(B)).  
ELISA analysis confirmed the inhibitory effects of c-Abl knock-down on IL-1β and IL-18 extracellular 
release (fig 7(C)).  Our results suggest that c-Abl plays a role in NLRP3 inflammasome activation 
induced by LPS and the aggravation of NLRP3 inflammasome signaling occurs following ROT-
induced excessive ROS generation.  We next examined the impact of siRNA-mediated knock-down of 
c-Abl in primary microglial cells exposed to LPS and ROT.  Upon verification of depletion of 
endogenous c-Abl levels by c-Abl targeted siRNA (fig 7(D)), we next investigated NLRP3 
inflammasome activation using WB analysis.  A diminished pattern of NLRP3 inflammasome 
activation as reflected by reduced expression levels of NLRP3 and secreted NLRP3, IL-1β and 
caspase-1 were evidenced in response to LPS and ROT in c-Abl siRNA transfected as compared with 
scramble transfected cells (fig 7(E)).  ELISA studies further corroborated that LPS and ROT 
potentiates NLRP3 inflammasome activation as reflected by increased IL-1β and IL-18 levels (fig 
7(F)).  These studies suggest that c-Abl mediates NLRP3 inflammasome activation via ROS generation 
in LPS-primed ROT-stimulated microglial cells.  
Dasatinib suppresses increased trafficking of NLRP3 to mitochondria in LPS-primed ROT-
stimulated microglial cells 
Previous studies have demonstrated that NLRP3 has the propensity to accumulate in the 
mitochondria upon exposure to NLRP3 inducing stimuli such as nigericin (Subramanian et al., 2013).  
Thus, we hypothesized that NLRP3 inflammasome activation is associated with NLRP3 translocation 
to mitochondria.  We performed immunofluorescence studies to determine the cellular localization 




Confocal double immunofluorescence analysis was performed using NLRP3 (green) and TOM20 (red) 
(fig 8), which is mitochondrial marker that is routinely used to demonstrate mitochondrial translocation 
in a wide variety of cells.  Examination of the distribution pattern of NLRP3 revealed that it exhibited 
a more dispersed expression pattern in the cytoplasm in primary microglial cells that were treated with 
the vehicle.  By contrast a dramatic increase in NLRP3 compartmentalization within the mitochondria 
was evidenced in primary microglial cells that were stimulated with LPS/ROT, while LPS and ROT 
displayed a modest increase in mitochondrial translocation.  Consistent with our data, in a recent study, 
Iyer et al. demonstrated that mitochondria play a pivotal role in NLRP3 activation via the direct 
interaction of NLRP3 to the mitochondria via cardiolipin (Iyer et al., 2013).  Remarkably, DAS 
inhibited NLRP3 trafficking to the mitochondria in LPS/ROT stimulated primary microglial cells (fig 
8, last row).  These results further show that DAS-induced attenuation of c-Abl activation may limit 
ROT-induced mitochondrial dysfunction and resultant redistribution of NLRP3 to mitochondria in 
LPS-primed cells as previously reported (Iyer et al., 2013; Subramanian et al., 2013). 
Dasatinib inhibits NF-κB activation in ROT-stimulated LPS-primed microglial cells 
Previously we and other have demonstrated that inflammagen LPS-induced NF-κB activation 
in BV2 microglial cells (Gao et al., 2013; Gordon et al., 2016; Panicker et al., 2015).  Likewise, in 
ROT-treated BV2 cells a marked increase in NF-κB activity was evidenced post drug treatment (Yuan 
et al., 2013).  Furthermore, NLRP3 expression has been shown to be induced by NF-κB in murine 
hepatocytes (Boaru et al., 2015).  Therefore, we hypothesized that exacerbated NF-κB activation in 
LPS/ROT-treated cells may underlie the amplified proinflammatory response evidenced in these cells. 
Activation of NF-κB transcription factor is crucial for pro-inflammatory gene transcription.  In the 
resting state, NF-κB is sequestered in the cytoplasm as an inactive complex via interaction with the 
IκBα inhibitory protein. Following exposure to inflammagens, IκBα in the NF-κB complex is 




system (UPS); thereby leading to the translocation of p65 to the nucleus (Aldieri et al., 2003; Karin, 
1999).  Thus, we assessed the magnitude of NF-κB activation in LPS/ROT-stimulated cells as 
compared with LPS or ROT treatment.  For this purpose, we determined the activation status of p65 
subunit of NF-κB by WB analysis in BV2 cells that were treated with LPS, ROT or LPS/ROT for 10 or 
20min. A rapid relocalization of p65 to the nucleus as early as 10min in BV2 cells exposed to LPS.  In 
contrast, LPS priming and subsequent stimulation with ROT for 6h resulted in a significant (p<0.05) 
increase in p65 nuclear translocation (fig 9(A)).  To further confirm NF-κB activation in these cells, we 
determined p-IκBα levels using WB analysis.  A marked upregulation of IκBα phosphorylation at 
Ser32 site was found to parallel nuclear translocation of p65 in LPS/ROT treated cells at 6h as 
compared with LPS or ROT only treated cells (fig 9(B)).  Indeed, nuclear translocation of p65 
correlated with increased levels of NF-κB gene products including IL-1β, IL-18 (fig 1(F)) and NOS2 
(fig 5(G)) in LPS/ROT treated BV2 cells.  Our results are consistent with previous studies showing 
that NF-κB activation is mediated via degradation of IκBα proteins and accompanying p65 nuclear 
translocation in cells that are stimulated with immune modulators (Sakurai et al., 2003; Vermeulen et 
al., 2003).    
In order to determine the effect of DAS on LPS/ROT-induced NF-κB signaling, BV2 
microglial cells were pretreated with DAS and subsequently primed with LPS and stimulated with 
ROT.  Incubation of BV2 microglia with 100nM DAS prior to LPS/ROT treatment for 1h significantly 
attenuated NF-κB activation as evidenced by the retention of p65 in the cytosol as assessed via 
immunoblotting (fig 9(C)) and immunofluorescence studies (fig 9(E)).  Likewise, our WB studies 
further confirmed the inhibitory effects of DAS on NF-κB activation in LPS/ROT treated BV2 cells as 
measured by decreased IκBα phosphorylation (pS32) (fig 9(D)) and nuclear translocation of p65 (fig 




mediated via suppression of c-Abl/NF-κB interplay presumably limiting the magnitude of the 
accentuated proinflammatory signaling cascade involving NLRP3 inflammasome activation. 
c-Abl is linked to the impairment of ALS in ROT-stimulated LPS-primed microglial cells 
Autophagy represents an intracellular cellular degradative machinery that degrades damaged 
organelles or misfolded proteins via lysosomal degradative machinery.  In a previous study ROT was 
found to induce disruption of autophagic flux in SH-SY5Y cells and in the substantia nigra (SNpc) in 
Parkinsonian rats (Wu et al., 2015).  In this context, excessive accumulation of autophagosomes with a 
concomitant disruption of lysosomal function was evidenced in these cells.  Moreover, multiple reports 
indicate that autophagy is a negative regulator of NLRP3 inflammosome activation (Chuang et al., 
2013; Nakahira et al., 2011; Saitoh et al., 2008).  Therefore, we examined whether autophagy changes 
occur following LPS or ROT stimulation or LPS and ROT sequential treatment by examining the 
expression levels of beclin1, p62, LC3B I and LC3B II using western blot analysis.  Beclin 1 is a 
critical component of the class III phosphatidylinositide 3-kinase (PI3K) complex, which been shown 
to participate in autophagosome formation (McKnight and Zhenyu, 2013).  p62 is an adaptor protein 
that is involved in the formation of a linkage between LC3B II and the ubiquitinylated proteins to be 
degraded and has been routinely used for monitoring autophagic flux (Komatsu and Ichimura, 2010).  
The microtubule associated protein LC3B I is present in the cytoplasm however, upon association with 
phosphatidylethanolamine (via an ubiquitin like conjugation reaction) of the membrane of 
autophagosome leads to the conversion to LC3B II, a widely used autophagosome marker (Tanida et 
al., 2008). Both p62 and LC3B II are degraded together with ubiquitinylated protein following 
autophagosome fusion with the lysosome (Komatsu and Ichimura, 2010; Tanida et al., 2008).  BV2 
microglial cells were incubated with either LPS or ROT or primed with LPS prior to ROT (0.5μM) 
stimulation for increasing time period (1, 3 and 6h).  As shown in fig 10(A), a sustained and dramatic 




p62 levels was evidenced in cells that were primed with LPS prior to ROT stimulation as compared 
with control cells.  Also, a significant increase in these markers was evidenced in cells exposed to LPS 
or ROT alone treated cells as compared with controls.  A similar scenario was evidenced in primary 
microglial cells exposed to LPS or ROT or combination (fig 10(B)).  Additionally, we also performed 
immunofluorescent studies to determine LC3B positive puncta.  Consistent with our WB findings, 
exposure of primary microglial cells to LPS and ROT resulted in a dramatic increase in LC3B positive 
puncta as compared with LPS or ROT treated cells (fig 10(F)).  Next, we determined whether 
LPS/ROT-induced autophagy upregulation is mediated in a c-Abl dependent manner.  Because 
maximal increments in autophagy related markers occurred at 6h post LPS/ROT stimulation, 6h was 
chosen to study the effects of DAS on ROT-induced impairment in autophagic flux in LPS-primed 
microglia.  Data show that DAS attenuated ROT-induced increases in autophagy markers in LPS-
primed cells as compared with controls (fig 10(C)).  To further ascertain the role of c-Abl in the 
upregulation of autophagic mediators in LPS/ROT stimulated cells, primary microglial cells were 
transiently transfected with siRNA targeting c-Abl or scramble siRNA.  Subsequently cells were 
primed with LPS (10ng/ml) for 3h and stimulated with ROT (30nM) for 4h in order to assess 
modulation of autophagic markers.  Our data revealed that LC3B II, beclin1, p62 levels after 
stimulation with ROT in LPS-primed cells was significantly lower in siRNA c-Abl transfected cells as 
compared with siRNA scrambled transfected cells (fig 10(G)).  Our results are consistent with previous 
studies demonstrating a positive association between c-Abl induction and disruption of autophagic flux 
(Hu et al., 2012; Mahul-Mellier et al., 2014).  Our studies suggest that c-Abl-mediated impairment in 
the clearance of autophagic vacuoles (AVs) might partly underlie the excessive buildup of AVs in 
LPS/ROT-stimulated microglial cells. 
It is well established that impairment in lysosomal function blocks autophagic degradation of 




the degradation of autophagosomes (Mizushima, 2007a; Mizushima, 2007b; Yang and Klionsky, 
2009).  Furthermore, lysosome-destabilizing agent mediated lysosomal rupture has been implicated in 
activation of NLRP3 inflammasome (Lima et al., 2013).  To ascertain whether lysosomal activity is 
modulated in LPS-primed ROT-exposed cells, we used the acridine orange immunofluorescence 
analysis.  Acridine orange dye can be trapped within intact acidic lysosomes resulting in red 
fluorescence, while in the cytoplasm they fluoresce green when the lysosomal acidity is lost.  
Consistent with previous studies (Carrithers et al., 2007; Mader et al., 2012), immunofluorescence 
analysis revealed that exposure of BV2 microglia to either ROT or LPS alone decreased lysosomal 
acidification indicating decreased lysosomal integrity.  Interestingly, cells sequentially treated with 
LPS and ROT displayed a marked attenuation of lysosomal acidification as judged by a near complete 
abolition of acridine orange florescence, as compared with control cells (fig 10(D)).  As expected, 
DAS pretreatment restored lysosomal acidity in LPS/ROT-treated cells as evidenced by a marked 
increase in the proportion of cells exhibiting red fluorescence.  Collectively, these results suggest that 
LPS priming might exacerbate ROT-induced impairment in autophagic flux via impairment of 
lysosomal function. 
The transcription factor EB (TFEB) has been shown to be a master regulator of the ALS 
pathway that is regulated by mTOR signaling events (Decressac et al., 2013).  In cellular models of 
protein misfolding and oxidative stress, enhancement of TFEB function has been found to be 
associated with improved protein clearance and neuroprotection.  Given that we observed excessive 
accumulation of autophagic mediators in cells that received a combination of LPS and ROT, we 
addressed the possibility whether impairment in lysosomal biogenesis might contribute to the 
impairment in autophagic flux.  For this purpose, we determined time-dependent regulation of TFEB 
levels in LPS or ROT or in LPS-primed cells that were exposed to ROT for varying duration using WB 




cells (0.5μM, 3 and 6h); however, in cells that were stimulated with LPS/ROT, a further time 
dependent increase in the depletion of TFEB levels was evidenced during the entire treatment duration 
as compared with control cells (Fig. 10(E)), which is suggestive of defective lysosomal biogenesis.  
Intriguingly, we found that DAS significantly attenuated ROT-induced depletion of TFEB in LPS-
primed cells further confirming its restorative effects on lysosomal function (Fig. 10(E)).  These results 
suggested that impairment in the clearance of AVs in LPS/ROT-stimulated cells might be attributed at 
least in part to lysosomal dysfunction originating from a failed lysosomal degradative machinery.  
Taken together, our data highlights the pivotal role of c-Abl in ROT-induced ALS dysfunction in LPS-
primed cells. 
Enhancement of PKCδ and c-Abl activation correlates positively with TH neuron loss in LPS-
primed ROT-stimulated midbrain neuron-glia cultures 
Given that both c-Abl and PKCδ displayed aberrant activation in LPS and ROT sequentially 
treated microglial cells as compared with LPS or ROT treatment (Fig. 1(H)), we next examined 
whether LPS and ROT exacerbated c-Abl and PKCδ activation in midbrain neuron-glia cultures and 
how this relates to the levels of TH.  As shown in Fig. 11(A), sequential treatment with LPS and ROT 
significantly increased p-c-Abl (Y412) and p-PKCδ (Y311) levels as compared with LPS or ROT only 
treated neuron-glia mixed cultures indicative of redox sensitive kinase activation. These results further 
confirmed activation of both c-Abl and PKCδ activation, which may, in part, elicit a heightened 
oxidative stress response in response to LPS and ROT in these cells.   Notably, we found that aberrant 
activation of the afore mentioned redox sensitive kinases positively correlated with TH loss and that 
DAS restored the loss of TH levels in LPS and ROT stimulated mixed neuron glia coculture (fig 




It has been found that ROT enhances oxidative stress response and DAgic cell death in mixed 
neuron-glia culture as compared with neuron enriched culture that were pretreated with LPS (Gao et 
al., 2002a).  Since DAS blocked the activation of the redox sensitive kinase, it is plausible that 
heightened glia-dependent c-Abl-mediated oxidative stress response may enhance proinflammatory 
cascade and subsequent dopaminergic neurodegeneration. However, further studies are needed to 
determine whether there is a differential loss of TH positive cells in midbrain neuron enriched culture 
upon LPS and ROT stimulation. 
Dasatinib treatment attenuates behavioral deficits, NLRP3 inflammasome activation and ALS 
dysfunction in the substantia nigra of LPS treated mice   
To determine whether data generated using isolated microglia could be translated into an in vivo 
setting, we used the LPS neuroinflammation model of PD.  We and others have demonstrated that LPS 
elicits a marked increase in proinflammatory mediators levels (de Pablos et al., 2014; Gordon et al., 
2016; Tomas-Camardiel et al., 2005).  Moreover, previous studies have demonstrated that DAS 
prevents neuroinflammatory response in a mouse model of Amyotrophic lateral sclerosis and AD 
(Dhawan and Combs, 2012; Katsumata et al., 2012).  Therefore, we next sought to determine the in 
vivo efficacy of DAS in LPS-treated mice.  The mice were administered 25mg/kg/d DAS via oral 
gavage for 30 days before LPS (5mg/kg, i.p.) administration. Based on the anti-inflammatory effects of 
DAS we hypothesized that blockade of c-Abl dependent downstream immune signaling cascade may 
suppress the sickness behavior in these mice.  To assess the severity of the sickness behavior we 
assessed motor activity.  Mice treated with LPS showed significant reduction in the cumulative 
distance traveled, vertical and horizontal activity as compared with the controls.  However, when mice 
were treated with DAS we observed a remarkable improvement in LPS-induced sickness behavior as 
reflected in the improvement of the locomotor activity.  To further evaluate sickness behavior, we 




shock is further confirmed in the Rotarod test.  The improved exploratory behavior in DAS-pretreated 
LPS-administered mice might be attributed to amelioration of LPS-induced septicemia or alternatively 
a rapid recovery from this illness.  These data highlight that interference of c-Abl activation via DAS 
can abrogate microglial proinflammatory signaling cascade via suppression of NLRP3 inflammasome 
related markers, which in turn may contribute to an improvement in sickness behavior after LPS 
treatment.   We next investigated whether DAS would directly reduce proinflammatory response in 
LPS treated mice.  We found that DAS reduced ionized calcium binding adapter molecule 1 (IBA-1, 
microglial marker) and NLRP3 expression in the substantia nigra of LPS treated mice (Fig. 12(J and 
K)).  Likewise, DAS attenuated the mRNA levels of NLRP3 and IL-1β but not TNFα and IL-18, and 
Cas-1 in the SNc of LPS treated mice as assessed via qRT-PCR analysis (Fig. 12 (E-I)).  Next, we 
determined whether DAS directly affected the activation of c-Abl and PKCδ.  Western blot analysis 
revealed that DAS attenuated LPS-induced hyperphosphorylation of c-Abl kinase at Tyr245 and Ty412 
residues and its downstream substrate PKCδ (pY311) (fig. 13(A)).  Next, we assessed whether DAS 
affected ALS markers in LPS treated mice.  As expected, in LPS-treated mice, increased protein 
expression of beclin1 was accompanied by down regulation of TFEB consistent with ALS dysfunction 
(fig 13(B)).  These changes in ALS markers were also significantly ameliorated by DAS.  Taken 
together these data suggest that the anti-inflammatory effects of DAS, might at least in part mediated 
via attenuation of redox sensitive kinases and restoration of the ALS function in LPS treated mice.  
Discussion 
Herein we demonstrate that c-Abl may have a potential regulatory role in the modulation of 
NLRP3 related markers in the LPS and ROT-stimulated microglia and in an in vivo LPS model of 
neuroinflammation.  Upon LPS priming and subsequent stimulation of microglia by ROT a dramatic 
increase in c-Abl levels, mitochondrial dysfunction, maturation and secretion of NLRP3 




dysfunction as compared with LPS or ROT-treated cells were evidenced.  Additionally, NLRP3 was 
significantly increased in the supernatant of microglia primed with LPS and stimulated with ROT, the 
role of altered plasma membrane permeability in the mechanism of NLRP3 release into the 
extracellular media cannot be entirely ruled out.  Similarly, acceleration of NLRP3 inflammasome 
activation and ALS dysfunction was evidenced in LPS-primed ROT-stimulated primary microglial 
cells.  Furthermore, antioxidant mitoTEMPO reduced activation of NLRP3, c-Abl, PKCδ as well as 
ROS generation in LPS-primed ROT-stimulated BV2 microglial cells.  Intriguingly, DAS, a tyrosine 
kinase inhibitor, was found to inhibit NLRP3 inflammasome activation.  Subsequent mechanistic 
studies revealed that DAS mitigated the activation of c-Abl induced by LPS and ROT.  Moreover, the 
anti-inflammatory effects of DAS on LPS/ROT-stimulated microglial activation was found to be 
mediated in part via inhibition of mitochondrial dysfunction, ROS generation, mitochondrial 
trafficking of NLRP3, NF-κB activation and ALS impairment, further confirming the multi-target 
directed effects of DAS.   However, the lack of selectivity and off target effects of these compounds 
promoted us to further investigate the role of c-Abl in the exacerbation of proinflammatory signaling 
cascade in LPS-primed ROT-stimulated microglial cells using c-Abl specific siRNA.  Our studies 
revealed the novel signaling events linking c-Abl to NLRP3 inflammasome activation in microglial 
cells.  Our in vivo studies validated the in vitro findings, whereby in a neuroinflammation LPS model 
of PD a positive association was evidenced between microglial activation, NLRP3 upregulation and c-
Abl activation.  Moreover, we found that the administration of DAS resulted in reduced sickness 
behavior and improved motor function in correlation with its anti-inflammatory effects in LPS treated 
mice.  The results are, to the best of our knowledge, the first to demonstrate that LPS priming and 
subsequent stimulation with ROT amplifies microglial activation response via an exacerbated NLRP3 
inflammasome activation response through mechanisms that involve mitochondrial ROS dependent c-




Central or peripheral inflammation has been shown to promote the transformation of primed 
state of microglia into an activated state, which can trigger or induce processes related to 
neurodegeneration.  Accumulating evidence demonstrate that systemic inflammation exacerbate PD-
associated neurodegenerative process (Ferrari and Tarelli, 2011).  For example, people infected with 
Japanese encephalitis virus ad H5N1 influenza virus showed an increased risk for developing PD (Jang 
et al., 2009; Shoji et al., 1993).  Additionally, inflammation triggered by bacteria or virus has been 
implicated in α-synuclein misfolding, aggregation and propagation (Lema Tome et al., 2013).  Thus, 
interplay between brain inflammation and systemic inflammation may contribute to the progression of 
neurodegenerative diseases including PD.  Therefore, improved understanding of the mechanisms that 
underlie microglial activation and their transition to a hyperactivated phenotype may lead to the 
development of therapeutics that reduces the exacerbation of PD symptomology and delay disease 
progression. 
Our present study demonstrates that NLRP3 inflammasome activation is enhanced in LPS-
primed and ROT-stimulated microglia.  In this context, we demonstrate that LPS priming and ROT 
stimulation exaggerated microglial NLRP3, IL-1β, IL-18 mRNA and protein expression levels as well 
as the secretion of mature IL-1β and IL-18.  Furthermore, activated caspase-1 was potentiated in LPS-
primed ROT-stimulated cells suggesting that NLRP3 inflammasome assembly has occurred which in 
turn has contributed to increased generation of pro-inflammatory cytokines.  Our data is consistent 
with a recent report demonstrating that microglia can release IL-1β and IL-18 in an NLRP3 
inflammasome dependent manner (Gustin et al., 2015).  In fact, in both AD brains and in AD 
transgenic mice NLRP3 inflammasome activation has been evidenced (Mitroulis et al., 2010).  
Additionally, transactive response DNA binding protein 43 (TDP-43) has been shown to activate 
microglia via the NLRP3 inflammasome (Zhao et al., 2015).  To further highlight the pivotal role of 




in primary microglia exposed to LPS or ROT or in combination.  Our data indicate that ROT 
stimulation induces a marked redistribution of NLRP3 to mitochondria, whereby a punctate pattern of 
mitochondrial colocalization was evidenced.  Recent reports suggest that upon activation NLRP3 
translocate to the mitochondria and mitochondria associated endoplasmic reticulum (ER) membranes 
(Zhou et al., 2011).  Moreover, upon stimulation with NLRP3 inflammasome activators, cardiolipin 
translocates from the inner to the outer mitochondrial membrane, which is believed to provide a 
docking position for NLRP3 and thereby facilitating the localization of NLRP3 (which is located in the 
ER prior to macrophage stimulation) to the mitochondria (Iyer et al., 2013).  Remarkably, DAS 
treatment resulted in the near complete blockade of NLRP3 relocalization to the mitochondria in 
primary microglia exposed to LPS and ROT.  Thus, it is plausible that mitochondria bound NLRP3 in 
the vicinity of elevated ROS generation may be important for NLRP3 inflammasome activation.   
Upon ROT administration, microglia-derived ROS such as superoxide, hydroxyl, and 
peroxynitrite has been shown to cause selective degeneration of SNc, owing to low levels of 
antioxidant defense and accompanying high levels of DA metabolism (Javed et al., 2016).  More 
specifically, microglia derived ROS was found to be indispensable for ROT-induced DA degeneration 
(Gao et al., 2003). In recent years, a growing body of evidence supports the pivotal role of ROS in the 
activation of NLRP3 inflammasome (Jang et al., 2015; Salminen et al., 2012; Zhou et al., 2010).  The 
mechanistic basis of ROS-dependent NLRP3 activation is poorly understood; however, both 
intracellular ROS and mitochondrial ROS has been implicated in the mechanism of NLRP3 
inflammasome activation.  Increasing evidence supports the involvement of mitochondrially derived 
ROS in NLRP3 inflammasome activation (Heid et al., 2013; Sorbara and Girardin, 2011; Zhou et al., 
2011).  Accordingly, in the present study ROT-induced mitochondrial electron transport chain (ETC) 
complex I inhibition and subsequent generation of ROS might have contributed to the excessive ROS 




induce NLRP3 inflammasome activation in the presence of an inflammasome activator (ATP) via a 
mechanism involving the generation of high grade mitochondrial ROS (Won et al., 2015).  In another 
study, the saturated fatty acid palmitate was found to induce NLRP3 inflammasome activation and the 
release of IL-1β via a mitochondrial ROS-mediated mechanism (Wen et al., 2011a).  In agreement with 
these findings, we demonstrated that cells that were sequentially treated with LPS and ROT showed a 
marked increase in ROS generation preceded elevated NLRP3 inflammasome activation as compared 
with LPS or ROT only treated cells.  Accordingly, mitoTEMPO, a mitochondria-targeted antioxidant, 
attenuated NLRP3 inflammasome activation and consequent IL-1β secretion and caspase-1 activation 
at least in part via inhibition of c-Abl and PKCδ activation in LPS-primed ROT-stimulated cells further 
highlighting the pivotal role of mitochondria-derived ROS in NLRP3 inflammasome activation.  
Likewise, DAS also exhibited significant antioxidant effects as evidenced by significant abrogation of 
MMP collapse (fig 5(C)) with a concomitant suppression of ROS levels (fig 5(D)) in LPS-primed 
microglial cells that were stimulated with ROT.  Here we provide direct experimental evidence that the 
continued presence of the initial triggers (e.g., LPS) was not required for persistent microglial 
activation and that the persistent ROS originating from defective mitochondria with disrupted 
mitochondrial ETC in the presence of ROT was sufficient to amplify the NLRP3 inflammasome 
activation in LPS-primed ROT-stimulated microglial cells. 
The ubiquitously expressed c-Abl is activated in response to diverse stimuli including growth 
factors, cell adhesion, oxidative stress and DNA damage (for a review see (Gonfloni et al., 2012)).  
Multiple lines of evidence document a role for c-Abl in oxidative stress-induced neuronal injury and 
high levels have been evidenced in postmortem PD brains (Brahmachari et al., 2016; Ko et al., 2010).  
For example, a recent report has demonstrated a role for c-Abl in oxidative stress-induced neuronal cell 
death via Cdk5/GSK3b activation and tau hyperphosphorylation (Cancino et al., 2008).  Treatment 




leading to the abrogation of neuronal cell death (Cancino et al., 2008).  Moreover, other studies have 
focused on understanding the role of c-Abl in dopaminergic neuronal cell death.  Despite this, only 
scant evidence is available regarding the regulatory effects of c-Abl in microglial activation response 
(Dhawan et al., 2012).  Consistent with the pro-inflammatory effect of c-Abl in an experimental model 
of AD (Schlatterer et al., 2011b), herein we show that an exaggerated c-Abl activation positively 
correlated with an accentuated NLRP3 inflammasome activation in microglial cells that were 
sequentially stimulated with LPS and ROT.  Conversely, DAS pretreatment not only inhibited c-Abl 
activation but also NLRP3 inflammasome activation as indicated by the inhibition of caspase-1 activity 
and resultant IL-1β and IL-18 secretion from these cells.  In accordance with the DAS results, siRNA 
mediated knockdown of c-Abl showed a marked reduction in the expression levels of NLRP3 
inflammasome related markers in BV2 cells (fig 7(B,C)) and primary microglial cells (fig 7(E,F)) 
sequentially treated with LPS and ROT.  This study demonstrated, for the first time, that c-Abl is a 
critical determinant of NLRP3 inflammasome activation.  Moreover, the extracellular release of 
NLRP3 alongside its activation might serve an additional regulatory role for the amplification of 
microglial proinflammatory response (Baroja-Mazo et al., 2014).  Thus, a combination of brain 
inflammation and agrochemicals exposure may trigger or promote dopaminergic neurodegeneration 
(Gao et al., 2003).  Indeed, in the present study we demonstrate that sequential stimulation of mixed 
neuro-glia culture with LPS and ROT leads to c-Abl activation and accompanying loss of TH positive 
neurons (fig 11), which may be probably mediated via enhanced oxidative stress and heightened 
microglial activation response.  Thus, c-Abl-mediated activation of microglia may increase the 
susceptibility of dopaminergic neurons to cell death owing to increased susceptibility to oxidative 
stress. 
The PKCδ signaling axis has been shown to regulate the release of proinflammatory mediators 




signaling axis as one of the key factors in conferring susceptibility to proinflammatory stimuli (Gordon 
et al., 2016; Wen et al., 2011b).  In this context, genetic ablation of PKCδ not only attenuated 
microglial activation response but also nigrostriatal dopaminergic neurotoxicity highlighting the 
pivotal role of redox sensitive kinase in microglial activation in response to diverse inflammagens.  
Here we demonstrate pronounced activation of redox sensitive kinase PKCδ in response to ROT 
stimulation in LPS-primed microglia as compared with LPS or ROT treated microglial cells.  
Collectively, these results suggest that interaction between c-Abl and PKCδ might at least in part 
contribute to the potentiation of the oxidative stress response and resultant exaggerated NLRP3 
inflammasome activation in microglial cells sequentially exposed to LPS and ROT.  
High levels of NF-κB activity have been identified in PD brains and anti-inflammatory agents 
have been shown to elicits their protective effects via inhibition of NF-κB signaling events (Ghosh et 
al., 2007).  In fact, ROT has been shown to induce microglial activation via the NF-κB in a MAPK 
pathway dependent manner leading to increased generation of inflammatory cytokines in BV2 
microglia (Gao et al., 2013).  Consistent with this report, stimulation of BV2 microglial cells with LPS 
and ROT-induced a rapid accentuation of NF-κB activity as compared with control cells.  NF-κB plays 
a key role in the regulation of transcription of several genes involved in the induction of an 
inflammatory response (Tak and Firestein, 2001; Wu et al., 2014).  Consistent with these reports, we 
observed an exacerbation of gene transcription as well as protein expression of proinflammatory 
mediators including NLRP3, IL-1β, IL-18 and NOS2 in BV2 microglial cells stimulated with LPS and 
ROT as compared with ROT treated BV2 cells.  Interestingly, Bauernfeind et al demonstrated that NF-
κB, transcription factor promotes NLRP3 priming consequently leading to NLRP3 inflammasome 
assembly formation (Bauernfeind et al., 2009).  The finding that microglial NLRP3 mRNA was 
sensitized to ROT following LPS priming further supports the involvement of this pathway in 




to be involved in doxorubicin induced NF-κB activation and imantinib, a c-Abl kinase inhibitor, 
treatment was found to attenuate its activation in breast cancer cells (Esparza-Lopez et al., 2013).  In 
accordance with these findings, DAS not only inhibited NF-κB activity but also diminished mRNA 
and protein levels of iNOS and secretion of IL-1β and IL-18.  Together, these data provide novel 
evidence that LPS priming and subsequent stimulation with ROT may accentuate proinflammatory 
signaling cascade presumably via c-Abl-mediated NF-κB-dependent NLRP3 inflammasome priming 
and subsequent activation.  Thus, our studies raise the possibility that DAS may dampen the 
heightened microglial activation by interfering with both step-1 (NF-κB activation) and step-2 (NLRP3 
activation) in cascade of events leading to NLRP3 inflammasome activation. 
Defective autophagy has been implicated in neurodegenerative diseases including PD and AD 
(Kesidou et al., 2013).  In this context, we recently demonstrated that methamphetamine (MA) induced 
dopaminergic neurotoxicity may be linked to concomitant impairment in mitochondrial function and 
autophagic flux (Kanthasamy et al., 2006; Lin et al., 2012).  Additionally, recent reports implicate 
aberrant activation of c-Abl in the impaired autophagic clearance of α-synuclein and subsequent 
induction of dopaminergic neurotoxicity (Hebron et al., 2013a; Hebron et al., 2013b).  
Pharmacological inhibition of c-Abl was found to promote autophagic clearance of α-synuclein and 
nigral dopaminergic neuron survival (Hebron et al., 2013a; Hebron et al., 2013b). In this study, we 
provide evidence that LPS priming amplifies ROT-induced ALS impairment.  Most importantly, our 
data demonstrates an exaggerated accumulation of autophagic markers and lysosomal dysfunction with 
a concomitant down regulation of TFEB, a master regulator of lysosomal biogenesis.  Our data 
showing accumulation of autophagic markers is consistent with reports in PC-12 neuronal cells 
exposed to ROT (Wu et al., 2015).  The loss of TFEB function has been shown to cause lysosomal 
dysfunction in several experimental models of neurodegenerative disease, which has been attributed to 




(Cortes et al., 2014; Siddiqui et al., 2015; Tsunemi et al., 2012).  We were also able to demonstrate that 
DAS effectively restored the function of ALS in LPS-primed ROT-stimulated BV2 cells.  Likewise, 
the knock down of c-Abl protein by siRNA elicited a similar response in primary microglial cells 
exposed to LPS and ROT.  Emerging evidence implicates autophagy as a negative regulator of NLRP3 
inflammasome (Nakahira et al., 2011; Zhou et al., 2011).  Additionally, activation of autophagy by 
inflammatory signals has been shown to limit IL-1β production by targeting ubiquitinated 
inflammasomes for degradation thereby eliminating active inflammasomes (Shi et al., 2012).  Given 
that c-Abl inhibits Parkin, a ubiquitin E3 ligase, and impairs autophagic clearance mechanisms (Ko et 
al., 2010), it is plausible that undegraded NLRP3 owing to impaired autolyosomal clearance 
mechanism may have contributed to the excessive inflammatory response evidenced in LPS/ROT-
stimulated cells.  Alternatively, it is plausible that exaggerated mitochondrial ROS levels originating 
from undegraded damaged mitochondria might have contributed to LMP, thereby leading to the 
disruption of lysosomal clearance of AVs and eventually to the enhancement of NLRP3 inflammasome 
activation.  Our studies support an integral role for c-Abl in the impairment of lysosome-mediated 
autophagic clearance which in turn may, at least in part, contribute to heightened proinflammatory 
outcomes.  Further studies are required to elucidate the relevance of disruption of mitophagy in the 
activation of NLRP3 inflammasome. 
Inhibition of c-Abl activity via a myriad of pharmacological inhibitors have been shown to be 
neuroprotective in animal models of PD and AD (Cancino et al., 2008; Estrada et al., 2016; 
Karuppagounder et al., 2014; Mahul-Mellier et al., 2014; Schlatterer et al., 2011a).  Dasatinib is an 
FDA approved drug for the treatment in cases of chronic phase Philadelphia chromosome-positive 
chronic myelogenous leukemia (CP-CML) (Brave et al., 2008).  Moreover, it has been shown to cross 
the blood-brain barrier (Katsumata et al., 2012; Porkka et al., 2008). Based on our in vitro data that c-




next sought to confirm and extend our findings in vivo.  Our results demonstrate that DAS suppresses 
NLRP3 inflammasome activation, microglial activation and ALS dysfunction in LPS treated mice (figs 
12, 13).  Consistent with our previous report (Gordon et al., 2016), here we show that systemic LPS 
challenge can induce CNS IL-1β synthesis and sickness behavior concomitant with a central 
inflammatory response.  A novel finding of this study is DAS improved exploratory behavior in DAS-
pretreated LPS-administered mice might be partly attributed to the amelioration of c-Abl dependent 
proinflammatory signaling cascade involving the NLRP3 inflammasome activation and associated 
ALS dysfunction. Although, the role of Src kinases cannot be excluded here.  Together, the emerging 
picture demonstrates that c-Abl mediated regulation of NLRP3 inflammasome activity is multifaceted. 
DAS appears to inhibit NLRP3 inflammasome but does this by inhibiting c-Abl and downstream 
proinflammatory signaling cascade, which may be attributed to the inhibition of oxidative stress 
response that may be conducive for microglial activation.  Further studies are needed to elucidate 
whether differential regulation of target cells might contribute to the anti-inflammatory effects of DAS 
in the LPS neuroinflammation model of PD. 
Our current results demonstrate, for the first time, that aberrant c-Abl kinase activation may be 
linked to the amplification of NLRP3 inflammasome activation, mediated in part via mitochondria-
derived ROS and presumably ALS dysfunction, in microglial cells exposed to LPS and ROT 
sequentially.  Our data also provide novel evidence highlighting the multifacted anti-inflammatory 
effects of DAS.  Notably, DAS administration attenuated both pro-inflammatory response in the brain 
and sickness behavior in LPS treated mice. Since the innate immune system has to recognize diverse 
damage associated molecular patterns (DAMPs) and pattern associated molecular patterns (PAMPs), 
our results suggest that c-Abl may serve as a pivotal oxidative stress sensor for NLRP3 inflammasome 
activation as well as anomalous protein aggregation mechanisms.  c-Abl appears to be an attractive 




implicated in the pathogenesis of PD.  Thus, c-Abl has potential therapeutic implications in the 
treatment of inflammation related disorders including PD. 
References 
Aldieri, E., et al., 2003. Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB 
activation. FEBS Lett. 552, 141-4. 
Alvarez, A. R., et al., 2004. Activation of the neuronal c-Abl tyrosine kinase by amyloid-beta-peptide 
and reactive oxygen species. Neurobiol Dis. 17, 326-36. 
Andreyev, A. Y., et al., 2005. Mitochondrial metabolism of reactive oxygen species. Biochemistry 
(Mosc). 70, 200-14. 
Baroja-Mazo, A., et al., 2014. The NLRP3 inflammasome is released as a particulate danger signal that 
amplifies the inflammatory response. Nat Immunol. 15, 738-748. 
Bauernfeind, F., et al., 2011. Cutting edge: reactive oxygen species inhibitors block priming, but not 
activation, of the NLRP3 inflammasome. J Immunol. 187, 613-7. 
Bauernfeind, F. G., et al., 2009. Cutting edge: NF-kappaB activating pattern recognition and cytokine 
receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J 
Immunol. 183, 787-91. 
Benetti, E., et al., 2013. The NLRP3 Inflammasome as a novel player of the intercellular crosstalk in 
metabolic disorders. Mediators Inflamm. 2013, 678627. 
Betarbet, R., et al., 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's 
disease. Nat Neurosci. 3, 1301-6. 
Block, M. L., et al., 2007. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. 
Nat Rev Neurosci. 8, 57-69. 
Boaru, S. G., et al., 2015. NLRP3 inflammasome expression is driven by NF-kappaB in cultured 
hepatocytes. Biochem Biophys Res Commun. 458, 700-6. 
Brahmachari, S., et al., 2016. Activation of tyrosine kinase c-Abl contributes to alpha-synuclein-
induced neurodegeneration. J Clin Invest. 126, 2970-88. 
Brasher, B. B., Van Etten, R. A., 2000. c-Abl has high intrinsic tyrosine kinase activity that is 
stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two 
distinct regulatory tyrosines. J Biol Chem. 275, 35631-7. 
Brave, M., et al., 2008. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive 





Burm, S. M., et al., 2015. Inflammasome-induced IL-1beta secretion in microglia is characterized by 
delayed kinetics and is only partially dependent on inflammatory caspases. J Neurosci. 35, 678-
87. 
Cancino, G. I., et al., 2008. STI571 prevents apoptosis, tau phosphorylation and behavioural 
impairments induced by Alzheimer's beta-amyloid deposits. Brain. 131, 2425-42. 
Carrithers, M. D., et al., 2007. Expression of the voltage-gated sodium channel NaV1.5 in the 
macrophage late endosome regulates endosomal acidification. J Immunol. 178, 7822-32. 
Chakrabarti, A., et al., 2015. RNase L activates the NLRP3 inflammasome during viral infections. Cell 
Host Microbe. 17, 466-77. 
Chang, C. Y., et al., 2013. Resveratrol confers protection against rotenone-induced neurotoxicity by 
modulating myeloperoxidase levels in glial cells. PLoS One. 8, e60654. 
Chao, C. C., et al., 1995. Glia, cytokines, and neurotoxicity. Crit Rev Neurobiol. 9, 189-205. 
Charli, A., et al., 2016. Alterations in mitochondrial dynamics induced by tebufenpyrad and pyridaben 
in a dopaminergic neuronal cell culture model. Neurotoxicology. 53, 302-13. 
Chen, L., et al., 2015. NLRP3 inflammasome activation by mitochondrial reactive oxygen species 
plays a key role in long-term cognitive impairment induced by paraquat exposure. Neurobiol 
Aging. 36, 2533-43. 
Chipuk, J. E., et al., 2006. Mitochondrial outer membrane permeabilization during apoptosis: the 
innocent bystander scenario. Cell Death Differ. 13, 1396-402. 
Chuang, S. Y., et al., 2013. TLR-induced PAI-2 expression suppresses IL-1beta processing via 
increasing autophagy and NLRP3 degradation. Proc Natl Acad Sci U S A. 110, 16079-84. 
Cortes, C. J., et al., 2014. Polyglutamine-expanded androgen receptor interferes with TFEB to elicit 
autophagy defects in SBMA. Nat Neurosci. 17, 1180-9. 
de Pablos, R. M., et al., 2014. Chronic stress enhances microglia activation and exacerbates death of 
nigral dopaminergic neurons under conditions of inflammation. J Neuroinflammation. 11, 34. 
Decressac, M., et al., 2013. TFEB-mediated autophagy rescues midbrain dopamine neurons from 
alpha-synuclein toxicity. Proc Natl Acad Sci U S A. 110, E1817-26. 
Dhawan, G., Combs, C. K., 2012. Inhibition of Src kinase activity attenuates amyloid associated 
microgliosis in a murine model of Alzheimer's disease. J Neuroinflammation. 9, 117. 
Dhawan, G., et al., 2012. Amyloid-beta oligomers stimulate microglia through a tyrosine kinase 
dependent mechanism. Neurobiol Aging. 33, 2247-61. 
Dorey, K., et al., 2001. Phosphorylation and structure-based functional studies reveal a positive and a 
negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene. 20, 8075-84. 
Dostert, C., et al., 2008. Innate immune activation through Nalp3 inflammasome sensing of asbestos 




Esparza-Lopez, J., et al., 2013. Doxorubicin induces atypical NF-kappaB activation through c-Abl 
kinase activity in breast cancer cells. J Cancer Res Clin Oncol. 139, 1625-35. 
Estrada, L. D., et al., 2016. Reduction of Blood Amyloid-beta Oligomers in Alzheimer's Disease 
Transgenic Mice by c-Abl Kinase Inhibition. J Alzheimers Dis. 54, 1193-1205. 
Estrada, L. D., et al., 2011. C-Abl tyrosine kinase signaling: a new player in AD tau pathology. Curr 
Alzheimer Res. 8, 643-51. 
Ferger, A. I., et al., 2010. Effects of mitochondrial dysfunction on the immunological properties of 
microglia. J Neuroinflammation. 7, 45. 
Ferrari, C. C., Tarelli, R., 2011. Parkinson's disease and systemic inflammation. Parkinsons Dis. 2011, 
436813. 
Gao, F., et al., 2013. Rotenone directly induces BV2 cell activation via the p38 MAPK pathway. PLoS 
One. 8, e72046. 
Gao, H. M., et al., 2002a. Distinct role for microglia in rotenone-induced degeneration of 
dopaminergic neurons. J Neurosci. 22, 782-90. 
Gao, H. M., et al., 2003. Synergistic dopaminergic neurotoxicity of the pesticide rotenone and 
inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci. 
23, 1228-36. 
Gao, H. M., et al., 2002b. Microglial activation-mediated delayed and progressive degeneration of rat 
nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem. 81, 1285-97. 
Gao, H. M., et al., 2011. Neuroinflammation and alpha-synuclein dysfunction potentiate each other, 
driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. 
Environ Health Perspect. 119, 807-14. 
Ghosh, A., et al., 2010. Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease 
model. Free radical biology & medicine. 49, 1674-84. 
Ghosh, A., et al., 2007. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal 
loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A. 104, 18754-9. 
Ghosh, A., et al., 2013. The peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in 
dopaminergic neurons: relevance to the pathogenesis of Parkinson disease. J Biol Chem. 288, 
21955-71. 
Gonfloni, S., et al., 2012. Oxidative Stress, DNA Damage, and c-Abl Signaling: At the Crossroad in 
Neurodegenerative Diseases? Int J Cell Biol. 2012, 683097. 
Gordon, R., et al., 2011. A simple magnetic separation method for high-yield isolation of pure primary 
microglia. J Neurosci Methods. 194, 287-96. 
Gordon, R., et al., 2016. Protein kinase Cdelta upregulation in microglia drives neuroinflammatory 
responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease. 




Gustin, A., et al., 2015. NLRP3 Inflammasome Is Expressed and Functional in Mouse Brain Microglia 
but Not in Astrocytes. PLoS One. 10, e0130624. 
Hebron, M. L., et al., 2013a. Nilotinib reverses loss of dopamine neurons and improves motor behavior 
via autophagic degradation of alpha-synuclein in Parkinson's disease models. Hum Mol Genet. 
22, 3315-28. 
Hebron, M. L., et al., 2013b. Tyrosine kinase inhibition facilitates autophagic SNCA/alpha-synuclein 
clearance. Autophagy. 9, 1249-50. 
Heid, M. E., et al., 2013. Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal 
damage and inflammasome activation. J Immunol. 191, 5230-8. 
Hu, W., et al., 2012. Mechanistic investigation of imatinib-induced cardiac toxicity and the 
involvement of c-Abl kinase. Toxicol Sci. 129, 188-99. 
Imam, S. Z., et al., 2011. Novel regulation of parkin function through c-Abl-mediated tyrosine 
phosphorylation: implications for Parkinson's disease. J Neurosci. 31, 157-63. 
Indo, H. P., et al., 2007. Evidence of ROS generation by mitochondria in cells with impaired electron 
transport chain and mitochondrial DNA damage. Mitochondrion. 7, 106-18. 
Ippagunta, S. K., et al., 2010. Inflammasome-independent role of apoptosis-associated speck-like 
protein containing a CARD (ASC) in T cell priming is critical for collagen-induced arthritis. J 
Biol Chem. 285, 12454-62. 
Iyer, S. S., et al., 2013. Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. 
Immunity. 39, 311-23. 
Jang, H., et al., 2009. Highly pathogenic H5N1 influenza virus can enter the central nervous system 
and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci U S A. 106, 14063-
8. 
Jang, Y., et al., 2015. Chlorpyrifos induces NLRP3 inflammasome and pyroptosis/apoptosis via 
mitochondrial oxidative stress in human keratinocyte HaCaT cells. Toxicology. 338, 37-46. 
Javed, H., et al., 2016. Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative 
Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone 
Model of Parkinson's Disease. Front Neurosci. 10, 321. 
Jha, S., et al., 2010. The inflammasome sensor, NLRP3, regulates CNS inflammation and 
demyelination via caspase-1 and interleukin-18. J Neurosci. 30, 15811-20. 
Jin, H., et al., 2014. Histone hyperacetylation up-regulates protein kinase Cdelta in dopaminergic 
neurons to induce cell death: relevance to epigenetic mechanisms of neurodegeneration in 
Parkinson disease. J Biol Chem. 289, 34743-67. 
Jing, Z., et al., 2009. Altered subcellular distribution of c-Abl in Alzheimer's disease. J Alzheimers 
Dis. 17, 409-22. 
Juliana, C., et al., 2010. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct 




Kanthasamy, A., et al., 2006. Methamphetamine induces autophagy and apoptosis in a mesencephalic 
dopaminergic neuronal culture model: role of cathepsin-D in methamphetamine-induced 
apoptotic cell death. Ann N Y Acad Sci. 1074, 234-44. 
Karin, M., 1999. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. 
Oncogene. 18, 6867-74. 
Karuppagounder, S. S., et al., 2014. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a 
preclinical animal model of Parkinson's disease. Sci Rep. 4, 4874. 
Katsumata, R., et al., 2012. c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an 
animal model of amyotrophic lateral sclerosis. PLoS One. 7, e46185. 
Kauppinen, A., et al., 2012. Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells--
implications for age-related macular degeneration (AMD). Immunol Lett. 147, 29-33. 
Keeney, P. M., et al., 2006. Parkinson's disease brain mitochondrial complex I has oxidatively 
damaged subunits and is functionally impaired and misassembled. J Neurosci. 26, 5256-64. 
Kesidou, E., et al., 2013. Autophagy and neurodegenerative disorders. Neural Regen Res. 8, 2275-83. 
Khare, S., et al., 2012. An NLRP7-containing inflammasome mediates recognition of microbial 
lipopeptides in human macrophages. Immunity. 36, 464-76. 
Kim, M. J., et al., 2016. Mitophagy: a balance regulator of NLRP3 inflammasome activation. BMB 
Rep. 49, 529-535. 
Kim, Y. S., Joh, T. H., 2006. Microglia, major player in the brain inflammation: their roles in the 
pathogenesis of Parkinson's disease. Exp Mol Med. 38, 333-47. 
Ko, H. S., et al., 2010. Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's 
ubiquitination and protective function. Proc Natl Acad Sci U S A. 107, 16691-6. 
Komatsu, M., Ichimura, Y., 2010. Physiological significance of selective degradation of p62 by 
autophagy. FEBS Lett. 584, 1374-8. 
Kowaltowski, A. J., et al., 2001. Mitochondrial permeability transition and oxidative stress. FEBS Lett. 
495, 12-5. 
Latz, E., 2010. The inflammasomes: mechanisms of activation and function. Curr Opin Immunol. 22, 
28-33. 
Lema Tome, C. M., et al., 2013. Inflammation and alpha-synuclein's prion-like behavior in Parkinson's 
disease--is there a link? Mol Neurobiol. 47, 561-74. 
Li, N., et al., 2003. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing 
mitochondrial reactive oxygen species production. J Biol Chem. 278, 8516-25. 
Lima, H., Jr., et al., 2013. Role of lysosome rupture in controlling Nlrp3 signaling and necrotic cell 




Lin, M., et al., 2012. Methamphetamine-induced neurotoxicity linked to ubiquitin-proteasome system 
dysfunction and autophagy-related changes that can be modulated by protein kinase C delta in 
dopaminergic neuronal cells. Neuroscience. 210, 308-32. 
Lombardo, L. J., et al., 2004. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- 
piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual 
Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 47, 
6658-61. 
Lu, W., et al., 2007. The phosphorylation of tyrosine 332 is necessary for the caspase 3-dependent 
cleavage of PKCdelta and the regulation of cell apoptosis. Cell Signal. 19, 2165-73. 
Mader, B. J., et al., 2012. Rotenone inhibits autophagic flux prior to inducing cell death. ACS Chem 
Neurosci. 3, 1063-72. 
Mahul-Mellier, A. L., et al., 2014. c-Abl phosphorylates alpha-synuclein and regulates its degradation: 
implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson's 
disease. Hum Mol Genet. 23, 2858-79. 
Martinon, F., et al., 2009. The inflammasomes: guardians of the body. Annu Rev Immunol. 27, 229-
65. 
McGeer, P. L., et al., 1988. Reactive microglia are positive for HLA-DR in the substantia nigra of 
Parkinson's and Alzheimer's disease brains. Neurology. 38, 1285-91. 
McKnight, N. C., Zhenyu, Y., 2013. Beclin 1, an Essential Component and Master Regulator of PI3K-
III in Health and Disease. Curr Pathobiol Rep. 1, 231-238. 
Mitroulis, I., et al., 2010. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. 
Eur J Intern Med. 21, 157-63. 
Mizushima, N., 2007a. Autophagy: process and function. Genes Dev. 21, 2861-73. 
Mizushima, N., 2007b. The role of mammalian autophagy in protein metabolism. Proc Jpn Acad Ser B 
Phys Biol Sci. 83, 39-46. 
Moresco, E. M., Koleske, A. J., 2003. Regulation of neuronal morphogenesis and synaptic function by 
Abl family kinases. Curr Opin Neurobiol. 13, 535-44. 
Moresco, E. M., et al., 2003. Abl family nonreceptor tyrosine kinases modulate short-term synaptic 
plasticity. J Neurophysiol. 89, 1678-87. 
Moriyama, Y., et al., 1982. Acridine orange as a fluorescent probe for lysosomal proton pump. J 
Biochem. 92, 1333-6. 
Mosley, R. L., et al., 2006. Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's 
Disease. Clin Neurosci Res. 6, 261-281. 
Nakahira, K., et al., 2011. Autophagy proteins regulate innate immune responses by inhibiting the 





Ozaki, E., et al., 2015. Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current 
perspectives. J Inflamm Res. 8, 15-27. 
Panicker, N., et al., 2015. Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell 
Culture and Animal Models of Parkinson's Disease. J Neurosci. 35, 10058-77. 
Plaza Davila, M., et al., 2015. Inhibition of Mitochondrial Complex I Leads to Decreased Motility and 
Membrane Integrity Related to Increased Hydrogen Peroxide and Reduced ATP Production, 
while the Inhibition of Glycolysis Has Less Impact on Sperm Motility. PLoS One. 10, 
e0138777. 
Porkka, K., et al., 2008. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central 
nervous system Philadelphia chromosome-positive leukemia. Blood. 112, 1005-12. 
Qin, L., et al., 2007. Systemic LPS causes chronic neuroinflammation and progressive 
neurodegeneration. Glia. 55, 453-62. 
Rubartelli, A., 2014. DAMP-Mediated Activation of NLRP3-Inflammasome in Brain Sterile 
Inflammation: The Fine Line between Healing and Neurodegeneration. Front Immunol. 5, 99. 
Saitoh, T., et al., 2008. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta 
production. Nature. 456, 264-8. 
Sakurai, H., et al., 2003. Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 
on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol 
Chem. 278, 36916-23. 
Salminen, A., et al., 2012. Mitochondrial dysfunction and oxidative stress activate inflammasomes: 
impact on the aging process and age-related diseases. Cell Mol Life Sci. 69, 2999-3013. 
Schlatterer, S. D., et al., 2011a. c-Abl in neurodegenerative disease. J Mol Neurosci. 45, 445-52. 
Schlatterer, S. D., et al., 2011b. Neuronal c-Abl overexpression leads to neuronal loss and 
neuroinflammation in the mouse forebrain. J Alzheimers Dis. 25, 119-33. 
Seo, J., et al., 2014. Antisense methods to modulate pre-mRNA splicing. Methods Mol Biol. 1126, 
271-83. 
Shi, C. S., et al., 2012. Activation of autophagy by inflammatory signals limits IL-1beta production by 
targeting ubiquitinated inflammasomes for destruction. Nat Immunol. 13, 255-63. 
Shoji, H., et al., 1993. Japanese encephalitis and parkinsonism. J Neurol. 240, 59-60. 
Siddiqui, A., et al., 2015. Mitochondrial Quality Control via the PGC1alpha-TFEB Signaling Pathway 
Is Compromised by Parkin Q311X Mutation But Independently Restored by Rapamycin. J 
Neurosci. 35, 12833-44. 
Sorbara, M. T., Girardin, S. E., 2011. Mitochondrial ROS fuel the inflammasome. Cell Res. 21, 558-
60. 
Stehlik, C., et al., 2003. Apoptosis-associated speck-like protein containing a caspase recruitment 




Stuart, J. R., et al., 2005. c-Abl regulates early growth response protein (EGR1) in response to 
oxidative stress. Oncogene. 24, 8085-92. 
Subramanian, N., et al., 2013. The adaptor MAVS promotes NLRP3 mitochondrial localization and 
inflammasome activation. Cell. 153, 348-61. 
Sun, X., et al., 2000. Interaction between protein kinase C delta and the c-Abl tyrosine kinase in the 
cellular response to oxidative stress. J Biol Chem. 275, 7470-3. 
Sutterwala, F. S., et al., 2014. Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci. 
1319, 82-95. 
Tait, S. W., Green, D. R., 2010. Mitochondria and cell death: outer membrane permeabilization and 
beyond. Nat Rev Mol Cell Biol. 11, 621-32. 
Tak, P. P., Firestein, G. S., 2001. NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 107, 
7-11. 
Tanida, I., et al., 2008. LC3 and Autophagy. Methods Mol Biol. 445, 77-88. 
Tansey, M. G., Goldberg, M. S., 2010. Neuroinflammation in Parkinson's disease: its role in neuronal 
death and implications for therapeutic intervention. Neurobiol Dis. 37, 510-8. 
Tansey, M. G., et al., 2007. Neuroinflammatory mechanisms in Parkinson's disease: potential 
environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol. 
208, 1-25. 
Tomas-Camardiel, M., et al., 2005. Blood-brain barrier disruption highly induces aquaporin-4 mRNA 
and protein in perivascular and parenchymal astrocytes: protective effect by estradiol treatment 
in ovariectomized animals. J Neurosci Res. 80, 235-46. 
Tremblay, M. A., et al., 2010. Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease 
tangles and can be a product of the Abl-related kinase, Arg. J Alzheimers Dis. 19, 721-33. 
Tremblay, M. E., et al., 2011. The role of microglia in the healthy brain. J Neurosci. 31, 16064-9. 
Tschopp, J., Schroder, K., 2010. NLRP3 inflammasome activation: The convergence of multiple 
signalling pathways on ROS production? Nat Rev Immunol. 10, 210-5. 
Tsunemi, T., et al., 2012. PGC-1alpha rescues Huntington's disease proteotoxicity by preventing 
oxidative stress and promoting TFEB function. Sci Transl Med. 4, 142ra97. 
van de Veerdonk, F. L., et al., 2011. Inflammasome activation and IL-1beta and IL-18 processing 
during infection. Trends Immunol. 32, 110-6. 
Vermeulen, L., et al., 2003. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and 
stress-activated protein kinase-1 (MSK1). EMBO J. 22, 1313-24. 
Wen, H., et al., 2011a. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with 
insulin signaling. Nat Immunol. 12, 408-15. 
Wen, J., et al., 2011b. Specific PKC isoforms regulate LPS-stimulated iNOS induction in murine 




Won, J. H., et al., 2015. Rotenone-induced Impairment of Mitochondrial Electron Transport Chain 
Confers a Selective Priming Signal for NLRP3 Inflammasome Activation. J Biol Chem. 290, 
27425-37. 
Wu, F., et al., 2015. Rotenone impairs autophagic flux and lysosomal functions in Parkinson's disease. 
Neuroscience. 284, 900-11. 
Wu, X. F., et al., 2014. Suppression of NF-kappaB signaling and NLRP3 inflammasome activation in 
macrophages is responsible for the amelioration of experimental murine colitis by the natural 
compound fraxinellone. Toxicol Appl Pharmacol. 281, 146-56. 
Yang, Z., Klionsky, D. J., 2009. An overview of the molecular mechanism of autophagy. Curr Top 
Microbiol Immunol. 335, 1-32. 
Yuan, Y. H., et al., 2013. Rotenone could activate microglia through NFkappaB associated pathway. 
Neurochem Res. 38, 1553-60. 
Yuan, Z. M., et al., 1999. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA 
damage. Nature. 399, 814-7. 
Zhao, W., et al., 2015. TDP-43 activates microglia through NF-kappaB and NLRP3 inflammasome. 
Exp Neurol. 273, 24-35. 
Zhou, R., et al., 2010. Thioredoxin-interacting protein links oxidative stress to inflammasome 
activation. Nat Immunol. 11, 136-40. 













Figure 1: Rotenone treatment induces NLRP3 inflammosome machinery in LPS primed 
microglia.  (A) Effect of Rotenone on cell viability.  BV2 microglial cells were either untreated or 
treated with LPS (1μg/ml) for 3h and subsequently stimulated with the indicated concentrations 




survival was represented as percent of control. The data represent mean ± S.E.M. of three independent 
experiments, N=8.  *p<0.05, **p<0.01, ***p<0.001 and **** p<0.0001 compared with control.  (B-D) 
BV2 cells were primed with LPS followed by stimulation with different concentrations of ROT or 
ROT alone for 6 hrs. At the end of the treatment period the whole cell lysates were collected and 
immunoblotted for (B) NLRP3, (C) caspase-1 (pro and cleaved), (D) IL-1β (pro-& cleaved).  A 
concentration dependent increase in NLRP3 related markers were evidenced in LPS and ROT 
stimulated cells.  The data represented as mean ± S.E.M. of at least three replicates.  *p<0.05 and 
**p<0.01 is compared with control group and #p<0.05 and # #p<0.01 represents significance between 
dose-matched ROT and LPS-primed ROT treated group.  (E) BV2 microglial cells were primed with 
LPS (1μg/ml) for 3 hours followed by stimulation with 0.5μM ROT or ROT alone for the indicated 
time period. At the end of the indicated times whole cell lysates or media supernatants (sup.) were 
collected and as indicated were immunoblotted for NLRP3, caspase-1 (pro and cleaved), IL-1β 
(cleaved), and β actin.  Densitometric scanning analysis reveals enhancement in NLRP3 marker levels 
in LPS primed ROT stimulated cells at 6h.  Data presented as mean ± S.E.M.  The blots are 
representative of at least three independent experiments.  *p<0.05, **p<0.01 and ***p<0.001 
compared with control cells, whereas #p<0.05 and # #p<0.01 indicates significance between time-
matched ROT and LPS-primed ROT treated group; n.s.: not significant.  (F) Bar graphs represent 
secreted IL-1β, IL-18 and TNFα as determined by ELISA. The ELISA data represents the mean ± 
S.E.M. performed in replicates of 4 and performed at least 4 independent times.  *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001 vs control, whereas #p<0.05, # #p<0.01, # # #p<0.001 and # # # #p<0.0001 
vs time-matched ROT; n.s.: not significant.  (G) BV2 microglial cells were treated as described above 
(1(E)).  At the end of the treatment times, cells were collected, lysed and RNA was extracted, and gene 
expression was analyzed using RT-PCR, normalized to 18s by the ΔΔCt method.  The normalized 




S.E.M. for each experiment performed in triplicate at least 3 times independently.  *p<0.05, **p<0.01 
and *** p<0.001 compared with control cells, whereas #p<0.05, # #p<0.01 and # # #p<0.001 indicates 
significance between time-matched ROT and LPS-primed ROT treated group; n.s.: not significant.  
(H) Immunoblot analysis of NLRP3 and processed/cleaved caspase-1 and IL-1β in whole cells lysates 
and supernatant of mouse primary mouse microglial cells treated with or without LPS (10ng/ml) for 3 
hours, followed by stimulation with ROT or ROT alone for 4h.  *p<0.05, **p<0.01 and ***p<0.001 vs 
control group; and # #p<0.01 vs LPS-primed ROT treated group.  (I) The levels of IL-1β and IL-18 
secreted in the media were determined by ELISA.   The data is presented as mean ± S.E.M. (n=4).  
*p<0.05, **p<0.01, ***p<0.001 and **** p<0.0001 compared with control cells.  #p<0.05, # #p<0.01, # 







Figure 2: Rotenone enhances free radical production and mitochondrial depolarization in LPS-
primed BV2 cells.  BV2 microglial cells were subjected to the same treatment conditions as detailed 
above (1(E)).  ROS generation (A), mitochondrial superoxide (B) and mitochondrial membrane 
potential (C) were measured spectrophotometrically using redox sensitive CM-H2DCFDA, mitosox 
and JC-1 dye respectively.  The data represent mean ± S.E.M., n=6 and expressed as percent of 
control.  (D) Spectrophotometric analysis of nitrite release using the Griess method.  The data 
represents the mean ± S.E.M. n = 6.  *p<0.05,**p< 0.01, ***p< 0.001 vs control;  #p<0.05, # #p< 0.01 
and # # #p< 0.001 denotes significant differences between ROT vs LPS-primed ROT treated group, 









Figure 3: Phosphorylation of c-Abl tyrosine kinase and PKCδ was enhanced in BV2 microglial 
cells following LPS priming and subsequent stimulation with ROT.  BV2 microglial cells were 
treated as described in 1(E).  Post treatment, whole cell lysate were prepared and immunoblotted for p-
c-Abl (Y412, Y245), c-Abl, p-PKCδ (Y311) and PKCδ (A).  β actin was used as loading control. The 
expression level of p-c-Abl is enhanced upon LPS/ROT stimulation.  Significant difference between 
control and the treatment groups are indicated as  *p<0.05 and **p< 0.01, whereas #p<0.05 and # #p< 
0.01 denotes significance between time-matched ROT and LPS-primed ROT groups.  The p-c-Abl and 
p-PKCδ band intensity were normalized to c-Abl and PKCδ, respectively.  The normalized band 
intensity represented as the mean ± S.E.M. of at least 4 independent experiments; n.s.: not significant.  
(B) Primary microglial cells were treated as described in 1(H).  Whole cell lysates were prepared and 
c-Abl phosphorylation status was probed by western blotting using antibodies specific to pY412, 
pY245 and c-Abl.  β actin was used as loading control.  The upper panels show bands of p-c-Abl, c-
Abl and β actin.  Densitometric scanning reveals significant increase in c-Abl activation in response to 
LPS and rotenone stimulation.  Data are expressed as mean ± S.E.M.; *p<0.05, **p< 0.01 and ***p< 
0.001 vs control, whereas # #p< 0.01 denotes significance between ROT and LPS-primed ROT groups.  
(C) Representative Immunofluorescent images depicting the distribution of p-c-Abl (Y412) (red) 
immunoreactive cells in primary mouse microglial cells subjected to same treatment conditions as 
described in 1(H).  The nucleus was counterstained with Hoechst stain (blue).  Immunofluorescence of 
p-c-Abl (Y412) was markedly enhanced in LPS-primed ROT-stimulated cells as compared with ROT 
treated cells.  Experiments were performed in triplicates and representative of at least three 
independent experiments.  Scale bar in E = 100μM. c-Abl= c-Abl tyrosine kinase and PKCδ= Protein 









Figure 4: Mitochondrial ROS drives the NLRP3 inflammasome activation, c-Abl and PKCδ 
phosphorylation and inflammatory mediators release in LPS-primed rotenone stimulated BV2 
cells.  (A) BV2 microglial cells were pretreated with MitoTEMPO (200µM or 500µM) for 1 hour, 
followed by priming with LPS (1μg/ml) for 3 hours.  The primed cells were subsequently stimulated 
with ROT (0.5μM) for 6h.  The reactive oxygen species production post treatment was quantified 
fluorometrically using CM-H2DCFDA dye.  The data is expressed as percent of control and is 
represented as mean ± S.E.M.; n=8. *p<0.05, **p<0.01 and ***p<0.001 versus control; a ap<0.01 vs 
ROT; while # #p<0.01 denotes significance between LPS-primed ROT treated groups with and without 
MitoTEMPO.  (B, C) The whole cell lysate were immunoblotted for NLRP3, caspase-1 (cleaved) (B), 
p-c-Abl (Y412), p-c-Abl (Y245), c-Abl, p-PKCδ (Y311) and PKCδ (C).  β actin was used as loading 
control.  The densitometric analysis of normalized band intensity for each treatment group was plotted 
on histogram and is represented as mean ± S.E.M. for each experiment performed with n=4.  *p<0.05, 
**p<0.01 and ***p<0.001 versus control; ap<0.05 and a ap<0.01 represents significant difference 
between ROT vs LPS-primed ROT treatment groups; while #p<0.05, # #p<0.01 and # # #p<0.001 denotes 
significance between LPS-primed ROT treated groups with and without MitoTEMPO; n.s.: not 
significant.  (D) The cell supernatant was assessed for secreted IL-1β and IL-18 by ELISA.  The data is 
represented as mean ± S.E.M. n=6. ***p<0.001 and ****p<0.0001 compared with control; a a a 
ap<0.0001 represents significant difference between ROT vs LPS-primed ROT treatment groups; while 
# #p<0.01 and # # #p<0.001 denotes significance between LPS-primed ROT treated groups with and 









Figure 5: Dasatinib attenuates c-Abl activation, oxidative stress, dissipation of mitochondrial 
membrane potential (MMP, ΔΨm) in LPS-primed ROT stimulated BV2 cells.  (A) Whole cell 
lysates from LPS (1μg/ml)-primed BV2 microglial cells that were pretreated with DAS (100nM, 1h) 
and subsequently stimulated with ROT (0.5μM) for 6h were assessed for activation of c-Abl using the 
in vitro c-Abl activity assay.  The values were converted to % control and are presented as mean ± 
S.E.M. *p<0.05 and ***p<0.001 compared with control cells; a a ap<0.001 represents significant 
difference between ROT vs LPS-primed ROT treatment groups; while #p<0.05 represents significance 
between LPS-primed ROT treated groups with and without DAS.  (B) Following the same treatment 
regimen as described above cell lysates were immunoblotted for c-Abl and p-c-Abl (Y412).  β actin 
was used as loading control.  Densitometric quantification of immunoblots bands (lower panel) of BV2 
microglial cells with or without DAS treatment demonstrated that LPS priming and ROT stimulation 
mediated increase in phosphorylation of c-Abl at Y412 is markedly reduced in DAS treated microglia.  
Data is presented as the mean ± S.E.M of three independent experiments. *p<0.05, **p<0.01 and 
***p<0.001 compared with control cells; a ap<0.01 and a a ap<0.001 represents significant difference 
between ROT vs LPS-primed ROT treatment groups; while #p<0.05 and # #p<0.01 represents 
significance between LPS-primed ROT treated groups with and without DAS.  (C-E) DAS attenuates 
MMP collapse and ROS generation in ROT-stimulated LPS-primed BV2 cells. BV2 microglial cells 
were treated as above. Post treatment changes in the mitochondrial potential (C), intracellular ROS (D) 
and mitochondrial superoxide (E) were determined by spectrofluormetry using JC-1, CM-H2DCFDA 
and mitosox dye, respectively, in BV2 microglial cells. The results are expressed as % of control and 
presented as mean ± S.E.M., N≤6.  (F-H) BV2 microglial cells were treated as above (5(A)).  Post 
treatment, cell supernatants were analyzed for nitrite release via Griess method (F), mRNA levels (G) 
and protein expression of iNOS (H) in BV2 cells.  The elevated expression of iNOS was antagonized 
by DAS in LPS primed ROT stimulated BV2 cells.  The mRNA data normalized to 18S is presented as 
mean ± S.E.M., n=4-6. β actin antibody was used as loading control in western blots.  The normalized 
densitometric analyses are representative of at least three independent experiments and data is 
expressed as mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 compared with 
control cells; a ap<0.01 and a a ap<0.001 represents significant difference between ROT vs LPS-primed 
ROT treatment groups; while #p<0.05 and # #p<0.01 denotes significance between LPS-primed ROT 











Figure 6. Dasatinib attenuates NLRP3 inflammasome in the LPS-primed ROT stimulated 




LPS primed rot stimulated primary microglial cells.  BV2 microglial cells were treated as described 
above, cell lysates were analyzed for NLRP3 (A), caspase-1 (pro and cleaved) (B), IL-1β (pro-& 
cleaved) (C) by immunoblotting.  Panel below shows densitometric scanning analysis of cleaved 
caspase-1 (p10) and IL-1β in the cell culture supernatants in cells treated same as in 5(A).  The data is 
expressed as % of control and represented as mean ± S.E.M and representative of three independent 
experiments.  *p<0.05 and **p<0.01 versus control; ap<0.05 represents significant difference between 
ROT versus LPS-primed ROT treatment groups; while #p<0.05 and # #p<0.01 represents significance 
between LPS-primed ROT treated groups with and without DAS.  (D) Caspase-1 activity was 
determined fluorometrically using caspase-1 specific substrate as described in the Materials and 
Methods section. The data represented as ± S.E.M. of % of control from three different experiments 
(n≤6).  *p<0.05 and ***p<0.001 vs control; a ap<0.01 represents significant difference between ROT 
vs LPS-primed ROT treated group; while # # #p<0.001 denotes significance between LPS-primed ROT 
treated groups with and without DAS.  (E) ELISA analysis of IL-1β and IL-18 in supernatants of BV2 
cells exposed to LPS or ROT or in combination.  The ELISA results are represented as mean ± S.E.M, 
n=6. ***p<0.001 and ****p<0.0001 vs control group; a a a ap<0.0001 represents significant difference 
between ROT and LPS-primed ROT treated group; while # #p<0.01 and # # #p<0.001 denotes 
significance between LPS-primed ROT treated groups with and without DAS.  n.s.: not significant.  
(F) Immunoblot analysis of whole cell lysates for NLRP3, p-cAbl (Y245 and Y412) and c-Abl in DAS 
(100nM) pretreated LPS (10ng/ml)-primed primary mouse microglial cells that were stimulated with 
ROT (30nM) for 4h.  The data is expressed as % of control and represented as mean ± S.E.M, n=4.  
*p<0.05, **p<0.01 and ***p<0.001 denotes significant difference from control; ap<0.05 and a ap<0.01 
represents significant difference between ROT vs LPS-primed ROT treatment groups; while #p<0.05, # 
#p<0.01 and # # #p<0.001 denotes significance between LPS-primed ROT treated groups with and 
without DAS.  n.s.: not significant.  (G) Posttreatment ELISA analysis of IL-1β and IL-18 in 
supernatants of primary microglia.  The ELISA results are represented as mean ± S.E.M, n=6.  
***p<0.001 and ****p<0.0001 vs control group; a a ap<0.001 and a a a ap<0.0001 represents significant 
difference between ROT and LPS-primed ROT treatment groups; while # #p<0.01 denotes significance 









Figure 7. RNAi-mediated knockdown of c-Abl attenuates LPS/rotenone-induced NLRP3 
inflammasome activation and pro-inflammatory cytokines release.  (A) The BV2 microglial cells 
were transfected with the indicated siRNAs for 48h and whole cell lysates were collected and analyzed 
by immunoblotting with c-Abl.  The level of c-Abl was dramatically reduced in c-Abl siRNA 
transfected cells as compared with scramble transfected cells.  (B) Immunoblotting for NLRP3 related 
markers in the supernatant (sup.) and whole cell lysates of BV2 cells subjected to the same treatment 
conditions as detailed above (fig 5(A)).  β actin was used as loading control. The bar graph represents 
densitometric analysis.  Bands were normalized to β actin and are presented as mean ± S.E.M. of % 
control of at least three independent experimental repeats.  *p < 0.05, **p < 0.01 and ***p< 0.001 
versus scrambled control, while # #p<0.01 and # # #p<0.001 denotes significance between LPS-primed 
scrambled transfected cells treated with ROT versus LPS-primed c-Abl knockdown transfected cells 
treated with ROT.  (C) Supernatants of the siRNAs transfected BV2 cells posttreatment were analyzed 
for Il-1β and IL-18 using ELISA.  The is represented as mean ± S.E.M. of 2 independent experiments 
with n=3-4 per experiment per group. ****p< 0.0001 versus scrambled control group and # # # # 
#p<0.0001 versus scrambled transfected cells treated with LPS+ROT.  (D) Primary mouse microglial 
cells were transfected with either scrambled or c-Abl siRNA.  48 hrs post transfection, primary 
microglial cells were subjected to immunoblot analysis for c-Abl to confirm efficient downregulation 
of c-Abl expression.  Representative immunoblot image confirming siRNA KD of c-Abl, but not 
scrambled siRNA, reduces c-Abl protein to less than 25% of control levels in primary microglial cells.  
(E) 48h post-siRNA transfection experiments primary microglial cells were subjected to the same 
treatment conditions as detailed above (7(D)).  Whole Cell lysate and culture supernatant (sup.) as 
indicated were collected and immunoblotted with antibodies against NLRP3, cleaved caspase-1 and 
IL-1β.  The immunoblots were normalized to β actin; values were presented as % of control and mean 
± S.E.M. of 4 independent experiments. *p < 0.05, ***p < 0.001 and ****p< 0.0001 versus scrambled 
control, while # #p<0.01 and # # #p<0.001 denotes significance between LPS-primed scrambled 
transfected cells treated with ROT versus LPS-primed c-Abl knockdown transfected cells treated with 
ROT.  (F) ELISA analysis of primary microglial cell culture supernatant for secreted IL-1β and IL-18. 
The ELISA data are expressed as means ± S.E.M. of at least three replicates per treatment and are 
representative of at least three independent experiments.  ****p< 0.0001 versus scrambled control, 
while # # #p<0.001 denotes significance between scrambled transfected vs c-Abl knock down primary 







Figure 8: Confocal images demonstrating the inhibitory effects of dasatinib on Rotenone-induced 
re-localization of NLRP3 to the mitochondria in LPS-primed primary microglia.  Primary 
microglia treated as described in 6(F). Representative confocal immunofluorescent images of cells that 
were co-immunostained for NLRP3 (green) and TOM20 (red) followed by staining with Hoechst for 
nucleus (blue). Merged images of NLRP3 and TOM20 (yellow) indicated by arrows.  LPS priming and 
ROT stimulation of primary microglial cells caused an increase in the colocalization of NLRP3 and 









Figure 9: Dasatinib inhibits Rotenone-induced NF-κB activation in LPS-primed BV2 cells.  (A, 
B) Rotenone augments LPS-induced p65 translocation to the nucleus.  Representative immunoblots 
reveal time course changes for p65 and phospho IκB.  (A) Immunobloting analysis were performed in 
BV2 cells that were primed with LPS for 10 and 20 minutes and subsequently treated with or without 
rotenone for 3 and 6h.   Subcellular fractionation studies were carried out and cytoplasmic and nuclear 
fractions were immunoblotted for p65.  The blots were further probed with lamin B and tubulin, 
respectively, for determining equal loading and to confirm the purity of nuclear and cytosolic fractions.  
Densitometric scanning analysis depicted below. The relative p65 was normalized to lamin B or 
tubulin.  Data presented is representative of at least 3 independent experiments. Values are converted 
to % control and expressed as mean ± S.E.M.  (B) BV2 cells were stimulated as described in 9(A).  At 
the end of the treatment period, whole cell lysate was immunoblotted for p-IκB and β actin.  The 
relative p-IκB and was normalized to β actin.  The % control values are expressed as mean ± S.E.M. 
*p<0.05, **p< 0.01 and ***p< 0.001 vs control group, whereas #p< 0.05 denotes significance between 
time-matched ROT and LPS-primed ROT groups; n.s.: not significant.  (C, D) DAS attenuates nuclear 
translocation of p65 and phosphorylation of IκB in LPS-primed ROT-stimulated BV2 cells.  BV2 cells 
were pretreated with DAS (100nM, 1h) followed by treatment with LPS (1µg/ml, 20min) and ROT 
(0.5µM, 6h).  Western blot analysis following fractionation of cellular extracts and whole cell lysates 
from microglial cells showed that DAS pretreatment attenuated nuclear translocation of p65 (C) and p-
IκB levels (D) in LPS-primed ROT-stimulated cells.  The normalized band intensity for each treatment 
group is represented as mean ± S.E.M.  *p<0.05, **p<0.01 and ***p<0.001 vs control group; ap<0.05 
represents significant difference between ROT and LPS-primed ROT treatment groups; whereas 
#p<0.05 and # #p<0.01 denotes significance between LPS-primed ROT treated groups with and without 
DAS.  (E) DAS attenuates excessive nuclear translocation of p65 in LPS primed ROT stimulated 
microglia.  Representative immunofluorescence images showing cellular localization of p65.  
Immunohistochemical staining was performed using an antibody against p65 (red) subunit of NF-κB 
while nucleus was counterstained with Hoechst stain (Blue).  Nuclear localization was determined in 
3-4 random fields per slide.  These results are representative of at least 3 independent experiments.  














Figure 10: Involvement of c-Abl in ROT-induced impairment of ALS in LPS primed microglial 
cells.  (A-B) Rotenone augments autophagolysosomal dysfunction in LPS-primed microglial cells.  (A) 
Enhancement of ALS markers in LPS-primed ROT stimulated BV2 cells. BV2 microglial cells were 
treated same as above (fig 1(E)) for the indicated time period.  Post treatment, whole cell lysates were 
collected and immunoblotted with antibodies for Microtubule-associated protein light chain 3B 
(LC3B), p62 and Beclin1.  A time-dependent increase in the expression of ALS markers is evidenced 
in LPS-primed ROT stimulated cells as compared with ROT treated cells.  The levels of indicated 
proteins were normalized to β actin and the normalized band intensity for each treatment group is 
represented as mean ± S.E.M. *p<0.05 and **p<0.01 compared with control, whereas #p<0.05 and # 
#p<0.01 represents significance between time-matched ROT vs LPS-primed ROT treated group; n.s.: 
not significant.  Results representative of at least 3 independent experiments.  (B) Primary microglia 
were treated as described above (fig 1(H)).  At the end of the treatment period, whole cell lysates were 
collected and immunobloted for p62 and beclin1.  The bar graphs represent densitometric scanning 
analysis of immunoblotted bands.  The representative immunoblots are an average of 4 independent 
experiments and represented as mean ± S.E.M. *p<0.05, **p<0.01 and ***p<0.001 vs control, while 
#p<0.05 and # #p<0.01 represents significance between time-matched ROT vs LPS-primed ROT treated 
group.  (C-E) Effect of DAS on ROT-induced ALS dysfunction in LPS-primed BV2 cells.  BV2 
microglial cells were treated as in fig 5(A).  Post treatment, whole cell lysate was collected and 
immunoblotted for the autophagy related markers: LC3B, Beclin1 (C).  β actin was used  as loading 
control.  LC3B and beclin1 levels were increased in LPS and ROT stimulated cells whereas these 
markers were further increased by LPS priming.  DAS pretreatment caused a near complete abrogation 
of LC3B and beclin1 levels in cells stimulated with LPS and ROT.  The densitometric analysis of band 
intensity for each treatment group normalized to the respective β actin and plotted on histogram as 
average of 3 independent experiments and represented as mean ± S.E.M. *p<0.05, **p<0.01 and 
***p<0.001 versus control; ap<0.05 and a ap<0.01 represents significant difference between ROT 
versus LPS-primed ROT treatment groups; while #p<0.05 and # # #p<0.001 denotes significance 
between LPS-primed ROT treated groups with and without DAS.  (D) DAS attenuates loss of 
lysosomal membrane potential (LMP) in LPS-primed ROT-stimulated BV2 cells.  BV2 microglial 
cells were treated as in fig 5(A).  Post treatment, BV2 cells were stained with acridine orange for the 
determination of lysosomal integrity.  ROT-induced loss of lysosomal membrane permeability was 
exaggerated by LPS priming.  DAS pretreatment attenuated ROT induced loss of LMP in LPS primed 




group is shown; n=3 coverslip pretreatment group and representative of two independent experiments.  
(E) Immunoblot analysis of whole cell lysates for lysosomal biogenesis marker (TFEB) and β actin.  
BV2 microglial cells were primed with LPS (1μg/ml) for 3h followed by ROT (0.5μM) for 3 and 6h. 
DAS (100nM, 1h) pretreatment was performed to analyze the role of c-Abl.  Panel below represent the 
densitometric analysis of TFEB normalized to β actin and presented as % of control. ROT causes 
dramatic reduction in TFEB level at 6h in LPS-primed BV2 cells, which was significantly recovered 
by DSA pre-exposure.  The values are plotted as mean ± S.E.M. of at least 4 experiments. *p<0.05, 
**p<0.01 and ***p<0.001 versus control; ap<0.05 versus time-matched ROT group; while #p<0.05 
denotes significance between LPS-primed ROT (6h) treated groups with and without DAS.  (F) 
Primary microglia were treated as described in fig 6(F).  The numbers of LC3B positive puncta were 
quantified.  The bar graph depicts the intensity of the puncta per cell.  Experiment was performed with 
n=3 coverslips per treatment group of at least two independent replicates. *p<0.05 and ***p<0.001 vs 
control, a ap<0.01 vs ROT and #p<0.05 vs LPS-primed ROT-treated group.  (G) Effect of c-Abl knock 
down on ROT-induced ALS dysfunction in LPS-primed primary microglia.  After transfection of 
mouse primary microglial cells with scrambled or c-Abl specific siRNA for 48h then cells were 
subjected to the same treatment conditions as described in fig 7(D).  Efficient c-Abl depletion was 
achieved in all microglia culture. Immunoblot analysis for expression of LC3B, p62, Beclin1 and 
TFEB were performed in lysates of cells transfected with scrambled or c-Abl specific siRNA. Reduced 
levels of ALS markers were evidenced in c-Abl siRNA transfected microglia as compared with 
scrambled siRNA transfected cells that were sequentially treated with LPS and ROT.  The bar graphs 
depict the densitometric scanning analysis of the immunoblot bands.  The relative ALS marker levels 
were normalized to β actin.  Data presented is representative of at least 4 independent experiments.  
The % control values are expressed as means ± S.E.M. ***p<0.001 versus scrambled control, while 
#p<0.05 and # #p<0.01 denotes significance between LPS-primed scrambled transfected cells treated 








Figure 11: Dasatanib attenuated the activation of c-Abl and partially reduced TH neuronal loss 
in ventral midbrain neuron glia culture primed with LPS and stimulated with ROT.  (A) Ventral 
mesencephalic culture were pretreated or not with DAS (100nM, 1h) then primed with LPS (1μg/ml, 
3h) and subsequently either left unstimulated or stimulated with ROT (0.5μM) for 6h.  Cell lysates 
were immunoblotted with indicated antibodies. DAS attenuated c-Abl and PKCδ activation in LPS 
primed ROT stimulated ventral midbrain cultures.  (B) Likewise, DAS inhibited TH depletion in LPS 
and ROT treated cells.  Band intensities were quantified using densitometric scanning analysis and the 
relative expression levels of c-Abl, p-c-abl, PKCδ, p-PKCδ were normalized to β actin.  Results are 
representative of at least two independent experiments.  Values are converted to % of control and 
expressed as means ± S.E.M.  *p<0.05 and ***p<0.001 vs non-treated control; a ap<0.01 and a a 
ap<0.001 denotes significant difference between ROT and LPS-primed ROT treatment groups; while 
#p<0.05 and # #p<0.01 indicates significance between LPS-primed ROT-treated groups with DAS vs 





















Figure 12: The anti-inflammatory effects of dasatinib on LPS-induced sickness behavior and 
expression of proinflammatory markers in the substantia nigra.  The mice were administered DAS 
(25mg/kg) or vehicle, once daily via oral gavage for 30 days followed by a single IP injection of LPS 
(5mg/kg) or vehicle. At the end of 6h following LPS treatment mice were assessed for locomotor 
activities using the VersaMax analyzer.  (A) total vertical activity, (B) total horizontal movement and 
(C) total distance travelled were quantified LPS-administered mice exhibited sickness behavior 
consistent with endotoxemia in comparison DAS-pretreated LPS injected mice exhibited normal 
behavior comparable to saline treated animals.  (D) Mice were also tested for motor performance on a 
rotarod.  The latency to fall off the rotarod was increased in DAS-pretreated LPS injected mice. Data 
are expressed as the mean ± S.E.M. from 3-4 mice.  The data is representative of at least three 
independent experiments.  **p<0.01 and ****p<0.0001 compared with saline-treated control group; 
#p<0.05 and # #p<0.01 shows significant difference between LPS treated group vs DAS+LPS treated 
group.  The effect of DAS on the LPS-induced upregulation of the mRNA expression of 
proinflammatory markers in the substantia nigra (SNpc). Mice were treated as indicated in 12(A).  At 
the end of behavioral analysis, qRT-PCR analysis was performed to evaluate the changes in mRNA 
expression of NLRP3 (E), IL-1β (F), IL-18 (G), TNFα (H) and Caspase-1 (I) in the SNAc.  DAS 
attenuated LPS-induced upregulation of NLRP3 and IL-1β but not TNFα, IL-18 or caspase-1.  Values 
are the mean ± S.E.M. (n=3-4 in each group).  **p<0.01 and ****p<0.0001 compared with saline-
treated control group; #p<0.05 and # #p<0.01 shows significant difference between LPS treated group 
vs DAS+LPS treated group; NS = not significant.  Suppression of glial activation by DAS treatment in 
the SN of LPS treated mice.  (J) Quantification of immunoblots for IBA1.  LPS treatment induced 
microglial activation in the SN as indicated by increased IBA1 expression, however, DAS pre-
treatment dramatically reduced LPS-induced microgliosis. Levels of β actin was used an internal 
loading control.  (K) Immunoblotting of NLRP3 in SN lysates.  LPS-treated mice showed increased 
protein expression of NLRP3, which was significantly blocked by DAS pretreatment.  Data expressed 









Figure 13: The therapeutic effect of DAS in ameliorating activation of redox sensitive kinases 
and ALS markers in the LPS treated mice.  DAS suppresses LPS-induced upregulation of redox 
sensitive kinases and ALS dysfunction in the SNpc. Mice were treated as indicated in fig 12.  (A) 
Representative immunoblot images showing relative levels of c-Abl and phospho-c- Abl (Y245 and 
Y412) in the SN of mice at 6h post LPS treatment.  Densitometric scanning analysis revealed that LPS 
treatment caused hyperphosphorylation of c-Abl tyosine kinase at both activation sites (Y245 and 
Y412), which was blocked significantly by DAS pre-treatment. Similarly, a marked increase in 
phosphorylation of PKCδ at Y311 residue was evidenced in LPS treated mice while DAS pretreated 
mice demonstrated a significant reduction in the phosphorylation of PKCδ.  Levels of β actin was used 
an internal loading control.  The p-c-Abl and p-PKCδ band intensity were normalized to c-Abl and 
PKCδ, respectively, and c-Abl and PKCδ were normalized to β actin.  Data expressed as the mean ± 
S.E.M. (N=3-4) of % control.  *p<0.05 and **p<0.01 versus saline-treated control group; #p<0.05 
versus LPS group.  (B) DAS protects against LPS-induced ALS dysfunction by decreasing beclin-1 
levels and increasing TFEB levels in the substantia nigra of LPS treated mice.  Whole cell lysates were 
prepared from the SNpc and immunoblotted for beclin-1 and TFEB.  Densitometric scanning reveals 
DAS significantly (p<0.05) ameliorated ALS dysfunction.  The bands were normalized to β actin. Data 
represented as the mean ± S.E.M. (N=3-4). **p<0.01 versus saline-treated control group; #p<0.05 








Sup. Fig. 1: Dasatinib causes dose-dependent attenuation of LPS-mediated activation of BV2 
microglial cells. (A, B) DAS inhibits LPS-mediated NF-κB activation. (A) BV2 microglial cells were 
pretreated with 100nM DAS for 1h followed by treatment with LPS (1µg/ml) for 30min. Using 
immunofluorescence imaging, intracellular localization of p65 (red), an NF-κB subunit, was observed. 
Hoechst (blue) was used to stain the nuclei. The images represent 2 different experiments perform 
independently. The third row shows that LPS caused nuclear translocation of p65. Whereas, DAS 
pretreatment reduced the LPS-induced p65 translocation (bottom row). (B) IκB protein expression was 
analyzed using immunoblotting technique. BV2 cells pretreated with DAS (10, 30 and 100nM, 1h) 
were treated with 1µg/ml LPS for 30min.  The whole cell lysates were collected at the indicated time 
and immunoblotted with the IκB antibody. Immunoblot reveals that LPS-mediated degradation of IκB 
was significantly recovered by DAS pretreatment in a dose-dependent manner. β actin was used as a 




BV2 cells were pretreated with DAS (10, 30 and 100nM) for 1h followed by LPS (1µg/ml) treatment 
for 24h. The cell free supernatant was analyzed for secreted nitric oxide (NO) levels using Griess 
colorimetric assay. LPS caused >9-fold increase in extracellular release of NO, which was significantly 
reduced by DAS in a dose-dependent manner. The data represents the mean ± S.E.M. performed in 
replicates of 6. ***p<0.001 and **** p<0.0001 compared with LPS alone group. (D, E) Luminex® 
analysis of released inflammatory cytokines. BV2 cells were treated as described in sup. fig. 1(C) and 
cell free supernatant was collected for analysis of cytokines levels using Luminex® multiplex assay. 
The bar graph represents the concentration of IL-6 (D) and TNFα (E) in pg/ml. LPS induced aberrant 
release of these proinflammatory cytokines, while DAS pretreatment attenuated this effect. The data is 
presented as mean ± S.E.M. (n=6). *p<0.05, **p<0.01 and ***p<0.001 compare significance between 
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Abstract 
Parkinson’s Disease (PD) is a progressive neurodegenerative disease characterized by the 
pronounced loss of nigrostriatal dopaminergic neurons.  Emerging evidence suggests that 
mitochondria-dependent oxidative stress and inflammation are critical correlates of dopaminergic 
neurodegeneration.  In this context, the activation of innate immune response via NLRP3 
inflammasome activation is becoming a pivotal component of neurodegeneration. However, the factors 
regulating NLRP3 inflammasome remain poorly understood.  Here, we demonstrate a novel mode of 
heightened inflammatory response as evidenced by increased c-Abl and cathepsin B activation that 
correlated with the activation of NLRP3 inflammasome in both primary microglial and BV2 microglial 




of c-Abl partially ameliorated microglial activation response via inhibition of cathepsin B.  
Mechanistically, genetic and pharmacological interventions aimed at reducing c-Abl and cathepsin B 
activation restored autophagoslysosmal function, leading to alleviation of NLRP3 inflammasome 
activation, which, in turn, promoted the dampening of the proinflammatory phenotype.  Moreover, the 
parkin-mitophagy pathway was involved in this c-Abl/cathepsin B-mediated activation of NLRP3 
inflammasome.  These findings were further confirmed in aged rats exposed to ROT and LPS in a 
sequential manner, in which microglial cathepsin B and NLRP3 inflamamsome activation positively 
correlated with TH neuronal loss in the substantia nigra.  Taken together, our studies suggest that 
dysfunctional c-Abl/cathepsin B/parkin axis is involved in PD pathogenesis, paving the way for the 






Neurodegenerative disorders affect the mostly older population and hence, have been a 
major health-economic burden on countries like the US and China (Brookmeyer et al., 2007; Kowal et 
al., 2013).  According to a report from World Health Organization, neurodegenerative diseases have 
been one of the most undermined health conditions and have now been included in Global Burden 
Diseases (GBD) category.  Alzheimer’s disease (AD) and Parkinson’s disease (PD) are two most 
prevalent neurodegenerative disorders among the population over the age of 60 years.  In the US, at 
least 2 out of 100 people over the age of 60 years have been diagnosed with PD, making it the second 
most common neurodegenerative disease (Moore et al., 2005).  PD is a progressive and chronic 
movement disorder, characterized by gradual loss of dopaminergic neurons from the midbrain region, 
called Substantia Nigra pars compacta (SNpc) (Jackson-Lewis et al., 2012; Jenner, 2007; Kowal et al., 
2013; Lee and Trojanowski, 2006).  Currently, there is no therapeutic cure for PD, and patients rely on 
symptomatic relief-targeted strategies.  Although etiopathogenesis of PD remains unclear, it is believed 
that gene-environment interactions may contribute to the disease etiology (Kanthasamy et al., 2008; 
Keeney et al., 2009; Lee and Trojanowski, 2006).  To date, mutations in more than 20 different genes 
have been shown in PD patients, with at least 12 more having a high potential of contributing to the 
disease (Ferreira and Massano, 2017).  Additionally, environmental factors such as, pesticides, heavy 
metals, tobacco, coffee, NSAIDs, and alcohol have been shown to modulate the disease risk 
(Campdelacreu, 2014).   
The pathophysiology of PD is complex and multiple factors have including oxidative stress, 
mitochondrial damage, lysosomal impairment, and proteasomal dysfunction (McNaught and Olanow, 
2006) have been implicated.  Neuroinflammation also plays a pathogenic role in the cellular and 
molecular changes involved in neuronal degeneration (Hirsch et al., 2012).  There is increasing 




neurodegeneration (Dheen et al., 2007; Gao et al., 2002; Kim and Joh, 2006; Tremblay et al., 2011).  
Pattern recognition receptors (PRRs) on the surface of microglia are activated by the damage or 
pathogen-associated molecular patterns (DAMPs/PAMPs), such as neuronal metabolites, triggers an 
immune response (Gordon et al., 2016b).  The over activated state of microglia produces reactive 
oxygen species and pro-inflammatory cytokines, which are toxic to neurons causing oxidative stress 
thereby leading to amplification of the disease (Block et al., 2007).  Several mechanisms have been 
proposed which produce the toxic levels of free radicals involving activation of enzymatic systems, 
such as intracellular nitric oxide synthase (iNOS), as well as other potential molecular pathways 
(Hirsch and Hunot, 2009).  Binding of ligands to PRRs also trigger downstream signaling cascades that 
promote expression of  pro-inflammatory proteins, such as NOD-like receptors (NLRs) that assemble 
protein complexes in the cytosol (Gordon et al., 2016b) .  
Multimeric protein complexes, called inflammasomes, are involved in the innate immune 
system that regulate host defense response to invading pathogens (Lamkanfi and Dixit, 2014).  The best 
characterized member of the NLR family is the NLRP3 inflammasome, and inappropriate activation of 
this complex is implicated in the pathology of several diseases, such as PD.  NLRP3 inflammasome 
activation involves two steps.  First is the ‘priming step’ or binding of PAMP to a receptor causing the 
transcription of precursors for IL-1ß, IL-18, and NLRP3 (signal 1).  Second is the activation step 
where in response to DAMP binding the proteins assemble the inflammasome complex and caspase-1 
is activated to process IL-1ß and IL-18 into active cytokines (signal 2).  Consequentially, increased 
activation of this inflammasome leads to increased production of the cytokines as well as accumulation 
of metabolic byproducts from caspase-1 (Tschopp and Schroder, 2010).  In this investigation, we 
examined the role of NLRP3 inflammasome activation and underlying mechanisms involved in 




Autophagy is a critical intracellular catabolic pathway also involved in the immune response.  
It maintains cellular and tissue homeostasis by degrading aberrant material in the cytoplasm via 
lysosomal degradation.  Activation of this process, specifically macroautophagy, induces the formation 
of an autophagosome around reactive material, which fuses with lysosome to ultimately form an 
autophagolysosome.  Studies have shown crosstalk between inflammasomes and autophagy to prevent 
tissue damage and infection with inflammation.  Autophagy negatively effects inflammasome 
activation (Yuk and Jo, 2013).  Ubiquitin-proteasome system is also responsible for the targeting for 
degradation of proteins (Banerjee et al., 2010).  Disruption of either of these pathways can cause 
leakage of lysosomal contents such as Cathepsin B, a lysosomal protein, which promotes IL-1ß and 
NLRP3 mediated activation (Orlowski et al., 2015).   
Genetic mutations in more than 20 genes have been identified in PD etiology.  Amongst these, 
mutation in parkin gene has been identified as one of the most common one (Bruggemann and Klein, 
1993; Ferreira and Massano, 2017).  In last decade, plethora of research demonstrates that parkin 
expression and mutation plays a major role in dopaminergic neurodegeneration, however, there are 
scarce evidences of role of parkin in glial cells (Dai et al., 2015; Dawson and Dawson, 2014).  Parkin, 
a 456 amino acid protein, is an E3 ubiqutin ligase and is invoved in clearance of damaged 
mitochondria through a regulated process called mitophagy.  Recent studies indicate that interactions 
of parkin with PTEN-induced putative kinase 1 (PINK1) holds a key for selectively targeting and 
clearing the dysfunctional mitochondria from neurons and other cells via autophagic destruction 
(Panicker et al., 2017).  
Rotenone (ROT) is a pesticide which has been implicated as a neurotoxin and is commonly 
used as a PD mimetic in cell culture.  It is implicated in neurodegenerative diseases as it inhibits the 
first complex in the electron transport chain therefore promotes the formation of mitochondrial 




commonly used as a pro-inflammatory stressor to simulate infection in cell culture (Tschopp and 
Schroder, 2010).  Traditional research of NLRP3 activation involve signal 1 followed by signal 2, 
however we will be switching to activation step followed by ‘priming’.  The effects of introducing 
rotenone to microglial cells, then exposing to infectious agents, such as LPS, is unknown (Jo et al., 
2016).  We will investigate this and the mechanisms of NLRP3 inflammasome activation in 
Parkinson’s disease in vitro using BV2 microglial cells and primary microglia models. 
Material and Methods 
Cell culture: BV2 microglial cell line was grown in 10% fetal bovine serum (FBS), 1% penicillin 
streptomycin (PS), 1% Glutamine (Q) in RPMI media. For treatment RPMI media containing 2% FBS, 
1%PS and 1%Q was used.  Cells were treated with 200nM Rotenone for 6h followed by LPS 
(100ng/mL) treatment for 3-18 h. 
Primary microglia were isolated following out previously published protocol (Sarkar et al., 
2017b).  Use of the animals and protocol procedures were approved by the Institutional Animal Care 
and Use Committee (IACUC) at Iowa State University (ISU), Am es, IA, USA.  Briefly, one-day old 
post-natal pups were sacrificed, the brain homogenized into single cell culture, and cultured in 10% 
FBS, 1% PS, 1% Q, 1% sodium pyruvate (SP), and 1% non-essential amino acid (NEAA) in DMEM-
F12 media (growth media) for 16 days.  Following the incubation, EasySep™ Mouse CD11b Positive 
Selection Kit II, was used to isolate CD 11b positive microglial cells.  Following isolation, these 
microglial cells were cultured for 48 h in the growth media and treated in DMEM-F12 media 
containing 2% FBS, 1%PS, 1%Q, 1% SP, and 1% NEAA. 
Ventral mesencephalic neuron-glia cultures: Neuron-glia mixed culture were isolated and maintained 
as described by Gao et al. (2002).  In brief, dispersed cells from ventral mesencephalic tissues of 




They cells were cultured in minimum essential medium (MEM) (supplemented with 10% heat-
inactivated fetal bovine serum (FBS) and 10% heat-inactivated horse serum (HS), 1 g/L glucose, 2 
mML-glutamine, 1 mM sodium pyruvate, 100 mM non-essential amino acids, 50 U/mL penicillin, and 
50 µg/mL streptomycin) and were maintained at 37°C with 5% CO2 in humidified condition.  For 
treatment, 7-day-old cultures were switched to MEM containing 2% FBS, 2% HS, 2 mM L-glutamine, 
1 mM sodium pyruvate, 50 U/mL penicillin, and 50 µg/mL streptomycin.  Cultures were sequential 
exposed to ROT (20nM, 48h) followed by LPS (5ng/ml, 24h) with or without CA074 pretreatment. 
Western blot: Immunoblot analysis was performed according to previous published protocol (Panicker 
et al., 2015). Briefly, cell pellets and tissue samples were homogenized using modified RIPA buffer 
followed by incubation for 10 mins in ice.  The samples were then sonicated for 2.5 mins with a pulse 
of 30 secs and centrifuged at 20,000 g for 45 mins.  Protein estimation was performed using Bradford 
reagent. 25-40µg of protein in each well was loaded in 10-15 % SDS-acrylamide gels and run for 2h 
for 110V following which, proteins were transferred to a nitrocellulose membrane at 27V for 18h at 
4°C.  The nitrocellulose membranes were blocked using LICOR blocking buffer for 1 h and incubated 
in primary antibodies for 3h to 18h, washed with PBS-Tween, incubated in IR-secondary antibodies 
obtained from LICOR, washed with PBS-Tween, and scanned using Odyssey® Imaging system (LI-
COR Biosystems, Nebraska).  The following antibodies were used from Cell Signaling Technology- 
phospho c-Abl (Tyr245), IL-1β, parkin, LC3, p62 and cathepsin B.  Antibody against c-Abl and TH 
were purchased from EMD Millipore.  PKCδ, phospho PKCδ (Tyr311), phospho c-Abl (Tyr412) and 
IBA1 antibodies were obtained from Santa Cruz Biotechnology and NLRP3, TFEB and caspase-1 
antibodies were purchased from Novus biotech. 
Immunocytochemicl (ICC) and immunohistochemical (IHC) imaging: Microglial cells were plated 
on glass coverslips coated with poly D-lysine (PDL) in a 24-well cell culture plate. After the cells were 




blocking in 1.5% bovine serum albumin (BSA), 0.05% Tween-20, and 0.5% Triton X for 1 h.  
Following blocking, the cells were incubated in primary antibodies at 4°C overnight.  The following 
primary antibodies were used IBA1 (1:400) (Wako Chem, # 019-19741), c-Abl (1:250) (EMD 
Millipore, #OP20), cathepsin B (1:250) (CST, #31718), TFEB (1:300) (Novus, #1030SS), LC3 (1:250) 
(CST, #3868), LAMP2 (1:250) (Abcam, # ab25631.  Following incubation, cells were washed with 
PBS, and then incubated with secondary antibody for 1 h.  Hoechst (1:5000) was used as nuclear stain, 
and mounted on slides using the Fluoromount mounting medium (Sigma).  Slides were dried overnight 
and then imaged using a Nikon Eclipse C1 microscope. 
Immunohistochemistry (IHC) was performed on striatal and SN sections of animals as 
described in our previous publications (Panicker et al., 2015; Sarkar et al., 2017a).  Briefly, citrate 
buffer at pH 8.5 was used to perform antigen retrieval (10 mM sodium citrate, pH 8.5).  Sections were 
then washed with PBS, blocked with blocking buffer (2% BSA, 0.5% Triton 100X, and 0.05% 
TWEEN 20) for 1 h, and incubated in primary antibodies overnight at 4°C.  Next, sections were 
washed with PBS, incubated in secondary antibodies for 1 h and stained with the nuclear dye Hoechst.  
Finally, sections were mounted on pre- coated slides and dried overnight before visualizing them under 
microscope.  
qRT-PCR: RNA isolation from microglial cells and tissues were performed using Trizol reagent 
following previously published protocol (Seo et al., 2014).  Following RNA isolation, 1 µg of RNA 
was converted to cDNA using High capacity cDNA reverse transcription kit (Thermo-Fisher 
#4368814). qRT-PCR was performed using SYBER green mastermix following previously published 
studies (Lawana et al., 2017).  The fold change was determined using ΔΔCt method where Ct 
represents the threshold values (Gordon et al., 2016a; Gordon et al., 2016b). 18S was used as a 




ROS (DCFDA) and MitoSOX: The cells were plated in 96-wellplate. Post treatment, the cells were 
incubated with redox sensitive CM H2DCFDA dye (1 μM) for 1 h. Following incubation, the cells 
were washed with PBS two times, and a plate reader was used to detect the fluorescent intensity at an 
excitation and emission wavelength of 488 nm and 525 nm, respectively.  The change in fluorescence 
units, directly indicate the change in levels of intracellular ROS. 
MitoSOX was performed following previously published protocol (Lawana et al., 2017).  
Briefly, microglial cells were washed with PBS post treatment and incubated with MitoSOX dye 
according to manufacturer’s protocol.  Following incubation, cells were washed properly to get rid of 
excess dye.  Cells were fixed and microscopic analysis was performed.  Change in fluorescence 
reading indicated the altered levels of mitotochondrial superoxide. 
MMP (JC-1) assay: Mitochondrial membrane integrity was measured using the lipophilic JC-1 dye 
(Invitrogen) following our previously published paper (Lawana et al., 2017).  Briefly, cells were 
treated with ROT for 6 h followed by LPS treatment for 3-18 h, with or without inhibitors. Following 
treatment cells were incubated for 30 mins with 2 μg/ml JC-1 dye and washed with PBS.  Analysis was 
performed by measuring red fluorescence at an excitation/emission of 590 nm/600 nm and green 
fluorescence excitation/emission of 485 nm/535 nm.  Change in mitochondrial potential is represented 
as the ratio of Red:Green florescence. 
LysosensorTM green assay: The analysis of lysosomal membrane permeability was performed using 
LysosensorTM Green dye purchased from Invitrogen, following manufacturer protocol.  In brief, BV2 
cells were grown in 96-well plate and were treated as desired.  Following the treatment, cells were 
incubated with 100nM Lysosensor dye for 30min.  Post-incubation cells were washed with PBS 
multiple times and were analyzed using SpectraMax fluorescence plate reader at excitation/emission of 




Acridine orange assay: Acridine orange (AO) dye can detect the acidic organelles in the cells.  AO 
dye displays red fluorescence at acidic pH, whereas in non-acidic environment the dye fluoresces green 
(Moriyama et al., 1982).  BV2 cells were plated and treated in 96-well plate.  At the end of treatment, 
treatment media was removed and cells were exposed to acridine orange (5 µg/ml) for 15 min followed 
by washes with 1X PBS four times for 10 min each.  Using SpectroMaxTM plate reader, we estimated 
red fluorescence at excitation/emission of 584/612 nm and green fluorescence at excitation/emission of 
485/520 nm, respectively.  The fluorescence readings ratio of green:red was calculated and was 
plotted.  The increase in the ratio may indicate elevated lysosomal permability and/or decease number 
of intact acidic vacuoles including lysosomes. 
Autophagy Tandem kit: We further estimated the stages of autophagic flux in treated BV2 microglial 
cells using Premo™ Autophagy Tandem Sensor RFP-GFP-LC3B Kit (Invitrogen, # P36239) following 
manufacturer protocol.  In brief,  50-60% confluent cells were exposed to LC3B reagent from the kit 
and were gently mixed.  After overnight incubation, cells were sequentially treated with ROT (200nM, 
6h) followed by LPS (100ng/ml, 12h) with or without CA074 (10µM, 1h), a cath B inhibitor, 
pretreatment and were analyzed using a plate reader.  Chloroquine (90 μM, 24 h) and Leupeptin A 
(200 μM, 24 h) treatments were used as positive and negative controls.  The fluorescence 
excitation/emission maxima used- Emerald GFP: 488/509 nm; TagRFP: 555/584 nm.  The reading for 
RFP and GFP plotted as grouped for each treatment. 
Cathepsin B activity assay: The activity of cathepsin B was measured as per manufacturer’s 
instrcuction using a fluorometric cathepsin B activity assay kit (ab65300) in BV2 cells after treatment.   
Lysosomal fractionation: Post treatment, BV2 cells were subjected to lysosomal fractionation using 
lysosome isolation kit from BioVision (#K235-50).  Briefly, cell pellets were resuspended in lysosome 




to new microcentrifuge tubes and were mixed with equal volume of lysosome enrichment buffer.  
Finally, lysosomes were purified using lysosome enrichment gradient solutions and were immediately 
transferred to -80°C storage, until used for immunoblotting. 
Cytokine detection: The BV2 or primary microglia were seeded in the 96-wellplate.  Post treatment, 
secreted cytokines such as IL-1β (RayBiotech, # ELM-IL1b), IL-18 (RayBiotech, # ELM-IL18-1) and 
TNFα (RayBiotech, ELM-TNFa-1) was measured in mediated supernatant using ELISA based 
immunoassay kits as per manufacturer instructions.  
Animal study:  Six months old Male Lewis rats were purchased from Hilltop Lab Animals, Inc.  Use 
of the animals and protocol procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at Iowa State University (ISU), Ames, IA, USA.  Animals were randomly 
divided in four treatment groups (i.e. Control, ROT, LPS and ROT+LPS) and all animals were housed 
under standard conditions of constant temperature (22 ± 1°C), humidity (relative, 30%), and a 12 h 
light/dark cycle.  Rats from ROT and ROT+LPS groups were subcutaneously injected with rotenone 
every 5 days (0.5mg/kg/d) for 4 weeks as described by Huang et al. (2017).  Control and LPS group 
received equal volume of vehicle.  Following the last ROT injection rats from LPS and ROT+LPS 
were intraperitoneally injected with 5mg/kg LPS and control and ROT groups were injected with 
normal saline (Noworyta-Sokolowska et al., 2013; Qin et al., 2007).  Post 24 h LPS injection, animals 
were subjected to behavioral examination and immediately sacrificed.  Brain sections were collected 
and stored at -80°C for future analysis. 
Behavior analysis: Twenty-four after LPS injection, animals were subjected to locomotor behavioral 
analysis using an automated device (Model RXYZCM-16; Accuscan Columbus, OH, USA) as detailed 
in our previous study (Langley et al., 2017; Lawana et al., 2018).  Briefly, rats were kept in activity 




acclimatization followed by 10 min test sessions.  Vertical and horizontal movement data were 
collected and analyzed by a VersaMax analyzer (Model CDA-8, AccuScan) and were processed using 
statistical tools listed below. 
HPLC analysis: Brains were harvested and different brain regions were collected and stored as 
described previously (Ghosh et al., 2012; Lawana et al., 2018).  Succinctly, striatal tissues were lysed 
using a freshly made lysis buffer (100 µM Perchloric acid, 0.05% EDTA and 0.1% Na2S2O5).  
Isopropenol was added to each sample as an internal standard.  Dopamine (DA) and 3,4-
dihydroxyphenyl acetic acid (DOPAC) were separated using a reversed-phase column high-
performance liquid chromatography at the flow rate of 0.6 ml/min.  A semi-automatic system equipped 
with temperature control refrigerator (ESA Inc, Bedforf, MA, USA) was used to perform the analysis.  
Data were collected and were normalized to tissue weight for each sample. 
Statistical analysis: All the results were expressed as mean ± standard error or mean (SEM).  The 
statistical analyses were performed using GraphPad Prism 6.0 software (GraphPad Software, San 
Diego, CA).  The p-values were determined by one way ANOVA followed by post hoc Tukey test and 
p-values < 0.05 were considered statistically significant. 
Results 
LPS stimulation induces oxidative stress and mitochondrial dysfunction in ROT pretreated BV2 
microglial cells 
Researchers have shown that combination of multiple intracellular events contribute to 
activation of a resting microglia (Guo et al., 2015b; Kim and Joh, 2006; Lull and Block, 2010; 
Tremblay et al., 2011).  For example, LPS has been shown to trigger oxidative stress mechanisms in 
microglial cells (Huo et al., 2011; Moon et al., 2012; Noworyta-Sokolowska et al., 2013; Zhang et al., 




microglial cells via activating p38 MAP kinase (Gao et al., 2013).  Additionally, another study 
demonstrated that ROT-induced ROS generation and NF-κB activation is responsible for activation of 
BV2 cells (Yuan et al., 2013).  Moreover, our previous study showed that sequential treatment of BV2 
cells with 1μg/ml LPS and 0.5µM ROT caused a massive increase in ROS production contributing to 
microglia activation (Lawana et al., 2017). 
In this study, we investigated the time-dependent effect of low dose LPS in murine BV2 
microglial cells pre-exposed to nontoxic dose of ROT (Gao et al., 2013).  We first treated the cells with 
200nM of ROT for 6h followed by exposure with 100ng/ml LPS for 3, 6, 12 or 18h.  Assessment of 
cell viability using colorimetric MTS assay revealed that ROT and LPS combinatorial treatment dose 
not elicit cell death at the indicated time points (Fig. 1(A)).  Next, we investigated the ROS levels in 
microglial cells sequentially treated with low doses of ROT and LPS, respectively, using cell 
permeable CM-H2DCFDA fluorogenic dye that is modified by ROS and detected fluormetrically.  Our 
data showed that ROT alone (p<0.01) or LPS alone (12 and 18h time-points, p<0.05) caused 
significant increase in ROS generation in BV2 cells (Fig. 1(B)).  Interestingly, cells pretreated with 
ROT and then stimulated with LPS displayed synergistic ROS generation (p<0.05).  In particular, cells 
treated with ROT/LPS showed 1.8-fold, 2.1-fold, 2.9-fold and 3.4-fold increase in ROS levels compare 
to LPS-treated cells at 3, 6, 12 and 18h, respectively. 
ROT ablates activity of the mitochondrial electron transport chain (ETC) complex I and ROT 
and LPS are known to depolarize mitochondrial membrane potential (MMP, ∆Ψm) (Radad et al., 2014; 
Sherer et al., 2003c; Zhou et al., 2007).  Sequential treatment of BV2 cells with ROT (200nM, 6h) and 
LPS (100ng/ml) caused the collapse of MMP as measured by JC-1 dye (Fig 1(C)).  JC-1 is a lipophilic 
dye and fluoresces green color in monomeric state, but upon accumulation in the intramembrane space 




to covert JC-1 dye to red polymer and have higher levels of green monomer.  Hence, decrease in the 
ratio of red to green indicates damage to the outer membrane of mitochondria leading to loss of MMP.  
Fig 1(C) indicates that ROT treatment caused approximately 40% reduction in MMP (p<0.001) 
whereas, LPS treatment caused no significant change until 12h.  At 18h LPS caused 22% decrease in 
RED:GREEN ratio (p<0.05).  However, in cells treated with ROT/LPS a 54% reduction in MMP was 
evidenced at 18h as compared to control group. Taken together our studies demonstrate that cells that 
received ROT and LPS in tandem exhibited an increased ROS generation and subsequent MMP 
collapse compared with cells that received either LPS or ROT alone (p<0.01).  
Time-dependent activation of c-Abl tyrosine kinase in BV2 microglial cells treated with 
ROT/LPS 
c-Abl is a redox sensitive intracellular tyrosine kinase and upregulation of c-Abl activity have 
been indicated in PD animal models and implicated as a regulator of widespread cellular dyfunction 
(Brahmachari et al., 2017)(Lawana et al., 2017).  To further assess the impact of ROT pretreatment on 
LPS-induced microglial activation, we analyzed the protein levels and phosphorylation of c-Abl using 
WB analysis.  Fig 1(D) demonstrates that exposure to ROT (200nM, 6h) or LPS (100ng/ml, 3-18h) 
resulted in a time-dependent increase in c-Abl kinase activation as indicated by hyperphosphorylation 
of c-Abl at Y412 and Y245 residues, respectively.  Next, we investigated whether PKCδ, another 
redox sensitive serione/threonine kinase, and a downstream substrate of c-Abl is activated in cells that 
received a combination of ROT and LPS (Lu et al., 2007).  Phosphorylation of PKCδ at Y311 site 
induces the kinase activity of the protein.  Exposure of BV2 cells to ROT and LPS induced a 
significant (p<0.05) increase in PKCδ Y311 phosphorylation (Fig 1(D)).  Taken together, our studies 
demonstrate a positive correlation between induction of ROS generation and activation of redox 
sensitive kinases, such as c-Abl and PKC delta further confirming the sensitivity of these kinases to 




NLRP3 inflammasome is activated in a time-dependent manner following treatment of BV2 
microglial cells with ROT and LPS in tandem  
Inflammasomes are intracellular multiprotein complexes, that contributes to innate immunity in 
the CNS (Broz and Monack, 2011; de Rivero Vaccari et al., 2014).  In microglial cells, NLRP3 
inflammasome have been well characterized and are shown to be involved in the activation of 
microglial cells (Guo et al., 2015a; Jo et al., 2016; Lawana et al., 2017).  BV2 Cells were subjected to 
the same ROT/LPS treatment conditions as detailed above then WB analysis was carried out using 
whole cell lysates.  Immunoblotting with NLRP3 antibody revealed that both ROT and LPS alone 
caused a slight increase in NLRP3 expression (fig 1(E)).  However, the combination caused an 
exaggerated time-dependent upregulation of NLRP3 protein expression.  At 6h and 12h time-points, 
ROT/LPS treatment showed increased expression of NLRP3 as compared with LPS-treated cells (2.2-
fold increase). Interestingly, 18h post LPS or ROT/LPS treatment, a slight reduction in NLRP3 
expression was observed indicative of extracellular release of NLRP3 (Baroja-Mazo et al., 2014; 
Lawana et al., 2017).   
A study in bone-marrow derived macrophages (BMDMs), revealed that cells primed with LPS 
and then treated with NLRP3-inflammsome activators (such as ATP) causes extracellular release of 
NLRP3, caspase 1 (p10) and IL-1β, amplifying the inflammatory response (Baroja-Mazo et al., 2014).  
We analyzed the extracellular release of NLRP3 and other inflammasome markers by concentrating the 
supernatant media from each treatment group and performed immunoblotting studies.  Fig 1(E, lower 
panel), demonstrates that ROT/LPS combination caused extracellular secretion of NLRP3, casp 1 
(p10) and IL-1β as early as 3h post LPS treatment (p<0.05).  At 18h time-point, the secretion of the 
proinflammatory mediators were increased by 84%, 96% and 93% for NLRP3, casp 1 (p10) and IL-1β, 




DAS, a pharmacological inhibitor, abrogates the ROT/LPS mediated oxidative stress, loss of 
MMP and activation of NLRP3 inflammasome 
c-Abl has been shown to promote dopaminergic neurodegeneration in experimental models of 
PD (Brahmachari et al., 2016; Mahul-Mellier et al., 2014; Pagan et al., 2016; Shin et al., 2011).  To 
address the role of c-Abl in ROT/LPS-induced microglial activation, BV2 microglial cells were 
pretreated with DAS (100nM) for 1h and at the end of an hour cell lysates were prepared and examined 
for the expression levels of c-Abl and p-c-ABL using WB analysis.  As shown in Fig. 2(A), cells that 
were treated with ROT and LPS in a sequential manner displayed a significant (p<0.001) increase in p-
c-Abl (Y412 and Y245) levels while inhibition of c-Abl with DAS produced a significant (p<0.001) 
reduction (55%) in p-c-Abl levels.  More importantly, DAS attenuated ROT/LPS-induced ROS 
generation and MMP collapse in line with our previous findings (Lawana et al., 2017).   
Next, we analyzed the effects of DAS on ROT/LPS-induced NLRP3 inflammasome activation.  
We hypothesized that DAS could suppress the secretion of IL-18 and IL-1β via inhibition of NLRP3 
inflammasome activation in response to ROT/LPS.  It is well known that NLRP3 inflammasome 
expression is increased in response to diverse inflammagens (Huaux, 2018; Machiya et al., 2010; 
Moquin et al., 2013; Sarkar et al., 2017a).  Thus, we determined the expression levels of NLRP3 using 
WB analysis.  As anticipated, DAS pretreatment significantly (p<0.001) reduced NLRP3 protein 
expression by more than 40% (Fig. 2(D)).  Next, we investigated to what extent DAS influenced 
ROT/LPS enhanced IL-18 and IL-1β.  Given that DAS inhibited ROT/LPS-induced NLRP3 
inflammasome expression levels, we determined the secreted levels of afore mentioned pro-
inflammatory cytokines using ELISA analysis in media supernatant.  Our results revealed that DAS 
abrogated the ROT/LPS-induced secretion of IL-1β and IL-18 by 40 and 38, respectively (Fig. 2(E)).  




MMP in BV2 cells in response to ROT/LPS.  Importantly, DAS was found to inhibit the maturation of 
IL-1β and IL-18 induced by ROT/LPS via inhibition of NLRP3 inflammasome activation. 
Lysosomal destabilization and cathepsin B activation linked to ROT/LPS-induced microglial 
activation response 
Lysosomal destabilization has been shown to contribute to both neurodegeneration (Ghavami et 
al., 2014; Micsenyi et al., 2013; Wu et al., 2015a) and microglial activation (Peppoloni et al., 2011; 
Terada et al., 2010).  In fact, lysosomal destabilization has been linked to α-syn-fibril-induced NLRP3 
inflammasome activation (Codolo et al., 2013).  Both LPS and ROT have been shown to increase LMP 
in microglial cells (Majumdar et al., 2007).  The fluorescent dye Lysosensor green exhibits a pH-
dependent increase in fluorescence intensity upon acidification as compared with Lysotracker probes.  
As shown in Fig. 3(A), we observed the both LPS and ROT treatment by itself-induced loss of 
fluorescence intensity starting at 6h and a persistent reduction was observed during remaining 
treatment period.  However, in cells that received a combination of ROT and LPS a synergistic 
reduction in fluorescence intensity was evidenced.  Decreased Lysososensor green fluorescence 
intensity could be attributed to decreased lysosomal volume.  As it is difficult to detect smaller 
reduction in the increases in lysosomal pH based on fluorescence based methods, we utilized the 
acridine orange method where the dye acridine range fluoresces red in healthy lysosomes and switches 
to green in cells with perturbed lysosomal function.  Hence, increase in Green:Red ratio may indicate 
the reduction in lysosomal acidity due to damaged lysosomal membrane and increased LMP.  Similar 
to Lysosensor results, a marked increase in green fluorescence was evidenced in ROT and this effect 





Increased LMP results in cytosolic release of lysozymes, mainly cathepsins (Halle et al., 2008a; 
Kirkegaard and Jaattela, 2009).  Cath B, a lysosomal cysteine protease, is essential for proteolysis and 
normal lysosomal function (Turk et al., 2001).  Multiple studies have demonstrated that with increased 
lysosomal membrane permeabilization, cath B gets released from the lysosomal compartment to the 
cytosol (Puissant et al., 2010).  Cath B is produced as a proenzyme form (37kDa) in cells and upon 
activation the protein gets cleaved in to a mature form (25kDa).  In this study, we evaluated the 
activation of cath B using two techniques, namely ELISA and WB analysis.  Fig 3(C) demonstrates the 
activation of cath B in a time-dependent manner post LPS treatment in ROT primed BV2 cells.  We 
observed that ROT (200nM, 6h) alone caused and apprxomimate 30% increase in cath B activity, 
whereas, LPS (100ng/ml) caused 25-40% increase in cath B activity regardless of exposure duration. 
Interestingly, cells that received a combination of ROT and LPS induced a time-dependent increase in 
cath B activity whereby a significant (p<0.05) increase in cath B activity was observed as early as 3h, 
and remained persistently elevated for the remaining treatment period.  Likewise, our immunoblotting 
result showed similar trend (Fig 3(D)), whereby maximal activation of cath B cleavage was observed 
at 18h post-ROT/LPS treatment in BV2 microglial cells. 
 To investigate whether lysosomal dysfunction and increase in cath B activity is linked to c-Abl 
activation, we next determined the effects of DAS on ROT/LPS-induced lysosomal dysfunction.  
Recently we demonstrated that inhibition of c-Abl attenuated rotenone-induced lysosomal dysfunction 
and autophagy in LPS stimulated BV2 cells (Lawana et al., 2017).  In line with these findings, herein 
we show that DAS pretreatment alleviated the ROT/LPS-mediated reduction in Lysosensor® green 
fluorescence (Fig. 3(E)) and increased AO Green:Red ratio (Fig 3(F)), indicating the restoration of 
lysosomal function.  Our WB analysis demonstrated that DAS pretreatment significantly (p < 0.01) 
reduced the cath B maturation (Fig. 3(G)) and markedly (p < 0.01) lowered the cath B activity (Fig. 




LC3B is a cytosolic protein (LC3B I) and upon conjugation with phosphatidylethanolamine 
(PE) is converted to LC3B II (LC3B-PE), which is required for formation of autophagic membranes in 
mammalian cells (Tanida et al., 2004).  SQSTM1/p62 (hereafter p62), a ubiquitin-adaptor protein, that 
binds directly to LC3B II and shuttles undegraded proteins tagged with ubiquitin into the 
autophagosomes for degradation and has been used as a marker for autophagic flux (Bjorkoy et al., 
2009).  Under normal homeostasis, both LC3B II and p62 are degraded following fusion of 
autophagosomes with lysosomes, indicating functional ALS (Bjorkoy et al., 2009; Tanida et al., 2008).  
Thus, increased LC3B II with p62 level indicates dysfunctional ALS.  We recently demonstrated that 
DAS pretreatment lowered the accumulation of autophagic vacuoles (AVs) in microglia exposed to 
LPS and ROT by reducing protein levels of autophagic markers including LC3B II and p62 (Lawana et 
al., 2017).  Likewise, in this study we showed that DAS pretreatment reduced the ROT/LPS mediated 
increase of LC3B II and p62 in BV2 cells (Fig. 3(I)).  Our immunoblotting results showed that DAS 
pre-exposure reduced the LC3 II levels and p62 levels by 42% and 48% respectively, in comparison 
with cells exposed to ROT/LPS combination. 
Cathepsin B inhibitor alleviates the oxidative stress and mitochondrial damage induced by LPS 
in ROT pre-exposed BV2 cells 
Cath B cytosolic release due to elevated lysosomal permeability has been linked with increased 
mitochondrial damage and elevated oxidative stress by directly depleting mitochondrial inner-
membrane potential (Boya et al., 2003; Fujisawa et al., 2007; Guicciardi et al., 2000; Nylandsted et al., 
2004; Wang, 2014).  Even more, cath B inhibitor, CA074, has been shown to reduce the mitochondrial 
damage in various infectious disease models (Boya et al., 2003; Fujisawa et al., 2007; Goyal et al., 
2015).  Therefore, we investigated the role of cath B in our model by pretreating cells with CA074, a 




First, we evaluated the cytotoxic potential of CA074 using different concentrations in our 
study.  As shown in Fig 4(A), all three concentrations (1, 5 and 10µM) of CA074 were not able to 
cause any cell death at 24h as examined by MTS cell viability assay.  We, then, treated the BV2 with 
10µM CA074 for 1h, followed by priming with ROT (200nM, 6h) and treatment with LPS (100ng/ml, 
12h).  To evaluate the cath B inhibitor effects of CA074, we estimated the cath B activity treated with 
ROT/LPS with or without CA074 pre-exposure, using ELISA analysis.  Our results demonstrate that 
CA074 significantly (p<0.001) abrogated the elevation of cath B activity (Fig. 4(B)) as well as increase 
expression of mature cath B (Fig. 4(C)) induced by ROT/LPS in BV2 cells.  
Next, we examined the amount of ROS generation using CM-H2DCFDA dye.  Our data 
showed that in CA074 pretreated cells a significant (p<0.01) reduction in the ROT/LPS-mediated ROS 
generation (50%) was observed (Fig. 4(D)).  Since the CM-H2DCFDA data shows the extent of 
intracellular oxidative species generation, we next used the mitoSOX® red, a dye routinely used to 
analyze the levels of mitochondria-generated superoxide species.  As shown in Fig. 4(E), the cells 
exposed to ROT/LPS with prior exposure to CA074 showed significantly (p<0.01) lower levels of 
mitochondrial superoxide as compare to ROT/LPS treated cells.  Lastly, we examined the role of 
cathepsin B inhibitor on MMP using JC-1 dye.  Our data established that cells treated with CA074 
(10µM) were able to partially protect against ROT/LPS mediated loss of MMP (Fig. 4(F)).  Overall, 
these data indicate that CA074 downregulates the ROT/LPS-induced oxidative and mitochondrial 
insults.  
CA074 protects against LPS-mediated impaired autophagic flux in ROT-pretreated BV2 
microglial cells 
A fully functional autophagolysosomal system is crucial for cellular homeostasis and digests 




proteins and obsolete organelles (Levine and Klionsky, 2004).  Oxidative stress originating from loss 
of lysosomal membrane integrity has been implicated in NLRP3 inflammasome activation (Heid et al., 
2013).  In this context, we analyzed the effect of CA074 on lysosomal integrity.  Using LysosensorTM 
Green dye (Fig. 4(G)) and AO assay (Fig 4(H)), our data show that CA074 pre-exposure abrogates the 
lysosomal damage in BV2 cells treated with ROT/LPS.  To further confirm loss of lysosomal function, 
we use the Premo™ Autophagy Tandem Sensor RFP-GFP-LC3B Kit.  This assay offers a combination 
of an acid-sensitive GFP and an acid-insensitive RFP tags, allowing a direct monitoring of fusion of 
autophagosome (neutral pH) to lysosome (with an acidic pH) (Law et al., 2014; Li et al., 2016b; Zhou 
et al., 2012).  Fig 4(I) shows that BV2 cells exposed to ROT/LPS had higher expression of both RFP 
and GFP fluorescence, indicating the neutralization of lysosomal pH and accumulation of AVs in cells.  
We also treated cells with chloroquine, a well-known inhibitor of ALS, and Leupeptin A, an inhibitor 
of autophagy.  Similar to ROT/LPS treated cells, chloroquine treatment showed increase in both RFP 
and GFP indicating accumulation of AVs owing to loss of fusion of autophagic vacuoles with the 
lysosomal membrane.  On the other hand, Leupeptin A increased only RFP indicating blockade of 
autophagy with modulating lysosomal acidity.  Using these positive controls, we affirm the validity of 
our say results demonstrating that ROT/LPS indeed impairs the function of ALS thereby leading to the 
accumulation of autophagic vacuoles and that CA074 restored lsysosomal function as evidenced by 
reduced fluorescence intensity of RFP and GFP (p<0.01).  Moreover, CA074 reduced the GFP 
fluorescence to control levels indicating improved fusion of autophagic vacuoles with the lysosomal 
membrane.   
As mentioned, LC3B I forms the AV by addition of phosphatidylethanolamine generating 
LC3B II.  Beclin1, a mammalian orthologue to autophagy-related gene 6 (ATG6), forms a core 
complex with proteins anchoring them to inner side of AV (Kang et al., 2011).  Researchers have 




Takenouchi et al., 2009).  Our immunoblotting results show that ROT/LPS caused aberrant 
upregulation in LC3B II and p62 expression in microglia, indicative of accumulation of AVs and 
dysfunctional ALS.  This was concurrent with loss of lysosomal function; hence, we investigated the 
effect of CA074 in our experimental model.  As expected, CA074 treatment decreased the ROT/LPS-
mediated accumulation of beclin1 and LC3B II.  Together, our data demonstrate that cathepsin B 
inhibition may reduce impairment in autophagic flux thereby facilitating the restoration of ALS. 
CA074 reduces NLRP3 inflammasome activation in BV2 cells sequentially treated with ROT and 
LPS 
Cath B release has been shown to activate the NLRP3 inflammasome in macrophages (Chu et 
al., 2009; Niemi et al., 2011), monocytes (Duncan et al., 2009; Hoegen et al., 2011), microglia (Gustin 
et al., 2015) and other immune cells (Bruchard et al., 2013; Halle et al., 2008b).  Morover, recent 
studies have shown that CA074 downregulates the NLRP3 inflammasome complex (Allen et al., 2009; 
Gustin et al., 2015; Hornung et al., 2008) .  Likewise, our results showed that CA074 blocked the 
ROT/LPS-mediated NLRP3 activation in BV2 cells.  Using similar experimental design as detailed 
above, we performed the WB analysis using whole cell lysates and media supernatant from either drug 
treated or vehicle treated cells.  Fig. 4(K) shows that CA074 reduced the ROT/LPS-induced NLRP3 
expression by 21%, 44% and 53% at 1, 5 and 10µM concentrations, respectively.  We also analyzed 
the extracellular release of inflammatory markers in supernatant and immunoblotting results show that 
CA074 reduced the media concentrations of NLRP3, caspase 1 (p10) and IL-1β by 34%, 38% and 
31%, respectively, compared with ROT/LPS-treated group (Fig. 4(L)).  Lastly, to further confirm the 
inhibitory effects of CA074 on NLRP3 inflammasome activation we employed ELISA technique to 
estimate the amount of proinflammatory cytokines in media.  Concurrent to WB data, we observed that 




cells.  Furthermore, cells treated with CA074 prior to ROT/LPS caused significantly reduced release of 
IL-1β and IL-18 as compared with cells that received a combination of ROT/LPS (Fig. 4(M)).  Several 
studies have also shown that CA074 reduces the NLRP3 inflammasome activation (Heid et al., 2013; 
Joly and Sutterwala, 2010; Lima et al., 2013).  Our data are in agreement with previously  published 
research (Bruchard et al., 2013; Hoegen et al., 2011) and indicates that cathepsin B plays a crucial role 
in NLRP3 inflammasome activation and release of proinflammatory cytokines. 
Genetic manipulation of cath B alters the NLRP3 activation in BV2 cells primed with ROT and 
treated with LPS 
 To further confirm the role of cath B in BV2 cells, we employed two techniques: siRNA-
mediated knockdown (KD) and wild-type (Mariathasan et al.) constructs mediated overexpression of 
cath B.  A recent study showed that shRNA-mediated knockdown of cath B reduced expression of 
NLRP3 and release of IL-1β in human monocytic cells (Holzinger et al., 2012).  Immunoblot in Fig. 
5(A) confirms that cath B RNAi-transfected cells have lower cath B protein expression by 70% 
compared to scramble siRNA transfected cells, suggesting effective KD.  Next, we analyzed the 
expression of NLRP3 in whole cell lysates.  Fig. 5(C) demonstrate that cath B KD BV2 cells showed 
40% lower (p<0.001) expression of NLRP3 compared with scramble siRNA transfected cells post 
ROT/LPS exposure.  Also, ROT/LPS-induced release of NLRP3 (p<0.01), casp 1 (p10) (p<0.05) and 
IL-1B (p<0.05) was significantly reduced with cath B KD (Fig. 5(C), lower panel).  Likewise, our 
ELISA results show that cath B KD reduced the secretion of proinflammatory cytokines IL-1β and IL-
18 five-times lower than scramble-transfected cells post ROT/LPS treatment (p<0.0001) (Fig. 5(D)).  
 On the contrary, we transfected BV2 cells with empty vector (EV) or cath B WT constructs and 
sequentially treated with ROT (200nM, 6h) and LPS (100ng/ml, 12h).  Analysis of whole cell lysates 




compared with EV (Fig. 5(E)).  Overexpression of cath B was directly related with increased 
expression of NLRP3 and increase secretion of NLRP3, casp 1 and IL-1β (Fig. 5(F)).  Our ELISA 
analysis supported the WB data demonstrating that cath B WT transfected cells have higher release of 
IL-1β and IL-18.  These results together confirm the out of CA074 results, suggesting the upstream 
role of cath B in NLRP3 activation in ROT/LPS-treated microglia. 
CA074 abrogates ROT/LPS-mediated NLRP3 activation in primary microglia 
 The effect of CA074 on in primary mouse microglia treated with ROT/LPS was analyzed 
similar to BV2 cells.  First, WB analysis revealed that CA074 treatment reduced the c-Abl activation 
(Fig. 6(A)) and cath B maturation in primary microglia (Fig. 6(B)).  Further, we observed that primary 
microglia preexposed to CA074 had 30% reduction in cellular NLRP3 levels compared to ROT/LPS 
group (Fig. 6(C)).  In addition, the extracellular release of NLRP3, IL-1β, casp 1 (p10) was reduced as 
analyzed by WB for supernatant concentrates (Fig. 6(C)).  Finally, our ELISA data showed that CA074 
pretreatment abrogated the ROT/LPS induced release of IL-1β, IL-18 and TNFα by 64, 71 and 38%, 
respectively (Fig. 6(D)). 
CA074 pre-exposure mitigates the cath B cytosolic translocation and ALS dysfunction in 
primary microglia treated with ROT/LPS 
 Loss of lysosomal membrane integrity leads to leakage of cath B to cytosol, which is shown to 
be responsible for binding with and activating the NLRP3 inflammasome (Bruchard et al., 2013; Chu 
et al., 2009; Hoegen et al., 2011).  Hence, we investigated the translocation of cath B in our primary 
microglial cells exposed to ROT/LPS with or without CA074.  Using lysosomal fractionation kit, we 
separated the lysosomal fractions from whole cell lysates and subjected them for immunoblotting.  
Data presented in Fig. 6(E) demonstrate that ROT/LPS treatment caused reduction in pro and mature 




cytosolic fraction by almost 2-fold.  We used LAMP2 and tubulin as markers for lysosomal and 
cytosolic fractions and to confirm the purity.  Interestingly, CA074 pretreatment showed a significant 
reduction in translocation of mature cath B (p<0.01) and also recaptured the loss of pro-cath B levels 
(p<0.01).  Further, we performed ICC analysis to visualize the cath B translocation.  Consistent with 
our WB results, our ICC images manifest reduced co-localization of cath B (green) and LAMP1 (red), 
indicating release of cath B from lysosomes; whereas, CA074 pretreatment increased the co-
localization (Fig. 6(F)).   
 We showed that ROT/LPS treatment upregulate the LC3B II and p62 levels, indicating ALS 
dysfunction.  To further verify the ALS functionality in primary microglia, we performed ICC for LC3 
and LAMP2.  Functional ALS requires AVs to fuse with lysosome in order to degrade the contents.  
However, autophagic flux impairment is caused when the fusion fails and AVs accumulate in the cells.  
Immunofluorescence imaging of LC3 (red) and LAMP2 (green) showed similar trend (Fig. 6(G)).  We 
observed that microglia treated with ROT and LPS has lower LAMP2 and LC3 colocalization.  Even 
more, the images showed that ROT/LPS treatment had higher accumulation of LC3-positive puncta 
marking AVs.  Similar to previous results, we noticed that CA074 reduced the AV accumulation as 
well as increased the colocalization of LC3 and LAMP2 (Fig. 6(G), bottom panel).   
CA074 abrogates the ROT/LPS-induced c-Abl/cath B/inflammasome activation and 
dopaminergic neurotoxicity in mixed neuron-glia primary culture 
 Since, ROT/LPS exposure aggravated the microglial activation, we further analyzed the effect 
of ROT/LPS in mixed neuron-glia culture obtained from mouse embryos as described in methods (Gao 
et al., 2002; Liu and Hong, 2003).  We treated the mixed neuron glia culture with very low dose of 
ROT (20nM, 48h) followed by LPS (5ng/ml, 24h).  The use of lower concentrations of ROT and LPS 




et al., 2002; Yang et al., 2008).  Consistent with our previoius experiments, we found increased 
phosphorylation of c-Abl (Y412 and Y245) in neuron-glia culture treated with ROT followed by LPS 
(Fig. 7(A)).  Interestingly, we also noticed increase levels of activated cath B in ROT/LPS group (Fig. 
7(B)).  Hence, we used CA074 to further analyze the role of cath B in neuron-glia culture. 
 Treatment of dopaminergic neurons with toxicants such as MPP+ have been shown to increase 
LMP and cytosolic release of cath B, which can contribute to dopaminergic neuronal death (Vila et al., 
2011).  Alternatively, extracellular secretion of mature cath B from microglia have also been shown to 
induce neurotoxicity (Kingham and Pocock, 2001).  Here, our results show that CA074 reduced the 
cath B maturation in mixed neuron-glia culture exposed to ROT/LPS (Fig. 7(B)).  Interestingly, we 
also noticed that CA074 reduced the c-Abl phosphorylation by 40 and 25% at Y245 and Y412 residues 
(p<0.05), respectively (Fig. 7(A)).  Even more, our WB analysis shows that ROT/LPS exposure 
increased the NLRP3 levels by 1.7-folds in whole cell lysates and 2.1-folds in media supernatant (Fig. 
7(C)).  The induction and release of NLRP3 was consistent with increased release of Casp-1 and IL-1β 
as observed by WB (Fig. 7(C)).  However, CA074 pretreatment reduced the intracellular levels of 
NLRP3 by 30% and extracellular neurotoxic NLRP3, caps 1 (p10) and IL-1β levels by 35, 27 and 
33%, respectively (Fig. 7(C)).   
 Next, CA074 pretreatment mitigated the autophagic flux damage in neuron-glia culture treated 
with ROT/LPS.  WB presented in Fig. 7(D) shows that ROT/LPS exposure significantly increased the 
LC3B II and p62 expression by 2.1- and 1.5-folds, while CA074 blocked the accumulation of these 
autophagic markers, indicating functional autophagic flux as described earlier.  Finally, we analyzed 
the level of TH as an indicator for dopaminergic neuron viability.  Immunoblot for TH indicates that 
sequential treatment of mixed mesencephalic neuron-glia culture with ROT and LPS caused >80% 
reduction in TH levels, suggesting loss of dopaminergic neurons (Fig. 7(E)).  Surprisingly, CA074 




neurons.  These data together suggest that ROT/LPS-mediated activation of cath B activates c-Abl and 
impairs ALS leading to microglial activation of NLRP3 and release of pro-inflammatory cytokines, 
which then promoted the dopaminergic neurotoxicity.  
Mdivi-1 reduces the ROT/LPS-mediated NLRP3 inflammasome activation in BV2 cells  
 Mitochondrial dynamics have been recently shown to modulate the microglial activation (Park 
et al., 2013).  Park et al demonstrated that LPS-mediated mitochondrial fission contributes to the 
activation of microglia, whereas pretreatment with Mdivi-1 (Mitochondrial division inhibitor 1) 
reduces the inflammatory activation (Park et al., 2013).  Mdivi-1 is direct an inhibitor of Drp-1, 
Dynamin-related protein 1, which is responsible for mitochondrial fission (Kim et al., 2017a; Park et 
al., 2013).  Dopaminergic neurons pretreated with Mdivi-1 shows reduced neurotoxicity (Cui et al., 
2010; Rappold et al., 2014).  Mdivi-1 has also been shown to reduce the ALS dysfunction and increase 
mitophagy, alleviating the removal of dysfunctional mitochondria (Gorojod et al., 2015; Wu et al., 
2018).  Even further, Mdivi-1 and other Drp-1 inhibitors have been shown to reduce the NLRP3 
inflammasome activation and release of inflammatory cytokines (Li et al., 2016a; Li et al., 2016c; Park 
et al., 2013).  Likewise, our immunoblotting results demonstrated that Mdivi-1 abrogated the NLRP3 
activation in LPS treated ROT primed BV2 cells (Fig. 8(A)).  We pretreated the BV2 cells with 5, 10 
or 25μM Mdivi-1 for an hour followed by treatment with ROT (200nM, 6h) and LPS (100ng/ml, 12h) 
and analyzed the cellular markers of NLRP3 inflammasome activation.  Our data showed 10, 16 and 
22% reduction in ROT/LPS-mediated NLRP3 induction in cells pretreated with 5, 10 and 25μM of 
Mdivi-1, respectively.  We also obsereved Mdivi-1-mediated dose-dependent reduction in secretion of 
NLRP3, casp-1 (p10) and IL-1β as analyzed by WB (Fig. 8(A), lower panel); and IL-1β and IL-18 
analyzed by ELISA (Fig. 8(B)) in media supernatants.  Additionally, we also noticed that Mdivi-1 
treatment reduced the activation of c-Abl kinase by 10-40% (Fig. 8(C)) and Cath B activation (Fig. 




that Mdiv-1-mediated mitophagy might be involved in suppressing the activation of NLRP3 
inflammasome in microglia. 
Mdivi-1 rescues the Parkin degradation in ROT/LPS exposed microglial cells 
 To further analyze the involvement of mitophagy in our system, we analyzed the protein 
expression of Parkin.  Parkin, an E3 ubiquitin ligase, is a cytosolic protein, however, upon activation, 
caused by mitochondrial damage, it gets recruited to mitochondrial outer membrane by PINK1 (Deas 
et al., 2011; Gegg and Schapira, 2011; Ivankovic et al., 2016).  Parkin then ubiquitinates the proteins in 
the mitochondrial outer membrane and tags them for autophagic clearance (Hwang et al., 2017; Kang 
et al., 2018; Olszewska and Lynch, 2016; Ordureau et al., 2014).   Accordingly, our data showed that 
parkin protein levels were decreased in BV2 microglial cells post ROT/LPS treatment in a time-
dependent pattern (Fig. 9(A)).  ROT treatment alone caused about 10% reduction and LPS caused 18, 
55 and 70% reduction at 6, 12 and 18h.  Interestingly, the ROT pre-exposure significantly (p<0.05) 
lowered the parkin levels post LPS treatment at 12h and 18h, compared with time-matched LPS alone 
group.   
Next, Mdivi-1 has been shown to improve the clearance of parkin-mediated damaged 
mitochondria in hippocampus (Kim et al., 2016) and reduces the autophagy dysfynction (Wu et al., 
2018).  On the contrary, other evidences demonstrate that Mdivi-1 reduces mitophagy and protects 
against toxicant mediated clearance of healthy mitochondria (Givvimani et al., 2012; Wu et al., 2018; 
Yang and Yang, 2013).  Interestingly, our results show Mdivi-1 significantly rescued the loss of parkin 






Parkin regulates the downstream activation of NLRP3 inflammasome induced by LPS in ROT-
primed BV2 cells 
 Next, to further analyze the role of parkin in our system, we transfected the BV2 cells with 
parkin WT, ubiquitin ligase hyperactive mutant (W403A) and ubiquitin ligase inactive mutant (C431S) 
of parkin.  Fig. 9(C) shows the level of parkin in BV2 microglial cells transfected with various 
constructs followed by treatment with ROT and LPS.  Intriguingly, our results revealed that cells 
transfected with parkin WT and W403A mutants has 2 times higher levels of parkin compared with EV 
group (p<0.05), whereas parkin C431S group had no change in parkin levels. 
 We then analyzed the activation pattern of NLRP3 inflammasome in aforementioned treatment 
groups.  Interestingly, our WB data demonstrated that ROT/LPS treated cells overexpressing the WT 
or W403A mutant abrogated the NLRP3 induction by 34 and 41%, respectively; whereas, C431S 
mutant expressing cells did not change the NLRP3 levels compared to EV group (Fig. 9(D)).  In 
addition, WB performed with supernatant concentrates showed that WT and W403A groups 
completely abrogated the release of NLRP3, casp 1 (p10) and IL-1β, but C431S mutants did not cause 
any significant change (Fig. 9(D), lower panel).  Also, ELISA analysis showed similar trend (Fig. 
9(E)), demonstrating >50% reduction in secreted IL-1b and IL-18 levels in parkin WT and W403A 
groups.   
 c-Abl phosphorylates parkin at Y143 residue and inactivates the protein, which in turn reduces 
level of mitochondrial biogenesis regulator (PGC-1a) contributing to greater mitochondrial 
dysfunction, oxidative stress and further activation of c-Abl (Dawson and Dawson, 2014).  
Accordingly, we demonstrated here that overexpressing the WT or hyper-ubiquitin active W403A, 
showed almost complete ablation of c-Abl phosphorylation in ROT/LPS treated BV2 cells (p<0.05) 




activation.  Following similar trend, we also noticed that WT and W403A groups had lower activation 
of cath B, whereas, C431S mutation increased the mature cath B levels post ROT/LPS exposure (Fig. 
9(G)).  Lastly, ROT/LPS-mediated increase in LC3B II and p62 levels were marginally reduced in 
parkin overexpressing and W403A expressing BV2 cells, while C431S expressing cells failed to 
demonstrate any change (Fig. 9(H)).  Taken together, our data show that ROT/LPS reduce the parkin 
levels, which may impede the clearance of impaired mitochondria by impairing ALS, contributing to 
NLRP3 induction. 
Acute LPS treatment exacerbates the ROT-mediated behavioral deficits in rats 
 ROT rat model of PD is believed to be one of the most accepted disease relevant animal 
models.  Studies demonstrate that ROT treatment in rats generates PD-like behavioral phenotypes 
(Cannon et al., 2009; Zhang et al., 2017); inclusion of α-Syn positive protein aggregates (Betarbet et 
al., 2006; Sherer et al., 2003d); increase oxidative stress and mitochondrial dysfunction in midbrain 
neurons (Betarbet et al., 2006; Karuppagounder et al., 2013; Panov et al., 2005; Sanchez-Reus et al., 
2007); and loss of TH positive neurons (Betarbet et al., 2006; Cannon et al., 2009; Sherer et al., 
2003d).  In particular, the chronic treatment of rats with ROT have been shown to generate several PD 
like neuropathophysiology. (Caboni et al., 2004a; Denny Joseph and Muralidhara, 2015; Marella et al., 
2008; Zhang et al., 2017).  Even more, ROT have been shown to also induce aberrant microglial 
activation in SNpc, which have been shown to significantly contribute to dopaminergic 
neurodegeneration (Huang et al., 2017; Sherer et al., 2003a).  On the other hand, LPS treatment have 
also been shown to cause substantial microglial activation and dopaminergic neurodegeneration in 
mice (Qin et al., 2007) as well as in rats (Chen et al., 2017; Choi et al., 2009; Huang et al., 2017; Shen 
et al., 2015) models of PD.  Interestingly, a recent study in rats demonstrated that a single systemic 
LPS (5mg/kg, i.p.) injection in adult rat potentiated the ROT (0.5mg/kg/d, 5d/wk for 4 wk, s.c.)-




Here, we used the similar treatment strategy with reversed the drug application: we treated the 
6 months old rats with ROT (0.5mg/kg/d) for 5d a week for 4 weeks subcutaneously and four weeks 
after last ROT injection, we gave a single intraperitoneal administration of LPS (5mg/kg).  24h post 
LPS injection, we analyzed the rat locomotor activity using VersaMax open field.  Fig. 10(A) shows 
the combined movement paths of animals in each treatment group.   Our results demonstrate that ROT 
alone treated animals had significant (p<0.001) lower locomotor activity with 58% lower vertical 
activity (Fig. 10(B)), 55% lower horizontal activity (Fig. 10(C)) and 70% reduction in total travelled 
distance (Fig. 10(D)) as compared with vehicle-treated control group.  Acute LPS treatment also 
caused aberrant depletion in aforementioned parameters by reducing vertical activity, horizontal 
activity and total length of travelled distance by 82, 86 and 91%, respectively, as compared with 
control group (Fig. 10(B,C,D)).  Notably, LPS treatment to ROT pretreated rats significantly depleted 
the locomotor activities even further compare to LPS alone (p<0.05), ROT alone (p<0.01) or control 
(p<0.0001) groups.  These evidences suggest that ROT perhaps sensitizes the dopaminergic system for 
LPS-mediated insult.  Hence, we further analyzed the biochemical alteration in SNpc lysates of these 
animals.  
ROT-mediated microglial activation and TH loss is aggravated by LPS in rat SNpc 
 Parkinsonian toxicant ROT has been shown to deplete the TH levels in rat midbrain region 
(Huang et al., 2017; Karuppagounder et al., 2013; Marella et al., 2008).  Consistent with this, we found 
that ROT treatment caused about 40% reduction in TH levels, however, LPS treatment had no effect 
on TH levels as analyzed by WB (Fig. 10(F)).  Intriguingly, rats treated with ROT and LPS had 
notably lower levels of TH as compare to all other three groups.  Densitometric analysis of normalized 
band intensity show that ROT+LPS group had 70% lower TH as compare to control or LPS group, and 




 Aberrant activation and accumulation of microglia in SNpc has been with both ROT (Huang et 
al., 2017; Sherer et al., 2003a) and LPS treatments (Lawana et al., 2017; Qin et al., 2007; Shen et al., 
2015) in vivo.  Similarly, rats exposed to chronic ROT treatment had 24 and 35% increase in IBA1 and 
iNOS protein levels, and acute LPS treatment caused 63 and 76% increase in IBA1 and iNOS protein 
levels, respectively, in SN lysates (Fig. 10(H)).  However, the animals treated with ROT+LPS had 140 
and 95% higher IBA1 and iNOS levels, respectively, significantly (p<0.05) greater than ROT or LPS 
alone groups.  Even more, qRT-PCR analysis showed similar trend for inflammatory markers (Fig. 
10(I-M)).  Our results show that LPS caused significant (p<0.05) increase in mRNA levels of TNFα 
(Fig 10(I)), NLRP3 (Fig. 10(J)), IL-1β (Fig. 10(K)), and NOS2 (Fig. 10(M)), however, ROT did not 
have any effect.  Following similar trend, ROT+LPS group showed significantly (p<0.01) greater 
increase in aforementioned mRNA levels compare to control and ROT.  Except NOS2, other markers 
did not show any difference between LPS and ROT+LPS groups.  Interestingly, casp 1 mRNA levels 
were not affected in any treatment groups (Fig. 10(L)), indicating posttranslational modification 
without affecting protein production.  Next, WB analysis of NLRP3 also had comparable outcomes 
(Fig. 10(N)).  We noticed that ROT alone and LPS alone groups had 18 and 54% higher protein levels 
of NLRP3, whereas, ROT+LPS had 125% more NLRP3 compared to control group.  These results, in 
combination, reveal that animals pre-exposed to dopaminergic toxicant have much greater 
susceptibility to endotoxin and can highten the dopaminergic neurodegeneration response. 
A single LPS injection infuriates the ROT-induced activation of c-Abl/cath B-mediated ALS 
dysfunction and α-Syn phosphorylation in rat SNpc 
 Our in vitro model demonstrates that microglial activation is modulated by c-Abl and cath B 
activity.  In a like manner, our in vivo data manifests similar trends.  Animals treated with ROT caused 
about 20-30% increase in phosphorylation (Y412 and Y245) and expression of c-Abl kinase in SN 




>120% increase in p-c-Abl (Y412 and Y245) as well as c-Abl, significantly more than control 
(p<0.0001), ROT (p<0.001) and LPS (p<0.01) treatment groups (Fig. 11(A)).  PKCδ, a substrate for c-
Abl kinase, showed similar trend, showing almost 100% more p-PKCδ (Y311) and PKCδ in 
ROT+LPS treatment group in comparison with vehicle-treated control.  
 Next, we analyzed the activation of cath B by determining the protein levels of cath B mature 
forms using WB method.  Our data demonstrate that ROT group had 37% higher and ROT+LPS group 
had 76% higher cath B (activated) levels.  Increase in mature cath B levels in ROT+LPS was greater 
than ROT and LPS alone groups, consistent with lysosomal dysregulation.  To further analyzed the 
autophagy dysfunction, we checked the protein levels of LC3B I/II and p62.  Our data demonstrate a 
marked (p<0.05) increase accumulation of LC3B II and p62 in both ROT and LPS groups (Fig. 11(C)), 
however, ROT + LPS treatment heightened the accumulation of these autophagic markers in SNpc of 
rats, suggesting an impaired ALS.  Further, we found that ROT increased the Y129 phosphorylation of 
α-Syn in SN lysates, however, LPS failed to exhibit any significant change.  Intriguingly, animals 
treated with ROT and then LPS caused significant greater Y129 phosphorylation of α-Syn compare to 
ROT alone group (p<0.01).  Collectively, combination of these data demonstrate that ROT toxicity is 
significantly worsen by single LPS exposure by hyperactiating c-Abl/cath B signal, leading to ALS 
dysfunction and α-Syn accumulation, responsible microglial activation and dopaminergic 
neurodegeneration. 
Discussion 
In the present study we used the ROT/LPS model to better understand the impact of prior 
exposure to a Parkinsonian toxicant on LPS-induced inflammatory response.  In addition, the 
downstream cell signaling events regulating ROT/LPS-induced microglial activation and dopaminergic 
neurotoxicity were investigated using both in vitro (microglial cells) and in vivo model (adult rats 




attenuates ROT/LPS-induced NLRP3 inflammasome activation partially through the restoration of 
autophagosomal lysosomal system (ALS) function and reinstatement of Parkin mediated mitophagy.  
Furthermore, analyses of ROS generation and mitochondrial function revealed that CA074 (cath B 
inhibitor) and DAS (c-Abl inhibitor) afforded anti-inflammatory effects via attenuation of ROS 
generation and mitochondria-mediated oxidative stress response.  Moreover, subjecting adult rats to 
sequential ROT and LPS treatment elicited marked activation of cath B with a concomitant depletion 
of DA, decreased locomotor activity, activation of PKCδ and c-Abl and accumulation of aggregated 
phospho α-synuclein (S129).  Taken together, our studies suggest that loss of lysosomal membrane 
permeability and concomitant cytosolic release of cath B might trigger mitochondrial oxidative stress 
response and resultant NLRP3 inflammasome activation and ultimately dopaminergic neurotoxicity in 
response to tandem exposure to ROT and LPS.   
 Exacerbated microglial activation has been implicated in the pathogenesis of many 
neurodegenerative diseases, including PD and AD (Dheen et al., 2007; Goldmann et al., 2013; Lull and 
Block, 2010; Tremblay et al., 2011).  In recent years, many cellular mechanisms have been shown to 
contribute to activation of microglia, including mitochondrial damage (Ferger et al., 2010; Moss and 
Bates, 2001), lysosomal dysfunction (Terada et al., 2010), activation of transcription factors 
(Kaltschmidt et al., 1997; Masuda et al., 2012), ER stress (Guo et al., 2015b) and inflammasome 
activation (Shi et al., 2012).  It is becoming clearer that multiple cellular mechanisms can in fact 
converge at a central target culminating in a heightened microglial activation response.  In recent years 
the activation of NLRP3 inflammasome complex has gained prominence as a likely convergence point 
and central mediator of inflammatory and pyroptotic pathways (Goldmann et al., 2013; Zhao et al., 
2015).  Researchers have shown that pathogen-associated and danger-associated molecular patterns 
(PAMPs and DAMPs, respectively) sequentially activate the NLRP3 activation (Jo et al., 2016; 




1, has been shown to precede the toxicant-mediated DAMP activation (signal 2) ultimately leading to 
inflammasome activation and release of inflammatory cytokines into the extracellular milieu (Jo et al., 
2016).  A study by Gustin et al. demonstrated that microglia primed LPS followed by ATP resulted in 
an exacerbated NLRP3 inflammasome activation and cleavage of pro-caspase-1 and pro-IL-1β to their 
respective mature forms (Gustin et al., 2015).  Another study performed in bone-marrow-derived 
macrophages (BMDMs) demonstrated that amyloid polypeptide-mediated inflammasome activation 
and IL-1β secretion require priming by LPS (Masters et al., 2010).  We recently showed that LPS 
primed microglia potentiated the ROT mediated activation of microglial NLRP3 inflammasomes 
(Lawana et al., 2017).  These studies demonstrate the synergistic effects of ROT/LPS on NLRP3 
inflammasome activation in microglial cells.  
A recent study demonstrated mitochondrial ROS (mtROS) can directly induce the NLRP3 
inflammasome activation (Juliana et al., 2012).  Juliana et al demonstrated that either LPS-mediated 
transcriptional priming or mitochondrial toxin-mediated non-transcriptional priming is crucial for 
NLRP3 inflammasome activation (Juliana et al., 2012).  Furthermore, mtROS-specific antioxidant, 
mitoTEMPO, has been shown to reduce the mitochondrial oxidative stress with a concomitant 
reduction in the activation of NLRP3 inflammasome (Juliana et al., 2012; Lawana et al., 2017).  
Accordingly, herein we show that sequential treatment with ROT and LPS increases the susceptibility 
of microglial cells to mitochondria-mediated oxidative stress thereby leading to a heightened 
inflammatory response. 
c-Abl kinase activation has been implicated in PD pathogenesis (Brahmachari et al., 2017).  
Phosphorylation of c-Abl at two tyrosine residues, Y245 and Y412, has been shown to activate the 
kinase activity of c-Abl and resulting downstream signaling pathways (Hantschel and Superti-Furga, 




phosphorylation of Y412 residue dramatically increased the catalytic activity of c-Abl, followed by 
Y245 phosphorylation (Brasher and Van Etten, 2000).  Several PD models demonstrate upregulated c-
Abl kinase activity in nigrostriatal regions (Brahmachari et al., 2016; Ko et al., 2010; Liu et al., 2012; 
Wu et al., 2016) as do brain samples collected from PD patients.  Additionally, inhibitor of c-Abl 
kinase or c-Abl KO have been shown to reduce the neurotoxicity induced by dopaminergic 
neurotoxicants (Hebron et al., 2013; Imam et al., 2013; Karuppagounder et al., 2014; Ko et al., 2010; 
Lindholm et al., 2016; Tanabe et al., 2014).  We recently demonstrated the upstream role of c-Abl in 
mediating LPS/ROT-induced microglial activation via an oxidative stress, mitochondrial damage and 
ALS dysfunction dependent manner (Lawana et al., 2017).  In our previous study, we showed that 
DAS pretreatment significantly reduced the NLRP3 inflammasome activation both in vitro as well as 
in vivo neuroinflammation models of PD (Lawana et al., 2017).  Consistent with our previous studies, 
we show that BV2 cells sequentially treated with ROT and LPS exhibits a time-dependent increase in 
c-Abl phosphorylation at Y412 and Y245 residues, respectively (Fig. 1(D)) and that DAS pretreatment 
reduced ROT/LPS-mediated oxidative stress, MMP loss and NLRP3 inflammasome activation (Fig. 2).   
Increased ROS and mitochondrial dysfunction have been shown to cause increase in lysosomal 
membrane permeabilization (LMP), leading to lysosomal dysfunction (Guicciardi et al., 2004; Heid et 
al., 2013; Kiffin et al., 2006).  Furthermore, in a ROT model of PD, impaired lysosomal activity has 
been demonstrated previously (Wu et al., 2015a).  Also, LPS exposure have been shown to increase the 
lysosomal pH thereby leading to lysosomal dysfunction (Forestier et al., 1999; Porte et al., 2003; 
Riches and Henson, 1986; Wang et al., 2016).  Additionally, our recent paper demonstrated that 
exposure of microglial cells to ROT and LPS led to a reduction in the level of TFEB, a lysosomal 
biogenesis regulator, indicating impairment in lysosomal function.  Likewise, our data showed that 
exposure of BV2 microglial cells to ROT and LPS in tandem resulted in lysosomal dysfunction (Fig. 




Furthermore, our confocal analysis and EM studies further validated ROT/LPS-induced accumulation 
of acidic vacuoles owing to an impairment in the lysosomal clearance mechanism.  Increased LMP and 
lysosomal damage leads to release of cath B into the cytoplasm, which has been shown to activate the 
NLRP3 inflammasome (Hornung and Latz, 2010; Talukdar et al., 2016; Yin et al., 2013).  Treatment 
of LPS-primed microglia with pathogenic Aβ, have been shown to cause activation and cytoplasmic 
translocation of cath B (Taneo et al., 2015).  Likewise, in the present study we demonstrated that 
exposure to ROT/LPS caused aberrant increase in cath B activity, increased expression of mature cath 
B, as well as cytosolic release of mature cath B.  Interestingly, Fiore et al recently showed that c-Abl 
can activate the cathepsins B and L by promoting their endosomal maturation (Fiore et al., 2014).  Our 
studies are in line with these findings whereby DAS, was found to inhibit autophagosomal lysosomal 
system (ALS) dysfunction.  In this context, we demonstrated that DAS significantly inhibited 
lysosomal permeability (LMP) thereby preventing ROT/LPS-induced cytosolic release of cath B (Fig. 
3(E,F,G,H)). 
A recent report showed that CA074, a pharmacological inhibitor, reduced the LPS-mediated 
inflammatory response in T cells (Wynick et al., 2016).  Several other studies also demonstrate that 
cath B inhibition or genetic knockdown reduces the activation of NLRP3 inflammasome (Bruchard et 
al., 2013; Chu et al., 2009; Duncan et al., 2009; Hoegen et al., 2011; Li et al., 2018).  Additionally, 
CA074 have been shown to reduce oxidative stress, mitochondrial damage and LMP (Fujisawa et al., 
2007; Nagakannan and Eftekharpour, 2017).  Likewise, we demonstrated that non-toxic concentrations 
of CA074 dramatically reduced the ROT/LPS-induced ROS generation, mitochondrial membrane 
depolarization and improved lysosomal function in BV2 cells (Fig. 4(D-H)).  Given that cath B can 
induce mitochondrial oxidative stress (Fujisawa et al., 2007), we also analyzed the level of 
mitochondrial superoxide in cells exposed to ROT and LPS.  Our results showed that ROT/LPS 




pretreatment (Fig. 4(E)).  Furthermore, using subcellular fractionation and ICC, we demonstrate that 
CA074 blocked ROT/LPS-induced cytosolic release of cath B (Fig. 6(E,F)). 
The exact contribution of autophagy in cell homeostasis remains elusive; however, impaired 
ALS has been shown to promote microglia activation (Cho et al., 2014; Kim et al., 2017b; Su et al., 
2016).  Also, we recently showed that ROT caused ALS dysfunction in LPS-primed microglia leading 
to NLRP3 activation (Lawana et al., 2017).  Cath B release in cytoplasm via LMP (Nagakannan and 
Eftekharpour, 2017), may lead to ALS deregulation thereby resulting in excessive accumulation of 
AVs,  as indicated by the accumulation of p62 (which anchors the non-degraded ubiquitin-bound 
proteins to autophagosomes) (Bjorkoy et al., 2009; Zhang et al., 2016).  Following autophagosome-
lysosome fusion, LC3B II and p62 are readily degraded, however, in case of impaired ALS these 
markers get accumulated (Bjorkoy et al., 2009; Lawana et al., 2018; Lim et al., 2011).  Furthermore, 
lysosomal function is tightly regulated by transcription factor EB (TFEB), which plays a key role in 
the biogenesis of lysosomes (Settembre et al., 2011).  Depletion of TFEB can also contribute to 
defective ALS.  In fact, in our previous study using BV2 microglia exposed to LPS/ROT, we 
demonstrated increased levels of LC3B II and p62 with a concomitant downregulation of TFEB levels 
(Lawana et al., 2017).  Our current data closely parallels our previous publication, showing 
dysregulated ALS.  Additionally, we also demonstrated that DAS reduced ROT/LPS-mediated LC3B 
II and p62 levels (Fig. 3(I)).  Furthermore, CA074 pretreatment mitigated the ROT/LPS-induced ALS 
malfunction and reduced the accumulation of AVs as assessed via levels of LC3B II and p62 in 
ROT/LPS treated microglia (Fig. 4(J), 6(I)).  Further, our ICC images showed that CA074 –induced 
marked nuclear translocation of TFEB further supporting the reversal of ROT/LPS-induced lysosomal 
dysfunction (Fig. 6(J)). 
  The link between mitochondrial dysfunction microglial activation response presumably via 




contribution of impairment in mitochondrial dynamics in microglial activation response remain poorly 
understood.  Mitochondrial fission and fusion regulate the mitochondrial integrity in the cells.  
Dynamin-related protein 1 (Drp1), a member of Dynamin GTPase family, causes mitochondrial 
fragmentation thereby leading to mitochondrial fission.  Recently,  excessive Drp1 activation via 
induction of microglial fission has been implicated in a heightened inflammatory response (Chae et al., 
2017; Park et al., 2017) and cell death (Xie et al., 2014; Ye et al., 2016).  On the contrary 
dopaminergic neurons harvested from Drp1 KO mice exhibit elongated and interconnected 
mitochondrial structure with reduced mitochondrial ROS generation (Wiemerslage and Lee, 2016).  
Mdivi-1 (mitochondrial division inhibitor 1) inhibits mitochondrial fission by blocking the Drp1.  Park 
et al showed that LPS treatment activates Drp1, which then gets translocated to mitochondria to initiate 
the mitochondrial fission thereby leading to excessive ROS generation and induction of gene 
transcription of inflammatory markers (Park et al., 2013).  However, Mdivi-1 or Drp1 KD cells 
showed lower induction of TNFα, iNOS, IL-1β and other inflammatory genes (Park et al., 2013).   
Additionally, another study showed that Mdivi-1 also inhibited the NLRP3 inflammasome activation 
and release of IL-1β and Il-18 by mitigating mitochondrial dysfunction in rat aortic endothelial cells 
(Li et al., 2016c).  Likewise, our study showed that Mdivi-1 reduced the NLRP3 induction and 
inflammasome activation with a concomitant reduction in cytokine secretion in addition to inhibition 
of ROT/LPS-induced activation of c-Abl and cath B (Fig. 8).  Future studies are needed to unravel the 
cell signaling events underlying Mdivi-1-induced anti-inflamamtory response. 
Impairment in mitophagy process has been implicated in NLRP3 inflammasome activation 
(Zhou et al., 2011).  PINK1-dependent recruitment of parkin to depolarized mitochondria has been 
shown to promote the autophagic clearance of damaged mitochondria (Amadoro et al., 2014; Panicker 
et al., 2017).  Loss of parkin has been shown to promote increased generation of mitochondrial ROS 




protective effects by degrading Drp1 in mouse neuroblastoma cells (Tang et al., 2016).  Intriguingly, 
microglia and macrophages exposed to LPS or TNFα shows marked reduction in parkin levels via an 
NF-κB-dependent mechanism (Tran et al., 2011).  Likewise, we discovered LPS-mediated time-
dependent decrease in parkin levels in ROT/LPS treated BV2 cells that positively correlated with NF-
κB activation (Sup. Fig. 1).   Several mutations in parkin have been shown to modulate the activity of 
parkin.  The W403A mutant of parkin has higher autoubiquitin ability and gets recruited by 
mitochondria faster, causing increased parkin-mediated mitophagy (Tang et al., 2017; Trempe et al., 
2013).  Whereas, mutating putative catalytic site (C431S) has been shown to reduce parkin 
translocation to mitochondria and possessed lower ubiquitin activity (Zheng and Hunter, 2013).  
Furthermore, loss of parkin impairs mitophagy thereby leading to the enhancement of mitochondria-
mediated oxidative stress (Tanaka, 2010).  Moreover, parkin deficient macrophages show aberrant 
increase in NLRP3 activity (Minton, 2016).  Herein we show that WT and W403 mutant parkin 
expressing cells had lower NLRP3 inflammasome activity concomitant with reduced activation of c-
Abl/cath B, consistent with improved mitophagy.  On the other hand, C431S mutant potentiated the 
ROT/LPS-mediated activation of c-Abl, cath B and NLRP3 inflammasomes consistent with impaired 
recruitment of Parkin to damaged mitochondria thereby leading to mitophagy dysfunction.  These data 
further illustrate the pivotal role of Parkin in limiting microglial activation response. 
 Emerging evidences draws attention towards the impact of systemic infection in 
neurodegenerative diseases, especially PD (Chiang et al., 2017; Collins et al., 2012; Ferrari and Tarelli, 
2011; Perry, 2004; Yu et al., 2016).  Almost one third of PD patients have been found to be positive for 
Helicobacter pylori infection which correlated with worsening of PD-associated motor deficits (Huang 
et al., 2018; Tan et al., 2015).  In another study, Hepatitis C viral infection in rats was found to kill 
more than 60% of dopaminergic neurons with an accompanying elevation of cytokines levels in the 




nigral neuroinflammation followed by loss of dopaminergic neurons (Lawana et al., 2017; Qin et al., 
2007).  Next, rats exposed to ROT systemically show specific loss of dopaminergic neurons, with 
increased accumulation of insoluble α-Syn and increased microgliosis (Caboni et al., 2004b; Cannon et 
al., 2009; Greenamyre et al., 2010; Monti et al., 2010; Sherer et al., 2003b).  Consistent with these 
studies, a close parallelism between microglial activation, dopaminergic neurotoxicity, and 
neurobehavioral deficits was evidenced in ROT/LPS treated rats suggesting that systemic infection has 
detrimental impact on dopaminergic neuronal wellbeing especially under conditions of perturbed 
dopaminergic neuronal function.  
A recent study showed exposure to LPS during adulthood followed by ROT caused dramatic 
increase in microglial activation and loss of dopaminergic neurons in the rat nigrostriatal regions 
(Huang et al., 2017).  Likewise, in the present study we treated six months old adult rats with 
0.5mg/kg/d ROT for 5d/wk for 4 weeks, subcutaneously.  Four weeks after last ROT injection, we 
administered 5mg/kg LPS (intraperitoneally) and 24h post LPS, rats were subjected to behaviour 
analysis and scarified for biochemical testing of SNpc and striatum.  In line with previous findings, 
chronic ROT exposure reduced the locomotor activity of rats (Cannon et al., 2009; Huang et al., 2017; 
Sonia Angeline et al., 2012).  LPS causes septic shock and dramatically reduces the animal activity 
(Mignon et al., 1999; Ritter et al., 2004; Yeom et al., 2017).  We recently showed that mice exposed to 
LPS for 24h had significant reduction in locomotor behavior (Lawana et al., 2017).  Similarly, in the 
present study we observed that rats exposed to LPS were lethargic.  Intriguingly, we noticed that rats 
pre-exposed to ROT followed by LPS displayed pronounced impaired horizontal and vertical activity 
with marked reduction in total distance travelled compared with vehicle-treated control, ROT-alone or 
LPS-alone groups (Fig. 10(A-D)).  Our previous study showed that acute LPS exposure caused 
hyperactivation of c-Abl with a concomitant impairment in ALS (Lawana et al., 2017).  In line with 




loss of TH levels, increased expression of neuroinflammatory markers in the SN (Fig. 10(E-L)).  In 
addition, ROT+LPS treatment significantly induced the activation of c-Abl and cath B with a 
concomitant increase in autophagy related markers.  Additionally, these changes were accompanied by 
marked reduction in striatal neurotransmitters, DA and DOPAC as compared with control animals 
(Fig. 10(E)).  
Post-mortem analysis of PD brains shows increased phosphorylation of α-Syn at serine 129 
residue (Anderson et al., 2006; Fujiwara et al., 2002; Mahul-Mellier et al., 2014).  Phosphorylation of 
α-Syn at S129 regulates its clearance though both UPS and autophagic pathways (Machiya et al., 2010; 
Oueslati et al., 2013).  A recent study showed that ROT exposure in rats also increases the p-α-Syn 
S129 levels in nigrostriatal neurons (Di Maio et al., 2016).  Similarly, we demonstrated here that 
exposure to ROT increased the S129 phosphorylation of α-Syn in nigral tissue.  Interestingly, our 
results showed that ROT+LPS treated rats exhibited even greater phosphorylation of α-Syn (Fig. 
10(G)).  Although, the exact role of hyperphosphorylated α-Syn in our model needs further 
investigation, our data demonstrate that chronic low dose exposure to ROT and acute LPS renders 
dopaminergic neurons more vulnerable to neuroinflammation-induced neuronal injury presumably via 
excessive microglial activation response. 
Using a ROT/LPS tandem treatment protocol in microglial cells for the first time we 
demonstrate synergistic microglial activation following exposure to a pesticide (ROT) and 
inflammagen (LPS).  Additionally, activation of c-Abl and cath B appears to be critical mediators of 
microglial NLRP3 inflammasome activation response through deregulated Parkin-dependent 
mitophagy and increased mitochondrial oxidative stress.  Furthermore, our in vivo studies suggest a 
model whereby cath B activation might be a key mediator of ROT/LPS-induced exaggerated 
dopaminergic neuronal loss and resultant neurobehavioral deficits presumably via accumulation of p-




inflammasome activation via c-Abl and cath B.  Improved understanding of the mechanistic basis of 
ROT/LPS-induced microglial activation response may lead the identification of effective strategies to 
stop the initiation and progression of this PD. 
References 
Allen, I. C., et al., 2009. The NLRP3 Inflammasome Mediates In Vivo Innate Immunity to Influenza A 
Virus through Recognition of Viral RNA. Immunity. 30, 556-565. 
Amadoro, G., et al., 2014. Morphological and bioenergetic demands underlying the mitophagy in post-
mitotic neurons: the pink-parkin pathway. Front Aging Neurosci. 6, 18. 
Anderson, J. P., et al., 2006. Phosphorylation of Ser-129 is the dominant pathological modification of 
alpha-synuclein in familial and sporadic Lewy body disease. Journal of Biological Chemistry. 
281, 29739-29752. 
Banerjee, R., et al., 2010. Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic 
implications. Trends Neurosci. 33, 541-9. 
Baroja-Mazo, A., et al., 2014. The NLRP3 inflammasome is released as a particulate danger signal that 
amplifies the inflammatory response. Nat Immunol. 15, 738-748. 
Benskey, M., et al., 2013. Sustained resistance to acute MPTP toxicity by hypothalamic dopamine 
neurons following chronic neurotoxicant exposure is associated with sustained up-regulation of 
parkin protein. Neurotoxicology. 37, 144-53. 
Betarbet, R., et al., 2006. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of 
the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. 
Neurobiol Dis. 22, 404-20. 
Binukumar, B. K., et al., 2010. Nigrostriatal neuronal death following chronic dichlorvos exposure: 
crosstalk between mitochondrial impairments, alpha synuclein aggregation, oxidative damage 
and behavioral changes. Molecular Brain. 3. 
Bjorkoy, G., et al., 2009. Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol. 
452, 181-97. 
Block, M. L., et al., 2007. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. 
Nat Rev Neurosci. 8, 57-69. 
Boya, P., et al., 2003. Lysosomal membrane permeabilization induces cell death in a mitochondrion-
dependent fashion. Journal of Experimental Medicine. 197, 1323-1334. 
Brahmachari, S., et al., 2016. Activation of tyrosine kinase c-Abl contributes to alpha-synuclein-
induced neurodegeneration. J Clin Invest. 126, 2970-88. 
Brahmachari, S., et al., 2017. c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential. J 




Brasher, B. B., Van Etten, R. A., 2000. c-Ab1 has high intrinsic tyrosine kinase activity that is 
stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two 
distinct regulatory tyrosines. Journal of Biological Chemistry. 275, 35631-35637. 
Brookmeyer, R., et al., 2007. Forecasting the global burden of Alzheimer's disease. Alzheimers 
Dement. 3, 186-91. 
Broz, P., Monack, D. M., 2011. Molecular mechanisms of inflammasome activation during microbial 
infections. Immunol Rev. 243, 174-90. 
Bruchard, M., et al., 2013. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor 
cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med. 19, 57-64. 
Bruggemann, N., Klein, C., Parkin Type of Early-Onset Parkinson Disease. In: M. P. Adam, et al., 
(Eds.), GeneReviews((R)), Seattle (WA), 1993. 
Buttle, D. J., et al., 1992. CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch 
Biochem Biophys. 299, 377-80. 
Caboni, P., et al., 2004a. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's 
disease. Chem Res Toxicol. 17, 1540-8. 
Caboni, P., et al., 2004b. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's 
disease. Chemical Research in Toxicology. 17, 1540-1548. 
Campdelacreu, J., 2014. Parkinson's disease and Alzheimer disease: environmental risk factors. 
Neurología (English Edition). 29, 541-549. 
Cannon, J. R., et al., 2009. A highly reproducible rotenone model of Parkinson's disease. Neurobiol 
Dis. 34, 279-90. 
Chae, U., et al., 2017. Chrysophanol suppresses pro-inflammatory response in microglia via regulation 
of Drp1-dependent mitochondrial fission. Immunopharmacology and Immunotoxicology. 39, 
268-275. 
Chen, G., et al., 2017. Galangin Reduces the Loss of Dopaminergic Neurons in an LPS-Evoked Model 
of Parkinson's Disease in Rats. Int J Mol Sci. 19. 
Chiang, P. L., et al., 2017. White matter damage and systemic inflammation in Parkinson's disease. 
BMC Neurosci. 18, 48. 
Cho, M. H., et al., 2014. Autophagy in microglia degrades extracellular beta-amyloid fibrils and 
regulates the NLRP3 inflammasome. Autophagy. 10, 1761-1775. 
Choi, D. Y., et al., 2009. Striatal neuroinflammation promotes Parkinsonism in rats. PLoS One. 4, 
e5482. 
Chu, J., et al., 2009. Cholesterol-dependent cytolysins induce rapid release of mature IL-1beta from 
murine macrophages in a NLRP3 inflammasome and cathepsin B-dependent manner. J Leukoc 
Biol. 86, 1227-38. 
Codolo, G., et al., 2013. Triggering of Inflammasome by Aggregated alpha-Synuclein, an 




Collins, L. M., et al., 2012. Contributions of central and systemic inflammation to the pathophysiology 
of Parkinson's disease. Neuropharmacology. 62, 2154-68. 
Cui, M., et al., 2010. Perturbations in Mitochondrial Dynamics Induced by Human Mutant PINK1 Can 
Be Rescued by the Mitochondrial Division Inhibitor mdivi-1. Journal of Biological Chemistry. 
285, 11740-11752. 
Dawson, T. M., Dawson, V. L., 2014. Parkin plays a role in sporadic Parkinson's disease. 
Neurodegener Dis. 13, 69-71. 
de Rivero Vaccari, J. P., et al., 2014. Activation and regulation of cellular inflammasomes: gaps in our 
knowledge for central nervous system injury. J Cereb Blood Flow Metab. 34, 369-75. 
Deas, E., et al., 2011. Mitophagy and Parkinson's disease: the PINK1-parkin link. Biochim Biophys 
Acta. 1813, 623-33. 
Deng, H., et al., 2007. A family with Parkinson disease, essential tremor, bell palsy, and parkin 
mutations. Arch Neurol. 64, 421-4. 
Denny Joseph, K. M., Muralidhara, 2015. Combined oral supplementation of fish oil and quercetin 
enhances neuroprotection in a chronic rotenone rat model: relevance to Parkinson's disease. 
Neurochem Res. 40, 894-905. 
Dheen, S. T., et al., 2007. Microglial activation and its implications in the brain diseases. Curr Med 
Chem. 14, 1189-97. 
Di Maio, R., et al., 2016. alpha-Synuclein binds to TOM20 and inhibits mitochondrial protein import 
in Parkinson's disease. Sci Transl Med. 8, 342ra78. 
Dranka, B. P., et al., 2012. Alterations in bioenergetic function induced by Parkinson's disease mimetic 
compounds: lack of correlation with superoxide generation. J Neurochem. 122, 941-51. 
Duncan, J. A., et al., 2009. Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the 
signaling activities of the NLRP3 and ASC-containing inflammasome. J Immunol. 182, 6460-
9. 
Ferger, A. I., et al., 2010. Effects of mitochondrial dysfunction on the immunological properties of 
microglia. J Neuroinflammation. 7, 45. 
Ferrari, C. C., Tarelli, R., 2011. Parkinson's disease and systemic inflammation. Parkinsons Dis. 2011, 
436813. 
Fiore, L. S., et al., 2014. c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the 
NM23-H1 metastasis suppressor in invasive cancer. Oncogene. 33, 4508-4520. 
Forestier, C., et al., 1999. Lysosomal accumulation and recycling of lipopolysaccharide to the cell 
surface of murine macrophages, an in vitro and in vivo study. J Immunol. 162, 6784-91. 
Frank-Cannon, T. C., et al., 2008. Parkin deficiency increases vulnerability to inflammation-related 
nigral degeneration. J Neurosci. 28, 10825-34. 
Fujisawa, A., et al., 2007. Disease-associated mutations in CIAS1 induce cathepsin B-dependent rapid 




Fujiwara, H., et al., 2002. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nature Cell 
Biology. 4, 160-164. 
Gao, F., et al., 2013. Rotenone directly induces BV2 cell activation via the p38 MAPK pathway. PLoS 
One. 8, e72046. 
Gao, H. M., et al., 2002. Distinct role for microglia in rotenone-induced degeneration of dopaminergic 
neurons. J Neurosci. 22, 782-90. 
Gegg, M. E., Schapira, A. H., 2011. PINK1-parkin-dependent mitophagy involves ubiquitination of 
mitofusins 1 and 2: Implications for Parkinson disease pathogenesis. Autophagy. 7, 243-5. 
Ghavami, S., et al., 2014. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog 
Neurobiol. 112, 24-49. 
Ghosh, A., et al., 2012. Anti-inflammatory and neuroprotective effects of an orally active apocynin 
derivative in pre-clinical models of Parkinson's disease. J Neuroinflammation. 9, 241. 
Givvimani, S., et al., 2012. Mitochondrial division/mitophagy inhibitor (Mdivi) ameliorates pressure 
overload induced heart failure. PLoS One. 7, e32388. 
Goldmann, T., et al., 2013. Love and death: microglia, NLRP3 and the Alzheimer's brain. Cell Res. 23, 
595-6. 
Gonfloni, S., et al., 2012. Oxidative Stress, DNA Damage, and c-Abl Signaling: At the Crossroad in 
Neurodegenerative Diseases? Int J Cell Biol. 2012, 683097. 
Gorbatyuk, O. S., et al., 2008. The phosphorylation state of Ser-129 in human alpha-synuclein 
determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A. 
105, 763-8. 
Gordon, R., et al., 2016a. Prokineticin-2 upregulation during neuronal injury mediates a compensatory 
protective response against dopaminergic neuronal degeneration. Nat Commun. 7, 12932. 
Gordon, R., et al., 2016b. Protein kinase Cdelta upregulation in microglia drives neuroinflammatory 
responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease. 
Neurobiol Dis. 93, 96-114. 
Gorojod, R. M., et al., 2015. The autophagic- lysosomal pathway determines the fate of glial cells 
under manganese- induced oxidative stress conditions. Free Radic Biol Med. 87, 237-51. 
Goyal, S., et al., 2015. Involvement of cathepsin B in mitochondrial apoptosis by p-phenylenediamine 
under ambient UV radiation. Journal of Hazardous Materials. 300, 415-425. 
Greenamyre, J. T., et al., 2010. Lessons from the rotenone model of Parkinson's disease. Trends in 
Pharmacological Sciences. 31, 141-142. 
Guicciardi, M. E., et al., 2000. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis 
by promoting mitochondrial release of cytochrome c. Journal of Clinical Investigation. 106, 
1127-1137. 




Guo, H., et al., 2015a. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat 
Med. 21, 677-87. 
Guo, M. L., et al., 2015b. Cocaine-mediated microglial activation involves the ER stress-autophagy 
axis. Autophagy. 11, 995-1009. 
Gurung, P., et al., 2015. Mitochondria: diversity in the regulation of the NLRP3 inflammasome. 
Trends Mol Med. 21, 193-201. 
Gustin, A., et al., 2015. NLRP3 Inflammasome Is Expressed and Functional in Mouse Brain Microglia 
but Not in Astrocytes. PLoS One. 10, e0130624. 
Halle, A., et al., 2008a. The NALP3 inflammasome is involved in the innate immune response to 
amyloid-beta. Nat Immunol. 9, 857-65. 
Halle, A., et al., 2008b. The NALP3 inflammasome is involved in the innate immune response to 
amyloid-beta. Nature Immunology. 9, 857-865. 
Hantschel, O., Superti-Furga, G., 2004. Regulation of the C-Abl and Bcr-Abl tyrosine kinases. Nature 
Reviews Molecular Cell Biology. 5, 33-44. 
Hebron, M. L., et al., 2013. Nilotinib reverses loss of dopamine neurons and improves motor behavior 
via autophagic degradation of -synuclein in Parkinsons disease models. Human Molecular 
Genetics. 22, 3315-3328. 
Heid, M. E., et al., 2013. Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal 
damage and inflammasome activation. J Immunol. 191, 5230-8. 
Hirsch, E. C., Hunot, S., 2009. Neuroinflammation in Parkinson's disease: a target for neuroprotection? 
Lancet Neurol. 8, 382-97. 
Hirsch, E. C., et al., 2012. Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord. 18 
Suppl 1, S210-2. 
Hoegen, T., et al., 2011. The NLRP3 inflammasome contributes to brain injury in pneumococcal 
meningitis and is activated through ATP-dependent lysosomal cathepsin B release. J Immunol. 
187, 5440-51. 
Holzinger, D., et al., 2012. Staphylococcus aureus Panton-Valentine leukocidin induces an 
inflammatory response in human phagocytes via the NLRP3 inflammasome. J Leukoc Biol. 92, 
1069-81. 
Hornung, V., et al., 2008. Silica crystals and aluminum salts activate the NALP3 inflammasome 
through phagosomal destabilization. Nature Immunology. 9, 847-856. 
Hornung, V., Latz, E., 2010. Critical functions of priming and lysosomal damage for NLRP3 
activation. Eur J Immunol. 40, 620-3. 
Huang, C., et al., 2017. Adulthood Exposure to Lipopolysaccharide Exacerbates the Neurotoxic and 




Huang, H. K., et al., 2018. Helicobacter pylori infection is associated with an increased risk of 
Parkinson's disease: A population-based retrospective cohort study. Parkinsonism Relat Disord. 
47, 26-31. 
Huaux, F., 2018. Innate immunity to inhaled particles: A new paradigm of collective recognition. 
Current Opinion in Toxicology. 10, 84-90. 
Huo, Y., et al., 2011. Dexamethasone inhibits the Nox-dependent ROS production via suppression of 
MKP-1-dependent MAPK pathways in activated microglia. BMC Neurosci. 12, 49. 
Hwang, C. J., et al., 2017. Parkin deficiency exacerbate ethanol-induced dopaminergic 
neurodegeneration by P38 pathway dependent inhibition of autophagy and mitochondrial 
function. Redox Biol. 11, 456-468. 
Imam, S. Z., et al., 2013. Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a 
murine Parkinson's disease model. PLoS One. 8, e65129. 
Imam, S. Z., et al., 2011. Novel regulation of parkin function through c-Abl-mediated tyrosine 
phosphorylation: implications for Parkinson's disease. J Neurosci. 31, 157-63. 
Ivankovic, D., et al., 2016. Mitochondrial and lysosomal biogenesis are activated following 
PINK1/parkin-mediated mitophagy. J Neurochem. 136, 388-402. 
Jackson-Lewis, V., et al., 2012. Animal models of Parkinson's disease. Parkinsonism Relat Disord. 18 
Suppl 1, S183-5. 
Jenner, P., 2007. Oxidative stress and Parkinson's disease. Handb Clin Neurol. 83, 507-20. 
Jing, Z., et al., 2009. Altered subcellular distribution of c-Abl in Alzheimer's disease. J Alzheimers 
Dis. 17, 409-22. 
Jo, E. K., et al., 2016. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol 
Immunol. 13, 148-59. 
Joly, S., Sutterwala, F. S., 2010. Fungal pathogen recognition by the NLRP3 inflammasome. 
Virulence. 1, 276-80. 
Juliana, C., et al., 2012. Non-transcriptional priming and deubiquitination regulate NLRP3 
inflammasome activation. J Biol Chem. 287, 36617-22. 
Kaltschmidt, B., et al., 1997. Transcription factor NF-kappaB is activated in primary neurons by 
amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer 
disease. Proc Natl Acad Sci U S A. 94, 2642-7. 
Kang, C., et al., 2018. Deficit in PINK1/PARKIN-mediated mitochondrial autophagy at late stages of 
dystrophic cardiomyopathy. Cardiovasc Res. 114, 90-102. 
Kang, R., et al., 2011. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 18, 
571-80. 
Kanthasamy, A. G., et al., 2003. Role of proteolytic activation of protein kinase Cdelta in oxidative 




Kanthasamy, A. G., et al., 2008. Environmental neurotoxin dieldrin induces apoptosis via caspase-3-
dependent proteolytic activation of protein kinase C delta (PKCdelta): Implications for 
neurodegeneration in Parkinson's disease. Mol Brain. 1, 12. 
Karuppagounder, S. S., et al., 2014. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a 
preclinical animal model of Parkinson's disease. Sci Rep. 4, 4874. 
Karuppagounder, S. S., et al., 2013. Quercetin up-regulates mitochondrial complex-I activity to protect 
against programmed cell death in rotenone model of Parkinson's disease in rats. Neuroscience. 
236, 136-48. 
Kauppinen, A., et al., 2012. Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells--
implications for age-related macular degeneration (AMD). Immunol Lett. 147, 29-33. 
Keeney, P. M., et al., 2009. Cybrid models of Parkinson's disease show variable mitochondrial 
biogenesis and genotype-respiration relationships. Exp Neurol. 220, 374-82. 
Khandelwal, P. J., et al., 2010. Parkinson-related parkin reduces alpha-Synuclein phosphorylation in a 
gene transfer model. Mol Neurodegener. 5, 47. 
Kiffin, R., et al., 2006. Oxidative stress and autophagy. Antioxid Redox Signal. 8, 152-62. 
Kim, H., et al., 2016. A mitochondrial division inhibitor, Mdivi-1, inhibits mitochondrial 
fragmentation and attenuates kainic acid-induced hippocampal cell death. BMC Neurosci. 17, 
33. 
Kim, H., et al., 2017a. Erratum to: A mitochondrial division inhibitor, Mdivi-1, inhibits mitochondrial 
fragmentation and attenuates kainic acid-induced hippocampal cell death. BMC Neurosci. 18, 
16. 
Kim, H. J., et al., 2017b. Deficient autophagy in microglia impairs synaptic pruning and causes social 
behavioral defects. Molecular Psychiatry. 22, 1576-1584. 
Kim, Y. S., Joh, T. H., 2006. Microglia, major player in the brain inflammation: their roles in the 
pathogenesis of Parkinson's disease. Exp Mol Med. 38, 333-47. 
Kingham, P. J., Pocock, J. M., 2001. Microglial secreted cathepsin B induces neuronal apoptosis. J 
Neurochem. 76, 1475-84. 
Kirkegaard, T., Jaattela, M., 2009. Lysosomal involvement in cell death and cancer. Biochim Biophys 
Acta. 1793, 746-54. 
Kitazawa, M., et al., 2001. Dieldrin-induced oxidative stress and neurochemical changes contribute to 
apoptopic cell death in dopaminergic cells. Free Radic Biol Med. 31, 1473-85. 
Ko, H. S., et al., 2010. Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's 
ubiquitination and protective function. Proc Natl Acad Sci U S A. 107, 16691-6. 
Kowal, S. L., et al., 2013. The current and projected economic burden of Parkinson's disease in the 
United States. Mov Disord. 28, 311-8. 




Langley, M. R., et al., 2017. Manganese exposure exacerbates progressive motor deficits and 
neurodegeneration in the MitoPark mouse model of Parkinson's disease: Relevance to gene and 
environment interactions in metal neurotoxicity. Neurotoxicology. 
Law, B. Y., et al., 2014. Natural small-molecule enhancers of autophagy induce autophagic cell death 
in apoptosis-defective cells. Sci Rep. 4, 5510. 
Lawana, V., et al., 2018. Organophosphate pesticide chlorpyrifos impairs STAT1 signaling to induce 
dopaminergic neurotoxicity: Implications for mitochondria mediated oxidative stress signaling 
events. Neurobiol Dis. 117, 82-113. 
Lawana, V., et al., 2017. Involvement of c-Abl Kinase in Microglial Activation of NLRP3 
Inflammasome and Impairment in Autolysosomal System. J Neuroimmune Pharmacol. 
Lee, V. M. Y., Trojanowski, J. Q., 2006. Mechanisms of Parkinson's disease linked to pathological 
alpha-synuclein: New targets for drug discovery. Neuron. 52, 33-38. 
Levine, B., Klionsky, D. J., 2004. Development by self-digestion: molecular mechanisms and 
biological functions of autophagy. Dev Cell. 6, 463-77. 
Li, A., et al., 2016a. Metformin and resveratrol inhibit Drp1-mediated mitochondrial fission and 
prevent ER stress-associated NLRP3 inflammasome activation in the adipose tissue of diabetic 
mice. Mol Cell Endocrinol. 434, 36-47. 
Li, M., et al., 2016b. Melatonin antagonizes cadmium-induced neurotoxicity by activating the 
transcription factor EB-dependent autophagy-lysosome machinery in mouse neuroblastoma 
cells. Journal of Pineal Research. 61, 353-369. 
Li, S., et al., 2018. Leptospira interrogans infection leads to IL-1β and IL-18 secretion from a human 
macrophage cell line through reactive oxygen species and cathepsin B mediated-NLRP3 
inflammasome activation. Microbes and Infection. 
Li, Y., et al., 2016c. Inhibition of Mitochondrial Fission and NOX2 Expression Prevent NLRP3 
Inflammasome Activation in the Endothelium: The Role of Corosolic Acid Action in the 
Amelioration of Endothelial Dysfunction. Antioxid Redox Signal. 24, 893-908. 
Liang, Y., et al., 2015. Rifampicin attenuates rotenone-induced inflammation via suppressing NLRP3 
inflammasome activation in microglia. Brain Res. 1622, 43-50. 
Lim, J., et al., 2011. Binding preference of p62 towards LC3-ll during dopaminergic neurotoxin-
induced impairment of autophagic flux. Autophagy. 7, 51-60. 
Lima, H., Jr., et al., 2013. Role of lysosome rupture in controlling Nlrp3 signaling and necrotic cell 
death. Cell Cycle. 12, 1868-78. 
Lindholm, D., et al., 2016. c-Abl Inhibitors Enable Insights into the Pathophysiology and 
Neuroprotection in Parkinson's Disease. Frontiers in Aging Neuroscience. 8. 
Liu, B., Hong, J. S., 2003. Primary rat mesencephalic neuron-glia, neuron-enriched, microglia-




Liu, J., et al., 2016. Impairing autophagy in retinal pigment epithelium leads to inflammasome 
activation and enhanced macrophage-mediated angiogenesis. Sci Rep. 6, 20639. 
Liu, W., et al., 2012. Regulation of neuronal cell death by c-Abl-Hippo/MST2 signaling pathway. 
PLoS One. 7, e36562. 
Lu, S., et al., 2017. Lysosomal adaptation: How cells respond to lysosomotropic compounds. PLoS 
One. 12, e0173771. 
Lu, W., et al., 2007. Tyrosine 311 is phosphorylated by c-Abl and promotes the apoptotic effect of 
PKCdelta in glioma cells. Biochem Biophys Res Commun. 352, 431-6. 
Lull, M. E., Block, M. L., 2010. Microglial activation and chronic neurodegeneration. 
Neurotherapeutics. 7, 354-65. 
Lutz, A. K., et al., 2009. Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial 
fragmentation. J Biol Chem. 284, 22938-51. 
Machiya, Y., et al., 2010. Phosphorylated alpha-Synuclein at Ser-129 Is Targeted to the Proteasome 
Pathway in a Ubiquitin-independent Manner. Journal of Biological Chemistry. 285, 40732-
40744. 
Mahul-Mellier, A. L., et al., 2014. c-Abl phosphorylates alpha-synuclein and regulates its degradation: 
implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson's 
disease. Hum Mol Genet. 23, 2858-79. 
Majumdar, A., et al., 2007. Activation of microglia acidifies lysosomes and leads to degradation of 
Alzheimer amyloid fibrils. Mol Biol Cell. 18, 1490-6. 
Marella, M., et al., 2008. Protection by the NDI1 gene against neurodegeneration in a rotenone rat 
model of Parkinson's disease. PLoS One. 3, e1433. 
Mariathasan, S., et al., 2006. Cryopyrin activates the inflammasome in response to toxins and ATP. 
Nature. 440, 228-32. 
Masters, S. L., et al., 2010. Activation of the NLRP3 inflammasome by islet amyloid polypeptide 
provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol. 11, 897-904. 
Masuda, T., et al., 2012. IRF8 is a critical transcription factor for transforming microglia into a reactive 
phenotype. Cell Rep. 1, 334-40. 
McFarland, N. R., et al., 2009. α-Synuclein S129 Phosphorylation Mutants Do Not Alter Nigrostriatal 
Toxicity in a Rat Model of Parkinson Disease. Journal of Neuropathology & Experimental 
Neurology. 68, 515-524. 
McNaught, K. S., Olanow, C. W., 2006. Protein aggregation in the pathogenesis of familial and 
sporadic Parkinson's disease. Neurobiol Aging. 27, 530-45. 
Micsenyi, M. C., et al., 2013. Lysosomal membrane permeability stimulates protein aggregate 




Mignon, A., et al., 1999. LPS challenge in D-galactosamine-sensitized mice accounts for caspase-
dependent fulminant hepatitis, not for septic shock. American Journal of Respiratory and 
Critical Care Medicine. 159, 1308-1315. 
Minton, K., 2016. Inflammasome: Anti-inflammatory effect of mitophagy. Nat Rev Immunol. 16, 206. 
Monti, B., et al., 2010. Valproic Acid is Neuroprotective in the Rotenone Rat Model of Parkinson's 
Disease: Involvement of alpha-Synuclein. Neurotoxicity Research. 17, 130-141. 
Moon, Y. J., et al., 2012. Inhibition of inflammation and oxidative stress by Angelica dahuricae radix 
extract decreases apoptotic cell death and improves functional recovery after spinal cord injury. 
J Neurosci Res. 90, 243-56. 
Moore, D. J., et al., 2005. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci. 28, 
57-87. 
Moquin, A., et al., 2013. Caspase-1 activity in microglia stimulated by pro-inflammagen nanocrystals. 
ACS Nano. 7, 9585-98. 
Moriyama, Y., et al., 1982. Acridine orange as a fluorescent probe for lysosomal proton pump. J 
Biochem. 92, 1333-6. 
Moss, D. W., Bates, T. E., 2001. Activation of murine microglial cell lines by lipopolysaccharide and 
interferon-gamma causes NO-mediated decreases in mitochondrial and cellular function. Eur J 
Neurosci. 13, 529-38. 
Nagakannan, P., Eftekharpour, E., 2017. Differential redox sensitivity of cathepsin B and L holds the 
key to autophagy-apoptosis interplay after Thioredoxin reductase inhibition in nutritionally 
stressed SH-SY5Y cells. Free Radic Biol Med. 108, 819-831. 
Niemi, K., et al., 2011. Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a 
cathepsin B-sensitive pathway. J Immunol. 186, 6119-28. 
Noworyta-Sokolowska, K., et al., 2013. LPS-induced oxidative stress and inflammatory reaction in the 
rat striatum. Pharmacol Rep. 65, 863-9. 
Nylandsted, J., et al., 2004. Heat shock protein 70 promotes cell survival by inhibiting lysosomal 
membrane permeabilization. Journal of Experimental Medicine. 200, 425-435. 
Olszewska, D. A., Lynch, T., 2016. PINK1, parkin, and autophagy receptors: A new model of 
mitophagy. Mov Disord. 31, 1628-1629. 
Ordureau, A., et al., 2014. Quantitative proteomics reveal a feedforward mechanism for mitochondrial 
PARKIN translocation and ubiquitin chain synthesis. Mol Cell. 56, 360-75. 
Orlowski, G. M., et al., 2015. Multiple Cathepsins Promote Pro-IL-1beta Synthesis and NLRP3-
Mediated IL-1beta Activation. J Immunol. 195, 1685-97. 
Oueslati, A., et al., 2013. Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance 
and suppresses its toxicity in vivo. Proc Natl Acad Sci U S A. 110, E3945-54. 
Pagan, F., et al., 2016. Nilotinib Effects in Parkinson's Disease and Dementia with Lewy Bodies. 




Panicker, N., et al., 2017. Activation mechanisms of the E3 ubiquitin ligase parkin. Biochem J. 474, 
3075-3086. 
Panicker, N., et al., 2015. Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell 
Culture and Animal Models of Parkinson's Disease. J Neurosci. 35, 10058-77. 
Panov, A., et al., 2005. Rotenone model of Parkinson disease: multiple brain mitochondria 
dysfunctions after short term systemic rotenone intoxication. J Biol Chem. 280, 42026-35. 
Park, J., et al., 2013. Mitochondrial dynamics modulate the expression of pro-inflammatory mediators 
in microglial cells. J Neurochem. 127, 221-32. 
Park, J., et al., 2017. Anti-inflammatory effect of oleuropein on microglia through regulation of Drp1-
dependent mitochondrial fission. Journal of Neuroimmunology. 306, 46-52. 
Peppoloni, S., et al., 2011. Role of the (Mn)superoxide dismutase of Enterococcus faecalis in the in 
vitro interaction with microglia. Microbiology. 157, 1816-22. 
Perry, V. H., 2004. The influence of systemic inflammation on inflammation in the brain: implications 
for chronic neurodegenerative disease. Brain Behav Immun. 18, 407-13. 
Porte, F., et al., 2003. Role of the Brucella suis lipopolysaccharide O antigen in phagosomal genesis 
and in inhibition of phagosome-lysosome fusion in murine macrophages. Infect Immun. 71, 
1481-90. 
Puissant, A., et al., 2010. Cathepsin B release after imatinib-mediated lysosomal membrane 
permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous 
leukemia cells. Leukemia. 24, 115-24. 
Qin, L., et al., 2007. Systemic LPS causes chronic neuroinflammation and progressive 
neurodegeneration. Glia. 55, 453-62. 
Radad, K., et al., 2014. Neuroprotective effect of rotigotine against complex I inhibitors, MPP(+) and 
rotenone, in primary mesencephalic cell culture. Folia Neuropathol. 52, 179-86. 
Rappold, P. M., et al., 2014. Drp1 inhibition attenuates neurotoxicity and dopamine release deficits in 
vivo. Nature Communications. 5. 
Raupach, B., et al., 2006. Caspase-1-mediated activation of interleukin-1beta (IL-1beta) and IL-18 
contributes to innate immune defenses against Salmonella enterica serovar Typhimurium 
infection. Infect Immun. 74, 4922-6. 
Riches, D. W., Henson, P. M., 1986. Bacterial lipopolysaccharide suppresses the production of 
catalytically active lysosomal acid hydrolases in human macrophages. J Cell Biol. 102, 1606-
14. 
Ritter, C., et al., 2004. Treatment with N-acetylcysteine plus deferoxamine protects rats against 
oxidative stress and improves survival in sepsis. Crit Care Med. 32, 342-9. 
Rodriguez-Navarro, J. A., et al., 2007. Mortality, oxidative stress and tau accumulation during ageing 




Ruffmann, C., et al., 2012. Lewy body pathology and typical Parkinson disease in a patient with a 
heterozygous (R275W) mutation in the Parkin gene (PARK2). Acta Neuropathol. 123, 901-3. 
Sanchez-Reus, M. I., et al., 2007. Standardized Hypericum perforatum reduces oxidative stress and 
increases gene expression of antioxidant enzymes on rotenone-exposed rats. 
Neuropharmacology. 52, 606-16. 
Sarkar, S., et al., 2017a. Mitochondrial impairment in microglia amplifies NLRP3 inflammasome 
proinflammatory signaling in cell culture and animal models of Parkinson's disease. NPJ 
Parkinsons Dis. 3, 30. 
Sarkar, S., et al., 2017b. Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with 
Enhanced Purity and Versatility. J Vis Exp. 
Schlatterer, S. D., et al., 2011. c-Abl in neurodegenerative disease. J Mol Neurosci. 45, 445-52. 
Schulz, J. B., et al., 2000. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem. 267, 
4904-11. 
Seo, J., et al., 2014. Antisense methods to modulate pre-mRNA splicing. Methods Mol Biol. 1126, 
271-83. 
Settembre, C., et al., 2011. TFEB links autophagy to lysosomal biogenesis. Science. 332, 1429-33. 
Shen, W., et al., 2015. L-F001, a multifunctional ROCK inhibitor prevents paraquat-induced cell death 
through attenuating ER stress and mitochondrial dysfunction in PC12 cells. Biochemical and 
Biophysical Research Communications. 464, 794-799. 
Sherer, T. B., et al., 2003a. Selective microglial activation in the rat rotenone model of Parkinson's 
disease. Neurosci Lett. 341, 87-90. 
Sherer, T. B., et al., 2003b. Selective microglial activation in the rat rotenone model of Parkinson's 
disease. Neuroscience Letters. 341, 87-90. 
Sherer, T. B., et al., 2003c. Mechanism of toxicity in rotenone models of Parkinson's disease. J 
Neurosci. 23, 10756-64. 
Sherer, T. B., et al., 2003d. Subcutaneous rotenone exposure causes highly selective dopaminergic 
degeneration and alpha-synuclein aggregation. Exp Neurol. 179, 9-16. 
Shi, F., et al., 2012. The NALP3 inflammasome is involved in neurotoxic prion peptide-induced 
microglial activation. J Neuroinflammation. 9, 73. 
Shimura, H., et al., 2012. Parkin and Parkinson disease. Clin Chem. 58, 1260-1. 
Shin, J. H., et al., 2011. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration 
in Parkinson's disease. Cell. 144, 689-702. 
Sollberger, G., et al., 2014. Caspase-1: the inflammasome and beyond. Innate Immun. 20, 115-25. 
Sonia Angeline, M., et al., 2012. Rotenone-induced parkinsonism elicits behavioral impairments and 





Su, P., et al., 2016. The role of autophagy in modulation of neuroinflammation in microglia. 
Neuroscience. 319, 155-67. 
Takenouchi, T., et al., 2009. The activation of P2X7 receptor impairs lysosomal functions and 
stimulates the release of autophagolysosomes in microglial cells. J Immunol. 182, 2051-62. 
Talukdar, R., et al., 2016. Release of Cathepsin B in Cytosol Causes Cell Death in Acute Pancreatitis. 
Gastroenterology. 151, 747-758 e5. 
Tan, A. H., et al., 2015. Helicobacter pylori infection is associated with worse severity of Parkinson's 
disease. Parkinsonism Relat Disord. 21, 221-5. 
Tan, E. K., Skipper, L. M., 2007. Pathogenic mutations in Parkinson disease. Hum Mutat. 28, 641-53. 
Tanabe, A., et al., 2014. A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal 
motor behaviors in a mouse model of Parkinson's disease. Frontiers in Cellular Neuroscience. 
8. 
Tanaka, A., 2010. Parkin-mediated selective mitochondrial autophagy, mitophagy: Parkin purges 
damaged organelles from the vital mitochondrial network. FEBS Lett. 584, 1386-92. 
Taneo, J., et al., 2015. Amyloid beta oligomers induce interleukin-1beta production in primary 
microglia in a cathepsin B- and reactive oxygen species-dependent manner. Biochem Biophys 
Res Commun. 458, 561-7. 
Tang, J., et al., 2016. Parkin Protects against Oxygen-Glucose Deprivation/Reperfusion Insult by 
Promoting Drp1 Degradation. Oxid Med Cell Longev. 2016, 8474303. 
Tang, M. Y., et al., 2017. Structure-guided mutagenesis reveals a hierarchical mechanism of Parkin 
activation. Nat Commun. 8, 14697. 
Tanida, I., et al., 2004. LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol. 36, 
2503-18. 
Tanida, I., et al., 2008. LC3 and Autophagy. Methods Mol Biol. 445, 77-88. 
Terada, K., et al., 2010. Involvement of cathepsin B in the processing and secretion of interleukin-
1beta in chromogranin A-stimulated microglia. Glia. 58, 114-24. 
Tran, T. A., et al., 2011. Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via 
nuclear factor-kappa B. PLoS One. 6, e23660. 
Tremblay, M. E., et al., 2011. The role of microglia in the healthy brain. J Neurosci. 31, 16064-9. 
Trempe, J. F., et al., 2013. Structure of parkin reveals mechanisms for ubiquitin ligase activation. 
Science. 340, 1451-5. 
Tripathi, R., et al., 2018. Abl and Arg mediate cysteine cathepsin secretion to facilitate melanoma 
invasion and metastasis. Sci Signal. 11. 
Tschopp, J., Schroder, K., 2010. NLRP3 inflammasome activation: The convergence of multiple 




Turk, V., et al., 2001. Lysosomal cysteine proteases: facts and opportunities. EMBO J. 20, 4629-33. 
Vila, M., et al., 2011. Lysosomal membrane permeabilization in Parkinson disease. Autophagy. 7, 98-
100. 
Wang, H., et al., 2011. Parkin ubiquitinates Drp1 for proteasome-dependent degradation: implication 
of dysregulated mitochondrial dynamics in Parkinson disease. J Biol Chem. 286, 11649-58. 
Wang, K., 2014. Molecular mechanisms of hepatic apoptosis. Cell Death & Disease. 5. 
Wang, L., et al., 2016. Ulinastatin attenuates pulmonary endothelial glycocalyx damage and inhibits 
endothelial heparanase activity in LPS-induced ARDS. Biochem Biophys Res Commun. 478, 
669-75. 
Wiemerslage, L., Lee, D., 2016. Quantification of mitochondrial morphology in neurites of 
dopaminergic neurons using multiple parameters. Journal of Neuroscience Methods. 262, 56-
65. 
Wu, F., et al., 2015a. Rotenone impairs autophagic flux and lysosomal functions in Parkinson's 
disease. Neuroscience. 284, 900-11. 
Wu, Q., et al., 2018. Mdivi-1 alleviates blood-brain barrier disruption and cell death in experimental 
traumatic brain injury by mitigating autophagy dysfunction and mitophagy activation. Int J 
Biochem Cell Biol. 94, 44-55. 
Wu, R., et al., 2016. c-Abl-p38alpha signaling plays an important role in MPTP-induced neuronal 
death. Cell Death Differ. 23, 542-52. 
Wu, W. Y., et al., 2015b. Hepatitis C virus infection: a risk factor for Parkinson's disease. J Viral 
Hepat. 22, 784-91. 
Wynick, C., et al., 2016. Lipopolysaccharide-Mediated Induction of Concurrent IL-1beta and IL-23 
Expression in THP-1 Cells Exhibits Differential Requirements for Caspase-1 and Cathepsin B 
Activity. J Interferon Cytokine Res. 36, 477-87. 
Xiao, L., et al., 2011. The c-Abl-MST1 signaling pathway mediates oxidative stress-induced neuronal 
cell death. J Neurosci. 31, 9611-9. 
Xie, N., et al., 2014. Inhibition of mitochondrial fission attenuates Abeta-induced microglia apoptosis. 
Neuroscience. 256, 36-42. 
Yang, J. S., et al., 2011. Discovery and Characterization of a Cell-Permeable, Small-Molecule c-Abl 
Kinase Activator that Binds to the Myristoyl Binding Site. Chemistry & Biology. 18, 177-186. 
Yang, J. Y., Yang, W. Y., 2013. Bit-by-bit autophagic removal of parkin-labelled mitochondria. Nat 
Commun. 4, 2428. 
Yang, S., et al., 2008. Curcumin protects dopaminergic neuron against LPS induced neurotoxicity in 
primary rat neuron/glia culture. Neurochem Res. 33, 2044-53. 
Yasuda, T., et al., 2011. Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-




Ye, S., et al., 2015. Carboxylic Acid Fullerene (C60) Derivatives Attenuated Neuroinflammatory 
Responses by Modulating Mitochondrial Dynamics. Nanoscale Res Lett. 10, 953. 
Ye, S. F., et al., 2016. Drp1-Dependent Mitochondrial Fission Mediates Toxicity of Positively Charged 
Graphene in Microglia. Acs Biomaterials Science & Engineering. 2, 722-733. 
Yeom, E., et al., 2017. Microfluidic system for monitoring temporal variations of hemorheological 
properties and platelet adhesion in LPS-injected rats. Scientific Reports. 7. 
Yin, Y., et al., 2013. Inflammasomes: sensors of metabolic stresses for vascular inflammation. Front 
Biosci (Landmark Ed). 18, 638-49. 
Yu, C. C., et al., 2016. Altered Striatocerebellar Metabolism and Systemic Inflammation in Parkinson's 
Disease. Oxid Med Cell Longev. 2016, 1810289. 
Yuan, Y. H., et al., 2013. Rotenone could activate microglia through NFkappaB associated pathway. 
Neurochem Res. 38, 1553-60. 
Yuk, J. M., Jo, E. K., 2013. Crosstalk between autophagy and inflammasomes. Mol Cells. 36, 393-9. 
Zhang, L., et al., 2010. Demethoxycurcumin, a natural derivative of curcumin attenuates LPS-induced 
pro-inflammatory responses through down-regulation of intracellular ROS-related MAPK/NF-
kappaB signaling pathways in N9 microglia induced by lipopolysaccharide. Int 
Immunopharmacol. 10, 331-8. 
Zhang, Y., et al., 2016. Resveratrol Enhances Autophagic Flux and Promotes Ox-LDL Degradation in 
HUVECs via Upregulation of SIRT1. Oxid Med Cell Longev. 2016, 7589813. 
Zhang, Z. N., et al., 2017. Subcutaneous rotenone rat model of Parkinson's disease: Dose exploration 
study. Brain Res. 1655, 104-113. 
Zhao, W., et al., 2015. TDP-43 activates microglia through NF-kappaB and NLRP3 inflammasome. 
Exp Neurol. 273, 24-35. 
Zheng, X., Hunter, T., 2013. Parkin mitochondrial translocation is achieved through a novel catalytic 
activity coupled mechanism. Cell Res. 23, 886-97. 
Zhou, C. H., et al., 2012. Monitoring autophagic flux by an improved tandem fluorescent-tagged LC3 
(mTagRFP-mWasabi-LC3) reveals that high-dose rapamycin impairs autophagic flux in cancer 
cells. Autophagy. 8, 1215-1226. 
Zhou, F., et al., 2007. Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons 
through inhibiting microglia-mediated neuroinflammation. Neuropsychopharmacology. 32, 
2570-80. 
Zhou, L., et al., 2017. c-Abl-mediated Drp1 phosphorylation promotes oxidative stress-induced 
mitochondrial fragmentation and neuronal cell death. Cell Death Dis. 8, e3117. 














Figure 1: LPS treatment mediates the time-dependent increase in oxidative stress, mitochondrial 
damage and activation of c-Abl and NLRP3 induction in ROT-primed microglial BV2 cells.  
Murine BV2 microglial cells were treated with 200nM ROT for 6h followed by treatment with LPS 
(100ng/ml) for 3-18h.  (A) MTS cell death analysis for cells treated with ROT and LPS.  After 
treatment, cells were exposed to MTS dye for 90 min and change in color was measured. The data 
converted to percentage of control group and presented as mean ± SEM, N = 8, from three different 
experimental replicates.  (B) Assessment of level of ROS generation in BV2 cells post treatment.  Cells 
were exposed to CM-H2DCFDA fluorogenic dye after ROT/LPS treatment and change in fluorescence 
was noted and presented as % control. H2O2 (100µM, 1h) was used as positive control.  The data 
converted to percentage of control group and presented as mean ± SEM, N = 6.  (C) Measurement of 




dye.  The fluorescence was measured for green monomer and red polymer of JC-1 dye and ratio of 
RED:GREEN is plotted as a bar graph indicative of change in MMP.  (D-E) BV2 cells were primed 
with 200nM ROT for 6h followed by treatment with 100ng/ml LPS for mentioned time points. At the 
end of treatment, cells lysates were prepared and subjected to western blotting for (D) p-c-Abl Y245, 
p-c-Abl Y412, c-Abl, p-PKCδ Y311 and PKCδ; and (E) NLRP3.  β-actin was used loading control.  
The bar graphs represent the normalized band intensity of respective proteins, calculated as mean ± 
SEM, n = 4.  The bottom panel in figure 1 (E) shows the immunoblotting of NLRP3, Casp-1 and IL-1β 
for concentrates of media supernatants (Sup.) collected after treatment.  The data was calculated as % 
control and represented as mean ± SEM for 3-4 independent repeats per group.  *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001 compared with control group, whereas #p<0.05, # #p<0.01 and # # 
#p<0.001 indicates significance between time-matched LPS and ROT-primed LPS treated group; NS = 









Figure 2. DAS, a c-Abl inhibitor, reduces the NLRP3 inflammasome activation by reducing 
oxidative stress and mitochondrial dysfunction.   BV2 cells were pretreated with 100nM DAS for 
1h followed by treatment with ROT (200nM, 6h) and LPS (100ng/ml, 12h).  Cell lysates were 
subjected to immunoblotting for p-c-Abl Y245, p-c-Abl Y412 and c-Abl (A); and NLRP3 (D).  
Histogram represents the densitometric analysis bands normalized to β-actin for all treatment groups as 
labelled.  The data represented as mean ± SEM, N = 4.  (B) Levels of intracellular ROS levels were 
measured using CM-H2DCFDA florigenic dye in BV2 cells treated with ROT/LPS with or without 
DAS pre-exposure.  The FU readings from two independent replicates were calculated as % control 
and were plotted as mean ± SEM, N = 6.  (C) Estimation of MMP in BV2 cells post treatment was 
performed using JC-1 dye.  Change in the ratio of red to green readouts is plotted as mean ± SEM for 
experiment performed with N = 4.  (E) ELISA analysis of IL-1β and IL-18 in supernatant media of 
BV2 cells treated with ROT/LPS with or without DAS.  Data represented as mean ± SEM for each 
experiment performed in duplicate with N = 3.  *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 
compared with non-treated control group, whereas #p<0.05, # #p<0.01, # # #p<0.001 and # # # #p<0.001 






Figure 3. Time-dependent increase of lysosomal membrane permeability and cath B activation in 
BV2 cells treated with ROT and LPS is modulated by DAS pretreatment.  (A-D) BV2 cells were 
pre-exposed to 200nM ROT for 6h followed by treatment with 100ng/ml LPS for 3, 6, 12 and 18h.  
Lysosomal integrity was measured using Lysosensor Green dye and acridine orange (AO) dye.  (A) 
Post treatment, BV2 cells were probed with Lysosensor® green dye for 20min.  The reduction in 
lysosensor green intensity indicates the loss of acidic pH.  The fluorescence unit (FU) were noted, 
calculated at % control and presented as mean ± SEM of control group, n=6.  (B) Post treatment, cells 




plotted as histogram, indicating change in LMP.  The data from two independent repeats are 
represented as mean ± SEM, N = 6.  (C)  Estimation of cellular cath B activity.  BV2 microglial cells 
treated with ROT and LPS were subjected to cath B activity analysis using Abcam assay kit as 
described in Methods.  The change in fluroscence intensity was measured for all samples and values 
were converted to % control and represented as mean ± SEM, N = 4.  (D) Cell lysates of BV2 cells 
exposed to ROT/LPS were subjected to WB for cath B.  Normalized densitometric analysis of mature 
cath B was plotted as % control.  The data represented as mean ± SEM, N = 4.  *p<0.05, **p<0.01 and 
***p<0.001 compared with control group, whereas #p<0.05, # #p<0.01 and # # #p<0.001 indicates 
significance between LPS and ROT + LPS treated group; NS = not significant.  (E-H) BV2 cells were 
pretreated with DAS (100nM, 1h) followed by sequential treatment with ROT (200nM, 6h) and LPS 
(100ng/ml, 12h).  After treatment, lysosomal impairment was measured using Lysosesnor Green and 
AO assay.  (E) The Lysosensor Green FU values were reported for each treatment group and plotted 
on as histogram.  (F) The change in ratio of green to red intensity indicating the change in LMP is 
plotted for all treatment groups.  Results from two independent repeats are represented as mean ± 
SEM, N = 6.  (G) WB analysis of cath B was performed for BV2 cells treated with ROT/LPS with or 
without DAS pretreatment.  β actin was used a loading control and normalized densitometric analysis 
was plotted as mean ± SEM, N = 4.  (H) Estimation of cath B activity in BV2 cells after treatment.  
The FU values were calculated as % control and presented as mean ± SEM, n = 4.   (I) Immunoblot for 
LC3B I/II and p62 in BV2 cells treated as mentioned before.  Normalized band intensity was plotted as 
% control of mean ± SEM, N = 3-4.  **p<0.01 and ***p<0.001 compared with non-treated control 
group, whereas #p<0.05, # #p<0.01 and # # #p<0.001 indicates significance between ROT/LPS-treated 











Figure 4. CA074, a pharmacological inhibitor of cath B, attenuates the ROT/LPS-induced 
oxidative stress, autophagolysosomal dysfunction and NLRP3 activation in BV2 cells.  (A) MTS 
cell death analysis of cells exposed to 1, 5 and 10µM CA074 for 24h.  (B) Estimation of cath B 




and treatment with LPS (100ng/ml, 12h).  The cells were analyzed for cath B activity using kit as 
described in Methods.  The change in fluorescence was measured, calculated as % control and 
represented as mean ± SEM for N = 4-6 per group from two independent experimental repeats.  (C)  
WB for cath B using whole cell lysates of BV2 cells treated ROT/LPS with or without CA074.  The 
densitometric analysis of normalized band intensity was plotted as % control, represented as mean ± 
SEM for n = 4.  (D) Measurement of cellular ROS levels using CM-H2DCFDA dye.  BV2 cells were 
treated with ROT/LPS with or without CA074 pre-exposure and at the end of treatment cells were 
exposed to CM-H2DCFDA fluorogenic dye.  The data represent mean ± SEM, n = 6 and expressed as 
percent of control.  (E) Analysis of mitochondrial superoxide in BV2 cells treated with CA074 and 
ROT/LPS.  Post treatment, cells were probed with MitoSOXTM Red dye, the change in fluorescence 
reading was noted and plotted as % control for all groups. The data represent mean ± SEM, n = 6.  (F) 
Estimation of MMP in BV2 cells using JC-1 cationic dye.  BV2 cells were exposed to ROT and LPS 
with or without CA074, as mentioned before followed by incubation with JC-1 dye.  The fluorescence 
readings were measured for red polymer and green monomer.  Histogram represents the ratio of 
RED:GREEN FU for all treatment groups as labelled.  The data represented as mean ± SEM, N = 4.  
(G-H) Estimation of lysosomal acidity using Lysosensor® Green substrate and AO pH sensitive dye.  
Post treatment, cells were exposed to Lysosensor® green dye or AO and the change in fluorescence 
unit measured.  The Lysosensor® Green FU values were plotted as mean ± SEM for N = 8 from two 
independent repeats.  The change in the Red:Green florescence ratio was reported as mean ± SEM for 
N = 6.  (I) Measurement of LC3-dependent autophagic vacuoles accumulation in BV2 cells.  BV2 cells 
were transduced with PremoTM Tandem Autophagy Sensor RFP-GFP-LC3 reagent as detailed in 
Methods section, followed by treatment with CA074 (10uM), ROT (200nM) and LPS (100ng/ml).  
Post treatment, cells were analyzed for RFP and GFP expression using a SpectraMax Plus Plate reader 
(Ex/Em at 555/585nm for RFP and 488/510nm for GFP).  The FU were plotted for each treatment 
group for RFP and GFP on same histogram.  Twenty-four hours treatment with chloroquine (CQ, 
50µM) and Leupeptin A (200µM) were used as positive and negative controls, respectively.  (J-M) 
BV2 microglial cells were pretreated with CA074 (1h) primed with ROT (200nM, 6h) followed by 
LPS treatment (100ng/ml, 12h).  Post treatment cell lysates were immunoblotted for LC3B I/II and p62 
(J); and NLRP3 (K).  β actin was used loading control.  The bar graphs represent the normalized band 
intensity of respective proteins from n = 4 replicates, expressed as % control.  (L) The representative 
blots showing NLRP3, casp 1 (p10) and IL-1β proteins in media.  The supernatant media from the 




subjected to immunoblotting.  (M) Estimation of secreted cytokines- IL-1β, Il-18 and TNFα, from 
media supernatant from BV2 cells after treatment.  The bar graph represented as % control shows band 
intensity for respective proteins calculated as mean ± SEM, N = 4.  *p<0.05, **p<0.01, ***p<0.001 
and ****p<0.001 compared with control group; ap<0.05, aap<0.01 and aaap<0.001 indicates 
significance between LPS and ROT+LPS treated group; and #p<0.05, # #p<0.01, # # #p<0.01 and # # # 
#p<0.0001 denotes significant difference between ROT+LPS treated group with or without CA074 













Figure 5. Cath B modulates activation of c-Abl and NLRP3 inflammasome in ROT/LPS treated 
BV2 cells.  (A-D) BV2 cells were transfected with siRNA against cath B (Cath B KD), followed by 
treatment with ROT (200nM, 6h) followed LPS (100ng/ml, 12h).  The cells were lysed for protein 
analysis and equal amount of protein was loaded for WB.  The representative blots for cath B (A); p-c-
Abl Y412, p-c-Abl Y245, c-Abl, p-PKCδ and PKCδ (B); and NLRP3 (C).  β-actin was used as a 
loading control.  Normalized band intensities were calculated expressed as % control on bar graphs for 
each protein.  (C) Bottom panel shows representative blots for NLRP3, casp-1 (p10) and IL-1β for 
media (Sup.) of BV2 cells treated as mentioned earlier.  Supernatant media concentrates were prepared 
as detailed in Methods and equal amount of protein were separated on polyacrylamide gels, transferred 
on nitrocellulose membrane and probed with specific antibodies for analysis.  The bar graph represents 
the densitometric analysis of each protein from different treatment groups as labelled.  The data 
represent mean ± SEM, N = 3-4.  (D) ELISA assay for secreted inflammatory cytokines- IL-1β, IL-18 
and TNFα.  Cath B KD BV2 cells were exposed ROT and LPS. The supernatant media were subjected 
to pre-validated commercial kits as mentioned in Methods.  The ELISA data represents the mean ± 
SEM performed in replicates of 4 and performed at least 2 independent times.  *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001 indicates level of significant difference from control group; ∆p<0.05, ∆ 
∆p<0.01, ∆ ∆ ∆p<0.001 and ∆ ∆ ∆ ∆p<0.0001 denotes significant difference between ROT+LPS treated 
group with or without cath B KD; NS = not significant.  (E-H) BV2 cells were transfected with empty 
vector (EV) or cath B WT constructs followed by treatment with ROT (200nM, 6h) and LPS 
(100ng/ml, 12h).  The whole cell lysates were subjected to immunoblotting for cath B (E); NLRP3 (F); 
and p-c-Abl Y412, p-c-Abl Y245, c-Abl, p-PKCδ and PKCδ (G).  β actin normalized densitometric 
intensity was plotted as % control and represented as mean ± SEM, N = 3-4.  The bottom panel in 
figure (F) represents the protein expression of NLRP3, casp-1 (p10) and IL-1β in media supernatant 
(Sup.).  (H) ELISA assay for secreted inflammatory cytokines- IL-1β, IL-18 and TNFα.  EV and Cath 
B WT transfected BV2 cells were exposed ROT and LPS and supernatant media were subjected to pre-
validated commercial kits as mentioned in Methods.  The ELISA data represents the mean ± SEM 
performed in replicates of 4 and performed at least 2 independent times.  Densitometric analysis 
represented as mean ± SEM bar graph, n = 4, expressed as % control.  **p<0.01, ***p<0.001 and 
****p<0.0001 compared with control group and #p<0.05 and # #p<0.01 denotes significant difference 


















Figure 6: CA074 reduced ROT/LPS-mediated cytosolic release of cath B, ALS dysfunction and 
NLRP3 activation in primary microglia.  Primary mouse microglia were cultured in optimal 
conditions as described in Methods and were pretreated with 10µM CA074 for 1h followed by 
sequential treatment with ROT (10nM, 4h) and LPS (10ng/ml, 3h).  Post treatment, cells were lysed 
and were immunoblotted for p-c-Abl Y412, p-c-Abl Y245 and c-Abl (A), cath B (A); and NLRP3 (C).  
Bands were normalized to β-actin loading control and data were presented as mean ± SEM, N = 4, 




1β for media (Sup.) of BV2 cells treated as mentioned earlier.  The bar graph represented as % control 
shows band intensity for respective proteins calculated as mean ± SEM, N = 3.  (D) Analysis of 
extracellular level of IL-1β, IL-18 and TNFα from different treatment groups.  ELISA was performed 
to analyze the level of cytokines in media supernatant post treatment to primary microglia.  The values 
were obtained and were presented as pg/ml for each cytokine from different treatment groups.  (E) WB 
analysis of cath B in cytosolic and lysosome-enriched fractions.  Using lysosomal fractionation kit, 
cytosolic and lysosomal fractions were separated in ROT/LPS treated primary microglia with or 
without CA074 pretreatment.  LAMP2 was used as lysosomal marker and tubulin cytosolic fraction.  
Densitometric analysis of proenzyme and mature cath B was normalized and plotted as % control of 
mean ± SEM, N = 4.  *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 compared with control 
group; aaap<0.001 and aaaap<0.0001 indicates significance between LPS and ROT + LPS treated group; 
whereas, #p<0.05, # #p<0.01, # # #p<0.01 and # # # #p<0.0001 denotes significant difference between ROT 
+ LPS treated group with or without CA074 pretreatment; NS = not significant.  (F,G) Confocal 
images of primary microglia co-stained with LAMP2 and cath B (F) and LC3 and LAMP2 (G).  The 
representative images from at least 2 experimental repeats are shown.  Hoechst was used to stain the 
nuclei.  The insert in figures (F) and (G) on the right shows the magnification of merged images.  
Scale bar = 10nM.  (H) Representative confocal images of primary microglia transfected with dsMito-
Red followed by treatment with CA074 ± ROT+LPS and labeled with LC3 (green).  Hoechst (blue) 
was used as nuclear stain.  (I) Immunoblot for LC3B and p62 from whole cell lysates of primary 
microglia treated to ROT/LPS ± CA074.  β actin normalized densitometry data was calculated as % 
control and represented as mean ± SEM for two independent experiments, N = 4.  ***p<0.001 and 
****p<0.0001 compared with control group; whereas, # # #p<0.01 and # # # #p<0.0001 denotes 
significant difference between ROT + LPS treated group with or without CA074 pretreatment.  (J) ICC 
images of TFEB in CA074 pretreated and ROT/LPS treated primary microglia.  Hoechst used for 









Figure 7: CA074 abrogates the ROT/LPS-induced c-Abl/cath B/NLRP3 inflammasome 
activation and dopaminergic neurotoxicity in mixed neuron-glia primary culture.  Mixed neuron-
glia cultures were obtained from rat embryos as described in Methods and were pretreated with CA074 
(10µM, 1h) followed by sequential treatment with ROT (10nM, 48h) followed by LPS (5ng/ml, 24h).  
Cells were lysed and the whole cell lysates were immunoblotted for p-c-Abl Y412, p-c-Abl Y245 and 
c-Abl (A); cath B (B); NLRP3 (C); LC3B and p62 (D); and TH (E).  β-actin was used as a loading 
standard.  Normalized band intensities were calculated as % control and were plotted as mean ± SEM, 
N = 4.  The bottom panel in figure (C) demonstrates the protein expression of NLRP3, casp 1 (p10) 
and IL-1β in media supernatant (Sup.).  The bar graph represents the band intensity from two 
replicates, represented as mean ± SEM, N = 3-4.  *p<0.05, **p<0.01 and ***p<0.001 compared with 
control group, whereas, ɸp<0.05, ɸ ɸp<0.01 and ɸ ɸ ɸp<0.001 denotes significant difference between 









Figure 8: Mdivi-1 reduces the ROT/LPS-mediated NLRP3 inflammasome activation in BV2 
cells.  BV2 cells were pretreated with Mdivi-1 (5, 10 or 25µM) for 1h followed by treatment with ROT 
(200ng/ml, 6h) and LPS (100ng/ml, 12h).  Whole cell lysates were prepared after treatment and were 
subjected to WB.  The membraned were examined for protein expression of NLRP3 (N = 3) (A); and 
p-c-Abl Y412, p-c-Abl Y245 and c-Abl (N = 4) (C).  Bands were normalized to β-actin loading control 
and data were presented as mean ± SEM, N = 4, expressed as % control.  The bottom panel in figure 
(A) represents the protein expression of NLRP3, IL-1β and IL-18 in supernatant (Sup.) media 
concentrates.  The band intensity was represented as mean ± SEM, N = 4, expressed % control.  (B) 
ELISA analysis of IL-1β and IL-18 in supernatant media of BV2 cells treated with ROT/LPS with or 
without Mdivi-1 pre-exposure.  (D) Estimation of cath B activity.  BV2 cells were pre-exposed to 
Mdivi-1 followed by ROT priming (200nM, 6h) and treatment with LPS (100ng/ml, 12h).  The cells 
were analyzed for cath B activity using premade kit.  The change in fluorescence was measured, 
calculated as % control and represented as mean ± SEM for N = 4 per group from two independent 
experimental repeats.  *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 compared with control 
group, whereas, #p<0.05, # #p<0.01, # # #p<0.001 and # # # #p<0.0001 denotes significant difference 










Figure 9: Parkin regulates the downstream activation of NLRP3 inflammasome induced by LPS 
in ROT-primed BV2 cells.  (A)  BV2 cells were pre-exposed to 200nM ROT for 6h followed by 
treatment with 100ng/ml LPS for 3, 6, 12 and 18h.  Whole cell lysates were analyzed for Parkin 




represented as % control of at least two independent repeats, N = 3.  *p<0.05, **p<0.01, ***p<0.001 
and ****p<0.0001 compared with control group, whereas #p<0.05 indicates significance between LPS 
and ROT + LPS treated group; NS = not significant.  (B) BV2 cells were pretreated with Mdivi-1 (5, 
10 or 25µM) for 1h followed by treatment with ROT (200ng/ml, 6h) and LPS (100ng/ml, 12h).  Whole 
cell lysates were prepared after treatment and were subjected to WB for parkin.  ***p<0.001 compared 
with control group, whereas # #p<0.01 and # # #p<0.001 denotes significant difference between 
ROT+LPS treated group with or without Mdivi-1 pretreatment.  (C-H) BV2 microglial cells were 
transfected with empty vector (EV), Parkin W403A mutant construct, Parkin wild-type (WT) construct 
and Parkin C431S mutant construct.  After 48h of transfection, BV2 cells were treated with ROT 
(200nM) for 6h followed by LPS (100ng/ml) for 12h.  Post-treatment, cell lysates were prepared and 
were immunoblotted for parkin (C); NLRP3 (D); p-c-Abl Y412, p-c-Abl Y245, c-Abl (F); cath B (G) 
and; LC3B and p62 (H).  β actin was used as a loading control.  Band intensities were normalized to 
loading control and were plotted as % control and represented as mean ± SEM, n=4.  The bottom panel 
in figure (D) represents the immunoblotting for NLRP3, IL-1β and casp-1 (p10) from supernatant 
(Sup.) media.  The media from the aforementioned treatments were collected and proteins were 
concentrated as explained in Methods and equal amount of protein was loaded to polyacrylamide gels 
for protein expression analysis.  (E) Analysis of secreted cytokines IL-1β and IL-18 were performed in 
media from the BV2 cells treated as mentioned earlier using ELISA kits.  The values were calculated 
to pg/ml of respective cytokine and were presented as mean ± SEM, N = 4.  *p<0.05, **p<0.01 and 
***p<0.001 compared with control group, whereas, #p<0.05, # #p<0.01 and # # #p<0.001 denotes 
significant difference between BV2 cells transfected with EV treated with ROT + LPS versus various 










Figure 10: ROT-mediated locomotor deficits, TH loss and microglial activation is potentiated by 
LPS treatment is rats.  Six months old male Lewis rats were treated with ROT (0.5mg/kg/d, 5d/wk, 4 
wk) via s.c. injections. One month after last last ROT injection, rats were treated with LPS (5mg/kg, 
i.p.).  Animals were subjected to behavioral analysis 24h post LPS and were sacrificed immediately 




Movement path recordings of animals from each treatment group (N = 6-8 per group).  Analysis using 
VersaMax software demonstrates the horizontal activity (B), vertical activity (C) and total distance 
travelled (D) by each animal in each group.  The bar graph represents the Mean + SEM values from 
each group with N = 6-8.  (E) High-performance liquid chromatography with electrochemical 
detection was used for determination of dopamine (DA) and 3,4-Dihydroxyphenylacetic acid 
(DOPAC).  (F-N) Brains were harvested from rats after behavior test and different brain regions were 
dissected out for biochemical analysis.  The immunoblot for TH (F); phospho α-Syn (s129) (G); IBA1 
and iNOS (H); and NLRP3 (N) were performed using SN lysates from animals from all treatment 
groups.  β actin was used as a loading control and normalized band intensity for N = 6 was calculated 
as % control and represented as Mean ± SEM.  The SN levels of mRNA for TNFα (I), NLRP3 (J), IL-
1β (K), caspase-1 (L) and NOS2 (M) were determined using qRT-PCR techniques as explained in 
methods section and fold-change in mRNA expression is represented for each gene.  The values were 
presented as mean ± SEM, N=4.  *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 compared with 
vehicle-treated control group; #p<0.05, # #p<0.01 and # # #p<0.001 denotes significant difference 
between ROT and ROT+LPS treatment groups; and Δp<0.05, Δ Δp<0.01 and Δ Δ Δp<0.001 indicates 

















Figure 11: Acute systemic LPS treatment to rats chronically treated with ROT exaggerated the 
activation of c-Abl/cathepsin B and ALS dysfunction in SN.  Six months old male rats were 
sequentially treated with ROT (0.5mg/kg/d, 5d/wk, 4 wk, s.c.) followed by LPS (5mg/kg, i.p.).  All 
animals were sacrificed 24 h after LPS treatment and brain regions were stored for biochemical 
analysis.  Representative immunoblots for p-c-Abl (Y245), p-c-Abl (Y412), c-Abl, p-PKCδ and PKCδ 
(A); cathepsin B (C); and LC3B and p62 (C) from all treatment groups.  β actin was used as a loading 
control and normalized band intensity for n=6 was calculated as % control and represented as Mean ± 
SEM.   *p<0.05, **p<0.01, ***p<0.0001 and ****p<0.001 compared with vehicle-treated control 
group; # #p<0.01 and # # #p<0.001 denotes significant difference between ROT and ROT+LPS treatment 
groups; and Δ Δp<0.01 and Δ Δ Δp<0.001 indicates significance between LPS and ROT+LPS groups.  NS 
= not significant.  (D-G) Representative immunohistochemical images of SN and striatal sections from 
control and ROT+LPS groups (N=3).  Sixty micron SN sections were probed with IBA1 (green) and c-
Abl (red) (D) or IBA1 (green) and cath B (red) (E) and images were captured using confocal 
microscopy.  Striatal sections (60µm thick) were analyzed for IBA1 (green) and c-Abl (red) (F) or 








Sup. Figure. 1: Inhibition of NF-κB reduces the ROT/LPS-mediated autophagy induction and 
activation of cath B and NLRP3 inflammasome.  BV2 microglial cells were pretreated with 20µM 
SN-50, an NF-κB inhibitor, followed by treatment with ROT (200nM, 6h) and LPS (100ng/ml, 12h).  
Posttreatment cells were subjected to immunoblotting analysis.  The membranes were probed for cath 
B (A), parkin (B), LC3B (C) and NLRP3 (D).  β actin was used a loading control.  Band intensities 
were normalized for at least 3 replicates, calculated as % control and represented as mean ± SEM.  
*p<0.05 and ***p<0.001 compared with vehicle-treated control group; # #p<0.01 and # # #p<0.001 
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Abstract 
Increased oxidative stress and persistent inflammatory response have been linked to the 
initiation and progression of PD.  Impairment in ER stress (ERS) response has been linked to 
PD-associated dopaminergic neuropathology; however; the triggers and mechanisms underlying 
ERS in the microglia remain poorly characterized.  A recent study from our lab has revealed a 
positive association between oxidative stress and c-Abl activation during microglial activation in 
response to a Parkinsonian neurotoxicant.  In the present study, we sought to investigate whether 
ROT-induced ERS via c-Abl is involved in the exacerbation of LPS-induced inflammatory 




primary microglia in culture) to ROT and LPS resulted in a time-dependent upregulation of ROS 
generation, mitochondrial dysfunction, NLRP3 inflammasome activation, c-Abl activation and 
ERS markers as evidenced by increased CHOP, ATF4, p-eIF2α.  Furthermore, upregulation of 
NLRP3 inflammasome was accompanied by upregulation of thioredoxin-interacting protein 
(TXNIP), an ERS sensitive pro-oxidant protein, with a concomitant downregulation of 
thioredoxin (Trx), an antioxidant protein, in ROT/LPS stimulated microglial cells.  
Pharmacological and siRNA-mediated downregulation of c-Abl demonstrated that ROT/LPS-
induced NLRP3 inflammasome activation involved the upstream activation of ERS with a 
concomitant reciprocal negative regulation between TXNIP and Trx levels in ROT/LPS-treated 
microglial cells.  Likewise, salubrinal, an eIF2α phosphatase inhibitor, attenuated mitochondrial 
oxidative stress, ERS, upregulation of TXNIP and down regulation of Trx as well as NLRP3 
inflammasome activation, thus inhibiting ERS-associated NLRP3 inflammasome activation.  
Intriguingly, siRNA-mediated gene silencing of TXNIP attenuated, while its overexpression 
augmented NLRP3 inflammasome activation indicating TXNIP is an upstream regulator of 
NLRP3 inflammasome activation.  Finally, in vitro findings were further validated in ROT/LPS 
treated aged rats, whereby ERS positively correlated with upregulation of TXNIP and NLRP3 as 
well as down regulation of Trx, increased microglial activation response and TH neuronal loss.  
Collectively, our findings demonstrate a novel mechanism of ROT/LPS-induced microglial 
activation response involving c-Abl-mediated activation of the ERS-TXNIP-NLRP3 signaling 
axis and implicate c-Abl-ERS axis as a novel drug target for the treatment of inflammation-







Neurodegenerative disease is a collective term used for conditions characterized by 
progressive degeneration and loss of neurons, especially in CNS.  PD is the second most 
common neurodegenerative disease, where more than 50,000 cases are reported every year in the 
U.S. (NIH, 2010).  Histopathologically, PD is characterized by the loss of tyrosine hydroxylase 
(TH) positive neurons in substantia nigra pars compacta (SNpc) ans striatal regions of brain and 
accumulation of protein aggregates known as Lewy bodies or Lewy neurites, consisting mainly 
of α-Synuclein (αSyn) (Dauer and Przedborski, 2003).  
The exact etiology of PD is not fully understood though a combination of exposure to 
environmental xenobiotics and genetic predisposition puts an individual at higher risk of 
developing PD (Dauer and Przedborski, 2003; Davie, 2008).  Several causative genes related to 
PD include LRRK2, αSyn (SNCA), DJ-1, PINK1 (PARK6) and UCH-L1 (PARK5), ATP13A2 
(Lesage and Brice, 2009; Satake et al., 2009).  Although patients are at higher risk with family 
history of PD, more than 90% of PD cases are sporadic, where environmental factors trigger the 
disease pathogenesis (Jellinger, 2012; Kidd, 2000; Olanow and Tatton, 1999).  These 
environmental factors include exposure to environmental pollutants (such as heavy metals and 
agrochemicals) (Baltazar et al., 2014; Bush, 2000; Montgomery et al., 1995), traumatic brain 
injury (Goldman et al., 2006; Williams et al., 1991) or other insults.    
Postmortem analysis of PD patients also demonstrate an increased neuroinflammation 
and microglial accumulation in nigrostriatal regions, indicating that sustained inflammation 
could be a major contributor for the neurodegeneration seen in PD (Frigerio et al., 2005; Kwon et 




understanding the mechanisms of neuroinflammation may help to negotiate the progressive 
neurodegeneration causing disease pathology.   
Etiologically, infections, trauma, stroke and toxins are known to trigger an immediate 
inflammatory response in brain (Tansey et al., 2007).  During acute inflammation, the resident 
immune cells of CNS (microglia) are activated and perform phagocytosis, secrete inflammatory 
cytokines and chemokines, and generate nitrosative and oxidative stress (Gustin et al., 2015; 
Inoue et al., 2012; Tang and Le, 2016).  This can cause neurotoxicity, which then activates more 
microglia, in a phenomenon known as reactive microgliosis (Lee et al., 2013; Sutterwala et al., 
2014).  Chronic and persistent neuroinflammation and accumulation of activated microglia is 
now considered as a hallmark event in neurodegenerative diseases, including Alzheimer’s 
disease (AD) and Parkinson’s disease (PD) (Mcgeer et al., 1988; Tang and Le, 2016).  Hence, 
learning the underlying mechanisms of microglial activation is becoming essential.  NLRP3 
inflammasome are extensively produced and activated in microglia (Cho et al., 2014; Goldmann 
et al., 2013; Lang et al., 2018; Lee et al., 2018; Lin et al., 2017; Sarkar et al., 2017a). and can 
lead to oxidative stress, mitochondrial dysfunction, autophagic flux impairment, irregularity in 
K+ ion efflux, and/or ER stress (reviewed in (Liston and Masters, 2017; Petrilli et al., 2007)). 
Our lab recently showed the significant role of mitochondrial dysfunction and oxidative 
stress in induction of NLRP3 inflammasome in LPS-primed rotenone (ROT, a mitochondrial 
toxicant and parkinsonian agent)-treated microglia (Lawana et al., 2017; Sarkar et al., 2017a).  
Even more, we demonstrated that a redox sensitive tyrosine kinase, c-Abl, plays a central role in 
modulating oxidative stress, mitochondrial dysfunction and autophagolysosomal impairment in 
microglia, leading to NLRP3 inflammasome activation (Lawana et al., 2017).  In recent years, 




al., 2016).  In particular, ER stress-mediated upregulation of thioredoxin-interacting protein 
(TXNIP) has been shown to play a crucial role in activating the NLRP3 inflammasome (Devi et 
al., 2013; Kaser et al., 2008; Lerner et al., 2012; Li et al., 2016).  TXNIP is an inhibitor protein 
of thioredoxin (Trx) oxidoreductase antioxidant enzyme and have been shown to be prooxidant 
(Patwari et al., 2006).  In this study, we evaluate the underlying mechanisms and upstream 
regulators of microglial activation connecting c-Abl, oxidative stress and mitochondrial 
dysfunction to ER stress and NLRP3 inflammasome.   
Even more, studies suggest that individual with history of systemic infection are at higher 
risk of developing neurodegeneration, especially PD (Chiang et al., 2017; Collins et al., 2012; 
Ferrari and Tarelli, 2011; Perry, 2004; Yu et al., 2016).  On the other hand, Pellegrino and 
Haynes demonstrated that microglia with impaired mitochondria are highly sensitive the 
bacterial infection (Pellegrino and Haynes, 2015).  In addition, LPS or ROT treatment to rodent 
models have been shown to mimic the PD pathogenesis, including α-Syn aggregate 
accumulation, microgliosis and loss of TH positive neurons from nigrostriatal regions (Caboni et 
al., 2004; Cannon et al., 2009; Greenamyre et al., 2010; Lawana et al., 2017; Monti et al., 2010; 
Qin et al., 2007; Sherer et al., 2003a).   Hence, in the present study we used ROT + LPS 
treatment model to investigate the activation patterns of microglia using BV2 microglial cells, 
primary microglia cultured from rat pups, and adult rats systemically treated with ROT and LPS.  
Our study reveals a novel pathway connecting oxidative stress to inflammatory response, 
involving c-Abl, ER stress, TXNIP and NLRP3 inflammasome, can provide avenues to develop 






Materials and Methods 
Cell culture: BV2 cells were grown in 10% fetal bovine serum (FBS), 1% penicillin 
streptomycin (PS), 1% Glutamine (Q) in RPMI media. For treatment RPMI media containing 2% 
FBS, 1% PS and 1% glutamine was used. Cells were treated with 200 nM Rotenone for 6 h 
followed by LPS (100 ng/mL) treatment for 12 h.  For inhibitor study, cells were pretreated with 
DAS (100 nM, 1h) or salubrinal (20, 50 and 100 µM, 6h) before ROT/LPS exposure. 
Microglia enriched primary glial cultures were prepared as described in our publications 
(Sarkar et al., 2017b). The animal treatment protocols were approved by IACUC, Iowa State 
University, Ames, IA.  In brief, brains were collected from 1-2 day old rat pups and were 
digested into single cell suspensions, which were filtered through 70 microne filters.  The filtered 
single cell cultures were incubated in DMEM/F12 growth media (containing 10% FBS, 1% PS, 
1% Q, 1% sodium pyruvate, and 1% non-essential amino acid).  After 12-15 days of incubation 
at 37°C with 5% CO2, microglia were extracted using EasySep™ rat CD11b Positive Selection 
Kit (Stemcell Technologies, Cambridge, MA).  The extracted microglia were incubated in 
DMEM/F12 growth media for 3-4 days and were treated as described. 
Transfection: Transfection of BV2 microglial cells and primary microglia was performed using 
Amaxa® Nucleofector Kit (Lonza Biologics Inc., New Jersey).  Briefly, 3X106 cells were 
suspended in 100 µl transfection buffer containing 400 µM ATP-disodium, 600 µM magnesium 
chloride, 100 µM potassium hypophosphate, 20 µM sodium bicarbonate and 5 µM glucose.  The 
1.5 nM of c-Abl siRNA (ThermoFisher, CAT # 162296), TXNIP siRNA (ThermoFisher, CAT # 
77129), or control siRNA (Santa Cruz Biotechnology, CAT# sc-37007) were added to the 
transfection mix. The cells were then transfected by electroporation using A-23 program of 




of GFP-TXNIP (Addgene, CAT# 18758), myc-TRX (Addgene, CAT# 21614) or empty vector 
constructs.  Detailed protocol can be found in our previous publication (Panicker et al., 2015).  
Post transfection, the cells were incubated for 48h followed by various treatment. 
Animal Study: Lewis male rats were purchased from Hilltop Lab Animals, Inc and were housed 
under standard conditions of constant temperature (22 ± 1°C), humidity (relative, 30%), and a 12 
h light/dark cycle. Use of the animals and protocol procedures were approved by the Institutional 
Animal Care and Use Committee (IACUC) at Iowa State University (ISU), Ames, IA, USA. 
After one week of acclimatization, 6 months old rats were subcutaneously injected with rotenone 
every 5 days (0.5mg/kg/d) for 4 weeks.  Following the last rotenone injection these rats were 
intraperitoneally injected with 5mg/kg LPS or vehicle.  Animals were sacrificed 24h post LPS 
injection and brain sections were collected and stored for future analysis. 
ROS (DCFDA): The cells were plated in 96-wellplate. Post treatment, the cells were incubated 
with redox sensitive CM H 2 DCFDA dye (1 μM) for 1 h. Following incubation, the cells were 
washed with PBS two times, and a plate reader was used to detect the fluorescent intensity at an 
excitation and emission wavelength of 488 nm and 525 nm, respectively. 
Mitochondrial Membrane Potential (MMP) Assay: Mitochondrial membrane integrity was 
measured using the lipophilic JC-1 dye (Invitrogen) following our previously published paper 
(Lawana et al., 2017). Briefly, cells were treated with Rotenone for 6 h followed by LPS 
treatment for 12 h. Following treatment cells were incubated for 30 mins with 2 μg/ml JC-1 dye 
and washed with PBS. Analysis was performed by measuring red fluorescence at an 
excitation/emission of 590 nm/600 nm and green fluorescence excitation/emission of 485 




florescence.  Decrease in ratio due to loss of red fluorescence, indicates depolarized 
mitochondria. 
Western Blotting: Immunoblot analysis was performed according to previous published protocol 
(Panicker et al., 2015). Briefly, cell pellets and tissue samples were homogenized using modified 
RIPA buffer followed by incubation for 10 mins in ice. The samples were then sonicated for 2.5 
mins with a pulse of 30 secs and centrifuged at 20,000 g for 45 mins. Protein estimation was 
performed using Bradford reagent. 25-40µg of protein in each well was loaded in 10-15 % SDS-
acrylamide gels and ran for 2h for 110V following which, proteins were transferred to a 
nitrocellulose membrane at 27V for 18h at 4°C.  The nitrocellulose membranes were blocked 
using LICOR blocking buffer for 1 h and incubated in primary antibodies for 3h to 18h, washed 
with PBS-Tween, incubated in IR-secondary antibodies obtained from LICOR, washed with 
PBS-Tween, and scanned using LICOR. The following antibodies were used from Cell Signaling 
Technology- phospho c-Abl (Tyr245), CHOP, IRE1α, phospho PERK (Thr980), PERK, phospho 
eIF2α (Ser51), eIF2α, ATF4, GRP78, TXNIP, Trx-1 and Trx-2.  Antibody against c-Abl and TH 
were purchased from EMD Millipore. PKCδ, phospho PKCδ (Tyr311), phospho c-Abl (Tyr412) 
and IBA1 antibodies were obtained from Santa Cruz Biotechnology and NLRP3 anybody were 
purchased from Novus biotech. 
Statistical Analysis: GraphPad 5.0 was used for statistical analysis with p≤0.05 considered 
statistically significant. One-way ANOVA was used for comparing multiple groups.  Tukey post 







LPS induces oxidative stress and mitochondrial dysfunction in ROT-primed BV2 
microglial cells without any cell death 
 Microglia are the host macrophages of the CNS and have been shown to play a major role 
in neuronal survival, function and degeneration (Dheen et al., 2007).  Following treatment with 
ROT followed by LPS we first analyzed cell survival using MTS and LDH assays.  Treatment 
conditions did not exert any notable cell death in BV2 cells (Sup. Fig. 1).  Next, we analyzed the 
level of intracellular ROS and mitochondrial membrane potential (MMP).  Using a CM-
H2DCFDA dye, we found ROT independently caused a 1.9-fold increase in ROS, however, the 
combination of ROT and LPS caused and 5.1-fold increase in ROS following 12 h incubation.   
We then analyzed the mitochondrial membrane potential (MMP, Δψm) using a cell 
permeable JC-1 cationic dye.  JC-1 is a fluorescent compound present as a green monomer, 
which is taken up by healthy mitochondrial outer membrane and is converted to red polymeric 
compound.  Hence, estimation of green to red fluorescence ratio is indicative of the integrity of 
the MMP where a higher ratio is indicative of healthy mitochondria (Perelman et al., 2012; Reers 
et al., 1995).   At 6h post ROT treatment MMP was reduced by 38% compared to control cells 
(p<0.05), whereas, LPS only caused 20% reduction only at 18h (Fig. 1(B)).  The sequential 
treatment, however, significantly (p<0.05) potentiated the loss of MMP by 45%, 48%, 52% and 
55% at 3, 6, 12 and 18h, respectively, compared to control group.  Together, these results 
demonstrate that ROT and LPS treatment alone may induce oxidative stress and mitochondrial 





ROT priming potentiates the LPS induced activation of c-Abl/PKCδ signaling axis in BV2 
microglial cells 
In recent years, redox sensitive c-Abl tyrosine kinase have been shown to play a crucial 
role in causing dopaminergic toxicity in various models of PD (Alvarez et al., 2004; 
Brahmachari et al., 2017; Gonfloni et al., 2012; Karuppagounder et al., 2014; Ko et al., 2010; 
Kumar et al., 2003; Mahul-Mellier et al., 2014; Schlatterer et al., 2011).  Furthermore, we have 
demonstrated that the activation of redox sensitive c-Abl tyrosine kinase plays a central role in 
regulating the mechanisms involved in the activation of microglial cells (Lawana et al., 2017).  
Hence, we analyzed the activation of c-Abl in the present study by evaluating the 
phosphorylation of c-Abl at two tyrosine residues (Y245 and Y412).  Western blot shown in Fig. 
1(C) demonstrates the time-dependent increase in phosphorylation of c-Abl at both residues.  We 
observed that ROT alone increased the Y245/Y412 phosphorylation by 20-25%, while LPS 
alone increased the phosphorylation by 30-40% at 18h, however, the ROT priming followed by 
LPS treatment increased the phosphorylation by 60-80% at 12 and 18h.   
c-Abl phosphorylates another redox-sensitive kinase Protein Kinase C δ (PKCδ) at 
tyrosine 311 moiety (Gonfloni et al., 2012).  Our previous work has shown that LPS-induced 
PKCδ activation can promote the microglial activation and promote dopaminergic 
neurodegeneration in PD models (Gordon et al., 2016).  Similarly, we also observed a time-
dependent increase in Y311 phosphorylation of PKCδ in ROT/LPS treated BV2 cells (Fig. 1(C)).  
Our results support previous works and demonstrate the time-dependent activation of c-




LPS-induced activation of NLRP3 inflammasome in BV2 cells is potentiated by ROT 
priming 
Induction and activation of nucleotide-binding oligomerization domain, leucine rich 
repeat and pyrin domain-containing (NLRP) 3 inflammasome has been shown to play a major 
role in the inflammatory activation of microglia during neurodegenerative diseases (Gustin et al., 
2015; Sarkar et al., 2017a).  The PAMP+DAMP-activated NLRP3 inflammasome further cleaves 
and activates pro-caspase-1 to caspase-1, which then cleaves the immature forms of 
proinflammatory cytokines (namely pro-IL-1β and pro-IL-18) to their mature form to be released 
from the cells generating an inflammatory response (Lamkanfi and Dixit, 2014; Strowig et al., 
2012; Szabo and Petrasek, 2015).  Hence, we measured the activation of NLRP3 inflammasome 
using WB of whole cell lysates and supernatant concentrate of microglia primed with ROT 
followed by LPS treatment.  Fig. 1(D) demonstrate that BV2 microglia treated with ROT (200 
nM, 6h) caused 0.2-fold increase in NLRP3 protein levels; whereas, LPS (100 ng/ml) caused an 
18-30% increase at 3 to 18h post exposure (Fig. 1(D)).  However, LPS treatment to BV2 cells 
primed with ROT caused an aberrant increase in NLRP3 levels by 30%, 45% and 100% at 3, 6 
and 12h, respectively.  Intriguingly, we observed that at 18h post ROT/LPS treatment the 
NLRP3 levels were reduced compared to 12h.   
We then analyzed the media supernatant from the treated cells for release of 
inflammatory mediators.  The WB for supernatant concentrates (Sup.) revealed that NLRP3 gets 
released from the microglia in a time-dependent manner (Fig. 1(D), lower panel).  we observed a 
70% increase in NLRP3 levels 18h post treatment with LPS in ROT-primed BV2 cells. These 




indicator.  Our results support the existing knowledge and suggest that NLRP3 secretion can also 
be involved post activation of immune cells (Baroja-Mazo et al., 2014; Lawana et al., 2017). 
To further investigate the role of NLRP3, we analyzed the release of other significant 
inflammatory markers using WB and ELISA techniques.  Lower panel of Fig. 1(D) demonstrates 
a time-dependent increase in secreted casp-1 (p10) and IL-1β.  Following a similar trend, we 
noticed that sequential ROT/LPS treatment significantly increased the release of casp-1 and IL-
1β by 80% and 110% at 18h, respectively (p<0.01, compared to control and p<0.01 compared to 
LPS 18h).  Likewise, our ELISA analysis showed similar results, showing a 5-fold increase in 
secreted IL-1β and IL-18, when treated only with ROT or LPS.  However, ROT treatment 
followed by LPS exposure in BV2 cells increased the IL-1β release by 15-fold and IL-18 levels 
by 10-fold 18h (Fig. 1(E)).  Collectively, our results indicate that ROT priming can increase the 
sensitivity of the microglial cells by decreasing mitochondrial membrane potential and because 
ROT is a specific complex I inhibitor indicates mitochondria are a contributing source of free 
radical production following ROS exposure.  Overall, LPS treatment to ROT-primed microglial 
cells results in excessive activation of NLRP3 inflammasome and release of inflammatory 
cytokines. 
LPS induced ER stress is potentiated by ROT priming in BV2 microglial cells 
In recent years, elevated ER stress has been shown to contribute significantly in 
activation of microglia.  For example, studies have demonstrated that aberrant 
hyperphosphorylation of IRE1α, eIF2α and PERK with increased ATF4 promotes microglial 




transcription factor (Guo et al., 2015b; Liao et al., 2016).  Furthermore, researchers demonstrated 
that excessive intracellular ROS can induce ER stress. 
We determined ER stress by first examining the UPR-related markers, GRP78 and 
IRE1α.  Phosphorylation of ER membrane protein, IRE1α, results in activation and 
oligomerization of this endonuclease enzyme, which then slices the mRNA of X-box protein 1 
(XBP1) transcription factor, leading to gene transcription of many ER chaperones, including 
GRP78, responsible for early ER associated degradation (ERAD) of misfolded protein in ER 
lumen (Mimura et al., 2012; Yoshida et al., 2001).  In our study, ROT did not alter the GRP78 
levels but increased the phosphorylation of IRE1α by 40%, when treated alone for 6h, while LPS 
alone caused a time-dependent increase of p-IRE1α and GRP78 (Fig. 2(A)).  Interestingly, the 
sequential exposure significantly (p < 0.05) increased the GRP78 protein levels by 20%, 80%, 
170% and 190%, as well as phosphorylation of IRE1α by 55%, 58%, 64% and 90% at 3, 6, 12 
and 18h, respectively. 
Induction of ER stress can mediate multiple downstream pathways responsible for 
cellular fate depending on cell type and stressor.  For example, ER stress-mediated 
phosphorylation and activation of another ER membrane protein, double-stranded RNA-
activated protein kinase (PKR)-like endoplasmic reticulum kinase (PERK) has been extensively 
shown during ER stress.  The phosphorylated PERK further phosphorylates and activates the 
cytosolic eukaryotic initiation factor 2α (eIF2α) (Harding et al., 1999; Liu et al., 2002; Shamu 
and Walter, 1996), which promotes the translation and production of transcription factors ATF4 




As shown in Fig. 2(B), ROT (200 nM, 6h) and LPS (100 ng/ml, 12 and 18h) caused 
moderate increase in PERK phosphorylation (p<0.05).  However, upon priming with ROT, LPS 
treatment significantly increased p-PERK as early as 3h (p<0.05), leading to a 2-fold increase by 
18h (p<0.01).  Likewise, phosphorylation of eIF2α followed a similar trend, showing 2-fold 
higher p-eIF2α post 18h LPS treatment in ROT-primed BV2 cells (Fig. 2(B)).  Next, the 
upregulation of ATF4 and CHOP was seen in a similar pattern.  Here, the sequential treatment of 
BV2 cells with ROT and LPS increased the ATF4 protein levels by 66%, 72%, 102% and 125%; 
and CHOP levels by 28%, 72%, 260% and 285% at 3, 6, 12 and 18h, respectively (Fig. 2(B)).  
These results strongly indicate that subsequent exposure to ROT followed by LPS causes 
aberrant elevation of ER stress-dependent UPR, and turns on several gene transcription 
regulators. 
Sequential treatment of BV2 cells with ROT and LPS modulate the Trx/TXNIP expressions 
Thioredoxins (Trx) are small redox-active proteins that complement the GSH system and 
play an important role in maintaining a reducing environment in the cell and protects cells 
against ROS (Arner and Holmgren, 2000). Thioredoxin interacting protein (TXNIP), also known 
as thioredoxin binding protein 2 (TBP2), binds directly to Trx at two cysteine residues, inhibiting 
the antioxidant activity of the enzyme (Patwari et al., 2006).   
 ROT/LPS treatment upregulated the protein levels of TXNIP in a time-dependent 
manner leading to a 3.2-fold higher expression at 18h (p < 0.001).  Even further, we analyzed the 
protein levels of cytosolic and mitochondrial Trx (Trx-1 and Trx-2, respectively).  As expected, 
we noticed that with increased oxidative stress (Fig. 1(A)) and TXNIP upregulation, both Trx-1 




reduced the Trx-1 levels by 23%, 35% and 60% and Trx-2 levels by 35%, 52%, and 58% at 6, 12 
and 18h (Fig. 2(C)).  Collectively, our results indicate that LPS-induced ER stress was 
potentiated by ROT priming. 
Dasatinib alleviates the LPS-mediated oxidative stress and mitochondrial dysfunction 
activation the ROT-primed BV2 cells 
c-Abl has been previously demonstrated to be activated in response to ROT/LPS 
treatment.  Hence, to establish the role of c-Abl in our present study, we employed a similar 
approach and pretreated the cells with DAS (Tokarski et al., 2006).  Consistent with published 
studies, DAS (100nM, 1h) pretreatment abrogated the ROT/LPS-mediated aberrant accumulation 
of ROS by 60% (Fig. 3(A)) and depletion of MMP by 38% (Fig. 3(B)). 
Dasatinib pretreatment ameliorates ER stress and TXNIP induction in BV2 microglial cells 
treated with ROT and LPS 
We analyzed the effect of DAS on ER stress in ROT/LPS treated BV2 microglial cells.  
Fig. 3(C) shows that DAS significantly (p < 0.05) decreased the phosphorylation of IRE1α by 
48% and eIF2α by 52%, and abolished the ATF4 upregulation in ROT/LPS-treated microglia.  
DAS pretreatment also mitigated the loss of Trx-1 by 42% (p < 0.01) and upregulation of TXNIP 
by 54% (p < 0.05) in LPS-treated BV2 microglial cells primed with ROT (Fig. 3(D)). 
c-Abl inhibition abrogates the activation of NLRP3 inflammasome in ROT/LPS-treated 
BV2 cells 
We previously demonstrated that c-Abl played a crucial role in microglial activation of 




et al., 2017). Oxidative-ER stress has also been shown to promote NLRP3 inflammasome 
activation (Bronner et al., 2015; Devi et al., 2013; Lebeaupin et al., 2015; Lerner et al., 2012).  
Here, we demonstrated that DAS pretreatment can reduced oxidative stress, mitochondrial 
dysfunction and ER stress in BV2 cells (Fig. 3(A,B,C)).  Hence, we further analyzed the effect of 
DAS on activation of NLRP3 inflammasome in our present model.  Similar to our previous study 
(Lawana et al., 2017), DAS pre-exposure completely abolished the increase in NLRP3 protein 
expression in ROT/LPS-treated BV2 cells (p < 0.01, Fig. 3(E)).  Furthermore, DAS also 
abrogated the inflammatory release of IL-1β and IL- by 48% and 45%, respectively, as analyzed 
by ELISA technique (Fig. 3(F)).  Together, we find results consistent with previous publications 
indicating an upstream role of c-Abl kinase in microglial activation of NLRP3 inflammasome by 
modulating the induction of oxidative, mitochondrial and ER stresses. 
Salubrinal mitigates oxidative stress and mitochondrial dysfunction in ROT/LPS-treated 
BV2 cells 
To evaluate the effect of salubrinal in the present study, we pretreated BV2 cells with 100 
µM Salubrinal for 1h followed by sequential exposure to ROT (200 nM, 6h) and LPS (100 
ng/ml, 12h).  We analyzed these cells for previously mentioned stress parameters.  We analyzed 
the level of ROS generation and MMP in cells treated with ROT/LPS with or without salubrinal.  
We observed that salubrinal pre-treated, ROT/LPS-treated BV2 microglial cells had reduce 
accumulation of ROS by 22% (p < 0.05, Fig. 4(A)) and 28% higher MMP (p < 0.01, Fig. 4(B)) 
compared to ROT/LPS treated group.  These results indicate that inhibition of ER stress by 





Salubrinal reduces ER stress in LPS-treated microglia primed with ROT 
A plethora of studies shows that salubrinal protects against ER stress-mediated cell death 
(Boyce et al., 2005; Ji et al., 2017b; Kim et al., 2014; Pae et al., 2007; Saxena et al., 2009).  
Mechanistically, salubrinal blocks the protein complexes GADD34/protein phosphatase 1 (PP1) 
and CReP/PP1, leading to inhibition of eIF2α dephosphorylation (Boyce et al., 2005; Long et al., 
2005). Salubrinal pretreatment inhibited the phosphorylation of PERK and reduced the induction 
of CHOP and ATF4 in in a dose-dependent manner in ROT-pretreated LPS-exposed BV2 cells 
(Fig. 4(C)).   
Furthermore, we validated our BV2 cells results in primary microglia.  Here, we treated 
the primary microglia using very low concentrations of ROT and LPS as demonstrated in our 
previous publication (Lawana et al., 2017).  In brief, we treated the primary microglia with 10 
nM ROT for 4h followed by 10 ng/ml LPS for 3h with or without salubrinal (100 µM, 1h) 
pretreatment.  Posttreatment, we analyzed the cells for ER stress markers using immunoblotting. 
Salubrinal reduced the expression of p-PERK, p-eIF2α and ATF4 expression by 28% (p<0.01), 
10% (p < 0.05) and 24% (p < 0.01), respectively, in ROT/LPS-treated primary rat microglia (Fig. 
5(B)), which was also observed in BV2 cells. 
ROT/LPS-induced activation of c-Abl/PKCδ signaling was attenuated by salubrinal in 
primary microglia 
We analyzed the ROT/LPS-induced activation of c-Abl and PKCδ in presence of 
salubrinal using primary microglia extracted from one-day old rats.  Microglia treated with ROT 
(10 nM) followed by LPS (10 ng/ml) with or without salubrinal (20, 50 or 100 µM) pretreatment 




salubrinal-pretreated microglia significantly (p < 0.001) reduced the ROT/LPS-mediated 
hyperphosphorylation of c-Abl Y412 by 30% and PKCδ Y311 by 38%, respectively (Fig. 5(A)). 
Salubrinal pretreatment modulates the expression of Trx/TXNIP in ROT/LPS treated 
microglia 
We demonstrate that salubrinal, an ER stress inhibitor, reduced the elevation of TXNIP in 
ROT/LPS-treated BV2 cells (Fig. 4(D)) and primary microglia (Fig. 5(C)).  Additionally, a 
recent study showed that inhibition of ER stress was associated with increased Trx levels in 
proximal tubular cell model of kidney diseases (Kim et al., 2017).  Consistent with this, our 
immunoblotting analysis for Trx-1 and Trx-2 showed a similar trend, demonstrating salubrinal-
mediated abrogation of loss of Trx reduction caused by ROT/LPS (Fig. 4(D) and 5(C)). Our 
results indicate that salubrinal can reduce TXNIP induction by blocking ER stress and reducing 
oxidative stress in a dose-dependent manner. 
ROT/LPS-induced activation of NLRP3 inflammasome was attenuated by salubrinal 
Many recent studies are suggesting a pivotal role of oxidative-ER stress in modulating 
downstream molecular mechanisms responsible for microglial activation (Guo et al., 2015b; Liao 
et al., 2016; Liu et al., 2010; Masson et al., 2015; Szpigel et al., 2018).  We analyzed the 
activation of NLPR3 in our model using salubrinal as an ER stress protectant.  Our protein 
expression analysis demonstrated that salubrinal (20, 50 and 100 µM, 6h) pretreatment reduced 
the ROT/LPS-induced aberrant increase of NLRP3 in BV2 cells by 40% (Fig. 4(E)) and primary 
microglia by 45% (Fig. 5(D)), respectively.  ELISA analysis of media supernatant for IL-1β and 
Il-18 showed more than a 25% reduction in secreted cytokines levels in salubrinal pretreated, 




Overall, our results are consistent with previous studies and demonstrate that salubrinal 
significantly diminishes the activation of NLRP3 inflammasome.   
siRNA-mediated TXNIP knockdown abrogates ROS accumulation and MMP depletion in 
ROT/LPS-treated BV2 cells 
The Trx system, which is composed of NADPH, thioredoxin reductase (TrxR), and 
thioredoxin, is a key antioxidant system in defense against oxidative stress through its disulfide 
reductase activity regulating protein dithiol/disulfide balance.  Using siRNA-mediated 
knockdown of TXNIP, an endogenous Trx inhibitor, we showed 70-80% depletion of TXNIP 
with concomitant restoration of Trx-1 and -2 in ROT/LPS-treated BV2 cells (Fig. 6(A)).  
Scramble siRNA was used as a negative control.  TXNIP depletion also attenuated intracellular 
ROS by 50% in LPS treated BV2 cells primed with ROT (Fig. 6(B)) and abrogated the loss of 
MMP (Fig. 6(C)). 
TXNIP knockdown ameliorates the ROT/LPS-induced ER stress in BV2 microglial cells 
TXNIP has been shown promote ER stress via inducing oxidative stress (Malone et al., 
2017; Qiao et al., 2015) and mitochondrial distress (Chen et al., 2010).  We demonstrate here 
that siRNA-mediated TXNIP KD significantly lowered the expression of ER stress markers, 
specifically, p-IRE1α (p < 0.01), p-eIF2α (p < 0.05), ATF4 (p < 0.05), CHOP (p < 0.01) and 






TXNIP KD reduced the ROT/LPS-mediated activation of NLRP3 inflammasome in BV2 
microglial cells 
In recent years, the regulators of NLRP3 inflammasome activation have been extensively 
investigated in microglia.  Interestingly, research from various mammalian immune cells 
demonstrates that TXNIP act as an vital mediator in oxidative stress-induced (Feng et al., 2016; 
Liu et al., 2015b; Wu et al., 2014; Zhou et al., 2010), mitochondrial damage-induced (Alfonso-
Loeches et al., 2014; Zhou et al., 2011) and ER stress-induced (Lerner et al., 2012; Li et al., 
2015a; Li et al., 2015b; Oslowski et al., 2012; Song et al., 2015) activation of NLRP3 
inflammasome. We demonstrated that, ROT/LPS treatment failed to increase the protein levels 
of NLRP3 inflammasome in TXNIP KD BV2 cells compared with scramble siRNA-transfected 
cells (Fig. 6(E)).  We further confirmed the activation of NLRP3 inflammasome by evaluating 
the extracellular release of IL-1β and IL-18.  We found that TXNIP KD reduced the media 
supernatant levels of IL-1β by 41% and Il-18 by 27% post ROT/LPS treatment, as compare to 
scramble siRNA group (p < 0.001, Fig. 6(F)).  Together, these results indicate that TXNIP may 
play a crucial role in modulating cellular oxidative, mitochondrial and ER stress, leading to 
hyperactivation of NLRP3 inflammasome. 
Overexpression of Trx-1 and TXNIP modulates the cellular stress in response to ROT/LPS 
treatment in BV2 microglial cells 
To further confirm the role of TXNIP in our model, we overexpressed TXNIP and Trx-1 
in BV2 cells using respective wild type (WT) contracts, followed by sequential treatment with 
ROT (200nM, 6h) and LPS (100ng/ml, 12h).  Empty vector (E.V.) was transfected as negative 




1 and TXNIP using immunoblotting.  As shown in Fig. 7(A), TXNIP WT construct transfected 
cells increased TXNIP expression by 20-35%.  On the contrary, Trx-1 overexpressing cells had 
significantly greater Trx-1 and Trx-2 with reduced TXNIP expression (p < 0.05, Fig. 7(A)). 
Since, overexpression of TXNIP has been shown to increase oxidative stress and impair 
mitochondrial integrity (Li et al., 2017; Nasoohi et al., 2018; Schulze et al., 2004), we analyzed 
the level of ROS and MMP in our present study.  Consistent with published literature, we found 
that when treated with ROT/LPS TXNIP WT cells exaggerated the ROT/LPS-mediated ROS 
production by 44% and MMP loss by 24%, while Trx-1 overexpression in ameliorated the ROS 
accumulation and MMP depletion by 38% and 30%, respectively, compared with E.V. BV2 
cells. 
Next, we evaluated ER stress markers in BV2 cells overexpressing TXNIP or Trx-1.  
Immunoblots shown in Fig. 7(D) shows that TXNIP WT BV2 cells treated with ROT/LPS 
induced hyperphosphorylation of IRE1α and eIF2α with more than 15% increased protein levels 
of ATF4, CHOP and GRP78 compared to ROT/LPS-treated E.V.-transfected BV2 cells (p < 
0.05, Fig. 7(D)).  In contrast, Trx-1 WT BV2 cells blocked the increased phosphorylation of 
IRE1α and eIF2α and significantly (p < 0.05) reduced the levels of ATF, CHOP and GRP78 by 
more than 30% post ROT/LPS exposure (Fig. 7(D)).  These data TXNIP overexpression can 







Trx-1 and TXNIP overexpression alters the activation of NLRP3 inflammasome in BV2 
microglial cells 
 Plethora of emerging evidences demonstrates that TXNIP can bridge 
oxidative/mitochondrial/ER stress to the activation of NLRP3 inflammasome (Chen et al., 
2018b; Lerner et al., 2012; Li et al., 2015a; Li et al., 2015b; Liu et al., 2015a; Sun et al., 2016; 
Wang et al., 2015; Xiao et al., 2014).  In this context, Zhao et al recently demonstrated that ER 
stress-induced TXNIP can activate NLRP3 inflammasome during inflammatory brain damage.  
The researchers also demonstrated that imbalance between Trx-1 and TXNIP protein levels leads 
to modulation in NLRP3 protein levels and cleavage of casp-1 and IL-1β (Zhao et al., 2017).  In 
addition, another study from macrophages showed that treatment with recombinant Trx-1 can 
reduce the inflammatory response and can stimulate the anti-inflammatory phenotype (El Hadri 
et al., 2012).  Interestingly, LPS-mediated activation of NLRP3 inflammasome has been shown 
to be dependent on TXNIP (Du et al., 2016; Feng et al., 2016). 
Similarly, in the present study we demonstrated that overexpression of TXNIP 
significantly increased the protein levels of NLRP3 by 42%, while Trx-1 overexpression 
abrogated NLRP3 induction by 30% in ROT/LPS-treated BV2 cells (Fig. 7(E)).  Even more, 
analysis of media supernatant revealed that TXNIP WT cells excreted significantly higher 
cytokines (IL-1β and IL-18), whereas, Trx-1 WT cells decreased the levels of secreted cytokines 
by more than 60% post ROT/LPS treatment (Fig. 7(F)).  These results indicate that TXNIP is 
essential for activation of NLRP3 inflammasome, while Trx-1 can amend the inflammasome 




Primary microglia transfected with c-Abl or TXNIP siRNA showed reduced cellular stress 
after ROT/LPS treatment 
We validated the BV2 cells results in a well-established primary microglia model.  
Primary rat microglia were extracted from one-day old pups and were transfected with siRNA 
against c-Abl or TXNIP, followed by treatment with ROT (10nM, 4h) and LPS (10ng/ml, 3h).  
Transfection with scramble siRNA was used as mock control.  Using WB, we evaluated the 
transfection efficacy from all treatment groups.  Fig. 8(A) and 8(B) show that siRNA transfection 
reduced the expression of c-Abl by 55% and TXNIP by 42% in vehicle-treated control microglia.  
Even further, c-Abl KD abolished the Y311 phosphorylation of PKCδ, as expected (Fig. 8(A)).  
Intriguingly, TXNIP KD also mitigated the phosphorylation of c-Abl Y412 and PKCδ Y311 in 
ROT/LPS-treated primary microglia (Fig. 8(A)).  We also noted that TXNIP KD as well as c-Abl 
KD significantly abrogated the depletion of Trx-1 and Trx-2 (p < 0.01, Fig. 8(B)), supporting the 
results from BV2 cells (Fig. 3(D) and 6(A)). 
Further, we analyzed the markers of ER stress in c-Abl and TXNIP KD primary 
microglia treated with ROT and LPS.  Here, c-Abl depletion in primary microglia reduced the 
ROT/LPS-induced ER stress by attenuating the expression of p-PERK by 38% (p<0.05), p-eIF2α 
by 42% (p < 0.001) and ATF4 by 26% (p < 0.01, Fig. 8(C)).  Likewise, in primary microglia 
transfected with TXNIP RNAi also reduced the phosphorylation of PERK and eIF2α followed by 
reduced ATF4 levels (p < 0.05, Fig. 8(C)).   
We recently demonstrated that c-Abl play a crucial role in modulating the activation of 
NLRP3 inflammasome by promoting NF-κB transcription factor activation, oxidative stress, 




(Lawana et al., 2017).  Likewise, in the present study we showed that c-Abl KD significantly 
reduced the LPS-mediated increase of NLRP3 levels (Fig. 8(D)) with extracellular release of IL-
1β and IL-18 cytokines (Fig. 8(E)) in ROT pre-exposed primary rat microglia. 
In addition, researchers identified that TXNIP directly binds to the LRR domain of 
NLRP3 protein causing the activation of the inflammasome complex and depletion of TXNIP 
blocks activation (Zhou et al., 2010).  Consistent with previous studies (Chen et al., 2018b; Feng 
et al., 2016; Lerner et al., 2012; Li et al., 2015b; Liu et al., 2015b; Liu et al., 2014; Wu et al., 
2014) and our BV2 cell data, we showed that TXNIP KD primary microglia markedly lowered 
expression of NLRP3 after treatment with ROT/LPS (p < 0.001, Fig. 8(D)).  In addition, TXNIP 
KD-ROT/LPS-treated primary microglia also showed significantly (p < 0.001) reduced levels of 
secreted cytokines compare to scramble siRNA cells treated with ROT/LPS (Fig. 8(E)).  Taken 
together, our data demonstrate that c-Abl may modulate ER stress leading to upregulation of 
TXNIP, which then further activates the NLRP3 inflammasome in ROT/LPS sequentially treated 
microglia. 
A single LPS injection potentiates the ROT-mediated accumulation of activated microglia 
and TH loss in rat SN 
 Using a dual hit approach, we treated the 6 months old adult rats with low dose of ROT 
(0.5 mg/kg/d, s.c.) for 5d/week for 4 weeks followed by single LPS (5 mg/kg, i.p.) injection one 
month after last ROT dose.  Post LPS injection, rats were sacrificed after 24h and brain regions 
were collected from all treatment groups for biochemical analysis.  Consistent with previous 
studies (Cannon et al., 2009; Ling et al., 2004; Sherer et al., 2003d; Sonia Angeline et al., 2012; 




45% reduction in TH levels (p < 0.01), however, 24h LPS treatment had no significant effect on 
TH levels as analyzed by WB (Fig. 9(D)).  Intriguingly, LPS treatment to rats chronically treated 
with ROT significantly exaggerated the TH loss up to 72% compare to control and LPS groups 
(p < 0.001) and 55% compare to ROT group (p < 0.01).  Our WB results further demonstrate that 
rats exposed to chronic ROT treatment have 30% increase in IBA1 levels, while LPS treatment 
caused 37% increase in IBA1 expression in SN lysates compare to vehicle-treated control group 
(p < 0.05, Fig. 9(A)).  Expectedly, rats sequentially treated with ROT and LPS demonstrate a 
potentiated effect, showing aberrant 106% increase in IBA1 protein levels (p < 0.001 compare to 
control). 
ROT-pretreatment aggravates the LPS-induced activation of c-Abl/ER stress/TXNIP 
signaling cascade in vivo 
 Earlier in this study, we demonstrated a central role of c-Abl and ER stress in activation 
of NLRP3 inflammasome using BV2 microglial cells and primary rat microglia.  To further 
corroborate our in vitro results, we performed immunoblotting for c-Abl and ER stress-related 
markers using SN lysates from rats treated with ROT, LPS or the combination.  As shown in Fig. 
9(B), our data reveal that ROT and LPS alone increased the Y412 phosphorylation of c-Abl by 
35-45% (p < 0.01) and Y311 phosphorylation of PKCδ by 40-52% (p < 0.05).  Intriguingly, rats 
sequentially treated with ROT and LPS showed a significant (p < 0.05) increase in c-Abl p-Y412 
and PKCδ p-Y311 expression by 60% and 42% in SN, respectively, compare to individual 
treatment. 
 Since, a recent study (Morita et al., 2017) and our in vitro analysis indicate that c-Abl 
kinase can modulate ER stress, we further evaluated the key ER stress markers in our in vivo 




p-PERK, p-eIF2α and ATF4 by 32%, 30% and 24% in SN lysates, respectively, compare to 
vehicle-treated control group (p < 0.05, Fig. 9(B)).  Interestingly, LPS treatment did not change 
the expression of ER stress markers, when treated alone.  However, LPS treatment to ROT-
pretreated rats induced aberrant hyperphosphorylation of PERK and eIF2α and increased the 
protein level of ATF4 (p < 0.01), indicating an elevated ER stress in nigral tissue (Fig. 9(C)). 
Next, we evaluated the changes in Trx and TXNIP protein levels.  Consistent with a 
previous study (Meurers et al., 2009), ROT group showed 45% higher TXNIP expression (p < 
0.01) compare to control.  Even further, ROT decreased the protein levels of Trx-1 and Trx-2 by 
>30% in SN (Fig. 9(D)).  However, a single LPS treatment failed to demonstrate any significant 
change in Trx/TXNIP expressions.  Interestingly, ROT+LPS sequentially treated rats showed a 
marked decrease in Trx-1 and Trx-2 expression by 46% (p < 0.01) and 32% (p < 0.05), while 
increased TXNIP levels by 55% (p < 0.01), compared to ROT alone group (Fig. 9(C)).  
Collectively, these results support of in vitro data and manifest that ROT pre-exposure primes 
the LPS-mediated microglial activation, perhaps by promoting c-Abl activation, ER stress and 
TXNIP upregulation. 
Sequential ROT and LPS treatment heightens the activation of NLRP3 inflammasome in 
rat SN  
Lastly, we analyzed the protein level of NLRP3 as an indicator of inflammasome activity 
in rats treated with ROT, LPS or ROT+LPS.  Our research group and other have previously 
demonstrated that exposure to ROT or LPS induces the NLRP3 inflammasome activation in vivo 
(Cai et al., 2016; Ma et al., 2014; Sarkar et al., 2017a; Zhou et al., 2011).  In fact, we previously 
showed that LPS may induce c-Abl-kinase-mediated activation of NLRP3 inflammasome in SN 




increased the protein levels of NLRP3 by 20 to 30% in nigral tissue (p < 0.05).  However, the 
sequential treatment significantly (p < 0.01) potentiated NLRP3 induction upto 75% in SN (Fig. 
9(E)). 
Taken together, the present data indicates that LPS toxicity is significantly exacerbated 
by pre-exposure to a parkinsonian toxicant via activation of c-Abl/ER stress/TXNIP/NLRP3 
pathway, leading microglial activation and dopaminergic neurodegeneration. 
Discussion 
Although ER stress and neuroinflammation have been implicated in PD pathogenesis, the 
causal link between ER stress and NLRP3 inflammasome activation during microglial activation 
remains unclear.  It has been reported that rotenone impairs dopaminergic neuronal function via 
induction of ER stress, therefore we were interested in investigating whether a similar process is 
operant during rotenone induced microglial activation and if so whether post treatment with LPS, 
a PAMP can exacerbate the ER stress associated NLRP3 inflammasome activation.  In the 
present study sequential exposure of either BV2 microglial or primary microglial cells in culture 
to ROT and LPS resulted in a marked upregulation of c-Abl activation (phosphorylation), 
mitochondrial oxidative stress response, ER stress response, TXNIP upregulation, Trx 
downregulation and associated NLRP3 inflammasome activation.  Moreover, pharmacological 
inhibition of c-Abl via dasatinib (DAS) or siRNA-mediated gene knockdown not only attenuated 
ER stress response (ERS) but also TXNIP-associated NLRP3 inflammasome activation. These 
results suggest that c-Abl is an upstream regulator of ERS and TXNIP-associated NLRP3 
inflammasome activation.  Likewise, genetic ablation of TXNIP diminished NLRP3 




activation as determined by elevated levels of mature IL-1β and IL-18.  Our studies further 
showed that pharmacological inhibition of eIF2α phosphatase via salubrinal inhibited ER stress 
response with a concomitant inhibition of NLRP3 inflammasome in a TXNIP-dependent manner, 
suggesting NLRP3 inflammasome activation occurs via ER stress-associated TXNIP induction.  
Our in vivo studies performed in aged rats confirmed our in vitro findings, further highlighting 
the positive correlation between ERS/TXNIP/NLRP3 inflammasome signaling axis in microglia 
and resultant dopaminergic neurodegenerative effect.  Taken together, we, for the first time, 
unravel that c-Abl-ERS-TXNIP-NLRP3 signaling axis is a critical determinant of ROT/LPS-
induced microglial activation response.  Our studies further highlight the therapeutic efficacy of 
DAS in combating heightened microglial activation response in a neuroinflammation model of 
PD. 
c-Abl, a redox sensitive kinase, has been shown to be activated in diverse experimental 
models of PD including a mouse MPTP model (Karuppagounder et al., 2014; Ko et al., 2010; 
Wu et al., 2016).  In fact, a positive association between c-Abl activation, α-synuclein 
aggregation and dopaminergic neuronal loss has been demonstrated further supporting the 
deleterious role of c-Abl in mediating oxidative stress-induced dopaminergic neuronal injury 
(Brahmachari et al., 2016).  In a recent study, we demonstrated that heightened microglial 
activation is associated with c-Abl activation with an accompanying impairment of 
mitochondrial function and oxidative stress response in a neuroinflammation LPS model of PD 
(Lawana et al., 2017).  Consistent with this report, herein we show a marked upregulation of c-
Abl in ROT/LPS-treated cells as assed via phosphorylation at Tyr412 residue of c-Abl (Dorey et 
al., 2001; Plattner et al., 1999).  Furthermore, in line with previous findings, a parallel activation 




Conversely, dastanib (DAS), a c-Abl inhibitor or genetic ablation of c-Abl attenuated PKCδ 
activation, further confirming the regulatory effects of c-Abl on PKCδ activation.  Taken 
together, these studies further confirm the notion that c-Abl-mediated mitochondrial dysfunction 
might contribute to elevated microglial activation response following sequential treatment with 
ROT and LPS. 
In recent years, we and others have demonstrated the activation of NLRP3 inflammasome 
and resultant release of proinflammatory cytokines from microglia upon exposure to diverse 
inflammagens (Cai et al., 2016; Gustin et al., 2015; Liang et al., 2015; Sarkar et al., 2017a).  In 
fact, experimental models and human samples of neurodegenerative diseases have demonstrated 
NLRP3 inflammasome activation further illuminating the role of innate immunity in mediating 
neurodegenerative effects (Debye et al., 2018; Heneka et al., 2013; Lee et al., 2018; Mao et al., 
2017; Meissner et al., 2010; Shao et al., 2017).  Mechanistically, activation of NLRP3 
inflammasome requires the induction of NLRP3 followed by recruitment of an adapter protein 
known as ASC (apoptosis-associated speck-like protein containing a caspase activation and 
recruitment domain (CARD)), which then activates caspase-1 required for cleavage of pro-IL-1β 
and pro-IL-18 (Lee et al., 2016).  Combination of pathogen-associated and danger associated 
molecular patterns (PAMP and DAMP, respectively) have been shown to promote the NLRP3 
inflammasome assembly and subsequent activation.  For example, priming with LPS potentiates 
the induction and activation of inflammasome following post treatment with oxidative 
stressors/mitochondrial toxicants (ATP, rotenone, and antimycin) (Ghonime et al., 2014; 
Murakami et al., 2012; Nadatani et al., 2016; Yang et al., 2015; Zhou et al., 2011), lysosomal 
system disruptors (crystalline materials and peptide aggregates) (Halle et al., 2008; Hornung et 




Planillo et al., 2013) or ER stress inducers (tunicamycin and thapsigargin) (Lebeaupin et al., 
2015; Menu et al., 2012; Wali et al., 2014; Wang et al., 2017).  Consistent with earlier reports 
from our lab (Lawana et al., 2017; Sarkar et al., 2017a), increased expression of NLRP3 as well 
as elevated levels of IL-1β and IL-18 in media supernatants were evidenced in ROT/LPS-treated 
microglial cells.  Furthermore, our in vivo study corroborated our in vitro findings whereby rats 
chronically exposed to ROT followed by acute LPS treatment exhibited an exacerbated NLRP3 
inflammasome activation in the SN as compared with LPS or ROT treated rats (Fig. 9(D)).  
Additionally, a remarkable reduction in TH levels in nigral tissue of ROT/LPS-treated rats as 
compared with ROT- or LPS-treated groups was evidenced, indicating that microglia-mediated 
release of neurotoxic mediators, presumably NLRP3 inflammasome-related markers, might 
participate in the accentuation of dopaminergic neuronal loss. 
 Exposure to diverse neurotoxicants can induce ER stress.  For example, mitochondrial 
toxicant rotenone induces the IRE1α phosphorylation and ER stress by impairing mitochondrial 
function and increasing oxidative stress in Neuro2A cells (Goswami et al., 2016a; Mori et al., 
2013).  Similar results were reported in rat retinal cells (Han et al., 2014), SK-N-MC 
neuroblastoma cells (Chen et al., 2008) and neuronal PC12 cells (Ryu et al., 2002).  Likewise, 
LPS has been shown to upregulate ER stress in brain (Masson et al., 2015) and liver (Lebeaupin 
et al., 2015) leading to activation of NLRP3 inflammasome and ER stress.  Consistent with these 
reports, our results reveal that  sequential exposure of BV2 microglial cells or primary rat 
microglia to ROT and LPS potentiates ER stress by increasing the expression of p-IRE1α, p-
PERK, p-eIF2α, ATF4, GRP78 and CHOP (Fig. 2(A,B) and 5(B)).  Additionally, we replicated 
our in vitro findings in an aged ROT/LPS model of PD.  Intriguingly, c-Abl kinase was found to 




neurotoxicity in Rat1 fibroblastic cells via mitochondria mediated oxidative stress mechanism 
(Ito et al., 2001).  More over, c-Abl KD was found to reduce the ER to mitochondrial 
translocation and resultant neuronal loss (Qi and Mochly-Rosen, 2008).  In accordance with 
these findings, both DAS and siRNA mediated c-Abl KD was found to reduce the induction of 
ER stress markers in microglial cells exposed to ROT and LPS in tandem (Fig. 3(C) and 8(B)).  
Taken together, our results suggest that exacerbated ERS in the microglia might atleast in part 
contribute to elevated neuroinflammatory response and resultant dopaminergic neuronal loss in 
animals that received a combination of ROT and LPS. 
To further evaluate the role of ER stress, we employed salubrinal, a selective inhibitor of 
protein phosphatase 1 complex required for dephosphorylation of p-eIF2α (Shrestha et al., 2012).  
Salubrinal has been shown to block the induction of ER stress in various cells.  (Gong et al., 
2012).  Accordingly, in the present study, we showed that salubrinal significantly reduced the 
ROS generation and ER stress in microglia sequentially exposed to ROT and LPS (Fig. 4(A,C) 
and 5(B)).  Furthermore, we also observed that salubrinal pretreatment reduced the activation of 
c-Abl/PKCδ signaling axis in ROT/LPS-treated primary microglia (Fig. 5(A)).  Based on 
previous reports by Mosley et al. (2006), it is plausible that inhibition of ER stress and 
mitochondrial dysfunction might be a likely contributor to reduced activation of redox sensitive 
c-Abl/PKCδ kinases in salubrinal-pretreated microglia. 
In recent years, thioredoxin-interacting protein (TXNIP) has been identified as a major 
player in the regulation of cellular redox environment (Yoshihara et al., 2014; Zhou and Chng, 
2013).  In this context, a well-established role of TXNIP involves the inhibition of both cytosolic 
and mitochondrial thioredoxins (Trx-1 and Trx-2, respectively), thereby leading to increased 




to protect against hyperglycemia-induced ROS accumulation in Muller glial cells.  Moreover, 
TXNIP was also shown to modulate ER stress in hyperglycemic Muller glial cells (Devi et al., 
2012).  Concordant with these findings, exposure of microglial to ROT and LPS in tandem was 
associated with an upregulation of TXNIP and downregulation of Trx-1 and Trx-2.  As 
anticipated, genetic depletion of TXNIP mediated by siRNA significantly blocked the depletion 
of Trx in ROT/LPS-treated microglia (Fig. 6(A) and 8(C)), while TXNIP overexpression further 
reduced the protein levels of Trx (Fig. 7(A)).  On the contrary, Trx-1 overexpression abrogated 
TXNIP induction in the ROT/LPS-treated microglia.  Furthermore, our studies revealed that 
TXNIP KD or Trx-1 overexpression in BV2 cells blunted ROT/LPS-mediated oxidative stress 
and mitochondrial dysfunction, while overexpression of TXNIP exacerbated the proxidant 
effects of ROT/LPS (Fig. 6(B,C) and 7(B,C)).  Hence, our data suggest that ER stress alongside 
mitochondria-mediated oxidative stress might mediate TXNIP upregulation while 
downregulating Trx, thereby promoting a proinflammatory microglial phenotype. 
Intriguingly, Tschopp and colleagues showed that TXNIP serves as a link between 
oxidative stress and NLRP3 inflammasome activation.  In fact, they revealed that arrestin 
structure of TXNIP can directly bind to NLRP3 and that TXNIP binding affinity is specific for 
NLRP3, and not to other inflammasome proteins (Zhou et al., 2010).  Additionally, TXNIP 
binding to NLRP3 leads to conformational changes that expose the pyrin domain of NLRP3, and 
activate the inflammasome complex (Lunov et al., 2013).  In line with these findings, our data 
demonstrated that genetic manipulation of TXNIP modulated the activation of NLRP3 
inflammasome in ROT/LPS-exposed microglia (Fig. 6(E,F) and 7(E,F)).  Further, microglia 
overexpressing Trx-1 demonstrated diminished ROT/LPS-mediated activation of NLRP3 




Collectively, our data demonstrate that ER stress-induced NLRP3 inflammasome 
activation in a TXNIP-dependent manner contributes to ROT/LPS-induced exacerbated 
microglial activation response.  We further showed that downregulation of c-Abl via 
pharmacological manipulation or genetic depletion ameliorated microglial activation response 
via suppression of ERS, mitochondrial oxidative stress response and TXNIP/NLRP3 
inflammasome activation (Fig. 10).  Notably, we demonstrated that downregulation of TXNIP 
and overexpression of Trx contributed to the attenuation of ROT/LPS-induced activation of 
NLRP3 inflammasome in microglial cells.  These findings identified the molecular correlates of 
heightened microglial activation under ERS conditions.  Further in vivo studies are needed to 
evaluate the therapeutic efficacy of salubrinal in ameliorating ROT/LPS-induced exacerbated 
microglial activation response and resultant dopaminergic neuronal loss. 
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Figure 1: Time-dependent LPS treatment elevated oxidative stress, mitochondrial 
dysfunction and activation of c-Abl kinase and NLRP3 inflammasome in ROT-primed 
murine BV2 microglial cells.  Murine BV2 microglial cells were treated with 200nM ROT for 
6h followed by treatment with LPS (100ng/ml) for 3-18h.  (A) Assessment of level of ROS 
generation in BV2 cells post treatment.  Cells were exposed to CM-H2DCFDA fluorogenic dye 




H2O2 (100µM, 1h) was used as positive control.  The data converted to percentage of control 
group and presented as mean ± SEM, N = 6.  (B) Measurement of mitochondrial membrane 
potential (MMP, ∆ψm) in ROT/LPS treated BV2 cells using JC-1 florescence dye.  The 
fluorescence was measured for green monomer and red polymer of JC-1 dye and ratio of 
RED:GREEN is plotted as a bar graph indicative of change in MMP.  (C-E) BV2 cells were 
primed with 200nM ROT for 6h followed by treatment with 100ng/ml LPS for mentioned time 
points. At the end of treatment, cells lysates were prepared and subjected to western blotting for 
(C) p-c-Abl Y245, p-c-Abl Y412, c-Abl, p-PKCδ Y311 and PKCδ; and (D) NLRP3.  β-actin was 
used loading control.  The bar graphs represent the normalized band intensity of respective 
proteins, calculated as mean ± SEM, N = 3-4.  The bottom panel in figure (D) shows the 
immunoblotting of NLRP3, Casp-1 and IL-1β for concentrates of media supernatants (Sup.) 
collected after treatment.  The data was calculated as % control and represented as mean ± SEM 
for N = 3 per group.  (E) ELISA analysis of IL-1β and IL-18 in supernatant media of BV2 cells 
treated with ROT/LPS.  Data represented as mean ± SEM for each experiment performed in 
duplicate with N = 3.  *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 compared with control 
group, whereas #p<0.05, # #p<0.01 and # # #p<0.001 indicates significance between time-matched 










Figure 2: Sequential treatment with LPS and ROT induces ER stress and interferes with 
thioredoxin system in BV2 microglial cells.  (A-C) BV2 cells were pre-exposed to 200nM 
ROT for 6h followed by treatment with 100ng/ml LPS for 3, 6, 12 and 18h.  Post treatment, cell 
lysates were subjected to WB for CHOP and GRP78 (A); p- IRE1α, IRE1α, p-PERK, PERK, p-
eIF2α, eIF2α and ATF4 (B); and Trx-1, Trx-2 and TXNIP (C).  Normalized densitometric 
analysis was plotted as % control.  The data represented as mean ± SEM, N ≥ 3.  *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001 compared with control group, whereas #p<0.05, # 
#p<0.01, # # #p<0.001 and # # # #p<0.0001 indicates significance between LPS and ROT + LPS 






Figure 3. DAS, a c-Abl inhibitor, reduces ER stress, TXNIP induction and NLRP3 
inflammasome activation by reducing oxidative stress and mitochondrial dysfunction.   
BV2 cells were pretreated with 100nM DAS for 1h followed by treatment with ROT (200nM, 
6h) and LPS (100ng/ml, 12h).  (A) Levels of intracellular ROS levels were measured using CM-
H2DCFDA florigenic dye in BV2 cells treated with ROT/LPS with or without DAS pre-




were plotted as mean ± SEM, n = 6.  (B) Estimation of MMP in BV2 cells post treatment was 
performed using JC-1 dye.  Change in the ratio of red to green readouts is plotted as mean ± 
SEM for experiment performed with N = 3-4.  (C-E) Cell lysates were subjected to 
immunoblotting for p-IRE1α, IRE1α, p-PERK, PERK, p-eIF2α, eIF2α and ATF4 (C); TXNIP 
and Trx-1 (D); and NLRP3 (E).  Histogram represents the densitometric analysis bands 
normalized to β-actin for all treatment groups as labelled.  The data represented as mean ± SEM, 
N = 3.  (F) ELISA analysis of IL-1β and IL-18 in supernatant media of BV2 cells treated with 
ROT/LPS with or without DAS.  Data represented as mean ± SEM for each experiment 
performed in duplicate with n=4.  **p<0.01, ***p<0.001 and ****p<0.0001 compared with non-
treated control group, whereas #p<0.05, # #p<0.01, # # #p<0.01 and # # # #p<0.0001 indicates 









Figure 4. Salubrinal attenuates the ROT/LPS-induced oxidative stress, mitochondrial 
dysfunction, ER stress and NLRP3 activation in BV2 cells.  BV2 cells were pretreated with 
salubrinal (20, 50 or 100µM, 6h) followed by ROT priming (200nM, 6h) and treatment with LPS 
(100ng/ml, 12h).  (A) Measurement of cellular ROS levels using CM-H2DCFDA dye.  BV2 
cells were treated with ROT/LPS with or without salubrinal pre-exposure and at the end of 
treatment cells were exposed to CM-H2DCFDA fluorogenic dye.  The data represent mean ± 
SEM, N = 6 and expressed as percent of control.  (B) Estimation of MMP in BV2 cells using JC-
1 cationic dye.  BV2 cells were exposed to ROT and LPS with or without salubrinal, as 
mentioned before followed by incubation with JC-1 dye.  The fluorescence readings were 
measured for red polymer and green monomer.  Histogram represents the ratio of RED:GREEN 
FU for all treatment groups as labelled.  The data represented as mean ± SEM, N = 3-4.  (C-E) 
BV2 microglial cells were pretreated with salubrinal primed with ROT (200nM, 6h) followed by 
LPS treatment (100ng/ml, 12h).  Post treatment cell lysates were immunoblotted for p-PERK, 
PERK, p-eIF2α, eIF2α, CHOP and ATF4 (C); Trx-1, Trx-2 and TXNIP (D) and NLRP3 (E).  β 
actin was used loading control.  The bar graphs represent the normalized band intensity of 
respective proteins from at least 3 indepent replicates, expressed as % control.  (F) ELISA 
analysis of IL-1β and IL-18 in supernatant media of BV2 cells treated with ROT/LPS with or 
without salubrinal.  Data represented as mean ± SEM for each experiment performed in duplicate 
with N = 3.  *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 compared with control group; 
and #p<0.05, # #p<0.01, # # #p<0.001 and # # # #p<0.0001 denotes significant difference between 









Figure 5. Salubrinal attenuates the ROT/LPS-induced oxidative stress, mitochondrial 
dysfunction, ER stress and NLRP3 activation in primary microglia.  Primary microglial 
cultures were prepared from one-day old rat pups as described in Methods.  Microglia enriched 
cultures were then sequentially treated with ROT (10nM, 4h) followed by treatment with LPS 
(10ng/ml, 3h) with or without salubrinal pretreatment (100µM, 1h).  (A-D) Post treatment cells 
were lysed for WB analysis for c-Abl p-Y412, p-PKCδ Y311 and PKCδ (A); p-PERK, PERK, p-
eIF2α, eIF2α and ATF4 (B); Trx-1, Trx-2 and TXNIP (C); and NLRP3 (D).  (E) ELISA 
analysis of IL-1β and IL-18 in supernatant media of BV2 cells treated with ROT/LPS with or 
without salubrinal pre-exposure.  The data represented as mean ± SEM, N = 3-4.  *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001 compared with control group, whereas, #p<0.05, # 
#p<0.01 and # # #p<0.001 denotes significant difference between ROT+LPS treated group with or 









Figure 6. TXNIP knock down inhibits the activation of ER stress/NLRP3 inflammasome 
signaling in ROT/LPS treated BV2 cells.  BV2 cells were transfected with siRNA against 
TXNIP (TXNIP KD), followed by treatment with ROT (200nM, 6h) and LPS (100ng/ml, 12h).  
Scramble siRNA was used as a negative control.  The cells were lysed for protein analysis and 
equal amount of protein was loaded for WB.  (A) The representative blots for Trx-1, Trx-2 and 
TXNIP, normalized with β-actin was plotted as histogram.  Normalized band intensities were 
calculated as % control on bar graphs for each protein.  The data represent mean ± SEM, N = 3-
4.  (B) Measurement of intracellular ROS levels in BV2 cells transected with scramble siRNA or 
TXNIP siRNA followed by ROT/LPS treatment.  At the end of treatment cells were exposed to 
CM-H2DCFDA fluorogenic dye.  The data represent mean ± SEM, N = 6 and expressed as 
percent of control.  (C) Analysis of MMP in BV2 cells.  BV2 cells (scramble siRNA or TXNIP 
siRNA transfected) were exposed to ROT and LPS, as mentioned earlier followed by incubation 
with cationic JC-1 dye.  The fluorescence readings were measured for red polymer and green 
monomer.  Histogram represents the ratio of RED:GREEN FU for all treatment groups as 
labelled.  The data represented as mean ± SEM, N = 4.  (D-E) Immunoblotting was performed 
with BV2 cell lysates genetically depleted with TXNIP followed by sequential treatment with 
ROT and LPS. Representative WB for p-IRE1α, IRE1α, p-eIF2α, eIF2α, ATF4, CHOP and 
GRP78 (D); TXNIP and Trx-1 (D) and NLRP3 (E).  β actin was used as loading control and 
normalized band intensities were plotted as %control for each sample, calculated as mean ± 
SEM, N = 3-4.  (F) ELISA assay for secreted inflammatory cytokines- IL-1β and IL-18.  TXNIP 
KD BV2 cells were exposed ROT and LPS. The supernatant media were subjected to pre-
validated commercial kits as mentioned in Methods.  The ELISA data represents the mean ± 
SEM performed in replicates of 4.  **p<0.01, ***p<0.001 and ****p<0.0001 indicates level of 
significant difference from control group; # #p<0.01, # # #0p<0.001 and # # # #p<0.0001 denotes 
significant difference between scramble siRNA and TXNIP KD cells treated with ROT+LPS; NS 











Figure 7: TXNIP and Trx-1 overexpression modulates LPS-mediated induction of ER 
stress and NLRP3 inflammasome in ROT pretreated BV2 microglial cells.  BV2 cells were 
transfected with empty vector (EV), TXNIP or Trx-1 WT constructs followed by treatment with 
ROT (200nM, 6h) and LPS (100ng/ml, 12h).  (A) The representative immunoblots for Trx-1, 
Trx-2 and TXNIP.  Band densities were normalized with β-actin and were expressed as % 
control on bar graphs for each protein.  The data represent mean ± SEM, N = 4.  (B) Assessment 
of ROS generation.  EV, TXNIP overexpressing or Trx-1 overexpressing BV2 cells were treated 
with ROT followed by LPS and were exposed to CM-H2DCFDA fluorogenic dye.  Change in 
fluorescence units was noted and data were represented as % control of mean ± SEM, N = 6.  (C) 
Estimation of MMP using JC-1 dye.  BV2 cells treated as described were assessed for MMP 
after treatment and   change in fluorescence readings ratio for red polymer and green monomer 
were noted.  Histogram represents the ratio of RED:GREEN FU for all treatment groups as 
labelled.  The data represented as mean ± SEM, N = 4.  (D-E) Immunoblotting was performed 
with BV2 cell lysates genetically depleted with TXNIP followed by sequential treatment with 
ROT and LPS. Representative WB for p-IRE1α, IRE1α, p-eIF2α, eIF2α, ATF4, CHOP and 
GRP78 (D); TXNIP and Trx-1 (D) and NLRP3 (E).  β actin was used as loading control and 
normalized band intensities were plotted as % control for each sample, calculated as mean ± 




KD BV2 cells were exposed ROT and LPS. The supernatant media were subjected to pre-
validated commercial.  The ELISA data represents the mean ± SEM performed in replicates of 4.  
*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 indicates level of significant difference from 
control group; #p<0.05, # #p<0.01, # # #p<0.001 and # # # #p<0.0001 denotes significant difference 






Figure 8. RNAi-mediated c-Abl or TXNIP knockdown blocks ROT/LPS-induced NLRP3 
inflammasome activation primary microglia.  Primary rat microglial transfected with 
scramble, c-Abl or TXNIP siRNAs were then sequentially treated with ROT (10nM, 4h) 
followed by treatment with LPS (10ng/ml, 3h).  (A-D) Posttreatment cell lysates were prepared 




Trx-2 and TXNIP (B); p-PERK, PERK, p-eIF2α, eIF2α and ATF4 (C) and NLRP3 (D).  β actin 
was used as loading control and normalized band intensities were plotted as %control for each 
sample, calculated as mean ± SEM, N = 3-4.  (E) ELISA analysis for IL-1β and IL-18 in 
supernatant media of primary microglia treated with ROT/LPS pre-exposure.  *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001 compared with scramble siRNA non-treated control 
group, whereas, #p<0.05, # #p<0.01 and # # #p<0.001, # # # #p<0.0001 denotes significant difference 






















Figure 9: Acute LPS potentiates ROT-induced activation of c-Abl/ER 
stress/TXNIP/NLRP3 inflammasome signaling in rat SN.  Six months old male Lewis rats 
were subcutaneously treated with ROT (0.5mg/kg/d, 5d/wk, 4 wk) for 4 weeks. One month after 
last ROT injection rats were intraperitoneally injected with 5mg/kg LPS.  Animals were 
sacrificed 24h post LPS injection and brain sections were collected and stored for future analysis.  
SN lysates were prepared and were subjected to immunoblotting.  Representative blots for IBA1 
and TH (A); p-c-Abl Y412, c-Abl, p-PKCδ Y311 and PKCδ (B); p-PERK, PERK, p-eIF2α, 
eIF2α and ATF4 (C); Trx-1, Trx-2 and TXNIP (D); and NLRP3 (E).  Bands were normalized to 
β actin and were presented as % control.  The data represent mean ± SEM, N = 6.  *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001 compared with vehicle-treated control group; #p<0.05, 
# #p<0.01 and # ## p<0.001 denotes significant difference between ROT and ROT+LPS treatment 
groups; and Δ Δp<0.01 and Δ Δ Δp<0.001 indicates significance between LPS and ROT+LPS 






Figure 10: Schematic representation of mechanism of rotenone and LPS-mediated 
induction of c-Abl/ER stress signaling, which mediated TXNIP-dependent activation of 






CHAPTER 6. FUTURE DIRECTIONS 
What are the mechanisms by which c-Abl modulates mitochondrial homeostasis in 
dopaminergic neurons during PD pathogenesis? 
Mitochondria are key organelles that regulate dopaminergic neuronal homeostasis.  In 
fact, known parkinsonian toxicants (MPTP and rotenone) exert their neurotoxicity by targeting 
mitochondria (Czlonkowska et al., 1996; Moon et al., 2005; Przedborski et al., 2004; Sherer et 
al., 2003).  Understanding the mechanisms by which environmental toxicant induce 
mitochondrial dysfunction is still under investigation.  Aberrant oxidative stress can induce 
mitochondrial impairment.  In this context, induction of redox-sensitive c-Abl kinase has been 
recently demonstrated to mediate oxidative stress-dependent dopaminergic neurodegeneration in 
PD models (Brahmachari et al., 2017).  Likewise, we also demonstrated that dichlorvos (an 
organophosphate) induces c-Abl activation can promote oxidative stress, mitochondrial decay 
and neurotoxicity (Chapter 2).  In addition, we showed that c-Abl modulated the biogenesis of 
mitochondria in pesticide-treated dopaminergic neurons. We intend to evaluate the exact 
mechanism of c-Abl in modulating mitochondrial biogenesis and homeostasis.  In this context, 
Ko et al. (2010) showed that c-Abl can phosphorylate and degrade parkin, a ubiquitin E3 ligase 
required for mitochondrial clearance and homeostasis, causing dopaminergic toxicity.  In PD 
models, two distinct parkin substrates are identified, namely aminoacyl-tRNA synthetase-
interacting multifunctional protein type 2 (AIMP2) (p38/JTV-1), and the PARkin Interacting 
Substrate (PARIS) (Lee et al., 2015; Lee et al., 2017; Shin et al., 2011).  Parkin knockout animal 
models show upregulation of PARIS, a zinc finger protein, which was shown to specifically kill 
dopamine neurons (Shin et al., 2011).  Interestingly, PARIS is a transcriptional repressor that 





transcriptional co-activator and a key regulator of mitochondrial biogenesis (Shin et al., 2011).  
With this background, we would like to demonstrate the role of c-Abl in (i) modulating 
mitochondrial health via oxidative stress; and (ii) regulating the generation of new mitochondria 
by mediating transcription factors.  We will use the DCV model to first identify the array of 
genes modulated by c-Abl in dopaminergic neurons.  We will then identify the genes involved in 
regulation of mitochondrial homeostasis.  Also, using in-silico and mass-spectrometry 
techniques, we will identify all proteins that interact with c-Abl and modulated mitochondrial 
health.  These results can then be confirmed using known PD models.  Successful completion of 
aforementioned studies can provide answers for following questions: (i) how does activation of 
c-Abl modulated the overall gene transcription patterns in neurons; (ii) what are the genes that 
can regulate mitochondrial homeostasis in dopaminergic neurons; and (iii) what is/are the targets 
for c-Abl that an alter this homeostasis?  These answers will provide avenues for developing 
strategies in the field of research, targeting mitochondrial pathways for neuronal survival and 
function.  
What is the cell-specific role of c-Abl in microglia during neurodegeneration? 
Accumulating evidences have conclusively indicated a pro-neurotoxic role of c-Abl in 
dopaminergic neurons.  In this context, our results from Chpater 2 and previous publications 
from other research groups have shown a significant role of c-Abl in toxicant-mediated 
dopaminergic neurodegeneration (Imam et al., 2011; Karuppagounder et al., 2014; Ko et al., 
2010; Lindholm et al., 2016; Mahul-Mellier et al., 2014; Wu et al., 2016).  Further, in chapters 3, 
4 and 5, we showed that c-Abl is also involved in microglia and activates the NLRP3 






Hence, to specifically demonstrate the role of microglial c-Abl activation contributing to 
NLRP3 inflammasome activation leading to dopaminergic neuronal death and PD-like 
phenotype, we will selectively knock out c-Abl in the microglial cells in vivo.  To accomplish 
this, we will employ cell-specific Cre-Lox knockout technique.  In brief, microglia, unlike other 
resident cells of CNS, express high amounts of the chemokine receptor CX3CR1 (Denes et al., 
2008; Fuhrmann et al., 2010).  Investigators have made use of the CX3CR1 gene promoter, 
replacing the gene downstream of the promoter with the gene for tamoxifen-inducible Cre 
recombinase fused to a mutant estrogen ligand binding domain (Er) which requires the presence 
of tamoxifen to be activated.  Similarly, we will utilize the CX3CR1 Cre-Er mice, available from 
Jackson laboratories (Patil et al., 2018).  These mice will be crossed to c-Ablflox mice, which are 
the floxed mutant mice possessing loxP sites flanking exon 5 of the ABL1 gene (Moresco et al., 
2005).  Upon administration of tamoxifen, the microglial cells will express Cre recombinase, 
which will then catalyze the site-specific recombination between the loxP sites, effectively 
knocking out c-Abl only in microglia after one month.  This strategy was utilized to selectively 
knock out the proteins from microglia (Goldmann et al., 2013; Safaiyan et al., 2016).  Ko et al 
and other showed that animals treated with MPTP increased c-Abl activity in Substantia nigra 
correlating with neurodegeneration.  Therefore, we will investigate the activation of c-Abl using 
the aforementioned transgenic model.  In brief, conditional c-Abl KO microglial mice will be 
subjected to the LPS and a mitochondrial toxicant (such as MPTP) using previously published 
study designs (Gao et al., 2003).  These animals will be monitored for locomotor behaviors and 
post treatment, the brain tissues will be analyzed for i) dopaminergic neurodegeneration, ii) 
microglial activation and accumulation in nigrostriatal regions, and iii) activation of NLRP3 





neurons using DAT-Cre/c-Abl-LoxP system, to further understand the role of c-Abl in DA 
neurons.  These findings will provide a clear understanding of role of c-Abl in microglia versus 
in neurons, causing the dopaminergic neuronal loss in toxicant-based models and can provide a 
strategy to develop therapeutic interventions for PD. 
What is the contribution of mitophagy and parkin/PINK1 pathways during microglial 
activation?  
In normal cellular homeostasis, impaired mitochondria are cleared by 
autophagolysosomal pathway, referred as mitophagy.  In recent years, several studies have 
indicated a pivotal role of mitochondrial impairment and mitochondria-generated oxidative stress 
(mtROS) in activation of NLRP3 inflammasome (Kim et al., 2016; Zhou et al., 2011).  Parkin 
(encoded by PARK2 gene), an E3 ubiquitin ligase, have been extensively shown to regulate 
mitophagy via interaction with PTEN-induced putative kinase 1 (PINK1), a mitochondrial 
serine/threonine kinase and regulator of mitochondrial quality (Andrew, 2018; Dai et al., 2015; 
Panicker et al., 2017).  In brief, PINK1 is recruited by mitochondrial outer membrane and spans 
throughout the mitochondrial inner membrane in healthy mitochondria.  After recruitment to 
inner membrane, PINK1 is readily degraded by mitochondrial proteases, keeping the PINK1 
levels in check (Jin and Youle, 2012).  However, in dysfunctional mitochondria, the 
mitochondrial membrane potential is reduced and mitochondrial membranes are depolarized, 
failing to degrade PINK1 at inner mitochondrial membrane.  The undegraded PINK1 activates 
and recruits parkin, which then binds to p62, an adapter protein, anchoring impaired 
mitochondria into an autophagosome via LC3 binding, leading to degradation of unhealthy 





Furthermore, mutations or depletion of PARK2 gene have been identified to play a major 
role in PD pathogenesis (Andrew, 2018; Bruggemann and Klein, 1993; Dawson and Dawson, 
2014).  Interestingly, our results from Chapter 4 also revealed a crucial role of parkin in 
activation of NLRP3 inflammasome in ROT/LPS exposed microglia.  We also showed that 
ROT/LPS treatment can deplete mitochondrial membrane potential and can impair autophagic 
flux in microglia.  Further, we showed that increased accumulation of autophagic LC3 puncta 
failed to co-localize with mitochondria in ROT/LPS.  With these data, we propose that ROT/LPS 
may impair mitophagy pathway in microglia, leading to reduced clearance of damaged 
mitochondria and increased mitochondrial oxidative stress, further contributing to activation of 
NLRP3 inflammasome in microglia.  However, the exact mechanism how impaired mitophagy 
can alter NLRP3 inflammasome and microglial activation needs to be further evaluated.  
Interestingly, a recent study in macrophages showed that NLRP3 inflammasome-mediated 
activation of caspase 1 can cleave parkin, leading to impaired mitophagy and further activation 
of NLRP3 inflammasome (Yu et al., 2014).  In this context, we intend to investigate the role of 
parkin in microglial NLRP3 inflammasome activation.  A recent study suggested that PARK2-/- 
microglia had reduced tumor necrosis factor alpha-induced protein 3 (also known as A20) 
activity, which negatively regulates the NLRP3 inflammasome (Mouton-Liger et al., 2018).  
Therefore it would be beneficial to investigate the factors that regulate mitophagy to develop 
novel therapeutics to mitigate aberrant inflammation associated disorders including PD.   
What is the role of c-Abl in astrocytes and how it can contribute to neuroinflammation and 
neurodegeneration during PD? 
Astrocytes, also known as astroglia, make around 30-60% of total glial population based 





Bartheld et al., 2016).  Astrocytes are involved in (i) regulating neuronal synaptic function via 
glutamate signaling; (ii) mobilization of Ca2+ via phospholipase C; (iii) maintains blood flow 
and vascular transportation of glucose; and (iv) provides structural support to the tissue 
(Maragakis and Rothstein, 2006; Phatnani and Maniatis, 2015).  A plethora of studies has 
reported astrocytic activation during neurodegenerative diseases including PD (Heales et al., 
2004; McGeer and McGeer, 2008; Niranjan, 2014; Rossi and Volterra, 2009).  In this context, 
dopaminergic neuronal fate can be modulated by astrocyte-released neurotrophic factors such as 
glial derived neurotrophic factor (GDNF) (Cunningham and Su, 2002; d'Anglemont de Tassigny 
et al., 2015; Ericson et al., 2005).  However, during PD pathogenesis, aberrantly activated 
astroglia can mediate neuronal injury and death through production of neurotoxic factors like 
glutamate, S100B, tumor necrosis factor alpha (TNF-α), prostaglandins, and reactive oxygen and 
nitrogen species (Niranjan, 2014).  Also, activation of astrocytes has been reported in animal 
models of PD (Hirsch and Hunot, 2009; Martin et al., 2016; Rivetti di Val Cervo et al., 2017).  
Hence, understanding the molecular mechanisms involved in activation of astroglia is also 
essential for developing a cure for PD.  
Further, studies from amyotrophic lateral sclerosis models show that oxidative stress 
conditions can increase the phosphorylation of c-Abl in neurons as well as in astrocytes, however 
the exact role of c-Abl in astrocytes is not yet identified (Rojas et al., 2015).  In this context, a 
recent study shows protective effect of c-Abl inhibitor in reducing the hydrogen peroxide-
mediated cell death in cultured astrocytes (Lee et al., 2014).  Interestingly, aberrant oxidative 
stress and mitochondrial dysfunction have been indicated to activate astrocytes and generate 
neurotoxic inflammatory response (Abramov et al., 2004; Cassina et al., 2008; Park et al., 2009; 





mutant mouse model demonstrate that astrocytes can also express and activate NLRP3 
inflammasome, leading to maturation of caspase-1 followed by IL-1β and IL-18, causing 
neurodegeneration (Johann et al., 2015).  In fact, another study showed that pre-exposure to a 
natural antioxidant molecule reduced the activation of NLRP3 inflammasome in astrocytes and 
microglia (Qiu et al., 2016).  Hence, based on current evidences it is plausible that exposure to 
mitochondria-targeted toxicants may activate astrocytes in PD models.  In future, we would be 
interested in investigating (i) the upstream pathways of inflammasome activation in astrocytes, 
compared to microglia; (ii) the role of c-Abl kinase in astrocytes in modulating oxidative stress, 
mitochondria homeostasis and inflammasome activation and (iii) cross-talk between astrocytes, 
microglia and neurons in PD models.  These studies will unravel a novel discovery in the field of 
neuroinflammation providing specific molecular targets for astrocytes and microglia.  
Understanding the role of c-Abl in astrocytes will further corroborate therapeutic strategies 
targeting against c-Abl in reducing neurodegeneration as well as neuroinflammation during PD 
progression, which lead to potential therapeutics that can be beneficial for patients. 
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CHAPTER 7. GENERAL CONCLUSIONS 
This section presents an overview of the results and findings detailed in the individual 
chapters of this dissertation, with a special emphasis on the role of c-Abl in dopaminergic and 
microglial activation following exposure to PD-related neurotoxicants such as dichlorvos and 
rotenone.  The major findings pertaining to each chapter have been detailed in the ‘results’ and 
‘discussion’ sections of the relevant chapters. 
c-Abl tyrosine kinase promotes apoptotic cell death via impairment in mitochondrial 
biogenesis and protein clearance machinery in dichlorvos (DCV)-treated dopaminergic 
neuronal cells 
The primary finding from Chapter 2 of the dissertation is that dichlorvos (DCV), a 
widely used household organophosphate (OP) insecticide, induces time- and dose-dependent 
dopaminergic neurotoxicity by exaggerating oxidative stress and mitochondrial dysfunction via 
impairment in cellular proteostasis in human SH-SY5Y neuronal cells as well as primary 
midbrain mouse mesencephalic neuronal cultures.  We recently revealed that chlorpyrifos, an 
OP, induces dopaminergic toxicity by promoting oxidative stress and mitochondrial dysfunction 
in a STAT1-dependent manner,, eventually leading to locomotor deficits in drug treated rats, 
further confirming the increased risk of developing PD following OP exposure (Singh et al., 
2018).  Previous studies  revealed that DCV can induce oxidative stress-dependent  
mitochondrial damage and promote dopaminergic toxicity in PC-12 cells and in rat brains 
(Binukumar et al., 2011; Binukumar et al., 2010a; Binukumar et al., 2010b; Binukumar and Gill, 
2010; Wani et al., 2014).  Consistent with these studies, our results revealed that DCV treatment 
to SH-SY5Y cells induces a time-dependent accumulation of intracellular ROS with a 





accompanies by- a time-dependent increase of 4-hydroxynoenal (4-HNE), a product of oxidative 
stress-induced lipid peroxidation (Kruman et al., 1997; McGrath et al., 2001), and 3-
nitrotyrosine, a product of ROS-induced tyrosine nitration (Ferrante et al., 1997; Nunomura et 
al., 2000) further confirming oxidative stress-induced dopaminergic neuronal injury.  
Intriguingly, DCV induced oxidative stress response was paralleled by the activation of redox-
sensitive protein kinases c-Abl and protein kinase c δ (PKCδ) in human SH-SY5Y dopaminergic 
neuronal cells.  Additionally, we demonstrated using a pharmacological inhibitor of c-Abl and 
genetic manipulation of c-Abl expression as well as by overexpression of the dominant c-Abl 
mutant that it is inexorably linked to oxidative stress-induced dopaminergic neuronal injury in 
DCV-treated SH-SY5Y cells.  
Furthermore, we demonstrated that DCV-induced MMP loss leads to cytosolic release of 
mitochondrial cytochrome C, via caspase-9 and caspase-3 activation and subseuquent proteolytic 
cleavage of PKCδ.  Given that accumulation of ubiquitin has been identified as a key 
pathological feature of protein aggregates PD, we sought to investigate whether cellular 
proteostasis is altered following exposure of SH-SY5Y cells to DCV (Pedersen and Heegaard, 
2013; Ross and Poirier, 2004).  Herein, we demonstrate that exposure to DCV reduces 20S 
proteasomal activity and results in the accumulation of ubiquitinated-heavy molecular weight 
proteins, indicating dysfunction of the ubiquitin-proteasomal system (UPS).  As anticipated, an 
accompanying impairement in autophagy was also evidenced in DCV-treated neuronal cells.  
Thus, our studies raise the possibility that c-Abl-dependent activation of oxidative stress 
response and resultant impairment in cellular proteastasis are critical determinants of DCV-





degradative pathways may shed light on whether DCV alters lysosomal biogenesis response in 
dopaminergic neurons. 
Involvement of c-Abl kinase in microglial activation of NLRP3 inflammasome and 
impairment in autolysosomal system 
Increased activation of microglia is a key characteristic feature of neurodegenerative 
diseases, including PD (Koshimori et al., 2015; Mcgeer et al., 1988).  Further, increasing 
evidences suggest a pivotal role of NLRP3 inflammasome in microglia-induced inflammatory 
response and resultant neurodegeneration in experimental models of PD (Lee et al., 2018; Mao et 
al., 2017; Sarkar et al., 2017).  Chapter 3 unravels the mechanisms of NLRP3 inflammasome 
activation responsible for inflammatory activation of microglia using the well-characterized BV2 
microglial cells, primary microglia-enriched cultures and in vivo LPS model (Liang et al., 2015; 
Liu et al., 2006; Panicker et al., 2015; Qin et al., 2007; Xu et al., 2018).  Here, we studied the 
upstream regulators of NLRP3 inflammasome, using pathogen-associated and danger-associated 
molecular pattern (PAMP and DAMP, respectively) activators.  We showed that LPS, an 
endotoxin and activator of TLR4 signaling (Jack et al., 2005; Qin et al., 2005), activates NF-κB 
transcription factor leading to production of pro-inflammatory genes including NLRP3, IL-1β, 
IL-18.  Notably LPS priming followed by rotenone (ROT), a mitochondrial complex I inhibitor, 
stimulation was found to exaggerate mitochondrial oxidative stress (mtROS) and impairment in 
autophagic flux contributing to heightened microglial response.  In this context, we demonstrated 
that inhibition of mtROS (mitochondrial oxidative stress) can reduce the activation of NLRP3 
inflammasome; while enchanced oxidative stress response was accompanied by the translocation 
of NLRP3  to the mitochondria.  On the other hand, autophagy has been considered to negatively 





here we demonstrated that LPS/ROT impaired functional autophagy as observed by increased 
accumulation of LC3B II and p62, autophagic markers, and reduced levels of transcription factor 
EB (TFEB), a lysosomal biogenesis regulator. 
A major finding of this study is that LPS/ROT treatment activated the redox-sensitive c-
Abl/PKCδ signaling axis in dose- and time-dependent manners.   In this context, we showed that 
c-Abl modulates NF-κB activation, mtROS generation and autophagolysosomal system (ALS) 
function in microglia.  Furthermore, using pharmacological and genetic manipulation studies, we 
showed that NLRP3 inflammasome activity was dependent on c-Abl activation.  Finally, we 
validated our in vitro findings in an in vivo LPS neuroinflammation model of PD, whereby in 
LPS-treatede mice, dasatinib pretreatment attenuated nigral NLRP3 inflammasome activation, c-
Abl and PKCδ activation as well as sickness behaviour.  Taken together our data support a model 
wherein oxidative stress-dependent activation of c-Abl/PKCδ signaling axis contribute to 
impairment in cellular proteostasis and resultant heightened microglial activation response. 
c-Abl-mediated cathepsin B activation augments microglial activation response and 
dopaminergic neuronal loss via the loss of parkin following sequential exposure to 
parkinsonian neurotoxicant rotenone and inflammogen lipopolysaccharide  
Increasing number of epidemiological studies indicates that individuals affected by 
systemic infectious disease and systemic inflammation are at higher risk of developing 
neurodegenerative disease including PD (Bu et al., 2015; Chiang et al., 2017; Dehner et al., 
2016; Ferrari and Tarelli, 2011; Perry et al., 2007; Tan et al., 2015).  In recent years, mounting 
evidence implicate pesticide (such as ROT)-exposure in dopaminergic neurodegeneration (Gao 
et al., 2017; Liu et al., 2003; Taetzsch and Block, 2013).  In Chapter 4, we demonstrated that 





NLRP3 inflammasome in microglia, using BV2 cells and primary microglial cultures.  Further, 
we examined the role of cathepsin B and lysosomal integrity in microglia exposed to ROT and 
LPS in tandem.  Our data revealed that ROT/LPS treatment increases lysosomal membrane 
permeability in a time-dependent manner, leading to cytosolic release of activated cathepsin B (a 
lysozyme).  Using genetic manipulation (knockdown and overexpression) and pharmacological 
inhibition (CA074 pretreatment), we showed that cathepsin B is required for activation of 
NLRP3 inflammasome in ROT/LPS treated microglia.  Our studies further unraveled the 
upstream role of c-Abl in modulating NLRP3 activation through a mechanism involving 
lysosomal dysfunction and cathepsin B release. 
We also demonstrated that exposure of microglial cells to ROT/LPS resulted in 
diminished parkin levels.  Furthermore, coimmunolabeling studies in microglia with LC3B and a 
mitochondrial marker showed that ROT/LPS treatment inhibited colocalization of autophagic 
vacuoles (AVs) with a mitochondrial marker, indicative of an impaired mitochondrial clearance 
mechanism.  To further characterize the contribution of mitochondrial clearance mechanism in 
NLRP3 inflammasome activation, we utilized site-directed mutagenesis studies. Our studies 
demonstrated that a W403A parkin mutant reduced NLRP3 inflammasome activation via down 
regulation of c-Abl activation.  In another study, Ko et al. (2010) showed that c-Abl can 
phosphorylate parkin leading to its degradation in dopaminergic neurons.  Consistent with this 
report, we also showed that inhibition of c-Abl reduced the parkin loss in ROT/LPS-treated 
microglia suggesting that c-Abl-mediated parkin down regulation may promote NLRP3 
inflammasome activation in response to ROT/LPS in microglial cells.   
Furthermore, in aged rats chronically treated with ROT an increased expression of 





loss of nigral TH neurons was augmented by sequential treatment with LPS.  Additionally, using 
immunohistochemical analysis in midbrain sections, we showed increased cathepsin B and c-Abl 
colocalization within microglia, suggestive that miocroglial c-Abl and cathepsin B might atleast 
in part contribute to ROT/LPS-dopaminergic neurodegenerative response.  Intriguingly, these 
effects were paralleled by hyperphosphorylation of α-synuclein (α-Syn) at serine 129, a well 
characterized marker of PD neuropathology (Di Maio et al., 2016; McFarland et al., 2009).   
Collectively, our data from Chapter 4 provides evidences suggesting an upstream role of 
c-Abl in inducing lysosomal dysfunction and cytosolic release of activated cathepsin B, which 
then causes the activation of NLRP3 inflammasome and ensuing release of mature cytokines 
including IL-1β and IL-18.  Future studies aimed at how lysosomal dysfunction contributes to 
cathepsin B-induced NLRP3 inflammasome activation in microglia may improve our 
understanding on the contribution of lysosomal dysfunction to neuroinflammation associated 
dopaminergic neuropathology. 
Targeting c-Abl-eIF2α rescues rotenone/LPS-induced microglial activation via attenuation 
of TXNIP-associated NLRP3 inflammasome activation 
In Chapter 5 we investigated the role of ER stress in ROT/LPS model of NLRP3 
inflammasome activation.  We showed that microglia sequentially treated with ROT and LPS 
increased endoplasmic reticulum (ER) stress and unfolded protein response (UPR) followed by 
increased thioredoxin-interacting protein (TXNIP) expression and thioredoxin depletion, leading 
to NLRP3 inflammasome activation in a time-dependent manner.  Multiple evidences 
demonstrated a crucial role of TXNIP in oxidative/ER stress-mediated activation of NLRP3 
inflammasome (Chen et al., 2018; Feng et al., 2016; Li et al., 2015; Yuan et al., 2017).  





antioxidant thioredoxin-1 attenuated the activation of NLRP3 inflammasome and release of pro-
inflammatory cytokines.  We also discovered that c-Abl played an upstream role in modulating 
ER stress/TXNIP/NLRP3 signaling.  Collectively, our study suggests that c-Abl-mediated 
oxidative stress induces ER stress consequently leading to NLRP3 inflammasome in a TXNIP-
Figure 1: Schematic representation of toxicant-induced c-Abl activation-related mechanisms in 
microglia and dopaminergic neurons. In microglia, c-Abl modulates transcription factor p65/NF-
κB activation, oxidative stress, mitochondrial dysfunction, lysosomal dysfunction-associated 
cathepsin B release, ER stress-associated TXNIP induction, leading to the activation of NLRP3 
inflammasome and release of inflammatory cytokines (IL-1β and IL-18).  In dopaminergic neuron, c-
Abl regulates oxidative stress, mitochondrial impairment, proteostasis dysfunction, activation of 
apoptogenic pathways, loss of mitochondrial biogenesis regulators and DNA fragmentation.  These 





dependent manner in microglial cells.  Notably, we validated our in vitro findings in an aged 
ROT/LPS model further highlighting the therapeutic advantage of targeting c-Abl/ERS signaling 
axis as novel interventional strategy for the treatment of neuroinflammatory disorders such as 
PD. 
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